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Genome-wide association studies (GWAS) have identified hundreds of loci at very 
stringent levels of statistical significance across many  different human traits. However, 
it is now clear that very large samples (n~104-105) are needed to find the majority  of 
genetic variants underlying risk for most human diseases. Therefore, the field has 
engaged itself in a race to increase study sample sizes with some studies yielding very 
successful results but also studies which provide little or no new insights. This project 
started early on in this new wave of studies and I decided to use an alternative approach 
that uses prior biological knowledge to improve both interpretation and power of 
GWAS. The project aimed to a) implement and develop new gene-based methods to 
derive gene-level statistics to use GWAS in well established system biology tools; b) 
use of these gene-level statistics in networks and gene-set analyses of GWAS data; c) 
mine GWAS of neuropsychiatric disorders using gene, gene-sets and integrative biology 
analyses with gene-expression studies; and d) explore the ability of these methods to 
improve the analysis GWAS on disease sub-phenotypes which usually  suffer of very 
small sample sizes.
In this project, we focused on the analysis of GWAS on bipolar disorder, however, 
GWAS from other complex disorders have also been analysed and are used throughout 
to compare the performance of the methods developed across disorders that, very likely, 
have different genetic architecture. From the analysis of these datasets, it  was possible 
to draw that conclusion.
I found that from a computational perspective the application of gene and gene-set 
analyses to GWAS is feasible, even if calculation are performed on a common desktop 
computer. As a genetic mapping tool, gene-based association of GWAS provides a 
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valuable complement to single SNP analysis methods. It  highlights true disease loci and 
generates an accurate association statistic for a gene. These gene-level statistics proved 
of merit for meta-analyses of GWAS and integrative analysis with protein-protein 
interaction networks or gene-expression studies. In this thesis, I combined results of 
GWAS and gene-expression studies and I was able to provide evidence of association 
with bipolar disorder for a protein-interaction network. This demonstrates the possibility 
of using GWAS to extract information of biological systems from GWAS of 
neuropsychiatric disorders. This information is not readily available from single SNP 
analyses, which also suffer from genetic heterogeneity. Therefore, these methods help  to 
improve the interpretation and provide an alternative to the simple but costly method of 
improving statistical power through increasing sample size. This ability proved to be 
important in our analyses of bipolar disorder sub-phenotypes, which had significantly 
smaller sample sizes. Analysis of disease sub-phenotypes showed that some genetic 
associations are shared with the main diagnosis but that others seemed largely  specific 
of the sub-phenotypes. This evidence allowed me to suggest that genetic association 
with sub-phenotypes should be analysed as both a follow up of association in a main 
diagnosis and an independently if the available evidence is suggesting that the genetic 
associations observed are largely  independent of those with the main diagnosis (e.g., as 
we found for age of onset of bipolar disorder). 
Despite the interesting new insights and potential relevance, our gene and gene-set 
associations with bipolar disorder require replication in independent samples. This is 
especially important for the association found with the bipolar disorder sub-phenotypes 
because their smaller samples size also makes them more prone to be false positives.
This project has also generated the software suite FORGE which allows users to 
perform fast  and robust analysis of GWAS, allowing researchers with a lack of 
ABSTRACT
3
experience in bioinformatics and statistical genetics, e.g. wet-laboratory  based 
biologists, to perform both gene-based and pathway analyses to generate a systems 
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Do we need to do all of this?
As a first year PhD student I used to ask myself, Do we need all these genetic 
studies? Are they relevant at all? Are we just  teasing ourselves while pleasing our big 
brain’s curiosity? Is the answer relevant just because we want to know it or can know it? 
Unfortunately, I still have no answer. 
I have learnt that beyond pleasing ourselves genetic research can be tremendously 
valuable when a real breakthrough occurs and people out there benefit from it. That is 
the reason I focused my efforts in help transforming GWAS into something useful to 
biologists, with the hope that it would help produce solutions for real people. I do think 
more genetic research should be funded and more genetic findings should end up in 
systems biology  efforts, where causality and complexity  can be studied systematically. 
At the end of the day complexity is at the heart of why we are in love with biology and 
why is so challenging. However, I have also learnt that we may  be missing an important 
bit in here. Many  diseases do have a strong genetic liability but also have an important 
environmental contribution. Many have risen in frequency beyond what genetics alone 
can explain. We inherited our genes and not our diseases. Changes in lifestyle may  be 
an important  aspect of decreasing disease morbidity, probably in some cases beyond 
what genetic findings can do.
I think human genetics will soon face great scientific challenges. The massive 
amounts of incoming data will enable us to test some of our wildest hypothesis with an 
accuracy  and depth not seen before. New sequencing technologies are opening the door 
to systematic and almost complete sampling of genetic material. Protein measurements 
may probably follow soon as will quantifications and sequencing of lipids and sugars. 
Biology  will move aways from a reductionistic science into a data driven technology. 
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Quantitative models will supersede speculation and medicine will become a science of 
forecasting, in the same way that weather forecasting changed in the last  80 years. 
Nevertheless, I think you still will have to go to the gym to lose weight  and get fit for 
the summer.
DO WE NEED TO DO ALL OF THIS?
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Figures
Figure 1.1. Effects of allele frequency and effect-size on sample-size 
requirements. The numbers of cases and controls that are required in an association 
study to detect disease variants with allelic odds ratios of 1.2 (red), 1.3 (blue), 1.5 
(yellow) and 2 (black) are shown. Numbers shown are for a statistical power of 80% at 
a significance level of p <10–6, assuming a multiplicative model for the effects of alleles 
and perfect correlative linkage disequilibrium between alleles of test markers and 
.......................................disease variants. Figure reproduced from (Wang et al., 2005). 34
Figure 1.2. Summary of Wellcome Trust Case Control Consortium GWAS 
results. Single SNP association significance is plotted on y-axis as -log10 of p-values 
and genomic position along the x-axis. Chromosome position names are shown on the 
x-axis. We have highlighted immune-system regions showing consistent  association 
...across the immune-system related diseases. Figure reproduced from (WTCCC, 2007). 
....................................................................................................................................  35
Figure 1.3. Proposed pipeline to apply Gene-Set Analyses to GWAS. SNP 
summary  statistics are mapped to genes and correction for gene-size biases is applied by 
either phenotype permutations or a statistical method using a measure of the number of 
effective tests. Genes-wide statistics are later mapped to networks and biological 
pathways to test for over-representation of association signals. We have highlighted 
databases and software publicly available to perform different steps of the analysis. For 
...........................................additional details see review by Pedroso and Breen (2009). 49
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Figure 2.1. Comparison of gene-wide p-values calculated with asymptotic and 
MND strategies. Each panel presents ~30,000 points. Axis scales are -log10 of gene p-
............................................................value. Filled line represents the 1-to-1 diagonal. 68
Figure 2.2. Quantile-quantile plots for gene p-values. Axis scales are -log10 of 
gene p-values. Y and x-axis present  the observed and expected quantiles, respectively. 
Filled and dotted line represent the 1-to-1 diagonal and the 95% confidence interval 
.............................................calculated for an assumed a null exponential distribution. 69
Figure 3.1. Correlation between asymptotic and empirical p-values. Trend lines 
were fitted using a linear regression model and the r2 is reported. Panel A; four methods 
implemented in FORGE. Panel B; Eigen value ratio (EVR) method. In panel A blue line 
is equivalent to the diagonal, in panel B we represented the 1-to-1 diagonal with the left 
........................most black line. Note that the scale of the x-axis differs in both panels. 81
Figure 3.2. Correlation between different asymptotic p-values. Trend lines (blue) 
were fitted using a linear regression model and the correlation is reported in the insert 
................................................................................................................................table. 82
Figure 3.3. In silico validation of gene-based associations. The ability of gene-
based analyses to identify true disease loci was benchmarked by: i) assessing how many 
of their significant findings are replicated in other studies; and ii) how many of these 
significant genes were not identified by  using single SNP analyses alone. Venn diagram 
and workflow boxes’ colours represent gene counts and steps, respectively, of the 
different analyses: light green (left) = gene-based association, light  blue (centre) = 
single SNP analyses and purple (right) = benchmark set from NHGRI GWAS 
Catalogue. Results were analysed regarding the proportion genes of the benchmark set 
identified only  by either single SNP analyses or gene-based association (see yellow 
boxes on “In silico benchmark”). In addition we evaluated the use of gene-based 
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association in integrative analyses with the protein-protein interaction network and 
biological pathways (see main text for details). Data presented on Venn diagram are the 
results of the Z FIX method on the WTCCC Crohn’s disease data set. (see Table 3.2, 
..............................................................................Figure 3.4 and main text for details). 84
Figure 3.4. Area under the curve for SNP and gene p-values results 
benchmarked against GWAS Catalogue. Each panel presents the AUC values and 
their 95% confidence interval for one of six GWAS. Results from single SNP and gene-
wide association methods are colour coded as indicated on the legend. Vertical dashed 
lines mark a p-value of 5 x 10-8 and the gene-wide p-value equivalent to a FDR = 0.1 
for each method (see colour code in legend). Horizontal dashed line marks the AUC = 
0.5, which marks what would be expected by chance. CD = Crohn’s disease, T1D = 
type 1 diabetes, T2D = type 2 diabetes, RA = rheumatoid arthritis, BD = bipolar 
disorder and CAD = coronary  artery  disease. Please note for the panel of the CD data 
that the line of the SIDAK and minimum p-value methods overlap  completely. To 
......................improve visualisation I set different scales for the x-axis on each panel.. 91
Figure 3.5. Hierarchical clustering of diseases and gene-sets. Clustering was 
performed with the complete linkage method with distances calculated using the 
Euclidean distance between gene-sets z-scores obtained from the association of gene-
sets with diseases. Colour scale represents the significance of the association between a 
gene-set and a disease, red=strong association and light-yellow=weak association. Panel 
A and B present clustering results from 3183 and 15 gene-sets that were nominally 
significant (uncorrected p  < 0.05) and significant at an FDR < 0.5 in at least  one 
.......................................................................................................disease, respectively. 97
Figure 3.6. Comparison of fix and random-effects estimates. Plotted for each 
gene (N ~20,000) is the log10 of the ratio of fix and random-effects gene p-values. 
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Insert (top right corner) presents data for the whole range of observed effective number 
of tests and main panel presents data on the range of effective number of tests where 
most differences between the two gene-wide p-value are seen. Points are coloured (see 
figure legend) by the gene’s statistical heterogeneity measure I2, which has range from 0 
..........(no evidence of heterogeneity) to 100% (maximum evidence of heterogeneity). 97
Figure 4.1. Data analysis strategy. Gene-wide p-values for association with BD 
were calculated on four GWAS and 2 gene-expression studies. Gene-wide results were 
mapped to the PPIN and a greedy search strategy (Ideker et al., 2002) was used to 
identify subnetworks of interacting proteins enriched with BD association signals. A 
meta-analysis of the GWAS gene-wide association p-values and PPIN subnetworks 
results was carried out. GWAS PPIN results were combined with gene-expression 
subnetwork results and significant subnetworks were characterised with regard to their 
biological functions and locus heterogeneity. Colour codes are: Grey  = statistical/
bioinformatic analyses, yellow = final results, blue = GWAS data and green = gene-
expression data. DLPFC: doroslateral prefrontal cortex and OFC = orbitofrontal cortex 
.............................................................................................................................tissue. 112
Figure 4.2. Significant network from PPIN-wide search and CGNet analysis. 
Blue nodes had a p-value < 0.05 in at least one study of the GWAS. Grey node had p-
values > 0.05 in all studies. A) PPIN-1576 sub-network found by PPIN-wide search and 
................B) CACNA1C sub-networks merged. CACNA1C is highlighted in yellow. 117
Figure 4.3. Gene-wide p-values for PPIN-1576. Plotted are -log10 gene-wide p-
values on the y-axis for each gene within PPIN-1576. Different  studies have been 
coloured as indicated in the legend and their bar plots were stacked to avoid over-
plotting and allow comparison. The main figure presents data for genes with p-values < 
0.05 in at least one study GWAS or the gene-expression DLPFC. Insert (top right) 
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presents the same information for all genes regarding of their p-value. Dashed line 
...........................................................................................marks -log10 equal to 0.05. 119
Figure 5.1. Association at 21q22.1. -log10 of the association p-values under an 
additive model are shown in the y-axis. Blue line represents the recombination rate in 
cM/Mb and the r2 between SNPs and rs4818065 is shown as red scale. Genes are 
..................depicted as green lines and chromosomal position indicated in the x-axis. 139
Figure 5.2. Association at 3p21.31. -log10 of the association p-values under an 
additive model are shown in the y-axis. The blue line represents the recombination rate 
in cM/Mb and r2 between SNPs and rs2352974 is shown as red scale. Genes are 
..................depicted as green lines and chromosomal position indicated in the x-axis. 140
Figure 5.3. Association at CBLN1 locus. -log10 of the association p-values under an 
additive model is shown in the y-axis. The blue line represents the recombination rate in 
cM/Mb and r2 between SNPs and the minimum p-values in the region (given in the 
panel title) is shown as red scale (see Figure legend). Genes are depicted as green lines 
and chromosomal position is indicated on the x-axis. A) Figure including SNPs used in 
the gene based analysis (20 kb around the gene) and B) SNPs up to 500 kb around the 
..............................................................................................................................gene. 142
Figure 5.4. Association of genes with FDR < 0.2 in different BD sub-phenotypes. 
Cells are coloured by -log10 of the gene p-value with more intense tones representing 
..................................................................................................................larger values. 143
Figure 5.5. Effect of analysis parameters on association of GABA(A) genes and 
SABP. -log10 of the association p-value is shown in the y-axis and x-axis shows the 
maximum number of SNPs included in the association SNP-set. Note that along the x-
axis we have plotted only the values used in our analysis and not a continuous range. 
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Different combinations of p-value and r2 thresholds were used the figure legend 
....................................................................................................indicates their coding. 145
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Table 1.1. Tools to explore GWAS  using GSA. We present a list of resources to 
...........................obtain gene-set definitions and software to perform GSA on GWAS.. 44
Table 1.2: Reports of GSA of GWAS. BD = bipolar disorder, CD = crohn’s disease, 
CAD = coronary artery disease, T2D = type 2 diabetes, HT = hypertension, T1D = type 
1 diabetes, CSB= cigarette smoking behaviours, PD = Parkinson’s disease, RA = 
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the additional sensitivity  to possible confounders of the gene-wide association methods.
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Table 3.2. Overlap recombination intervals with significant SNP or genes among 
replicated genes. Gene counts correspond to the number of recombination intervals, as 
defined by  the HapMap project phase 2, with genes highlighted by single SNP analysis 
or gene-based methods. Within parentheses is the number of genes indexed in the 
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values are calculated with the binomial distribution. CD = Crohn’s disease, T1D = type 
1 diabetes, T2D = type 2 diabetes, RA = rheumatoid arthritis, BD = Bipolar Disorder, 
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replicated genes are genes mapped to SNPs reported in the NHGRI GWAS Catalogue 
reaching p-value = 5 x 10-8 (see Material and Method for details), excluding findings 
reported in (WTCCC, 2007). CAD = coronary artery disease, CD = Crohn’s disease, 
HT = hypertension, RA = rheumatoid arthritis, T1D = type 1 diabetes, T2D = type 2 
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total number of replicated genes. See Methods in main text for more details. CAD = 
coronary  artery disease, CD = Crohn’s disease, HT = hypertension, RA = rheumatoid 
....arthritis, T1D = type 1 diabetes, T2D = type 2 diabetes and BD = Bipolar Disorder. 89
Table 3.7. Overlap between recombination intervals with significant SNPs or 
genes among replicated loci. Gene counts correspond to the number of recombination 
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SNP analyses or gene-based methods. Within parentheses is the number of genes 
indexed in the NIHGRI GWAS Catalogue for that disorder (Hindorff et al., 2009). 
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among replicated loci after excluding significant SNPs. Gene counts correspond to 
the number of recombination intervals, as defined by the HapMap project phase 2, with 
genes highlighted by gene-based methods after excluding genes with SNP p-values < 
5x10-8. Within parentheses is the number of genes indexed in the NIHGRI GWAS 
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Catalogue for that disorder (Hindorff et al., 2009). Enrichment p-values are calculated 
with the binomial distribution. CD = Crohn’s disease, T1D = type 1 diabetes, T2D = 
type 2 diabetes, RA = rheumatoid arthritis, BD = Bipolar Disorder, CAD = coronary 
............................................................................artery disease and HT = hypertension. 94
Additional Table 3.1. Gene-Set Analysis with gene-wide p-values in the WTCCC 
phase 1 study. Gene-sets from Gene Ontology  Database (www.geneontology.org) are 
described with the database’s description. Gene-sets derived from the protein-protein 
interaction (PPI) network were characterised using GeneGO MetaCore database and we 
report the three best biological categories and the over-representation p-value 
(calculated using the hypergeometric distribution). CD = Crohn’s disease, HT = 
..........................hypertension, RA = rheumatoid arthritis and T1D = type 1 diabetes.. 102
Table 4.1: Gene-based meta-analysis of bipolar disorder GWAS. Table reports 
statistics for genes reaching FDR < 0.2 in the gene-based GWAS meta-analysis. For 
each GWAS dataset  we report z-scores obtained from the gene p-values using the 
normal distribution inverse cumulative distribution function. For the meta-analysis of 
GWAS results we report the pooled z-scores estimate (ZGWAS) and the FDR value for 
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Genetic mapping can be defined as the identification of correlations between genetic 
variants and phenotypes (Altshuler et al., 2008). Its simplest form was introduced by 
Sturtevant for fruit flies in 1913. However, it  was not until the 1980s that its application 
to human diseases became common and not until the last 6 years that it became 
widespread. We are currently at  the middle of extraordinary  growth in the data 
describing human genetic variation and its correlation with multiple phenotypes. 
Until recently, genetic mapping of human diseases, especially for complex traits, was 
a fierce battle of ideas and theoretical models often with little or no empirical data, 
simply  because the technology  to collect the data was not available. This changed with 
the development of enabling technologies, such as high density  oligonucleotide arrays 
and high throughput sequencing, allowing an international consortium of geneticists to 
develop a foundational resource called the HapMap (described in section 1.1.3). The 
HapMap project enabled the development of a new generation of genetic studies. After 
the resulting first wave of large scale studies, new questions have emerged while old 
ones have been reformulated and the theoretical models underlying much of our 
analysis have been challenged and greatly enriched. 
1.1.1. Sweet and sour: From Mendelian to complex diseases
Initially, genetic mapping of human diseases was impeded by human’s relatively 
small family  size, their mating (which cannot be experimentally controlled) and the few 
classical genetic markers available to trace inheritance patterns (Lander and Schork, 
1994). Development of linkage maps in the 1980s and 1990s provided the genetic 
markers to systematically study families and identify genomic regions associated with 
human diseases (Altshuler et al., 2008). These regions were usually followed up by 
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cloning and sequencing to identify the causal mutations and the affected gene in a 
process termed Reverse Genetics, the most well known example of which is the 
localisation of the CFTR gene as a cause of cystic fibrosis (Kerem et al., 1989; Collins, 
1995). The approach led to a rapid increase in the number of human Mendelian 
disorders mapped to specific loci, from ~100 by the late 80s to >2000 today 
(www.ncbi.nlm.nih.gov/Omim).
Soon researchers aimed to disentangle the genetic basis of complex traits. The most 
common and chronic human diseases are complex traits, many of which present 
significant familial clustering and heritability and yet  have no clearly  discernible 
Mendelian inheritance pattern (Lander and Schork, 1994). Linkage mapping in complex 
disorders resulted in mixed results. Success was found with Mendelian-subtypes of 
complex traits, e.g., in breast cancer (Welcsh and King, 2001), hypertension (Lifton, 
2004), and diabetes (Bell and Polonsky, 2001), but these variants were mostly  rare and 
explained only a small proportion of the population risk 1 . In common forms of the 
diseases, linkage results provided poorly  replicated results and it  gradually emerged that 
complex traits were not driven by one or several genes of major effect  but instead were 
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1 A commonly used method to calculate the additive genetic variance attributable to a 
genetic variant is described in Risch (2000). Briefly, for continuously measurable traits, 
we consider a single locus L with two variant alleles A and a with population 
frequencies p  and q = 1 – p, respectively. We first defined two parameters. 
Displacement (t) is the number of standard deviations difference between the mean 
values of the two homozygotes AA and aa (assuming equal variance within each 
genotype). The second parameter, d, represents the mean value of heterozygotes Aa 
relative to the two homozygotes: d = 1 corresponds to equal means for genotypes AA 
and Aa (that is, A is dominant), d = 0 corresponds to equal means for genotypes Aa and 
aa (that is, A is recessive) and d = 0.5 corresponds to the additive situation. Then the 
population variance attributable to segregation of the alleles is given by VG(L) = VA(L) 
+ VD(L), where VA(L) = 2pqt2(p(1 – d)+qd)2 is the ‘additive’ genetic variance and VD
(L) = p2q2t2(d – 0.5)2 is the ‘dominance’ genetic variance. The proportion of total 
variance attributable to locus A, which we denote as h2(L), is then given by VG(L)/(1 + 
VG(L)), assuming the variance within genotype to be 1.0. The formulas for the 
dichotomous case are analogous but we replace t by the genotypic risk ratio (GRR).
likely to driven by polygenic risk resulting from the cumulative contribution of many 
risk loci throughout the genome (Altshuler et al., 2008). 
1.1.2. The common disease-common variant model
In 1996, Risch and Merikangas proposed that association studies, using a case-
control or sib-pair design, should supersede linkage studies in the search for risk alleles 
of complex traits. The argument was relatively straightforward: linkage and association 
have good statistical power to detect different kinds of diseases-susceptibility  alleles. 
Linkage provides good power to pick loci harbouring one or multiple common or rare 
alleles with large effects but is not well suited to the identification of alleles with low 
effect-sizes. Association studies are more suited to the identification of risk alleles that 
are of intermediate frequency. However, there was an additional proposal in this model: 
“Despite the small effect size of common alleles the magnitude of their attributable risk 
(the proportion of people affected due to them) may be large because they are quite 
frequent in the population, making them of public health significance...” (Risch and 
Merikangas, 1996). This argument forms the basis of the so called common disease-
common variant (CDCV) hypothesis, also proposed by others (Lander, 1996; Cargill et 
al., 1999; Chakravarti, 1999). The opposite model proposes that common diseases can 
be genetically underpinned by multiple rare variants each explaining a small fraction of 
the population risk, known as the common disease-rare variant (CDRV) hypothesis. In 
this model, it is possible that initial linkage studies did not find more loci simply 
because they had a small effect size but it argues that  these could still be rare (<1% 
frequency) and would be picked up by  larger linkage but not association studies. The 
genetic architecture of most traits likely lies in between the two extreme models and 
variants across the frequency and effect size range will be associated with human 
complex traits (Altshuler et al., 2008).
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The CDCV strategy  fits better in a simple model conceiving a single risk variant per 
loci. If there are 2 or more independent susceptibility variants within the same locus 
(allelic heterogeneity) or genetic risk is spread across multiple locus (locus 
heterogeneity), association studies have less power (Terwilliger and Weiss, 1998; 
Pritchard, 2001). There is empirical and theoretical evidence supporting the presence of 
allelic and locus heterogeneity for alleles associated with human diseases at low 
frequency and intermediate to large effect sizes (Lander and Schork, 1994; Terwilliger 
and Weiss, 1998; Pritchard, 2001; Eyre-Walker, 2010).
After Risch and Merikangas (1996), it  would take almost another decade until the 
CDCV hypothesis could be tested extensively because it demanded the generation of an 
unprecedented volume of data and new technological advances. The advent of this 
technology has also allowed further exploration of the CDRV hypothesis but not as 
thoroughly. Both models will be tested more comprehensively in the coming years.
1.1.3. Construction of public resources to analyse human genetic 
variation
A major limitation for large association studies was the lack of a comprehensive map 
of genetic variants across the human genome. The SNP Consortium was launched at the 
end of the 1990s and generated an initial map of 1.4 million single nucleotide 
polymorphisms (SNPs)2  by 2001 (Sachidanandam et al., 2001). The International 
HapMap Project was launched in 2002, with the goal of characterising SNP frequencies 
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2 Single nucleotide polymorphisms constitute the most common genetic variation across 
the human genome and represent position. They  are classically defined as genomic 
positions where more than one allele is present in the population. SNPs are usually  bi-
allelic but tri-allelic are also found (Huebner et al., 2007). Although deletions or 
insertions of a single nucleotide may also be considered SNPs, they are usually not.
and linkage disequilibrium (LD)3  patterns across the human genome in 270 samples 
from Europe, Asia, and West Africa. The project genotyped ~1 million SNPs by 2005 
(International HapMap Consortium, 2005) and more than 3 million by 2007 (Frazer et 
al., 2007). In a subsequent phase more than 1 million polymorphic sites, including many 
rare and copy number variants, were genotyped in a larger panel of 1184 individuals 
(Altshuler et al., 2010). It was also found that, association studies would need to test 
every  variant in the genome, but because genetic variants are correlated due to 
recombination patterns, a sub-set  of markers could suffice to capture most of the genetic 
information of common variants (Gabriel et al., 2002; International HapMap 
Consortium, 2005). Thus it became feasible to perform genome-wide association testing 
using an informative sub-set of common variants to detect association with complex 
traits. This model has been severely criticised because correlations between genetic 
variants may not always provide as much information on disease susceptibility  as 
originally  proposed, simply because the assumptions built into these models do not 
always hold, e.g. multiplicativity of correlations (Terwilliger and Hiekkalinna, 2006). 
Since the initial HapMap report, the evidence showed that most common SNPs have 
high correlation with nearby  genetic variants and suggested that about half a million 
SNPs would provide coverage for more than 90% of common SNP variation in non-
African populations and that a million SNPs would provide the same level of coverage 
for African populations (International HapMap Consortium, 2005).
This fundamental data set became the basis for the development of a range of 
competing high-throughput  microarray  genotyping technologies, which made dense 
genome-wide analysis of large sample sets possible. SNP genotyping was initially 
CHAPTER I INTRODUCTION
32
3 Linkage disequilibrium is a measure of the correlation between alleles at two loci. Its 
calculation is not equal but numerically it is equivalent to the Pearson’s correlation 
between the alleles counts (Devlin and Risch, 1995).
performed one SNP at a time, at a cost of ~$1 per measurement. Multiplex genotyping 
of hundreds of SNPs on DNA microarrays was demonstrated in the late 1990s (Wang et 
al., 1998), and capacity per array grew from 10,000 to 100,000 SNPs in 2002 and from 
500,000 to 1 million SNPs by 2007. In parallel, cost fell to $0.001 per genotype, or less 
than $1000 per sample for a whole-genome analysis. By 2006, multiple technological 
platforms could genotype hundreds of thousands of SNPs at high levels of completeness 
and accuracy (for details see Altshuler et al. (2008) and references therein). 
In 2007, the 1000 genomes project (www.1000genomes.org) was launched to 
discover and describe haplotype information for all types of DNA polymorphisms in 
multiple human populations. Specifically, its goal was to characterise over 95% of 
variants that are in genomic regions accessible to second-generation sequencing 
technologies and have an allele frequency of 1% or higher in five human population 
groups (Durbin et al., 2010). By combining microarray-based genotyping with 
imputation technologies (Marchini and Howie, 2010), geneticists are now able to access 
millions of common genetic variants and many thousands of rare variants for 
association tests (Altshuler et al., 2010). Ongoing projects, such as the UK10K 
(www.uk10k.org), will provide whole genome sequences for thousands of individuals, 
enabling for the first time a systematic analysis of variants across the frequency 
spectrum. However, some variants at the low frequency  extreme (~1/10,000) may  need 
larger cohorts and probably additional pedigree or population information to be called 
or imputed accurately; for examples see (Kong et al., 2008; Stefansson et al., 2008).
1.1.4. Genome-wide association studies
Genome-wide association studies systematically analyse genetic variation across the 
genome to study its effects on phenotypic change. Their success can be determined by 
factors like sample size, genotyping quality and coverage of genetic variants (Wang et 
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al., 2005). Initial studies had modest sample sizes of several thousands of individuals 
and generally had sufficient power only  for allelic odd-ratios > 1.5 and incomplete 
coverage of common genetic variants (Figure 1.1) (Wang et al., 2005).
The early  landmark study using these technologies was the Wellcome Trust Case 
Control Consortium (WTCCC), which reported genetic mapping results for over 
500,000 SNPs in 7 disease sample sets of ~2000 individuals each and ~3000 control 
individuals (WTCCC, 2007). Several of the diseases studied by the WTCCC had 
notable results. For example, known disease susceptibility loci were supported, e.g., 
SNPs within NOD2 in Crohn’s disease and the human leukocyte antigen (HLA) loci at 
chromosome six in immune-system related disease (Figure 1.2), and new loci were 
highlighted at high significance levels (WTCCC, 2007). The WTCCC established its 
significance threshold for multiple testing correction at 7.5 x 10-7 by  assuming the 
number of risk variants at ~10 and 
a statistical power of ~50% 
(WTCCC, 2007) . Current ly, 
genome-wide significance level is 
widely  regarded as 5 x 10-8 as 
proposed by Dudbridge and 
Gusnanto (2008). Thus, some of the 
WTCCC results would currently 
only  be considered as having 
s u g g e s t i v e s i g n i f i c a n c e 
(approximate p-value = 0.5/(# 
tests)).
An important result of the WTCCC 
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Figure 1.1. Effects of allele frequency and 
effect-size on sample-size requirements. The 
numbers of cases and controls that  are required in 
an association study to detect disease variants 
with allelic odds ratios of 1.2 (red), 1.3 (blue), 
1.5 (yellow) and 2 (black) are shown. Numbers 
shown are for a statistical power of 80% at  a 
significance level of p <10–6, assuming a 
multiplicative model for the effects of alleles and 
perfect correlative linkage disequilibrium 
between alleles of test markers and disease 
variants. Figure reproduced from (Wang et al., 
2005).
study was to show that common risk variants with large effect-sizes (>2) were unlikely 
to exist  for complex diseases, in agreement with linkage studies. Therefore, larger 
sample sizes would be needed to establish compelling evidence of association with 
alleles of low effect size. For example, it took another 2 years to pool together sample 
sizes in the order of tens of thousands of individuals to robustly identify hypertension 
risk alleles with odd-ratios around 1.1 to 1.2 (Levy et al., 2009; Padmanabhan et al., 
2010). Few (if any) single research centres can undertake such a study on their own and 
international collaborations are usually  set up to coordinate these large meta-analyses. 
These efforts confirmed that replication in several independent studies is crucial to 
identify alleles of low effect  size and overcome potential false positives, e.g. due to 
biases of individual studies or the winner’s curse effect (Frayling et al., 2007; Yu et al., 
2007; Zollner and Pritchard, 2007; Kraft et  al., 2009; Lehrer, 2010). Increasing sample 
size has recently led to GWAS of very large size, e.g., with more than 50,000 for 
Crohn’s disease (Franke et al., 2010), 100,000 for blood lipid levels (Teslovich et  al., 
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Figure 1.2. Summary of 
Wellcome Trust Case 
Control Consortium 
GWAS results. Single 
S N P a s s o c i a t i o n 
significance is plotted on 
y-axis as -log10 of p-
values and genomic 
position along the x-axis. 
Chromosome position 
names are shown on the 
x - a x i s . W e h a v e 
highlighted immune-
system regions showing 
consistent association 
across the immune-
system related diseases. 
Figure reproduced from 
(WTCCC, 2007).
2010) and 200,000 samples for body mass index (Speliotes et  al., 2010). These efforts 
have identified many genetic variants associated with diverse human traits, robustly 
implicating common genetic variants in the aetiology  of common human diseases. The 
reader is referred to the NIHGRI Catalog of Published GWAS for a compendium of 
published studies (www.genome.gov/gwastudies). Interestingly, as happened with low 
frequency variants discovered by  linkage and positional cloning, researchers were 
puzzled by the fact that common variants reaching significance in GWAS explained 
only a small proportion of the estimated additive genetic contribution of a trait variation 
(Manolio et al., 2009). However, significant  variants from the latest meta-analysis in 
Crohn's disease explained up to 23% (Franke et al., 2010) of the phenotypic variance 
attributable to genetic variation, for BMI between 6-11% (Speliotes et al., 2010), for 
lipid levels between 25–30% (Speliotes et al., 2010) and, for height, all SNPs 
simultaneously explained up to 45% (Yang et al., 2010a). 
It is likely that by augmenting the sample size, the contribution of common variants 
alone will be better realised. Recent development in statistical technologies have shown 
that a large proportion of the phenotypic variance can be explained by  combining 
additively information on hundred of thousands of genetic variants (first shown by 
Purcell et al., 2009 and more completely analysed and explored in Yang et al., 2010a; 
Lee et al., 2011; Yang et al., 2011). These studies show clearly how many and how 
much genetic variants with statistical associations under the genome-wide significance 
threshold contribute to a trait variation and disease risk. The statistical methods used in 
these studies only provide an overall measure of the heritability  explained by all these 
genetic variants together and additional methods, e.g., those discussed in this thesis, are 
needed to identify their genomic location and biological meaning.
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One significant issue is that most reported significant GWAS results to date are from 
studies in a few traits that have reached large sample sizes, such as Crohn’s disease, 
height, type 2 diabetes and blood lipid levels, and might likely  benefit from additional 
GWAS of common variants, but what does the future hold for studies of phenotypes 
with unsuccessful GWAS?
Until now, GWAS have only provided statistical power to detect high frequency 
disease susceptibility  variants (Figure 1.1 and Wang et  al. (2005)). An exception is some 
disorders that have been analysed for low frequency structural variants, e.g., in 
schizophrenia some variants identified have odds ratios of 3-10 but their frequency 
tends to be <0.1% in the cases and <0.01% in controls (Stefansson et al., 2008). This 
means that diseases with a genetic architecture with a contribution from predominantly 
low frequency alleles (< 1%) will consistently  have poor results in GWAS. For 
example, for psychiatric traits, it has been proposed that rare variants play a 
predominant role because mental illness usually  has an onset  early  in reproductive age 
and is associated with a substantial reproductive disadvantage. Therefore, susceptibility 
variants should be under strong negative selection (Uher, 2009). Although there is 
evidence to sustain this argument (Stefansson et al., 2008; Uher, 2009), the picture is 
likely more complicated. GWAS in psychiatric genetics may  offer poor results because 
an important contribution to the genetic aetiology  comes from low frequency  variants 
but, on the other hand, a genome-wide search for rare variants requires substantial 
sample sizes to achieve statistical power. Family linkage studies are aimed at identifying 
these loci but have not  been notably successful at identifying rare variants in fields such 
as neuropsychiatry. This is probably due to issues such as phenotypic heterogeneity, 
incomplete penetrance and disease diagnostic heterogeneity. Furthermore, recent studies 
have shown that  there is a huge amount of rare variation in the human genome and that 
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normal individuals carry about 250 to 300 loss-of-function variants in annotated genes 
and 50 to 100 variants previously implicated in inherited disorders (Durbin et al., 2010). 
So, even if we can afford the large samples sizes that provide statistical power for a rare 
variant search, how are we going to distinguish normal variation from pathogenic or 
pathogenic variation with low penetrance? 
We think that a key problem here is our poor understanding of how genetic variants 
lead to phenotypic change, how they relate, add and interact in a non-linear fashion and 
how to build experimental models leading to the study of these phenomena (Weiss and 
Fullerton, 2000; Weiss and Terwilliger, 2000; Weiss, 2008). Some studies have been 
able to combine risk variants identified by genetic studies in humans with experiments 
aiming to understand their effect on cellular and physiological phenotypes relevant for 
the disease (Badano et al., 2005; Zaghloul and Katsanis, 2010; Davis et  al., 2011). 
Others have, for example, resorted to system genetic analyses to infer the causal effect 
of risk alleles on cellular and physiological pathways that are later the focus of detailed 
research (Chen et al., 2008; Schadt et al., 2009a; Schadt et al., 2009b; Schadt, 2009; 
Webster et al., 2009; Yang et al., 2009; Quigley et al., 2011). The first strategy requires 
good animal models to dissect in detail the link between genotype, biological 
mechanisms and disease risk. Such models are not available for many diseases but when 
available, they  have proven an important complement to genetic mapping in humans 
(Zaghloul and Katsanis, 2010). The ciliopathies are one such case, which have focused 
efforts to assess the effect of risk variants on the function of the cilia (Badano et al., 
2006). Interestingly, the number of proteins in the cilia is ~1000 (Gerdes et al., 2009), 
which is similar to that detected in the neuronal post-synaptic density in human and 
mouse (~1500 proteins (Bayés and Grant, 2009)), suggesting that an experimental 
system to study  the effect of risk variants of mental illness on neurone function may be 
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feasible and would be fruitful. A systems genetic approach requires enough statistical 
power to perform causal modelling and to test  for interaction effects. These types of 
datasets are not abundant yet, but are likely to be become more common and be a 
powerful complement to other genomic technologies, e.g., Webster et al. (2009) and 
Choi et al. (2011) are examples of the application of systems genetic to neuropsychiatric 
disorders.
Undoubtedly, psychiatric genetics would greatly benefit from a strategy 
incorporating both large genetic studies of common and rare variants and adequate 
experimental models targeting discrete biological systems (e.g. post-synaptic density) to 
understand the effect and properties of risk conferred by genetic variants. However, a 
major challenge for the psychiatric genetic field will be to define biological systems or 
functions that are relevant to understand disease aetiology or treatment and that merit 
detailed scientific study. Access to good quality post-mortem brains from psychiatric 
patients is not easy and thus genomic technologies cannot be powerfully leveraged to 
provide biological clues as in other diseases with easier tissue access (e.g. cancers). We 
think that genetics and GWAS have great potential to take on this challenge.
1.2. Challenges of current GWAS
GWAS of neuropsychiatric diseases have provided few robust genetic associations, 
e.g., Ferreira et al. (2008) and Stefansson et  al. (2009). Large odds-ratios for common 
variants are not common and may  not exist in many disorders. In addition, there is 
mounting evidence to suggest that genetic and phenotypic heterogeneity are important 
concerns (for example in bipolar disorder, see (Alda, 1999; Alda, 2004; Schulze et al., 
2009)). Phenotypic heterogeneity may be particularly  problematic in psychiatric 
genetics, where tests for physical symptoms or biomarkers are not available or are 
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poorly defined, and environment is thought to play a key role (Caspi et al., 2003). 
Genetic heterogeneity  is to be expected based on empirical evidence and theoretical 
models (Lander and Schork, 1994; Terwilliger and Weiss, 1998; Pritchard, 2001). 
There has been strong criticism of GWAS due to the low predictive power of 
common risk alleles (e.g., Goldstein (2009)). A notable exception in psychiatric genetics 
is the APOE ɛ-4 allele (Pericak-Vance et al., 1991), which may account for more than 
half the genetic variance in risk for Alzheimer’s disease (AD). Although it was 
discovered by positional cloning of a linkage region in the pre-GWAS era, it is one of 
the few replicated loci for AD in GWAS. Furthermore, its discovery has not so far led 
directly  to new treatments or genetic testing for AD, although it is showing potential to 
influence clinical practice and treatment on the basis of sub-classification of the disease 
into early and late onset forms (Roses et al., 2007). 
It is important to make a distinction between acquiring predictive power and 
increasing biological knowledge. As noted by Altshuler et al. (2008), a good example is 
Brown and Goldstein’s studies of hypercholesterolemia (Brown and Goldstein, 1974a; 
Brown and Goldstein, 1974b), which affects ~0.2% of the population and accounts for a 
tiny  fraction of the heritability of low-density  lipoprotein (LDL) and myocardial 
infarction. Studies of hypercholesterolemia led to the discovery of the LDL receptor and 
supported the development of 3-hydroxy-3-methyl glutaryl–coenzyme A reductase 
(HMGCR) inhibitors (also known as statins) for lowering LDL, the use of which is not 
limited to hypercholesterolemia risk variants carriers. Although SNPs in HMGCR have 
only a small effect (~5%) on LDL levels (Kathiresan et al., 2008; Willer et al., 2008), 
drugs targeting the encoded protein decrease LDL levels by  a much greater extent 
(~30%). This is because the effect of an inherited variant is limited by natural selection 
and pleiotropy, whereas the effect of a drug treatment is not. Thus, the primary objective 
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of GWAS may not be to produce powerful predictors but to reveal clues about the 
biological underpinnings of a disorder which can be gathered to improve treatment and 
diagnosis.
I propose that some of the most important challenges of GWAS concern data 
interpretation and that these will transcend the analysis of both common and rare 
variants. I have formulated my concerns as follows:
i) How to extract biologically  meaningful results from GWAS. After applying 
the stringent statistical thresholds necessary for multiple testing correction, 
there are very few significant variants (often none!) presenting little 
information about the underlying biology of phenotypic variation.
ii) How to identify the many real disease susceptibility  loci that do not reach 
genome-wide significance in individual studies, e.g. PPARG in type 2 diabetes 
(Altshuler et al., 2000). Although combining data sets by meta-analysis has 
been a successful approach, it  faces problems in the presence of genetic 
heterogeneity (and data availability).
iii) How to tackle genetic heterogeneity present as both allelic and locus 
heterogeneity. It  is known that genetic heterogeneity will decrease the power of 
GWAS and methods robust to it are needed to extract information from GWAS. 
An additional challenge is to quantify this genetic heterogeneity.
The many  thousands of marginally significant results could hold the “higher hanging 
fruit” of real associations that fail to reach genome-wide significance. This may be due 
to a lack of power caused by either low allele frequency, effect  size or phenotypic 
heterogeneity. It may prove useful to interpret these genetic associations in the context 
of the genes and biological processes they may  influence, the aim being to identify 
biological processes acting as (subtle) drivers of the cellular and physiological changes 
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that confer disease susceptibility. Therefore, improving interpretation of GWAS and 
helping to increase its power to detect small effect size alleles by clustering them in 
common biological processes may in turn prove a fruitful target to develop new 
treatments (for an example see Fleming et al. (2011)).
1.3. Gene-set and network analyses
GWAS analyses are most commonly performed by  testing the strength of association 
between individual genetic variants and phenotypes. This univariate strategy  has 
parallels with analysis of gene-expression data where the association between each 
probe and the phenotype is tested. We will exploit this similarity  to present gene-set 
analyses (GSA) and network analyses for GWAS. 
In contrast to gene-centric approaches, such as assessing expression differences of 
individual genes or gene products, GSA and network analysis aim to capture the 
collective activity of sets of molecules by testing the group instead of each component 
individually. For example, large expression differences in one molecule provide 
supporting evidence for its perturbed state but little information to answer relevant 
questions like What are the biological processes that explain this large differential 
expression? How do the molecules showing large differences relate to each other? or 
Are there any small expression changes likely to be biologically significant? These are 
some of the questions that GSA aims to address.
There are hundreds of variants of GSA (reviewed in (Nam and Kim, 2008; 
Ackermann and Strimmer, 2009)). All aim to find association with gene-sets rather than 
individual genes. Gene-sets are simply  groups of gene products that have been put 
together using some criteria, e.g., participating in the same biological process or having 
the same sub-cellular localisation. Thus, GSA centres the focus of attention on changes 
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in biological processes. This strategy is supported by the fact that  cellular and 
physiological changes are driven by groups of gene products acting coordinately, e.g., to 
execute cellular functions or process signalling information. Finding an association with 
a biological process can, potentially, help  to infer something about that biological 
process on the condition of interest. For example using evidence from a gene-expression 
study one can suggest that genes of a signalling pathway are up-regulated by 20% in 
cases compared with controls.
Ackermann and Strimmer (2009) analysed 261 different GSA methods and proposed 
a general framework to describe them. An interesting result from their report is that 
most methods, although differing in the statistical methods used, provide very similar 
results. Major differences in sensitivity  were related to differences in relatively  few 
methodological steps, such as summarising the evidence at the gene-set level or the 
choice of the null hypothesis. For example, calculating a simple statistics like the mean 
gene-expression change within a gene-set had more statistical power than complicated 
methods, such as the popular gene-set enrichment analysis (GSEA) (Subramanian et al., 
2005) or Hotelling-type statistics (Kong et al., 2006; Dinu et al., 2007).
Gene-sets (see Table 1.1 for some sources) can be constructed via literature review or 
compilation of results from high throughput experiments and allow the incorporation of 
previous knowledge, such as tissue specific expression profiles or manually curated 
gene-gene interaction information. They allow us to test specific biological hypothesis 
across datasets and methodological techniques (Lehner and Lee, 2008). A drawback of 
GSA is its strong dependence on the availability and quality  of gene-sets. Better 
annotation is expected for well studied processes, for example cancer related pathways, 
compared with biological processes that are difficult  to study or the focus of limited 
research. Manual curation of bionformatic resources is greatly valued and of 
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commercial value, for example see www.genego.com or www.ingenuity.com. 
Unfortunately, manual curation has not scaled up to the speed of data generation by 
newer genomic technologies. Generation of gene-sets from high-throughput 
experiments is currently a challenge (Davies et al., 2010) and how to incorporate the 
uncertainty of each gene-set and experimental source into the GSA is currently  very 
much unexplored.
Much of the information used as input in constructing gene-sets relates to the 
interaction between biological molecules, e.g. phosphorylation or co-expression, which 




















Table 1.1. Tools to explore GWAS using GSA. We present a list of resources to 
obtain gene-set definitions and software to perform GSA on GWAS. 
the interaction information4  and aims to identify groups of interacting gene products 
associated with a phenotype (Ideker and Sharan, 2008). They  are somewhat more 
flexible than GSA because the groups of genes being tested, equivalent to gene-sets, can 
be defined in different ways (for examples see Ideker et al. (2002), Chuang et al. (2007) 
and Dittrich et al. (2008)). Some of the limitations of network analysis are: a) finding 
significant sub-networks is an NP-problem, i.e. execution time scales exponentially and 
usually  computationally intensive algorithms are used, and b) the exponential nature of 
the interaction information makes its acquisition slow and biased against interactions or 
molecules difficult to study, such as transmembrane proteins or interactions involving 
sugars or RNA molecules (see review by Schwartz et al. (2009)). It is possible to 
overcome some of these biases by constructing networks using functional genomics 
data (Lage et al., 2007; Webster et al., 2009; Lage et al., 2010). This strategy  makes 
used of information from different sources, such as gene-expression, proteomics, text 
mining and protein-protein interaction assays. Each of these technologies has its own 
biases. Therefore, it is possible to combine interactions gathered with different 
technological platforms to construct  an integrated network with better coverage and 
more information than any produced with a single experimental source (for examples 
see Lee et al. (2008), Lehner and Lee (2008) and Zhu et al. (2008)).
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4 A gene-set does not provide any  information on how the molecules interact with each 
other whereas in a network the pairwise interactions are explicit. Often, additional 
information is available for these interactions. For example, the network can be 
undirected providing only  information about the pairwise connections or it can be a 
directed network, in which case the interactions have a directionality. Furthermore, each 
interaction can be characterised by  its strength or nature (e.g. phosphorylation in the 
case or kinases or DNA-binding for transcription factors). These information can be 
explicitly integrated into the statistical analyses, e.g., giving more importance to 
molecules with more or stronger connections. We refer the interested reader to an 
introductory book by Newman (2010) and a review article by Ideker and Sharan (2008) 
for additional details. 
Both GSA and network analysis have been successfully used to characterise, 
prioritise and shed new light on the molecular processes underlying phenotypes in 
human and model organisms (Fuller et  al., 2007; Chen et al., 2008; Emilsson et al., 
2008; Ideker and Sharan, 2008; Presson et al., 2008; Zhu et al., 2008). Thus their 
development as a tool to interrogate GWAS is promising. For example, replication of 
results across studies and experimental platforms is often easier at the gene-set  level 
than using individual genes (Chuang et al., 2007; Chen et al., 2008; Emilsson et al., 
2008). GSA and network analyses can help  to reduce multiple testing and facilitate 
follow up studies because often the biological role of a gene-set is better understood that 
that of single genes (Schadt et al., 2009b).
1.4. GSA and network analyses in GWAS
Before commenting on GSA and network analyses in GWAS, I need to point out 
some caveats. GSA was originally developed for and has been extensively applied to 
gene-expression data. In gene-expression data is common to observe high correlation of 
the gene’s expression. This high autocorrelation makes the analysis of gene-sets easier 
because gene expression changes occur in a concerted manner. Furthermore, gene-
expression analyses capture changes that can be the cause or consequence of the 
phenotype (Schadt, 2009) and such changes are often of several orders of magnitude. 
On the other hand, genotype-phenotype correlations of common variants with complex 
traits discovered with GWAS have subtle effect sizes of much smaller magnitude than 
those of gene-expression studies and are not correlated with each other beyond what is 
expected due to local LD. These differences have important practical consequences. 
Whereas a strong GSA finding on a gene-expression study is usually  supported by 
several genes, providing evidence that a significant portion of a biological process has 
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changed. On the other hand, in a GWAS one significant association in the same gene-set 
may not be statistically significant  in GSA but its functional consequences may indeed 
perturb the entire biological process. Although this does not invalidate the application of 
GSA methods, it suggests that  biological processes affected by a single SNP will not be 
found by  GSA of GWAS. This is an important aspect to consider when interpreting the 
results of this thesis. On the other hand, significant association in a GSA or network 
analysis of GWAS provides strong evidence for the biological processes contributing to 
phenotype variation because each of the signals is independent from each other (in as 
far as the genetic variants are not in LD), i.e. each represents additional evidence and 
they are not a consequence of the phenotype.
There is a theoretical background as well as empirical evidence supporting the use of 
gene-set methods in GWAS (Gibson, 2009; Wang et  al., 2010). The main arguments 
being: a) the underlying cause of phenotypic variability are changes in biological 
processes at the cellular and organismal level; b) perturbations can arise from any 
element acting on these process; and c) many alleles with small affect size will explain 
phenotypic variation of complex traits. Wang et  al. (2007) introduced GSA to GWAS 
with an implementation of the GSEA algorithm (Subramanian et al., 2005). Since then, 
there has been an increasing number of studies applying or proposing new GSA and 
network methods for GWAS, witnessing the interest of the field for their development. 
Published articles range from the application of gene-expression analysis techniques to 
new approaches exploiting additional information for genetic mapping, such as genetic 
interactions or integration with functional data like gene-expression. Table 1.2 provides 
a representative list of publications using GSA and network analyses in GWAS. Figure 






Reference Phenotype Method Software
Wang et al., 2007 PD, AMD GSEA GenGen Package
Inada et al., 2008 TD Fisher exact test Ingenuity Pathway 
Analysis
Lesnick et al., 2007 PD Regression methods
Iossifov et al., 2008 BD, SZC, AU Gene mixture 
generative model
Walsh et al., 2008 SZC Fisher exact test Ingenuity Pathway 
Analysis
Craddock et al., 2010 SABP mean chi-square Manually curated
Breuer et al., 2010 SABP mean chi-square Manually curated
Holden et al., 2008 GSEA-SNP GSEA-SNP
Torkamani et al., 2008
 BD, CD, CAD, 
T2D, T1D, RA, 
HT
Hypergeometric test MetaCore
Srinivasan et al., 2009 PD Boosted decision 
trees
Wang et al., 2009 CD GSEA GenGen Package
Perry et al., 2009 T2D GSEA GenGen Package








Chen et al., 2009 BD, CD, CAD, 
T2D, HT
Pathway total risk 
estimation




Baranzini et al., 2009 MS Network analysis jActive Modules
Peng et al., 2010
BD, CD, CAD, 
T2D, HT, PD, 
AREDS, ALS
multivariate method
Luo et al., 2010 RA multivariate method
Table 1.2: Reports of GSA of GWAS. BD = bipolar disorder, CD = crohn’s disease, 
CAD = coronary artery disease, T2D = type 2 diabetes, HT = hypertension, T1D = type 
1 diabetes, CSB= cigarette smoking behaviours, PD = Parkinson’s disease, RA = 
rheumatoid arthritis, SZC = schizophrenia, AU = autism, TD = treatment-resistant 
tarditive dyskinesia, AMD = age-related macular degeneration, SABP = schizoaffective 
bipolar disorder sub type, AREDS = age-related eye disease, ALS = amyotrophic lateral 
sclerosis.
Probably the most relevant methodological finding to date has been the ability of 
GSA to provide successful replication at the pathway level in the presence of allelic and 
locus heterogeneity (Baranzini et al., 2009; Wang et al., 2009; Luo et al., 2010; Peng et 
al., 2010). These examples open the door for the application of GSA in large scale 
studies, which in the long term will offer the evidence to judge the relative contribution 
of GSA to genetic mapping studies. 
In the psychiatric genetics field, several reports have found significant association 
with biological processes using GWAS. Analysis of the WTCCC bipolar disorder 
GWAS and its meta-analysis with another GWAS provided evidence of association 
within biological processes involved in the modulation of transcription and cellular 
activity, including that of hormone action and adherens junctions (Baranzini et  al., 2009; 
Holmans et al., 2009; O'Dushlaine et al., 2011). Craddock et al. (2010) observed a 
strong enrichment for associations within the GABRB1 genes in patients diagnosed 
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Figure 1.3. Proposed pipeline to apply Gene-Set Analyses to GWAS. SNP summary 
statistics are mapped to genes and correction for gene-size biases is applied by either 
phenotype permutations or a statistical method using a measure of the number of 
effective tests. Genes-wide statistics are later mapped to networks and biological 
pathways to test for over-representation of association signals. We have highlighted 
databases and software publicly available to perform different steps of the analysis. For 
additional details see review by Pedroso and Breen (2009).
Map SNPs to Genes
Association testing
Test for enrichment with 
significant genes, e.g., 
contingency table
Enrichment using all results, 
e.g, mean statistic of genes 
within v/s outside of gene-set
Uncorrected gene p-values 
Permutation of phenotype values 
using individual level data
Gene or SNP re-sampling to derive 
distribution of statistic on the null 
(need to account for correlations 
between SNPs and genes) or 
asymptotic significance
~20 kb each side and in LD with 
functional variation
Include functional evidence (eQTL)
Haplotype Blocks
Number of effective tests
Visualization
e.g. Cytoscape, Vizant, GenMAPP
Gene-Set and Network Analysis
BioMart, Galaxy, Ensembl API, Tamal, 
GenGen Package annotation
Corrected p-values 
Gene-sets definitions: KEGG, BioCarta, GO
e.g. Fisher exact test, hypergeometric 
test, permutation of gene across gene sets
e.g. SNP SET analysis on PLINK
with the subtype schizoaffective bipolar disorder type (SABP). Associations with SNPs 
within the genes GABRA4, GABRB3, GABRA5 and GABRR1, all subunits of the 
GABRA A receptor, providing a system wide association p-value = 7 x 10-5. Recently, 
Breuer et al. (2010) successfully replicated the association between GABRA A receptor 
genes and SABP (p-value = 0.003). However, as we will see in Chapter V, these two 
associations with the GABRA A receptor genes may not be as clear as they currently 
look. O'Dushlaine et al. (2011) found replicated association with five gene-sets in two 
large schizophrenia studies. One of these gene-sets, cell adhesion molecules (hsa04514), 
was also associated with bipolar disorder. Baranzini et al. (2009) overlaid results of 
eleven GWAS of 9 diseases in a protein-protein interaction network to find network 
modules associated with one or more disorders. They found that in general, each 
disorder is represented by a distinctive group  of modules but  some modules are shared 
across disorders, such as modules associated with HLA gene products across 
autoimmune disorders or modules shared between central nervous system disorders like 
bipolar disorder, Alzheimer’s disease and multiple sclerosis. This suggests that common 
genetic variation can be used not only to reveal associations with network modules but 
also to explore the molecular basis of similar, and often comorbid, disorders.
However, caution is required when interpreting reports of GSA of GWAS. For 
example, some authors do not control for the number of variants tested within a gene-set 
and a large number of false positives may be observed in GSA simply  because some 
gene-sets have more or larger genes (Elbers et al., 2009; Jia et al., 2010). During my 
literature review, I noted several of these cases, suggesting that some results may be the 
product of the gene-set size bias; examples are  Torkamani et al. (2008), Walsh et al. 
(2008) and Askland et al. (2009).
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1.5. Objectives of this thesis
GSA and network analysis are proving to be a good complement to conventional 
approaches for the analysis of GWAS. There are several areas in which methods can be 
developed in order to extract the most from their results. For example, most studies 
have used the minimum p-value in the gene to represent association. However, recent 
evidence suggests that allelic heterogeneity  in studies of genetic association with 
common alleles may be more common than expected, for example (Schulze et al., 2009; 
Lango Allen et al., 2010). A sensible strategy might therefore be to combine the effect 
of multiple variants at the gene and pathway level. In addition, by combining 
information from multiple SNPs it is possible to improve the information capture of 
poorly tagged variants (Chapman and Whittaker, 2008). To this end it may be crucial to 
integrate information on the predicted functionality of genetic variants in order to find 
biologically relevant  signals. As more functional information for the human genome is 
accumulated, this avenue may be useful to prioritise and understand the effect of the 
identified variations (Curtis et al., 2007; Eskin, 2008). 
Methods to mine GWAS in a systems biology approach may potentially uncover 
findings of potential relevance to understand the genetic nature of phenotypic variation. 
Integration with functional genomic data will be crucial to identify  key biological 
molecules to monitor and manipulate biological processes to improve drug efficacy and 
disease diagnosis and treatment. Although there have been significant advances in this 
direction (Schadt et al., 2009b; Yang et al., 2009), this is still an open field. Additional 
development of data mining and statistical methods is required to integrate and 




This PhD project started soon after the WTCCC publication (WTCCC, 2007), during 
the first  wave of GWAS, when most efforts were focused on increasing statistical 
power, e.g., by increasing the sample size or imputation to increase genomic coverage 
(Marchini et al., 2007). I decided to focus on improving interpretation of GWAS by 
incorporating independent biological knowledge, such as information of gene function 
and biological processes. The aims of the thesis were to: 
i) Develop, implement and provide the wider scientific community with software 
tools to perform gene-set and network analyses of GWAS. Chapter II;
ii) Assess the ability of these methods to find and replicate genetic association. 
Chapter III and IV;
iii) Evaluate the feasibility  of GWAS for data integration with other genomic 
datasets in a systems biology framework. Chapter IV and V; and 
iv) Provide association evidence for genes and biological processes to help  the 
wider scientific community to define biological systems which merit additional 





A software suite to perform gene-
based and gene-set analyses of 
Genome-Wide Association Studies
2.
Adapted from: Inti Pedroso, Michael R. Barnes, Anbarasu Lourdusamy, Ammar Al-
Chalabi and Gerome Breen. FORGE: a software suite to perform gene-based and gene-
set analyses of Genome-Wide Association Studies. In preparation.
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2.1. Introduction
Genome-Wide Association Studies (GWAS) have led to the discovery  of many 
replicated variants associated with diverse human phenotypes (Hindorff et  al., 2009). 
However, most GWAS have low statistical power to detect true effects due to low 
effect-sizes and the need for stringent genome-wide significance thresholds to correct 
for multiple testing, e.g., 5 x 10-8 (Dudbridge and Gusnanto, 2008). Multivariate 
analyses considering a group of genetic markers across a genomic region can potentially 
increase statistical power by  a) improving tagging of a single causal variant by 
combining information from several SNPs and enabling the capture of more information 
than any single SNP alone, b) combining information from unlinked alleles potentially 
associated with the phenotype, c) generating fewer tests genome-wide and d) generating 
gene p-values for system biology  and integrative analyses (Neale and Sham, 2004; 
Chapman and Whittaker, 2008; Pedroso and Breen, 2009; Wang et al., 2010). Currently 
a major limitation to their application is the lack of software implementing available 
gene-wide association methods to make them more accessible to the wider community, 
e.g., methods proposed by Galwey et al. (2009) and Luo et al. (2010).
FORGE is a software suite implementing different methods to perform region-wide, 
gene-wide and gene-set association with GWAS summary results. The software offers 
the possibility  to calculate significance with asymptotic approximations or by 
simulation using a multivariate normal distribution approximation. In Section 2 (below) 
the association methods implemented in FORGE are described, example data are then 
used to highlight some of the features of the software suite.
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2.2. Gene-based analyses of GWAS
There is increasing interest in the application of gene-based association methods to 
GWAS. This strategy can potentially allow for genetic heterogeneity and provide gene 
level statistics that can be used for meta-analysis or systems biology approaches 
(Pedroso, 2010). Gene-wide analyses of GWAS have used methods that generate a 
corrected minimum p-value per gene or methods that combine association statistics 
across genetic variants within a gene. The minimum p-value per gene has been used 
with correction for the number of SNPs or, more accurately, the number of effective or 
independent tests per gene by application of Sidak’s correction (Sidak, 1971) or 
Simers’ correction (Simers, 1986). To combine association statistics from several loci 
across a genomic region authors have used statistical methods such as rank tests (Yu et 
al., 2009), truncated products (Moskvina et al., 2008) and multivariate tests (Wessel and 
Schork, 2006; Chapman and Whittaker, 2008; Galwey, 2009; Lin and Schaid, 2009). 
Each strategy has its merits. For example, correcting the minimum p-value is likely  to 
be a better choice when there is one well tagged causal variant within a gene but  it  may 
underestimate evidence in the presence of multiple causal variants or a single causal 
variant weakly tagged by several markers (Chapman and Whittaker, 2008).
Linkage Disequilibrium (LD) among genetic variants introduces correlation between 
their association statistics and makes the distribution of the gene-wide statistic under the 
null hypothesis of no association with the phenotype difficult to estimate 
asymptotically. Therefore, calculation of the significance of gene-wide statistics 
requires either estimation of the number of effective tests (which is usually less than the 
number of polymorphisms tested) within the gene, permutations to estimate significance 
empirically  or simulations strategies, e.g., the method of Liu et  al. (2010) described later 
in this chapter. Empirical estimation of significance, via permutations, is the “gold-
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standard” approach but for tens of thousands of genes and increasingly  large GWAS 
datasets imposes a large computational burden, and are practically unfeasible for most 
researchers. Permutation also requires access to raw rather than summary data. There is 
a need for fast gene-wide association methods that provide both accuracy similar to 
empirical estimates and which can be computed from SNP level summary statistics or 
raw data. Several authors have addressed this, proposing statistics to calculate the 
number of effective tests for groups of genetic variants (Nyholt, 2004; Li and Ji, 2005; 
Galwey, 2009), allowing fast calculation of gene-wide p-values. The method proposed 
by Galwey (2009) was and improvement on that of (Nyholt, 2004; Li and Ji, 2005) but, 
as I will show in Chapter III, gene p-values calculated with this method do not correlate 
well with empirical estimates. Recently, Liu et al. (2010) introduced a sampling-based 
estimation of significance for gene-wide statistics. The method models the individual 
SNP statistics within a gene using a multivariate normal distribution (MND) with a 
covariance matrix defined by the correlation between these SNPs. This strategy is 
slower than asymptotic estimates but it was shown to provide statistics with very good 
agreement with those calculated by phenotype permutations.
2.3. Gene-set analyses
In section 1.3, I provided an introduction to GSA. Here I continue the discussion of 
this topic. To recapitulate, GSA aims to find association with gene-sets rather than 
individual genes. Gene-sets are simply groups of gene’s products that have been put 
together using some criteria, e.g., participating in the same biological process or having 
the same sub-cellular localisation. Thus, GSA focuses attention on changes in biological 
processes. GSA analyses can be characterised by  two features: the null hypothesis tested 
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and the statistics used in the analysis (Goeman and Buhlmann, 2007; Liu et al., 2007; 
Wang et al., 2010). 
2.3.1. Different null hypotheses
Goeman and Buhlmann (2007) proposed a characterisation of the null hypothesis of 
GSA: a self-contained strategy tests if the association in the gene-set is greater than 
expected by chance and a competitive if the association is greater than expected 
compared with the rest of the genome. The self-contained strategy only needs 
information on the statistics of the genes in the gene-set of interest. On the other hand, 
competitive methods compare the statistics of genes in the gene-set with that of genes 
outside the gene-set. In order to perform this comparison it is necessary  to account for 
the correlation structure of genes in and outside the gene-set, which remains a challenge 
in GSA for GWAS (Wang et al., 2010).  
2.3.2. Using SNP versus gene-based statistics
If the analysis is based on SNP statistics, gene-set statistics may  be calculated based 
on all SNPs mapped to the genes within the gene-set but an alternative strategy is 
calculation of gene p-values as an intermediate step. Gene p-values are then aggregated 
to obtain a gene-set level association statistics. This also provides useful information at 
the gene level and allows the use of network and other methods in addition to GSA.
2.3.3. Methods implemented in FORGE
In FORGE self-contained statistics are implemented to avoid bias due to the 
correlation between SNPs. GSA methods have been implemented with and without need 
of calculation of gene p-values as an intermediate step.
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2.4. Methods
2.4.1. Region or gene-wide statistics
Data consists of m genetic markers, e.g., within a gene or biological pathway, and 
their p-values obtained from a two-sided test  of significance. A single statistic is 
calculated for the group of genetic markers.
2.4.1.1. Sidak’s correction of the minimum p-value
Sidak’s correction of the best SNP p-value, pcorrected = 1! (1! praw )k where praw is the 
gene’s minimum p-value and k is the number of effective tests (Gao et al., 2008).
2.4.1.2. Modified Fisher’s method to combine correlated p-values
In order to obtain a combined test (T) taking the correlation among the genetic 
markers into account, I use the method originally  derived by Brown (1975) and 
modified by Makambi (2003) and Kost and McDermott (2002) which leads to the 
approximately  distributed chi-square variable with υ degrees of freedom 
T = 0.5 !" !MF ,m , where MF ,m = !2 " #i=1
m wi " log(pi )  is the weighted version of the 
Fisher’s method, pi is the p-value of ith marker and wi are weights greater than zero that 
sum to one. The possible use of weights will be discussed later. The degrees of freedom 
a r e ! = 8 var(MF,m )  w i t h 




, w h e r e ρ i j i s t h e 
correlation between the log(pi) and log(pj). How to determine ρij will be discussed later.
2.4.1.3. Fixed-effect z-score statistic
I a l s o c a l c u l a t e a f i x e d - e f f e c t s e s t i m a t e o f a s s o c i a t i o n b y 
Z fix = !i=1m ziwi !i=1m wi( ) "Vfix#0.5  where zi are the p-values transformed to z-scores using the 
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standard normal distribution inverse cumulative distribution function (c.d.f.) and 
Vfix = !i=1m ! j=1m wiwj!ij is the variance of the test (Huedo-Medina et al., 2006). This 
method is equivalent to that presented by Luo et al. (2010).
2.4.1.4. Random-effect z-score statistic
A random-effects estimate is given by 
Zrandom = !i=1m ziwi* !i=1m wi*( ) "Vrandom#0.5 , with 
variance 
Vrandom = !i=1m ! j=1m wi*wi*!ij  and weights equal to wi
* = ! 2 + wi"1( )"1
w h i c h a r e a d j u s t e d w i t h t h e h e t e r o g e n e i t y  m e a s u r e 
! 2 =max 0, Q '! (m !1)( ) "wi ! "wi2 "wi( )#$ %& . In calculating τ2 Cochran's heterogeneity 
statistics  is normally used. This is an approximately 
distributed chi-square variable with m-1 degrees of freedom when the combined 
statistics are uncorrelated (Huedo-Medina et al., 2006). However, in my application, the 
z-scores are correlated and the distribution of Q does not follow a chi-square 
distribution with m-1 degrees of freedom. Since Q is obtained by re-scaling and adding 
the original z-scores, we approached the correlation problem using the modified 
Fisher’s method for correlated statistics described in section 2.4.1.2 and calculate τ2 
using Q’ as we describe now. In order to obtain Q’, I first calculate the tail probability of 
Q (pQ) using the modified Fisher’s method (describe in section 2.4.1.2) and then 
calculate Q’ as the chi-square value from a chi-square distribution with m-1 degrees of 
freedom for the probability pQ.
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2.4.1.5. Significance of gene-wide statistics by sampling from a MND
To estimate the significance of the gene-wide statistics using the multivariate normal 
distribution (MND) approximation proposed by  Liu et al. (2010), the algorithm depicted 
in Figure 2.1 and described below is used:
I. Specify  a set  of m SNP loci in the gene under consideration. For each locus, 
obtain the p-value representing the association between genotype and phenotype. 
From this set of m p-values, obtain a gene-wide statistic, o, using one of the 
methods described in Section 2.4.1. Steps II to VII of this algorithm produce a set 
of values of the same statistic, designated o*, simulated on the null hypothesis 
(i.e. no association at any  locus), to provide a distribution with which this 
observed value can be compared.
II. Obtain the m x m correlation matrix among the genotypes, Csnp. For this 
purpose, a heterozygote is a given a score intermediate between the corresponding 
homozygotes: for example, the genotypes AA, AG, GG may be coded as 2,3,4.
III. Obtain the Choleski decomposition matrix of Csnp, designated Asnp.
IV. Generate a vector, designated xm, comprising m random numbers from a MND 
with variance-covariance structure Csnp. This is done by the following steps: 
a. Obtain a vector l, comprising m independent random values from a standard 
Normal distribution. That is, l is an observation of L, where L~ N(0, I), with 0 
equal to a vector of zeroes of length m and I = the m x m identity matrix. 
b. Obtain xm = µ + Asnp • l, where µ is a vector of length m of the means of the 
multivariate normal distribution. In my application µ is a vector of zeroes.
V. Transform xm to a set of p-values, designated p*, a vector of length m. The sign 
of the association between each locus and the phenotype is not meaningful, and 
therefore this is done by comparing the square of value in xm with the chi-square 
CHAPTER II FORGE SOFTWARE SUITE
60
distribution (two-tailed test), rather than by comparing the untransformed value 
with the standard Normal distribution (one-tail test). Thus pi = P(Q > zi2) where pi 
= ith value in p*, zi2 = ith value in xm and Q ~ χ12. 
VI. Obtain the gene-wide statistic o* and p*, using the same method as in Step I.
VII. Repeat Steps IV-VI n times stopping when #(o* > o) = 10, i.e. when 10 values 
of o* that surpass the observed values o have been obtained.
VIII. Obtain the estimated gene p-value = (1 + #(o* > o))/(1 + n).
It is notable that while the observed p-values and the gene-wide statistic derived 
from them (o) are obtained using both the genotype and the phenotype data, the 
corresponding values p* and o* simulated on the null hypothesis are obtained from the 
genotype data only. This method for obtaining an empirical distribution for o on the null 
hypothesis is much less computationally intensive than the standard approach, for two 
reasons, namely: 
• it does not require random permutation of a large set of phenotype values
• the test statistic is samples from multivariate normal distribution, rather than being 
derived by calculations performed in a large data set.  
2.5. Gene-set Analyses
2.5.1. SNP to gene-sets strategy
In this case we treat gene-sets as large genes, i.e. map  to it  all SNPs of its constituent 
genes and apply the statistics described in Section 2.4.1, also allowing for correlations 
between genes, such as those that exist in gene-clusters.
2.5.1.1. Gene-sets analysis using gene p-values
GSA is performed using the same basic algorithm described in Figure 2.1 and section 
2.4.1.5. The main difference is that a correlation matrix between the gene-statistics, 
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denoted CG, is needed and replaces Csnp in Figure 2.1. This correlation matrix is derived 
as described by Luo et al. (2010) using the genotypes of each gene in the gene-set. 
Briefly, the correlation between the ith and jth gene-statistics of two genes with mi and 
m j n u m b e r o f S N P s , r e s p e c t i v e l y , i s d e f i n e d b y 
CGij =
corr(Miu ,M jv )v=1
mj∑u=1
mi∑
Vgi ⋅Vgj , where u and v are indexes running from 1 
to mi and mj, respectively; Miu and Mjv correspond to the genotypes at the uth and vth 
SNP in the ith and jth genes, respectively; and Vgi = Csnp,gi∑  and 
Vgj = Csnp,gj∑  are the variances of the gi and gj gene statistics that equal the sum 
over the gene’s SNP p-value correlation matrix (Csnp, gi) as defined in section 2.4.1.3 
(note that differently from section 2.4.1.5 I have added the gi and gj to the notation of 
the correlation matrices to clarify  which genes I am referring to). It is important to note 
that this expression for the correlation matrix of gene statistics is valid for the Z FIX 
method as was shown by Luo et al (2010). It is also valid for the Z RANDOM  method 
after including the weights and it is possibly a good approximation for the modified 
Fisher’s methods but I did not explore its use with the latter method. Similarly to the 
gene-wide association the GSA can be performed asymptotically  or using the MND 
simulation method. The asymptotic approximation is performed by using the methods 
described in Section 2.4.1 and replacing SNP p-values for gene p-values and the 
correlation matrix of the SNP statistics for the CG matrix describe above. The methods 
described in Section 2.4.1 lead to z-scores or chi-square values whose statistical 
significance can be estimated by comparing them to the standard Normal distribution or 
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a chi-square distribution with degrees of freedom calculated with the modified Fisher’s 
method, respectively.
2.5.1.2. Reducing the number of simulations needed of p-values << 1.
The strategies introduced in section 2.4 allow calculation of a minimum p-value of 1/
(1+n), with n being the number of samplings from a MND performed. If very small p-
values are present in the data-set this strategy may  require a prohibitively large number 
of samplings to produce accurate p-values. Knijnenburg et al. (2009) proposed to use 
extreme value distribution theory  to approximate the p-values by using a much smaller 
number of simulations. They showed it allows to estimate p-values below 10-9 
accurately with as little as 106 simulations. I have implemented their methods with the 
difference that parameter estimation is done with the method described by Zhang 
(2010), which has smaller error over a wider range of parameter values. This method 
has been implemented for completeness of the software but it was used in my analyses 
here. I refer the reader to the original reports for details, see (Knijnenburg et al., 2009; 
Zhang, 2010).
2.6. Implementation
I implemented these methods in a program called FORGE written in Perl 
(www.perl.com) using the PDL, PDL::Stats and PDL::LinearAlgebra libraries, all freely 
available at the Comprehensive Perl Archive Network (www.cpan.org) and PDL (Perl 
Data Language, http://pdl.perl.org). Perl provides single numerical precision natively 
but the PDL library  allows to performed calculation in double numerical precision and 
threading in memory for matrix and vectorial operations.
The FORGE code is freely available at https://github.com/inti/FORGE/wiki with 
documentation and instructions to use the example files. A master branch is maintained 
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with the official release version and several parallel development branches to produce 
new code and features. The code is developed under controlled version and is currently 
open for the wider community to contribute or use the software in independent projects. 
Currently the code contains over 30,000 words in more than 5000 lines of code and 
documentation. However, all major function have been implemented as separated 
modules or routines to allows an easy modification and improvement of the code.
2.6.1. Software features
2.6.1.1. Input files
The program reads input and output files and genotype file formats of commonly 
used GWAS analysis software, e.g., genotype files in Linkage Pedigree, Pedigree 
Binary  Format , genotype probabi l i ty f i les in the BEAGLE (ht tp: / /
faculty.washington.edu/browning/beagle/beagle.html) as well as IMPUTE (http://
www.stats.ox.ac.uk/%7Emarchini/software/gwas/file_format.html) formats. SNP 
association files with columns labelled in a header are accepted, e.g., files produced by 
PLINK (Purcell et al., 2007). Gene-set definitions may also be provided and the above 
described statistics are calculated from SNPs in all the genes of a given gene-set. 
2.6.1.2. SNP-SNP correlations.
Our formulas use estimates of the correlation between the test statistics. The user can 
calculate them prior to using FORGE by, e.g., performing permutations and 
randomising the phenotype to derive statistics under then null distribution and then 
calculating the correlation between these SNP statistics. This can be done in PLINK by 
using it with the “--mperm 1000 --mperm-save-all” flags. The resulting output files with 
extension *.mperm.dump.all have permuted statistics that can be input to forge.pl to use 
the SNP-SNP correlations (ρij) as the correlation between the test statistics. 
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Alternatively, ρij can be approximated as the correlation between the Mi and Mj markers, 
either Pearson’s correlation or LD. Despite the latter being an approximation to the 
correlation between the test  statistics, both strategies provide approximately equivalent 
results. Pearson’s correlations are calculated with the methods proposed by Schafer and 
Strimmer (2005) that ensure the correlation matrix is positive definite, which is 
important for the Cholesky decomposition needed for the MND sampling.
2.6.1.3. SNP-to-Gene annotations
Pre-computed files with genetic variants mapped to genes up  to 500 kb from gene 
coordinates are available at the FORGE website. A Perl script to update the annotation 
using the Ensembl API (Rios et al., 2010) is distributed as a utility of FORGE.
2.6.1.4. Additional features
User provided SNP weights, e.g. functional scores, can be used and will be re-scaled 
to sum to 1 within each gene. Genomic-control correction (Devlin and Roeder, 1999) 
can be automatically  performed within the program. Analyses can be restricted to 
chromosomes, gene lists or gene types (e.g. protein coding or miRNA genes). 
Affymetrix SNP identifiers are accepted. The program also reports the I2 heterogeneity 
statistics (Huedo-Medina et al., 2006). Example files, documentation and tutorials are 
available on the software’s website. These methods have been implemented as a web-
server where the user can run the analyses by simply uploading a file with SNP p-
values. The web-sever was developed in collaboration with David To and Richard 
Dobson a t the BRC Nucleus ( IoP) and i t i s ava i lab le a t h t tps : / /
compbio.brc.iop.kcl.ac.uk:8443/forgeweb.
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2.6.2.  Running time
Analysis of an example file which involved the calculation of a p-value using the 
asymptotic approximation for a region of 19 SNPs required approximately 10 seconds 
and in my experience a whole genome analysis involving ~40,000 genes and ~450,000 
SNPs requires ~3-4 hours on a single 2.2 GHz 32 bit computer with 4 gigabytes of 
RAM. Using the multivariate normal distribution approximation with 106 sampling for 
the same region of 19 SNPs took ~6 minutes.
2.7. Results and conclusion
To demonstrate the use of FORGE to calculate gene p-values I applied it to the 
GWAS of total blood haemoglobin levels reported by Ferreira et al. (Ferreira et al., 
2009). Identifying alleles regulating total blood haemoglobin level is of potential 
interest to understand haemoglobin level abnormalities present in some human diseases. 
This GWAS was made publicly  available by the authors together with GWAS of another 
twelve haematological traits. I choose to analyse the GWAS of total blood haemoglobin 
level because it  had a lambda for genomic control of 1.01 (reported in the 
Supplementary  Material of Ferreira et al. (2009)) and had no genome-wide significant 
results at p  < 5 x 10-8). Thus, this is a GWAS with no inflation of the SNP statistics (i.e. 
SNP associations are mostly  under the null hypothesis) that offers us the possibility  to 
analyse a real data set instead of a simulated one that might not  present the complexities 
of a real GWAS. In addition, by  not having genome-wide significant SNPs this data sets 
enable use to test if my methods can identify as significant some potentially  interesting 
loci. I will explore further this argument in Chapter III of this thesis. I downloaded 
summary  statistics of the GWAS of total blood haemoglobin level for 1,872,255 SNPs 
(file “HB.qimr.mdd.assoc”) from the authors’ website, used genotypes of the CEU 
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samples of the HapMap  Project Phase 2 (files hapmap-ceu.bed, hapmap-ceu.bim and 
hapmap-ceu.fam available at the PLINK software website (Purcell et al., 2007)) to 
calculate SNP-SNP correlation and used the SNP-to-gene mapping files distributed with 
FORGE. HapMap Phase 2 genotyped were used because the authors of the original 
study performed imputation using those genotypes as a reference panel and therefore 
these genotypes cover most of the SNP association statistics available in the GWAS 
results. To perform the analysis using the asymptotic approximation I used the 
command line:
$perl forge.pl –bfile hapmap-ceu –assoc HB.qimr.mdd.assoc –snpmap 
ensemblv59_SNP_2_GENE.txt –out HB.qimr.forge.txt
This took approximately  6 hours to run on a single CPU of computer with 8 GB of 
RAM. To use the multivariate normal distribution sampling I used the command:
$perl forge.pl –bfile hapmap-ceu –assoc HB.qimr.mdd.assoc –snpmap 
ensemblv59_SNP_2_GENE.txt –out HB.qimr.forge_mnd.txt -mnd -mnd_max 1000000
The -mnd command sets the program to use the MND sampling strategy and the -
mnd_max sets the maximum number of samplings. This command took ~ 60 hours to 
run on the same computer.
Comparison of gene p-values calculated with both strategies shows an overall good 
agreement (Figure 2.1). In Figure 2.2 I present the quantile-quantile plots for the four 
gene p-values methods calculated with both strategies. The p-values calculated with 
sampling provide a better fit to the uniform distribution expected under the null 
hypothesis than those calculated asymptotically. However, it is also important to note 
that p-values will have a uniform distribution if they are representative of the null 
hypothesis (i.e. in my case that  is no association with the phenotype). When analysing 
real datasets it is possible that deviation from the uniform distribution is due to real 
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Figure 2.2. Quantile-quantile plots for gene p-values. Axis scales are -log10 of gene 
p-values. Y and x-axis present the observed and expected quantiles, respectively. Filled 
and dotted line represent the 1-to-1 diagonal and the 95% confidence interval calculated 
for an assumed a null exponential distribution.



















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































genetic associations rather than unreliability  of the gene-wide association methods. 
Although this complicates the use of the quantile-quantile plots as technical diagnostic 
tool for the gene-wide p-values, it is important to remember that this GWAS has a 
lambda for genomic control of 1.01 indicating little or no inflation of the statistics, 
suggesting most genetic association signal are representative of the null hypothesis. 
Therefore, I would expect  most of the gene-wide p-values generated from this GWAS to 
agree with the null hypothesis. 
As an example of FORGE’s results, Table 2.1 presents the gene p-values for the top 
10 genes for the Z FIX model using both the asymptotic and MND sampling methods. 
One of the top ten genes, the hemochromatosis gene, HFE is a known locus underlying 
haemoglobin levels based on evidence from rare variants (Beutler et  al., 2003) and 
GWAS (Chambers et al., 2009; Ganesh et al., 2009). Table 2.2 presents the correlation 
between the gene p-values and the gene’s number of SNPs for each method.
In summary, FORGE produces gene p-values unbiased by gene size (Table 2.2) and 
complements single SNP associations analysis (Table 2.1). It is flexible regarding input 











Z FIX 0.015 0.003
Z RANDOM 0.014 0.003
MND Sampling
SIDAK 0.085 < 2.2x10-16
FISHER 0.004 4.1E-01
Z FIX 0.014 4.2E-03
Z RANDOM 0.015 2.2E-03
Table 2.2. Correlation between gene p-values and number of 
SNPs within the gene. Spearman’s rank correlation between gene 
p-values and number of SNPs mapped to the gene (within 20 kb of 
genes coordinates). N = ~20,000.
file formats and implements for the first time, to the best of my knowledge, a random-
effects model and the use of SNP weights for gene-wide association. In addition, it 
implements both asymptotic and simulation based p-values providing users the ability 
to balance the trade off between speed and accuracy. 
The FORGE version described here and the code presented in Appendix A 
corresponds to the software version 1 as of Feb 2011. Results presented in the following 
chapters were performed with a previous version providing the same functionality 
except for the MND sampling strategy, which was reported after completion of the 
analyses.
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Chapter III
G e n e - b a s e d g e n o m e - w i d e 
association reveals true disease loci 
not found by single SNP analyses.
3.
Adapted from: Inti Pedroso, Michael R. Barnes, Anbarasu Lourdusamy, Ammar Al-
Chalabi and Gerome Breen. Gene-based genome-wide association reveals true disease 
loci not found by single SNP analyses. PLoS ONE. Under review.
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3.1. Introduction
As I review in Chapter I, genome-wide association studies (GWAS) can be a 
powerful tool to discover genetic associations and have been successful for many 
human phenotypes (see www.genome.gov/gwastudies for a catalogue of studies). It is 
not without its drawbacks, however. The stringent genome-wide significance thresholds 
needed to correct for the millions of univariate tests performed in each study (e.g., 5 x 
10-8, Dudbridge and Gusnanto (2008)) mean that in many GWAS projects few, if any, 
genetic variants reach genome-wide significance. Indeed, 81% (199 out of 246) of the 
traits recorded in the NIHGRI GWAS Catalogue (as of 10 December 2010)(Hindorff et 
al., 2009) have no genome-wide significant associations. Clearly, for any  trait, 
researchers will greatly benefit from gathering large sample sizes (104 or 105 samples) 
(for examples see Franke et al., 2010; Speliotes et al., 2010; Teslovich et al., 2010). 
However, assembling sample sets of this magnitude requires extensive international 
collaborations and may prove very difficult for traits with low population prevalence 
such as Anorexia Nervosa (4.2 to 8.3 cases per 100,000) (Miller and Golden, 2010) or 
phenotypes requiring costly  characterisation, such as neuroimaging. Thus, it is desirable 
to increase power through alternative strategies in parallel to efforts aimed at increasing 
sample size.
Multivariate analysis strategies, such as gene-wide testing, are an attractive 
complement to individual SNP analysis of GWAS (Neale and Sham, 2004). I and others 
have shown that this can allow for allelic heterogeneity, result in fewer genome-wide 
tests and provide p-values for each gene that can be used with pathway analysis 
methods or simply to find genes associated with a phenotype of interest (Furney et al., 
2010; Pedroso, 2010; Peng et al., 2010; Wang et al., 2010). Shifting the focus towards 
genes and biological processes can aid interpretation of GWAS results and generate 
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hypotheses for follow up  studies (Pedroso, 2010; Peng et al., 2010; Wang et  al., 2010). 
Gene-wide analyses can provide better replication than single SNP analyses and 
establish accurate estimates of the statistical evidence within a gene (Liu et al., 2010; 
Luo et al., 2010; Peng et  al., 2010; Wang et al., 2010). In addition, some reports have 
demonstrated that  gene-based association can find a wider range of loci than single 
SNP analyses, including loci with smaller effect-sizes (Furney et al., 2010; Liu et  al., 
2010; Luo et al., 2010; Peng et  al., 2010). In this study, I re-analysed the seven GWAS 
of the Wellcome Trust Case Control Consortium phase 1 (WTCCC, 2007) using a set of 
gene-wide analysis methods and compared these results with a set of known 
susceptibility loci for each disorder, aiming to quantify the ability  of gene-based 
association methods to discover true disease susceptibility genes. 
3.2. Methods
3.2.1. Genotypic data analyses
SNP association summary  statistics of the Wellcome Trust Case-Control Consortium 
study (WTCCC, 2007) were downloaded from the European Genotype Archive (EGA) 
with formal data access permission of the WTCCC Data Access Committee. (See 
(WTCCC, 2007) for details of quality control (QC) undertaken by the WTCCC.) I also 
obtained WTCCC bipolar disorder (BD) GWAS genotype and phenotype data from the 
EGA website, for analysis in conjunction with the association data on this disease. 
Routine QC was performed by excluding samples as indicated in the files provided by 
the WTCCC and SNPs with rate of missingness ≥ 1%, minor allele frequency  (MAF) ≤ 
1%, Hardy-Weinberg equilibrium (HWE) p-value ≤ 10-3 in controls and p-value ≤ 10-5 
in cases as previously described (WTCCC, 2007). I calculated multidimensional scaling 
(MDS) values using PLINK (Purcell et al., 2007) and used the first five as covariates in 
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a logistic regression model in the BD GWAS to correct for population structure. To 
investigate the effect  of genotype calling quality, I analysed the same GWAS but with 
genotypes recalled with BEAGLECALL, which has been shown to provide a significant 
improvement in data quality (Browning and Yu, 2009). BEAGLECALL genotypes were 
obtained from the authors of Browning and Yu (2009) with authorisation of the 
WTCCC Data Access Committee. QC was performed by excluding samples as 
indicated in the files provided by the WTCCC and SNPs with a rate of missing 
genotypes ≥ 1%, MAF ≤ 1%, HWE p-value ≤ 10-3 and p-value ≤ 10-5 in controls and 
cases, respectively.
3.2.2. Gene-wide Association
Gene-wide statistics were calculated for approximately 19,550 protein-coding, long 
intergenic non-coding RNA and micro-RNA genes annotated in Ensembl version 59 and 
whose SNPs passed QC in the WTCCC studies. I mapped SNPs to genes if the SNP was 
within 20 kb upstream or downstream of the annotated coordinates aiming to include 
95% of potential expression quantitative trait loci (eQTL) (Veyrieras et  al., 2008). Gene-
wide p-values were calculated with the Perl software FORGE, which is freely available 
at https://github.com/inti/FORGE/wiki and described in detail in Chapter II. Along with 
the four gene-wide p-values described in Chapter II, I implemented the estimate of 
effective number of tests proposed by  Galwey (2009), the Eigen value ratio (EVR) 
method. Briefly, this method estimates the effective number of tests (Meff) of a group of 
genetic variants by , where λi are the e positive eigenvalues of the 
genotype correlation matrix. Meff is used to calculate gene-wide statistics (EVR gene-
wide p-value) with an re-scaled Fisher’s method to combine p-values (Galwey, 2009) by 




2 = −2 Meffm ln(pi)i=1
m
∑
, where χ2adjusted is a variable with an approximate chi-square 
distribution with 2*Meff degrees of freedom under the null hypothesis.
I approximated the correlation between test statistics at each SNP locus as the 
Pearson’s correlation between the allele counts. I used a local False Discovery Rate 
(FDR) < 0.1 (Efron et al., 2001; Efron, 2010) as implemented in the “fdrtools” package 
version 1.2.6 (Strimmer, 2008) for R (R Development Core Team, 2010) to select a 
group of interesting genes.
3.2.3. Gene-Set Analysis
Gene-Set Analysis (GSA) was performed with the FORGE software suite using the 
gene-wide p-values calculated as describe above (see Chapter II for details). I compiled 
gene-sets ranging from 2 to 200 genes in size from three sources: a) 161 from the 
KEGG database (Kanehisa et al., 2008); b) 1,181 from Gene Ontology (GO) level 4 
databases (Carbon et al., 2009); and c) 5,384 gene-sets derived from the Human Protein 
Reference Database protein-protein interaction network (PPIN)(Keshava Prasad et  al., 
2009). The PPIN gene-sets were constructed with the following algorithm. Sub-network 
searches started from each node in the PPIN, termed the seed node. A sub-network was 
defined by adding sequentially the direct neighbours of every node in the sub-network 
(initially only the seed node). I allowed searches to go to a maximum of five 
interactions from the seed node and generated sub-networks ranging from 2 to 200 
nodes in size. Each of these sub-networks was used as a gene-set. 
As with gene-based analyses I used a FDR threshold equal to 0.1 to select interesting 
sub-networks. I interpreted the biological function of the significant sub-networks using 
MetaCore (GeneGo, Inc.; www.genego.com). GeneGO generates biological networks 
using information curated by systematic literature review of genes and interactions of 
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gene products. It also provides bioinformatic tools to analyse genomic data sets for 
enrichment in these biological networks. GeneGO’s tools assess the significance of the 
overlap between the PPIN sub-networks and their manually  curated biological processes 
using hypergeometric distribution statistics. The p-value from this statistical analysis 
essentially  represents the probability that the overlap between genes of a significant 
network and a GeneGO’s biological processes arise by chance (assuming a null 
hypergeometric distribution), considering the numbers of genes in the PPIN sub-
network, the number of genes in the GeneGO biological processes included in the 
experiment and the total number of genes included in the experiment mapped to any 
GeneGO biological process. Additional details of the calculation of this p-value can be 
found at GeneGO’s website (https://portal.genego.com/help/P-value_calculations.pdf) 
and the report by Ekins et al. (2006).
3.2.4. Permutation study 
To compare FORGE’s asymptotic statistics with their equivalent obtained 
empirically  I generated SNP association statistics under the null hypothesis (i.e. no 
association with the phenotype) by permuting the case-control labels. For each gene I 
generated sets of SNP statistics under the null hypothesis and recalculated the gene-
wide statistic until the asymptotic gene-wide p-value was observed at least  ten times 
(Doerge and Churchill, 1996). I used this strategy to calculate empirical p-values for all 
genes on chromosome 22 (905 genes) and the top 20 genes from the bipolar disorder 
genome-wide analysis. The empirical p-value was calculated as described by North et 
al. (2003) using pempirical = (R+1)/(N+1), where R is the number of times the observed 
statistics was surpassed during simulations and N is the total number of simulations. 
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3.2.5. In silico validation of FORGE results
For each disease studied in the WTCCC dataset (WTCCC, 2007), I constructed a list 
of replication genes using the studies recorded in the NIHGRI GWAS Catalogue (as of 
10 December, 2010)(Hindorff et al., 2009). I removed results derived directly from the 
WTCCC paper (WTCCC, 2007) and mapped the SNPs with p-values < 5x10-8 to genes 
as explained in Section 3.2.2, generating a set of replication genes for each disease. I 
excluded SNPs entries of the GWAS Catalogue that  did not pass QC in the WTCCC 
GWASs. I calculated two measures of enrichment for the WTCCC results among the 
genes of the replication sets. First, I selected genes highlighted by significant SNPs and 
gene-based association from the WTCCC studies and calculated their overlap with the 
GWAS Catalogue replication sets. The significance of this overlap was tested against an 
assumed null binomial distribution using R (R Development Core Team, 2010). This 
analysis was performed at commonly used significance thresholds, i.e., FDR of 0.1 for 
gene-based analyses and a p-value of 5 x 10-8 for single SNP analyses. I calculated a 
second enrichment measure that allowed me to explore the enrichment in replicated 
genes at different significance thresholds. Receiver operating characteristic (ROC) 
curves were calculated for the seven GWAS datasets using the GWAS Catalogue genes 
as a benchmark set. The area under the curve (AUC) is related to a rank correlation 
statistics, e.g., rank correlation between SNP p-values and a binary variable 
characterising if the SNP was replicated or not. It can take values between 0 and 1 (or 0 
and 100% depending on the notation) and in my application represents as a measure of 
how well the GWAS results prioritise or find disease genes. An AUC value of 0.5 
represents the classification expected simply by  chance and a value of 1 a perfect 
classification, i.e. maximum sensitivity and specificity. I calculated the AUC at different 
p-value thresholds for the results of single SNP analyses and different gene-wide 
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association methods to provide a measure of their ability to prioritise genes of the 
GWAS Catalogue replication sets at different levels of significance. AUC values and 
their confidence intervals were calculated by bootstrapping with the package “pROC” 
version 1.3.2 (Robin et al., 2011) for R (R Development Core Team, 2010).
3.2.6. Hierarchical clustering
Hierarchical clustering was performed in R (R Development Core Team, 2010) using 
Euclidean distance and the complete linkage method. As input for the clustering 
algorithm I used the z-scores for each gene-set obtained from the test  of association 
with the phenotype. Heat-maps were drawn using R (R Development Core Team, 2010).
3.3. Results
3.3.1. Performance of gene-wide association methods
Calculation of gene-wide p-values requires computing of the correlation between 
SNP genotypes.  I found that the analysis was approximately  50 times faster when using 
a correlation matrix derived from the genotypes of a reference population, e.g., HapMap 
project samples, compared with using the WTCCC BD GWAS data. There were 
Pearson’s correlation values of r > 0.99 for all gene-wide p-values when calculated with 
either the WTCCC BD or the HapMap Phase 3 CEU population genotypes. All results 
presented hereafter were calculated using the HapMap Phase 3 CEU genotypes. 
Analysis of a GWAS took roughly 3-4 hours for approximately 20,000 genes annotated 
in Ensembl v59 on a single 2.2 GHz 32-bit dual core computer with 4 gigabytes of 
RAM.
There was a high correlation between the asymptotic gene-wide p-values and 
empirical estimates (minimum Pearson’s correlation r = 0.98; Figure 3.1). There was 
appreciable over-dispersion in the gene-wide p-values derived from the EVR method 
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(Figure 3.1). The results presented before and hereafter are based on the SIDAK, 
FISHER, Z FIX and Z RANDOM methods.
Multivariate methods might  be more sensitive to confounders like population 
stratification and genotyping error than single SNP analyses (Moskvina et al., 2006) 
because there is potential to combine the noise in the same way they  combine 
association signals. To address the effects of these confounders, the analysis was 
repeated in the BD GWAS with two modifications: a) I re-analysed the WTCCC 
genotypes and included covariates to correct for population structure and b) I used a set 
of better genotype calls, obtained with the software BEAGLECALL (Browning and Yu, 
2009). In Table 3.1 I report the correlation of SNP and gene p-values calculated with 
and without correction for possible confounders. The correlation of the gene-wide 

































Figure 3.1. Correlation between asymptotic and empirical p-values. Trend lines 
were fitted using a linear regression model and the r2 is reported. Panel A; four 
methods implemented in FORGE. Panel B; Eigen value ratio (EVR) method. In 
panel A blue line is equivalent to the diagonal, in panel B we represented the 1-to-1 
diagonal with the left most black line. Note that the scale of the x-axis differs in 
both panels.
A B
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SIDAK FISHER Z FIX
FISHER 0.821
Z FIX 0.722 0.959
Z RANDOM 0.719 0.954 0.999
Figure 3.2. Correlation between different asymptotic p-values.  Trend 
lines (blue) were fitted using a linear model and the correlation is reported in 
the insert table.
MDS MDS re-scaled BEAGLECALL BEAGLECALL 
re-scaled
Single SNP 0.959 0.982
SIDAK 0.955 0.996 0.978 0.996
FISHER 0.959 1.000 0.987 1.006
Z FIX 0.922 0.962 0.979 0.997
Z RANDOM 0.922 0.962 0.979 0.997
Table 3.1. Effect of possible confounders on gene p-values. We report  Spearman’s 
rank correlation between the gene p-values calculated from the summary statistics 
provided by the WTCCC and those using correction for population stratification 
(Multidimensional Scaling, MDS) and genotypes called with BEAGLECALL. Re-
scaled correlations were constructed by dividing the correlation of each gene-wide 
association method by that of the single SNP association results. This ratio informs on 
the additional sensitivity  to possible confounders of the gene-wide association 
methods.
associations calculated under different  corrections is not expected to be higher that of 
the single SNP analysis itself because they depend directly  on single SNP statistics and I 
expect gene p-values to change at least as much as single SNP statistics do after 
correcting for a confounder. Therefore, in Table 3.1 I also provide a correlation for the 
gene p-values re-scaled with that of the single SNP analyses. This ratio provides a better 
insight because it accounts for the change in gene p-values beyond that of single SNP p-
values alone. There was marginal evidence for gene-wide association being more 
sensitive than single SNP analysis to potential confounders, such as population 
stratification or genotyping error (Table 3.1). I also inspected the agreement between the 
different gene-wide p-values. There was a high correlation between all gene-wide p-
values (minimum correlation r > 0.7) and the correlations between multivariate methods 
were higher (minimum correlation r > 0.95) (Figure 3.2).
3.3.2. Gene-wide analysis of GWAS of seven common disorders
Figure 3.3 presents the analysis workflow performed on the WTCCC GWASs. Gene-
wide association p-values were calculated in the GWAS of Crohn’s disease (CD), type 1 
diabetes (T1D), type 2 diabetes (T2D), rheumatoid arthritis (RA), bipolar disorder (BD), 
coronary  artery disease (CAD) and hypertension (HT) (WTCCC, 2007) using the 
summary  statistics provided by  the WTCCC and HapMap Phase 3 CEU population 
genotypes.
For each disease, I calculated the overlap between genes identified by the gene-based 
methods (FDR < 0.1) and those highlighted by SNPs (p-value < 5 x 10-8) in studies 
reported in the NHGRI GWAS catalogue (Hindorff et al., 2009). I excluded SNPs 
reported solely by the initial WTCCC article (WTCCC, 2007). Comparison of FDR and 
SNP p-value thresholds showed that in general a FDR < 0.1 corresponded to SNP p-
values < 5 x 10-8 (not shown).
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SNPs reached significance in four out of the seven WTCCC GWAS. These SNPs 
showed significant enrichment in replicated loci (Table 3.2). All gene-based methods 
identified genes with FDR < 0.1 and these were also overrepresented within the 
replicated set. To take an example, the Venn diagram depicted in Figure 3.2 presents the 
results of the CD analysis. In this case, 40% (13 out of 32) of the replicated genes were 
only identified by the gene-based association, this is approximately  twice the number of 
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Figure 3.3. In silico validation of gene-based associations. The ability of gene-based 
analyses to identify true disease loci was benchmarked by: i) assessing how many of 
their significant findings are replicated in other studies; and ii) how many of these 
significant genes were not identified by using single SNP analyses alone. Venn diagram 
and workflow boxes’ colours represent gene counts and steps, respectively, of the 
different analyses: light green (left) = gene-based association, light blue (centre) = 
single SNP analyses and purple (right) = benchmark set from NHGRI GWAS 
Catalogue. Results were analysed regarding the proportion genes of the benchmark set 
identified only by  either single SNP analyses or gene-based association (see yellow 
boxes on “In silico benchmark”). In addition we evaluated the use of gene-based 
association in integrative analyses with the protein-protein interaction network and 
biological pathways (see main text for details). Data presented on Venn diagram are the 
results of the Z FIX method on the WTCCC Crohn’s disease data set. (see Table 3.2, 






Data Integration In silico benchmark
7 Disorders of the WTCCC: 
Crohnʼs Disease, Type 1 Diabetes, Type 2 Diabetes, 
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risk alleles
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replicated genes identified by  the single SNP analysis alone (Table 3.2). Interestingly, 
gene-based association found most genes identified by the single SNP analysis (SIDAK 
= 99%, FISHER = 94%, Z FIX = 88% and Z-RANDOM  = 87%). After exclusion of 
genes found by single SNP analysis, the gene-wide association results were still 
significantly enriched with replicated genes (Table 3.3). A list of these replicated genes 
highlighted by gene-based but not single SNP analysis can be found in Table 3.4.
These results were derived with thresholds of FDR < 0.1 and an SNP to gene 
mapping distance of 20 kb. These were my initial criteria and I performed post-hoc 










CUL2 1x10-4 0.83 0.03 0.19 0.18 Barrett et al., 2008
KIF21B 6x10-5 0.84 0.03 0.14 0.14 Barrett et al., 2008
ZNF300 1x10-7 0.06 3x10-7 1x10-2 0.14 Barrett et al., 2008
APEH 2x10-6 0.18 2x10-4 2x10-3 2 x10-3
Parkes et al., 2007; 
Barrett et al., 2008
RNF123 4x10-5 0.59 8x10-3 0.09 0.09 Barrett et al., 2008
STAT3 2x10-5 0.67 0.03 0.14 0.13 Barrett et al., 2008
MST1 1x10-6 0.18 1x10-4 1x10-3 9x10-4
Parkes et al., 2007; 
Barrett et al., 2008
PTPN2 1x10-7 0.1 5x10-3 0.02 0.02
Parkes et al., 2007; 
Barrett et al., 2008
TNFSF15 1x10-4 0.83 0.06 0.19 0.18 Barrett et al., 2008
C5orf56 1x10-6 0.25 1x10-5 3x10-4 2x10-4 Barrett et al., 2008
AL390240.
1 1x10
-4 0.83 0.08 0.3 0.3 Barrett et al., 2008
IRGM 1x10-7 0.06 4x10-7 1x10-4 1x10-4 Parkes et al., 2007
CAD
PSRC1 2x10-5 1 0.04 0.25 0.24 Samani et al., 2007
MYBPHL 2x10-5 1 0.04 0.3 0.29 Samani et al., 2007
RA C5orf30 2x10-4 1 0.05 0.28 0.28 Stahl et al., 2010
T1D
SMARCE1 2x10-5 0.3 8x10-3 0.04 0.04 Barrett et al., 2009
SH2B3 4x10-7 0.04 2x10-4 1x10-2 0.02 Barrett et al., 2009
CTLA4 3x10-5 0.37 9x10-3 0.23 0.57
Cooper et al., 2008; 
Barrett et al., 2009
ATXN2 3x10-5 0.28 9x10-3 0.18 0.27 Barrett et al., 2009
T2D
ZFAND6 1x10-5 1 0.07 0.22 0.23 Voight et al., 2010
TSPAN8 2x10-6 1 3x10-3 0.05 0.07 Zeggini et al., 2008
RBMS1 3x10-6 1 0.04 0.18 0.17 Qi et al., 2010
Table 3.4. Genes highlighted only by gene-based analyses that were replicated in 
other studies. References as reported in the GWAS Catalogue (Hindorff et  al., 2009). 
CD = Crohn’s disease, T1D = type 1 diabetes and T2D = type 2 diabetes.


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































analyses to assess their effects on my results. First, using the FISHER method with 
different FDR and distance mapping I found that enrichment with replicated genes 
weakened with larger SNP to gene mapping distances and FDR values. The best 
enrichment was found with FDR values around 0.05 to 0.1 and a mapping distance of 
20 kb. Only the CD data set showed enrichment when including only SNPs between the 
start and end locations of a gene (Table 3.5 and 3.6). Second, I assessed how well the 
SNP or gene-wide association p-values classify  loci as replicated using the GWAS 
Catalogue entries as the benchmark. I calculated receiver operating characteristic curves 
and the AUC for the single SNP analysis and gene-wide association results at different 
p-value thresholds for six out of the seven diseases (the GWAS of HT did not have 
GWAS Catalogue entries with p-values < 5x10-8). Before describing the results of this 
analysis I would like to remind the reader that the interpretation of a significant p-value 
depends among other things on the number of hypothesis tested during the course of the 
experiment. I have tested approximately  one order of magnitude fewer genes than 
SNPs, so simple comparison of SNPs and gene p-values is not straightforward. In 
Figure 3.4 I present the AUC values with the estimated 95% confidence intervals for the 
SNP and gene-wide association analyses of the six different diseases. To facilitate 
comparison with the results presented in Tables 3.2 and 3.3, Figure 3.4 also gives the 
multiple testing correction thresholds used in these previous analyses, i.e. a p-value = 
5x10-8 for single SNP and a p-value equivalently to a FDR of 0.1 for gene-wide 
association results. The results presented in Figure 3.4 show that after multiple testing 
correction both the single SNP analyses and gene-wide association methods find a 
significant proportion of true disease loci, as was already suggested by the results 
presented in Tables 3.2 and 3.3. The AUC profiles allow us to assess the ability  of these 
methods to find disease loci at different significance thresholds, which was not a feature 
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of my previous analyses. I found that single SNP p-values correctly  classify many of the 
replicated loci at p-values above of 5 x 10-8. The amount of signal remaining above this 
threshold, as measured by the SNP association p-value at  which the AUC ≤  0.5, seems 
to vary between datasets. A second result emerging from this figure is that there is little 
difference between gene-wide association methods regarding their AUC profile. Finally 
and more importantly, these results show that in general gene-wide association methods 
have higher AUC values than the single SNP results. This pattern is more prominent in 
GWAS where single SNP analyses provided several significant hits, e.g., GWAS of RA 
or CD as compared to those of BD or CAD. This pattern is also observed in the results 
of gene-set  analyses (see later in this chapter) and I discuss it  further in Chapter VI of 
this thesis. Overall, the AUC analysis results lend additional support to the observations 
obtained at the fixed significance thresholds that I presented in Tables 3.2 and 3.3.
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Figure 3.4. Area under the curve for SNP and gene p-values results benchmarked 
against GWAS Catalogue.Each panel presents the AUC values and their 95% 
confidence interval for one of six GWAS. Results from single SNP and gene-wide 
association methods are colour coded as indicated on the legend. Vertical dashed lines 
mark a p-value of 5 x 10-8 and the gene-wide p-value equivalent to a FDR = 0.1 for 
each method (see colour code in legend). Horizontal dashed line marks the AUC = 0.5, 
which marks what would be expected by  chance. CD = Crohn’s disease, T1D = type 1 
diabetes, T2D = type 2 diabetes, RA = rheumatoid arthritis, BD = bipolar disorder and 
CAD = coronary artery  disease. Please note for the panel of the CD data that the line of 
the SIDAK and minimum p-value methods overlap completely. To improve 


































































































































































Significant gene-wide associations were often physically clustered due to LD 
extending beyond gene boundaries and my allowance for SNPs to map multiple genes. I 
verified that clustered genes do not  drive the results by  calculating the overlap between 
gene-wide results and the replication sets in terms of recombination intervals containing 
significant or replicated genes instead of individual genes. I defined recombination 
intervals as the regions between adjacent recombination hot-spots midpoints (Frazer et 
al., 2007). The results remained significant (Tables 3.7 and 3.8).
I acknowledge that false positives exist  among the significant regions from gene-
based analyses which have not been identified in other studies. However, I hypothesise 
that some associations are true disease susceptibility loci that have not yet been 
identified by sufficiently large GWAS meta-analyses. To explore this possibility  I 
rebuilt the replication set for CD using the NHGRI GWAS Catalogue (data taken on 9 
February, 2011) (Hindorff et al., 2009), which included the latest meta-analysis 
analysing over 50,000 samples (Franke et al., 2010) and recalculated the overlap with 
the WTCCC results. The new replication set had 91 genes. Only the FISHER method 
found additional replication in the new set. The FISHER method deemed 84 genes to be 
significant for CD, with 23 overlapping the new replication set. I also further examined 
the results of the CAD GWAS because, unlike the CD GWAS, it did not have SNPs 
reaching significance in the original analysis (WTCCC, 2007). It may be possible that 
gene-based association methods could help prioritise targets for follow up. I performed 
a literature search in PubMed for the 22 genes (within 16 recombination intervals) 
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highlighted by the Z FIX method. Five of them had known or possible links with CAD5:
i) SEMA3C has mechanistic roles in cardiac neural crest  cells migration during 
heart development (Lepore et al., 2006; Toyofuku et al., 2008; Kodo et al., 
2009);
ii) Patients with CAD had higher levels of OGDH protein compared with controls 
in a proteomic study (Banfi et al., 2010); 
iii) Common variants within PTGER2 have been associated with acute coronary 
syndrome in CAD (Szczeklik et al., 2008);
iv) Mutations in MTMR14 are associated with autosomal dominant centronuclear 
myopathy (Tosch et al., 2006) and its gene product has been shown to 
participate in the regulation of calcium signalling (Shen et al., 2009) and 
muscle contraction (Dowling et al., 2010); 
v) Finally, SNPs within MIA3 have been associated with Early Onset Myocardial 
Infarction and CAD (Samani et al., 2007; Kathiresan et al., 2009). The 
WTCCC samples were included in the study of Kathiresan et al. (2009).  
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5 It is difficult to asses if finding five genes with links to CAD out of the twenty-two 
deemed significant is more than it would be expected by chance. Without compelling 
single SNP associations reaching a p-value of 5x10-8, gene-based association may be 
able to highlight genes and genomic regions that  researchers might prioritise for 
additional research after a detailed review of the known functions of the associated 
genes plus the investigator own knowledge on the disease’s molecular aetiology. I 
acknowledge this is not an interpretation of the data free of biases but for many diseases 
the molecular aetiology is not  well defined and a GWAS is just the first step towards its 
elucidation.
3.3.3. Using gene-wide p-values for Gene-Set Analysis of GWAS
I performed gene-set analysis with the Z FIX gene-wide p-values results6 and found 
significant gene-sets after correction for multiple testing (FDR < 0.05) for four diseases 
(Additional Table 3.1 at the end of this chapter). I identified in the CD data set 
association with PPIN sub-networks of genes involved in interleukin (IL) 23/12 
(PPIN-4224, FDR = 4 x 10-4) and IL-6 signalling pathway (PPIN-4339, FDR = 1 x 
10-3), closely  matching the known aetiology of CD and several previous reports 
(reviewed by Wang et al. (2010)). For HT, there was an association with a PPIN sub-
network of genes (PPIN-2605, FDR = 0.04) involved in cortisone, androstenedione and 
testosterone biosynthesis and metabolism. For RA, I identified several PPIN sub-
networks involved in the interaction between cell and the extracellular matrix and 
immune response, including antigen presentation and T cell receptor (TCR) signalling. 
Several gene-sets reached significance in the T1D GWAS but I could only obtain 
bioinformatic characterisation for genes in GO0031497 (FDR = 3x10-3) and PPIN-5144 
(FDR = 8x10-3), which are involved in chromatin assembly and DNA repair. 
I performed hierarchical clustering of diseases and gene-sets using gene-sets with 
nominal significance, an uncorrected p-values < 0.05 in at least one study, and a more 
stringent significance level of FDR < 0.05 in at least one study  (Figure 3.5). By using 
the nominally  significant gene-sets, I obtained a cluster with T1D, RA and CD, all of 
which are immune system related diseases (Figure 3.5-A). Furthermore, I found a 
cluster with T2D and CAD, both metabolic diseases. In contrast, none of these groups 
were found by clustering of the more stringent significance criteria. For example, T1D 
and RA were placed outside the tree (Figure 3.5-B), suggesting that  their sub-networks 
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6  I choose the Z FIX method because the gene-gene correlation calculated from the 
gene-set analysis methods implemented on FORGE are better suited to deal with gene 
p-values from the Z FIX methods than from the other methods. See Chapter II section 
2.5.1.1 for details.
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Figure 3.6. Comparison of fixed and random-effects estimates. Plotted for each gene 
(N ~20000) is the log10 of the ratio of fix and random-effects gene p-values. Insert (top 
right corner) presents data for the whole range of observed effective number of tests and 
main panel presents data on the range of effective number of tests where most 
differences between the two gene-wide p-value are seen. Points are coloured (see figure 
legend) by the gene’s statistical heterogeneity  measure I2, which has range from 0 (no 
evidence of heterogeneity) to 100% (maximum evidence of heterogeneity).
Effective number of tests
A B
Figure 3.5. Hierarchical clustering of diseases and gene-sets. Clustering was 
performed with the complete linkage method with distances calculated using the 
Euclidean distance between gene-sets z-scores obtained from the association of gene-
sets with diseases. Colour scale represents the significance of the association between a 
gene-set and a disease, red=strong associattion and light-yellow=weak association. 
Panel A and B present clustering results from 3183 and 15 gene-sets that were nominally 
significant (uncorrected p < 0.05) and significant at an FDR < 0.5 in at  least  one disease, 
respectively. 
may be disease specific.
3.3.4. Comparison of fix and random-effects gene-wide statistics
Figure 3.6 presents a comparison of the fixed and random-effects gene-wide statistics 
of the BD GWAS. My results show that differences are commonly  observed only in the 
case of (relatively  small) genes with less than 30 effective SNPs or ~45 SNPs. 
Moreover, these differences are small, being less than one order of magnitude of the 
gene p-value. For larger genes, the statistical heterogeneity measure I2 is rarely  different 
from zero.
3.4. Discussion
Our results indicate that  multivariate gene-based methods are useful for finding 
disease susceptibility loci. The gene-based methods found most of the replicated genes 
highlighted by single SNP analysis as well as additional genes that reached significance 
in other studies (Tables 3.2 and 3.3 and Figure 3.4). However, gene-based methods 
failed to perform well in disorders where SNP analysis did not perform well, e.g., BD, 
but succeeded in finding multiple loci that later reached the genome-wide significance 
level in the other disorders, such as CD (Tables 3.2 and 3.3 and Figure 3.4). 
One potential confounder in my analysis is the fact that several of the studies indexed 
in the NHGRI GWAS catalogue include some of the WTCCC data in their analyses or 
as part of meta-analyses. This possibly complicates the use of this catalogue to define a 
replication set despite our removal of the original WTCCC reported data. While this is 
problematic, I do not think it is a major confounder as it  means that loci found by gene-
based methods might (if taken into the replication stage) reach genome-wide 
significance by subsequent meta-analysis of the single SNP association results. 
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Multivariate gene-wide association methods can potentially  increase the power of 
GWAS to find true disease susceptibility  loci by  alleviating the effect of allelic 
heterogeneity or the incomplete tagging of causal variants (Furney et al., 2010; Liu et 
al., 2010; Luo et  al., 2010). For example, the association highlighted between the 
TSPAN8 (tetraspanin 8) and T2D (Table 3.4) is supported by two SNPs, rs14953977 (p-
value = 1.3 x 10-6) and rs7961581 (p-value = 3.6 x 10-6), in low LD, r2 = 0.26 and D’ = 
0.85. Haplotype analysis is also expected to improve statistical power in these scenarios 
(Schaid, 2004). Interestingly, Browning and Browning (2008) found this region and 
another three to be of genome-wide significance through haplotype analysis but not 
single SNP analysis in the same GWAS analysed here (see Table 1 in Browning and 
Browning (2008)). Three of these regions were found by all multivariate gene-wide 
methods at FDR < 0.1. None of my methods highlighted the haplotype association at 
chromosome 15q26.2 in HT, which to the best of my knowledge has not been replicated 
yet. While both multivariate gene-wide association and haplotype analysis provides 
increased power, haplotype analysis is more computationally  intensive and requires 
access to raw genotype data whereas gene-based association is more efficient, needing 
only the more easily  obtainable summary data. Importantly, gene-wide statistics are 
useful for gene-set analyses, as I have shown for several diseases (Additional Table 3.1), 
and have the potential to be used in other strategies, including data integration for the 
establishment of convergent evidence towards molecular systems underpinning human 
diseases. Haplotype analyses results might be useful for gene-set analyses but 
considerations regarding the effect  of gene-size bias would need to be taken into 
account. Additionally, I showed that gene-set results can be used to group  disease in 
physiological meaningful categories. The hierarchical clustering results correctly 
grouped together immune-system diseases, CD, T1D and RA, and metabolic diseases, 
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T2D and CAD (Figure 3.5-A). These results suggest that disease classification may be 
easier using findings of association that reach only  nominal significance rather than the 
very few that achieve genome-wide significance. It is possibly the top  findings may be 
more relevant to understanding disease specific features whereas more general 
biological signatures emerge at lower significance levels. Although my analysis of the 
PPIN are equivalent to those of Baranzini et al. (2009), I failed to find as many 
associations with PPIN sub-networks and, intriguingly, with those related with the 
immune-system in T1D. Differences may have arisen due to the following: i) they used 
a different gene p-value method (Sidak’s correction); ii) I performed correction for 
multiple testing on my  results and they declared significance at a gene-set z-score > 3 (p 
< 0.0013) which matches a FDR > 0.2 in my analyses; and iii) I explicitly corrected my 
gene-set statistics using the correlation among the genes’ statistics, which can be 
particularly problematic in regions of high LD when most genes belong to the same 
biological processes, such as the human leukocyte antigen (HLA) region. 
My comparison of gene p-values derived with fixed and random-effects models 
suggest that random-effects models, or at least those implemented here, are unlikely to 
give very different results. When differences do occur they are in small genes (Figure 
3.6). This is to be expected since only a small fraction of genetic variation is likely to be 
associated with any given phenotype. Therefore, in large genes (compared with small 
genes) a smaller proportion of the genetic variants is expected to be associated with any 
given phenotype7. For larger genes, most of the evidence will point to lack of 
association and the statistics will be more homogeneous (low I2), indicating the 
CHAPTER III GENE AND GENE-SET ANALYSIS OF WTCCC1 
100
7 This argument comparing small and large genes does not include variables like LD, 
allele frequency distribution, haplotype diversity or functional effects of the genetic 
variation in a gene’s product among other variables that  likely  differ between genes and 
are relevant to identify genetic association. Therefore, this argument should be 
interpreted as the expected pattern while keeping all these additional variables constant 
between genes.
relationship  between statistical heterogeneity and genetic heterogeneity may not be 
simple. Thus statistical heterogeneity (i.e., non-uniformity of effect sizes) and random-
effects may not be an effective strategy to tackle genetic heterogeneity (i.e., unlinked 
associated variants), contrary to what some authors have proposed (Lebrec et al., 2010). 
Development of a method to quantify  genetic heterogeneity still remains an unsolved 
challenge.
I acknowledge several limitations of my study. By necessity  I had to validate my 
results against the results from single SNP analysis rather than each method’s own 
replication success. This could have favoured the SNP based analysis, as I cannot 
account for genes that  would have been found and replicated only by  gene-wide 
methods. Despite this limitation, my validation is useful in showing that gene-wide 
methods provide replicable findings. Furthermore, based on my benchmarking strategy, 
the SNP univariate analyses had higher precision (a higher proportion of significant 
genes replicated in later studies) than the gene-wide methods. Apart from bias in favour 
of replication by single SNP analysis, this can be partially explained by an increased 
tagging power of gene-based methods that enables the gene-based associations results to 
extend into overlapping genes and gene clusters in high LD across several genes (like 
the HLA region). I showed that accounting for overlapping genes does not change my 
results (Table 3.3). Likewise, multivariate methods could amplify technical artefacts 
such as genotyping error and be more sensitive to population stratification, thereby 
generating false positives. Although I did observe minor effects of this kind of 
confounders, I appreciate that  in the future their influence will be reduced due to rapidly 
improving methods to deal with population stratification (Kang et al., 2010) and 
genotype calling (Browning and Yu, 2009).
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Multivariate gene-wide association methods aid in the identification of disease loci. 
Furthermore, they  benefit from being fast and applicable to summary statistics. As the 
cost of genotyping large cohorts decreases, GWAS is becoming an increasingly 
ubiquitous genetic research tool. Application of these methods can help by enhancing 
both power and interpretability of GWAS.
 
3.5. Additional Tables
GWAS Gene Set Z-score FDR Biological Process/Description Genes
CD
PPIN-4224 5.78 4x10-4
I m m u n e r e s p o n s e _ I L - 2 3 
signalling pathway (P = 2x10-11), 
I m m u n e r e s p o n s e _ I L - 1 2 
s i g n a l l i n g p a t h w a y ( P = 
3x10-10), Inflammation Jak-
STAT Pathway (P = 8x10-10)
IL12B IL12RB1 IL12RB2 
IL23A IL23R JAK2 STAT3 
STAT4
PPIN-4339 5.52 1x10-3
Inflammation_IL-6 signalling (P 
= 2x10-14) , Erythropoietin 
p a t h w a y ( P = 2 x 1 0 - 1 2 ) , 
I n f l a m m a t i o n _ T R E M 1 
signalling (P = 2x10-10)
AKT1 EPOR GAB1 GRB2 
HYAL2 JAK2 MST1 PIK3R1 
PLCG1 RELA SFN SHC1 
S R C Y E S 1 Y W H A B 
YWHAE YWHAH YWHAQ 
YWHAZ
HT PPIN-2605 5.08 0.04
Cortisone biosynthesis and metabolism 
(P = 5x10-5), Androstenedione and 
testosterone biosynthesis and 
metabolism p.3 (P = 2x10-5)
C Y P 1 1 A 1 C Y P 1 1 B 1 
CYP11B2 FDX1
PPIN-4493 7.77 4x10-9
Role of tetraspanins in the 
integrin-mediated cell adhesion 
(P = 3x10-4), Role of cell-cell 
and ECM-cell interactions in 
oligodendrocyte differentiation 
and myelination(P = 5x10-4), 
Phagosome in antigen 
presentation (P = 5x10-4)
CD63 CD74 CD82 CTAG1B 
H L A - D M A H L A - D M B 
H L A - D R A H L A - D R B 1 
HLA-DRB3 HLA-DRB4 
HLA-DRB5 MAGEC1 MBP 
PRPF40B
PPIN-792 6.32 1x10-5
Cell-matrix interactions (P = 
1x10-8), Inhibition of 
remyelination in multiple 
sclerosis: role of cell-cell and 
ECM-cell interactions (P = 
6x10-7), Antigen presentation by 
MHC class II (P = 2x10-6), 
ERBB-family signalling (P = 
7x10-6)
AP4M1 CANX CD19 CD1D 
CD4 CD44 CD63 CD74 
CD82 CD9 CTSF CTSL1 
DPM1 DPM2 DPM3 EGFR 
ERBB2 ERBB3 HBEGF 





DRB5 IGSF8 ITGA3 ITGA4 
ITGA6 ITGB1 ITGB2 LRP1 
MBP MIF NUP88 PI4K2A 
P I G A P I G C P R P F 4 0 B 
PTGFRN TIMP1 VANGL1
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pathways (P = 4x10-15)
ATP5L CTAG1B ECHDC2 
GTF2F1 H2AFZ HLA-DMA 
H L A - D R A H L A - D R B 1 
HLA-DRB3 HLA-DRB4 
H L A - D R B 5 M A G E C 1 




pathways (P = 2x10-18), 
Melanocyte development and 
pigmentation (P = 3x10-5)
CTAG1B FGF10 HLA-DRB1 
HLA-DRB3 HLA-DRB4 
H L A - D R B 5 M A G E C 1 
MC1R MC2R MC4R MC5R 
MEP1A NRD1 PAM POMC 
VTN
PPIN-1432 4.96 7x10-3
Immune response TCR 
signalling (P = 9x10-8), Immune 
response Antigen presentation 
(P = 1x10-7)
CANX CD1D CD247 CD3D 
CD3E CD3G HLA-A HLA-B 
HLA-DRB1 HSPA5 LEF1 
T R A @ T R AT 1 T R B @ 
TRD@ TRG@
PPIN-1768 4.96 7x10-3
Role of tetraspanins in the 
integrin-mediated cell adhesion 
(P = 2x10-8), Gastrin in cell 
growth and proliferation (P = 
1x10-7), Immune response 
Antigen presentation (P = 
2x10-7)
AP4M1 APTX ATN1 ATXN1 
BMP2K CANX CD19 CD1D 
CD4 CD44 CD63 CD74 
CD82 CD9 CDK12 CLK1 
CTAG1B CTDSP1 CTSF 
CTSL1 DPM2 DYRK1B 
E F H A 1 E G F R E R B B 2 





DRB1 HLA-DRB5 HTT 
IGSF8 IRAK1 ITGA3 ITGA4 
ITGA6 ITGB1 ITGB2 LRP1 
MAG MAPK1 MAPK11 
MAPK13 MAPK14 MAPK15 
MAPK3 MAPKAPK5 MBP 
MELK MIF MKNK1 MMP7 
N E K 9 N U P 8 8 P A K 1 
PI4K2A PLP1 PRKACA 
PRKCA PRKCD PRKCI 
PRKCZ PRMT1 PRMT5 
PRPF40B PTGFRN RAN 
RPS6KA5 RTN4 SRPK1 
STK16 STK39 STK4 TIMP1 
TLK1 TLK2 TRA@ TRAF6 
TRB@ TRPM7 VANGL1
PPIN-6512 4.61 0.03
Immune response Antigen 
presentation (P = 2x10-7), 
Immune response TCR 
signalling (P = 9x10-8)
CANX CD1D CD247 CD3D 
CD3E CD3G CD63 CD74 
CD82 CTAG1B HLA-A 
HLA-B HLA-DMA HLA-
DMB HLA-DOA HLA-DRA 
HLA-DRB1 HLA-DRB3 
HLA-DRB4 HLA-DRB5 
HSPA5 LEF1 MAGEC1 
M B P P R P F 4 0 B T R A @ 
TRAT1 TRB@ TRD@
T1D
PPIN-1723 6.61 5x10-4 NS
H I S T 1 H 1 A H I S T 1 H 1 C 
H I S T 1 H 3 G H I S T 1 H 3 H 
HIST2H3C LUC7L2 NASP 
ULK2
GO0031497 6.09 3x10-3 Chromatin assembly
PPIN-5144 5.82 8x10-3 Role of Brca1 and Brca2 in 
DNA repair (P = 6x10-4)
BCCIP BRCA2 CAPZB 
C D K N 1 A F A M 4 6 A 
HIST1H2BN ITSN2 PTN 
RAD51 RPL23
PPIN-964 5.47 0.03 NS
DGCR6L SUFU ZNF165 
ZNF193 ZNF232 ZNF24 
ZNF263 ZNF434 ZNF446 
ZNF496 ZSCAN16
PPIN-5780 5.41 0.03 NS
DGCR6L EMG1 NOL12 
SLC25A38 SUFU ZNF165 
ZNF193 ZNF232 ZNF24 
ZNF263 ZNF434 ZNF446 
ZNF496 ZSCAN16
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GWAS Gene Set Z-score FDR Biological Process/Description Genes
Additional Table 3.1. Gene-Set Analysis with gene-wide p-values in the WTCCC 
phase 1 study. Gene-sets from Gene Ontology Database (www.geneontology.org) are 
described with the database’s description. Gene-sets derived from the protein-protein 
interaction (PPI) network were characterised using GeneGO MetaCore database and we 
report the three best biological categories and the over-representation p-value 
(calculated using the hypergeometric distribution). CD = Crohn’s disease, HT = 
hypertension, RA = rheumatoid arthritis and T1D = type 1 diabetes.
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Chapter IV
Integrative biology analyses of 
bipolar disorder GWAS
4.
Adapted from: Inti Pedroso, Anbarasu Lourdusamy, Marcella Rietschel, Markus M 
Nöthen, Sven Cichon, Peter McGuffin, Michael R. Barnes and Gerome Breen. Common 
genetic variants and gene-expression changes associated with bipolar disorder are over-




Bipolar disorder (BD) is a chronic and episodic psychiatric condition characterised 
by extremes of mood ranging from mania to severe depression, usually accompanied by 
disturbances in cognition and behaviour. Psychotic features such as delusions and 
hallucinations often occur. Despite a convincing and substantial genetic contribution to 
the aetiology of BD (McGuffin et al., 2003), its genetic and molecular underpinnings 
remain largely  unknown. Its diagnosis is based solely on observed clinical features. 
Genome-wide association studies (GWAS) and linkage studies have highlighted several 
genomic regions (Lewis et al., 2003; Ferreira et al., 2008) and recently  replicated 
evidence implicating specific loci has also been reported (Ferreira et al., 2008; 
O'Donovan et al., 2008; Breen et al., 2011). 
These and other large scale association studies of common genetic variation have 
reinforced the notion that many low risk genetic variants are involved in the aetiology 
of BD (Ferreira et al., 2008; Scott et al., 2009; Purcell et  al., 2009). Analyses of GWAS 
of Crohn’s disease and multiple sclerosis have highlighted genetic heterogeneity  within 
single genes and biological processes, i.e. 2 or more polymorphisms within a gene being 
independently associated and different sets of genes within the same pathway  associated 
in different studies (Baranzini et al., 2009; Wang et al., 2009). There is some evidence to 
suggest this may also be true for BD (Schulze et al., 2009). Thus, recent findings lend 
support to the idea that genetic heterogeneity is a major feature of the genetic 
architecture of common risk variants of complex traits, for example see McClellan and 
King (2010). Although the extent to which this is true for different phenotypes is not yet 
clear. Thus allelic heterogeneity (i.e. statistical association at unlinked alleles in a 
locus), and locus heterogeneity (i.e. different regions across the genome), are a 
challenge for ongoing meta-analytical strategies that aim to combine the increasing 
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volume of GWAS data now available for psychiatric disorders (Psychiatric GWAS 
Consortium, 2009).
Genetic heterogeneity might have multiple sources: 
i) When the effect-size of a single genetic variant is not consistent across 
multiple measurements or studies. This may be quantified with statistics 
commonly used in meta-analyses, such as the Q statistic or I2 index (Huedo-
Medina et al., 2006). A possible scenario of heterogeneity  at a single site 
occurs when an allele shows association only  in one or a few studies; for 
example: in the extreme case in which an allele is significantly  associated in a 
single study. This would lead to an overall heterogeneous association pattern, 
showing signs of allelic heterogeneity or locus heterogeneity (see below).
ii) Allelic heterogeneity  may occur when alleles at  different genomic positions 
appear to be correlated with the phenotype because they are proxies or tag 
either a single same causal variant  or multiple, potentially independent, causal 
variants. Allelic heterogeneity can occur simply due to differences in 
recombination patterns between populations or samples. Currently, there is not 
good quantitative measure for allelic heterogeneity.
iii) Locus heterogeneity refers to alleles at different loci that are correlated with 
the phenotype. This kind of heterogeneity is implicitly  related to allelic 
heterogeneity since the key  differences reside in how we define the physical 
limits of a locus. In this work the gene’s coordinates define the limits.  
If allelic associations are homogenous they will be found by SNP based meta-
analysis, provided there is enough statistical power. However, in the case of allelic or 
locus heterogeneity, SNP based meta-analyses are likely to be less successful. An 
alternative strategy would be to aggregate or group allelic associations, e.g., within 
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genes or biological processes. An assumption built into this strategy is that the relevant 
commonality of genetic risk across populations, samples and potentially individuals 
does not relate to the alleles themselves but their underlying functional effects. The 
underlying commonalities may be partially  a reflection of the biological function of the 
genes where these association lie. This leads to the hypothesis that by grouping genetic 
associations into their respective biological processes one can tackle genetic 
heterogeneity. This strategy can potentially help under both heterogeneity models and 
we employ it here to enhance the information extracted from GWAS of BD.
A systems biology oriented approach to tackle heterogeneity and improve both 
power and interpretation of GWAS is feasible because disease susceptibility variants 
cluster within genes and biological processes (recently  reviewed in (Wang et al., 2010)). 
This approach has started to reveal valuable information from BD GWAS. Analysis of 
the Wellcome Trust Case Control Consortium (WTCCC) BD GWAS and its meta-
analysis with another GWAS provided evidence of association within biological 
processes involved in the modulation of transcription and cellular activity, including 
that of hormone action and adherens junctions (Baranzini et  al., 2009; Holmans et al., 
2009; O'Dushlaine et al., 2011). Also, an association between the gamma-aminobutyric 
acid (GABA) A receptor pathway genes and the BD schizoaffective subtype has been 
the only replicated system-level finding in BD to date (Breuer et al., 2010; Craddock et 
al., 2010). (This finding is analysed in detail in Chapter V.) 
Increasing evidence suggests that gene-expression studies can be used successfully to 
prioritise GWAS results (see refs (Hsu et al., 2010; Zhong et al., 2010a; Zhong et al., 
2010b)). For example, Zhong et al. (2010a) showed that gene-expression changes and 
genetic-susceptibility  variants conferring risk to type 2 diabetes cluster in common 
biological pathways.
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Here we present a systems biology oriented analysis aiming to identify biological 
processes associated with BD. By combining three GWAS with gene-expression studies 
we provide convergent and robust evidence of association with BD despite locus 
heterogeneity.
4.2. Methods
4.2.1. Samples and genotype data
We re-analysed GWAS of BD from the Wellcome Trust Case Control Consortium 
study (2007), Cichon et al. (2011) and Sklar et al. (2008) studies, which we refer to as 
WTCCC, Bonn and Sklar respectively. We used individual level genotype and 
phenotype data from the Bonn study and summary statistics from the two other studies. 
The quality control undertaken in the WTCCC BD GWAS was described in Chapter III 
and for the Sklar and Bonn studies can be found in the original reports. BD samples of 
all studies met DSM-IV criteria to establish BD diagnosis. Statistical association in the 
Bonn GWAS was performed with a logistic regression model using PLINK (Purcell et 
al., 2007). We also analysed summary statistics from six GWAS in common non-
psychiatric disorders reported by the WTCCC. These were GWAS of Crohn’s disease, 
type 1 diabetes, type 2 diabetes, rheumatoid arthritis, coronary artery disease and 
hypertension (WTCCC, 2007). Detailed description of each sample can be found in the 
WTCCC report. We used the summary data provided by  the WTCCC and excluded 
SNPs as per WTCCC (WTCCC, 2007).
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4.2.2. Gene and network analyses
We calculated gene-wide p-values using the FORGE software including in our 
analyses approximately  20000 protein-coding, lincRNA (long non-coding RNA)8  and 
miRNA (micro RNA) genes annotated in Ensembl v59. We mapped SNPs to genes if 
the SNP was within 20 kb of the annotated coordinates of the gene. We utilised the 
asymptotic Z FIX gene-wide association p-values calculated by FORGE and performed 
gene-set analyses with these gene-wide p-values and gene-sets derived from the protein-
protein interaction network (PPIN), as described in Chapter III. For all analyses we used 
the HapMap Phase 3 CEU genotypes (Altshuler et al., 2010) to calculate SNP-SNP 
correlations. We interpreted the biology of the significant PPIN sub-networks using 
MetaCore (GeneGo, Inc.; www.genego.com). GeneGO provides biological networks 
constructed by literature reviews of genes and gene product interactions and 
bioinformatic tools to analyse genomic data sets for enrichment in these biological 
networks. GeneGO’s tools assess the significance of the overlap  between our sub-
networks and their manually curated biological processes using hypergeometric 
distribution statistics. Please see Section 3.2.3 for additional details on the analyses 
performed with GeneGO’s biological processes annotations. We also tested the 
enrichment of the gene p-values obtained from the test of differential expression of 
between BD and control’s brains among PPIN sub-networks. This enrichment was 
assessed using the parametric analysis of gene set enrichment (PAGE) method (Kim and 
Volsky, 2005). To select significant genes and sub-networks we used the local false 
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8 lincRNA is a particular class of RNA molecules that do not code for protein products. 
Other classes of non-protein coding RNAs include the regulatory RNAs known as 
miRNA or the tRNA involve in protein translation. We have included lincRNA in our 
analyses because recent evidence suggest they have major roles in regulation of cellular 
processes and association with them is of potential interest. We refer the reader to 
(Guttman et al., 2009; Khalil et  al., 2009; Marques and Ponting, 2009; Loewer et  al., 
2010) for additional information.
discovery  rate (FDR) (Efron et al., 2001; Efron, 2010) as implemented in the package 
“fdrtools” version 1.2.6 (Strimmer, 2008) for R (R Development Core Team, 2010).
4.2.3. Meta-analyses
Gene and network level statistics from different studies were combined using the 
fixed-effect model described in Chapter II for the gene-wide testing. We set study 
specific weights calculated as the square root of the sample size: WTCCC =70.71, Sklar 
= 59.16 and Bonn = 44.72. When combining GWAS and gene-expression studies, equal 
weights were used. The use of weights equal to the square root  of the sample sizes is a 
common practice in meta-analyses when no additional information is available to 
quantify the uncertainty of the individual association statistic. We refer the interested 
reader to a recent discussion in the topic by Zaykin (2011). 
4.2.4. cDNA microarray analysis
The gene-expression data of dorsolateral prefrontal cortex (DLPFC) tissue from 61 
subjects (30 control and 31 bipolar patients) and orbitofrontal cortex (OFC) tissue from 
21 subjects (10 controls and 11 bipolar patients) reported by Ryan et al. (2006) was 
downloaded from the ArrayExpress database (Parkinson et al., 2009) under accession 
number E-GEOD-5392. Raw intensity values of Affymetrix Human Genome U133A 
arrays were normalized with the Robust Multi-Average (RMA) algorithm (Irizarry  et 
al., 2003). Pre-filtering removed transcripts not detected (marked as ‘absent’ by  using 
MAS5 detection call algorithm) in all samples and were not considered further. Please 
see Ryan et al. (2006) for details of demographic variables of cases and controls. We 
used as covariates variables that showed differences between cases and controls or were 
correlated with RNA quality  measures and therefore can be considered as potential 
confounders. The generalised linear model (GLM) with covariates was used to assess 
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differential expression for each probe in each brain region: for the DLPFC samples we 
used the GLM  model with disease status (control/BD) as the main effect while 
controlling for brain pH and fluphenazine equivalents; and for the OFC samples, we 
used fluphenazine equivalents as a covariate.
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Figure 4.1. Data analysis strategy. Gene-wide p-values for association with BD were 
calculated on four GWAS and 2 gene-expression studies. Gene-wide results were 
mapped to the PPIN and a greedy search strategy  (Ideker et al., 2002) was used to 
identify subnetworks of interacting proteins enriched with BD association signals. A 
meta-analysis of the GWAS gene-wide association p-values and PPIN subnetworks 
results was carried out. GWAS PPIN results were combined with gene-expression 
subnetwork results and significant subnetworks were characterised with regard to their 
biological functions and locus heterogeneity. Colour codes are: Grey = statistical/
bioinformatic analyses, yellow = final results, blue = GWAS data and green = gene-
expression data. DLPFC = doroslateral prefrontal cortex and OFC = orbitofrontal cortex 
tissue.
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4.3.1. Gene-based association 
We combined results from three GWAS (WTCCC, 2007; Sklar et al., 2008; Cichon 
et al., 2011) and two gene-expression studies of BD (Ryan et al., 2006). The combined 
data was analysed using gene and network analyses to identify biological processes 
enriched among BD associated genetic variants and gene-expression changes (Figure 
4.1). Detailed descriptions of these datasets have been provided elsewhere. All studies 
used DSM-IV criteria to establish BD diagnosis and quality control included sample 
and genetic marker filters to exclude low quality data.




















DHH 3.31 2.61 2.31 4.79 0.04 - - - -
LMBR1L 3.09 2.61 2.31 4.65 0.049 1.97 1.06 4.68 4.04
LMAN2L b 2.86 1.79 3.29 4.44 0.073 0.36 1.65 3.39 4.31
RHEBL1 3.61 1.69 1.70 4.21 0.108 - - - -
ENSG00000211987 3.57 0.34 3.28 4.09 0.129 - - - -
MURC 2.90 1.96 2.03 4.02 0.143 - - - -
DUSP28 4.37 0.65 1.30 3.96 0.157 - - - -
ITIH3 a 2.66 1.79 2.37 3.90 0.169 -0.22 1.33 2.6 3.70
ENSG00000246653 2.86 1.30 2.65 3.88 0.174 - - - -
Table 4.1: Gene-based meta-analysis of bipolar disorder GWAS. Table reports 
statistics for genes reaching FDR < 0.2 in the gene-based GWAS meta-analysis. For 
each GWAS dataset we report z-scores obtained from the gene p-values using the 
normal distribution inverse cumulative distribution function. For the meta-analysis of 
GWAS results we report the pooled z-scores estimate (ZGWAS) and the FDR value for 
each gene. For the gene-expression data we report z-scores obtained from the p-values 
calculated with the test of differential gene-expression between cases and controls for 
each brain region (ZOFC and ZDLPFC). For the combined analysis of GWAS and gene-
expression we report z-scores obtained by pooling the ZGWAS with each brain region z-
score, which gave raise to two meta-analysis z-scores, ZGWAS-DLPFC and ZGWAS-OFC. 
DLPFC= doroslateral prefrontal cortex and OFC = orbitofrontal cortex tissue. Loci 
with previously  reported genetic association with bipolar disorder by a Scott et al.
(2009) and b Ferreira et al. (2008). 
We calculated gene-wide association p-values for the three GWAS using the FORGE 
software and for the gene-expression studies using a standard differential expression 
analysis with covariates (see Methods). Gene-based GWAS meta-analysis showed 
significant (FDR < 0.05) and suggestive evidence (FDR < 0.2) for 2 and 7 genes, 
respectively (Table 4.1). The two significant genes, DHH and LMBR1L, are within a 
region on chromosome 12q13.12 with high LD spanning several genes that had FDR < 
0.2, including RHEBL1. The haplotype block containing ITIH3 and 
ENSG00000246653 has been reported to have genome-wide significance for BD (Breen 
et al., 2011). The loci of LMAN2L and DUSP28 had high but sub-threshold significance 
in the meta-analysis by Ferreira et al. (2008) (rs2314398 p-value = 3 x 10-6) and 
WTCCC report (WTCCC, 2007). Finally, the MURC region has not been previously 
associated with BD and ENSG00000211987 is a miRNA gene predicted based on its 
similarity to MIR548C (hsa-mir-548c). We found no evidence of expression for 
ENSG00000211987 in public databases. Of the genes with FDR < 0.2 only LMBR1L 
had evidence of differential expression in brains of BD patients compared with controls 
(Table 4.1).  
 To identify groups of interacting gene products enriched among BD association 
signals, we mapped gene-level results from the GWAS and gene-expression studies to 
the protein-protein interaction network (PPIN) and tested the association of 
approximately 6100 sub-networks between 2 and 200 nodes (gene products) in size. We 
did not identify  significant sub-networks by meta-analysis of the GWAS results but 
several reached suggestive levels. To strengthen the results from the genetic data alone, 
we combined the evidence of GWAS and gene-expression studies at the PPIN sub-
network level. There were 3 and 1 sub-networks with FDR < 0.2 in the meta-analysis of 
GWAS and DLPFC or OFC gene-expression, respectively (Table 4.2). The best sub-
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network, PPIN-1576 (GWAS-DLPFC 
meta-analysis z-score = 4.73, p-value 
= 1 x 10-6 and FDR = 0.1) had > 60% 
overlap with the other two sub-
networks (Table 4.3), which suggests 
that all three sub-networks captured 
the same signal. We focused on 
PPIN-1576, depicted in Figure 4.2, for 
additional bioinformatic analyses to 
characterise its possible biological 
functions. 
Genes of PPIN-1576 were strongly 
enriched (FDR < 0.001) among the 
GeneGO biologica l ca tegor ies 
gonadotropin-releasing hormone 
(GnRH) signalling pathway (p-value = 
2 x 10-9), transmission of nerve 
impulse (p-value = 2 x 10-9) and 
hemopoiesis and erythropoietin 
pathway (p-value = 3 x 10-7) (Table 
4.4). In common with previous reports 
(Baranzini et al., 2009; Wang et al., 
2009; O'Dushlaine et al., 2011), we 
found that genes driving the network 
associations were different in each 






















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































data set  (Figure 4.3 and Additional Table 4.1). 
Only SYNCRIP1 out  of 181 PPIN-1576 genes 
had nominally significant gene p-values in 
more than one GWAS. In line with gene-set 
analysis results of schizophrenia GWAS 
(O'Dushlaine et al., 2011) there was no evidence of association with PPIN-1576 in six 
non-psychiatric complex diseases (Table 4.5). This may suggest some degree of 
specificity to psychiatric illness. However, this evidence is relatively weak because we 
do have less statistical power on these six GWAS than on our combined BD GWAS data 
set. Furthermore, we are not testing gene-expression data on these other six disorders, 
which in the case of bipolar disorder was important to identify the association with 
PPIN-1576.
4.3.2. Candidate-Gene-Networks of bipolar disorder GWAS hits
The significant PPIN-1576 network was identified after a hypothesis free analysis of 
the PPIN. However, if disease susceptibility  genes are known it is possible to define 
regions of the PPIN that are likely  to harbour additional disease genes (Goh et al., 2007; 
Wu et al., 2008). Thus, we hypothesised that the network environment of BD 
susceptibility genes should be over-represented with genetic susceptibility variants and 
gene expression changes, potentially  enabling us to strengthen the evidence for these 
putative susceptibility genes. We identified nine genes as candidates based on their 
proximity (< 20 kb) to genetic variants reported with p-values < 5 x10-8 in BD GWAS: 
ANK3, CACNA1C, PBRM1, NT5DC2, NCAN, HALPN4 and TM6SF2 from three 
meta-analyses (Ferreira et al., 2008; Cichon et al., 2011) and PALB2, DCTN5 and 
DGKH from two individual studies (WTCCC, 2007; Baum et al., 2008). We then tested 
for association 45 Candidate-Gene-Networks (CGNets, PPIN sub-networks including 




PPIN-5042 0.63 0.99 121
Table 4.3. Fraction of genes 
s h a r e d b e t w e e n P P I N 
subnetworks with FDR < 0.2. 
Diagonal reports the total number of 
genes in each subnetwork.



















































































































































































the BD candidate genes) with less than 50 nodes to capture information from the genes’ 
adjacent network environment. We found a CGNet for the gene CACNA1C that was 
significant after multiple testing correction (PPIN-6152 GWAS meta-analysis corrected 
p-value = 0.01) that was supported by  the gene-expression datasets (Table 4.6 and 
Figure 4.2). Two other CACNA1C CGNets, PPIN-4800 and PPIN-4877, were not 
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Biological Category Genes in/total P-value
Reproduction: GnRH signaling pathway 17/91 2 x 10-9
Neurophysiological process: Transmission of nerve 
impulse 20/129 2.1 x 10
-9
Reproduction: Gonadotropin regulation 17/116 9 x 10-8
Development: Hemopoiesis, Erythropoietin pathway 15/98 3 x 10-7
D e v e l o p m e n t : B e t a - a d r e n e rg i c r e c e p t o r s 
transactivation of EGFR 8/22 7.4 x 10
-7
Deregulation of PSD-95-dependent signaling in 
Huntington's disease 8/22 7.4 x 10
-7
Signal transduction: NOTCH signaling 20/185 1 x 10- 6
Signal transduction: Neuropeptide signaling pathways 14/97 1.6 x 10-6
Signal transduction: ESR1-membrane pathway 11/61 2.4 x 10-6
Development: Neuromuscular junction 14/101 2.6 x 10-6
Development: Gastrin in cell growth and proliferation 10/43 3 x 10-6
Signal transduction: WNT signaling 16/134 3.7 x 10-6
Neurophysiological process: Long-term potentiation 9/42 4.6 x 10-6
Neurophysiological process: Receptor-mediated axon 
growth repulsion 9/37 6.5 x 10
-6
Neurophysiological process: Dopamine D2 receptor 
transactivation of PDGFR in CNS 5/9 8.4 x 10
-6
Development: Delta-type opioid receptor signaling via 
G-protein alpha-14 6/17 2.4 x 10
-5
Development: G-Proteins mediated regulation 
MARK-ERK signaling 7/26 3.6 x 10
-5
Development: Angiotensin signaling via PYK2 7/26 3.6 x 10-5
Development: Angiotensin activation of ERK 6/19 5 x 10-5
Development: Alpha-2 adrenergic receptor activation 
of ERK 7/28 6.1 x 10
-5
Table 4.4. Top 20 biological  categories characterizing PPIN-1756 sub-network’s 
genes. Gene counts denote the number of PPIN-1756 genes within the biological 
category and the category’s total size. Significance for the overlap of PPIN-1756 genes 
and those annotated on the biological process was calculated p-value was calculated 
assuming a null hypergeometric distribution (see Methods for additional details). All 
categories reported reached an FDR < 0.001.




























































































































































































































































significantly associated in the GWAS data but had significant evidence of differential 
gene-expression (Table 4.6 and Figure 4.2). Two ANK3 CGNets, PPIN-3052 and 
PPIN-6701, reached significance when the GWAS and DLPFC gene-expression results 
were combined (Table 4.7). In Additional Table 4.2, we report results for the 45 CGNets 
tested for the 6 candidate genes present in the PPIN. ANK3 CGNets had almost 
complete overlap and their genes were best characterised by biological processes related 
to apoptosis signalling cascades, such as FAS (p-value = 7 x10-12) or IAP-proteins 
signalling (p-value = 3 x10-8). Biological categories over-represented in CACANA1C 
CGNets included synaptic vesicle exocytosis (p-value = 4 x10-16), synaptogenesis (p-
value = 4 x10-15), calcium transport (p-value = 4 x10-12) and GABAergic 
neurotransmission (p-value = 1 x10-9). We repeated the CGNet analysis by removing the 
candidate gene and the associations remained significant, suggesting that these CGNet 
associations were not driven by the candidate gene statistics (data not shown).
4.4. Discussion
Our results show that genetic variants and gene-expression changes associated with 
BD are not randomly distributed across genes, but cluster into discrete groups. These 









Table 4.5. Enrichment of association signals of 6 non-psychiatric disorders in sub-
network PPIN-1576. Table reports p-values for the gene-set  analysis of PPIN-1576 in 
the 6 non-psychiatric GWAS results of the WTCCC (2007). Null hypothesis of no 
enrichment was tested. I have added z-scores for easier comparison with the results 
presented on Table 4.2. CAD = coronary  artery  disease, CD = Crohn’s disease, HT, 
hypertension, RA = rheumatoid arthritis, T1D = type 1 diabetes and T2D = type 2 
diabetes. 
































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































can be identified with information from disease association signals and evidence of 
direct or indirect interaction in the context of a protein-protein interaction network 
(Table 4.2). By  combining GWAS and gene-expression data we provided significant 
convergent evidence for PPIN-1576 (Figure 4.2). PPIN-1576 is a PPIN sub-network 
characterised by biological processes related to GnRH signalling, transmission of nerve 
impulse and hemopoiesis (Table 4.4). Interestingly, post-hoc analyses showed that 
PPIN-1576 overlaps significantly with the human post-synaptic density (hPSD) recently 
described by  a large proteomic study: 22% of overlap  compared with 12% expected by 
chance (p-value = 6 x10-9). The hPSD was shown to be enriched with genes affected by 
mutations causing neurological, central nervous system (CNS) and cognitive 
phenotypes, such as mental retardation or Alzheimer’s disease (Bayes et al., 2011). 
Therefore, not only rare mutations with large effect-size but also common variants and 
gene expression changes seem to affect the hPSD as a mediator of disease risk. 
Furthermore, data presented here and by  others highlight the potential to shed light on 
the molecular basis of complex diseases by  combining statistical signals normally 
buried under strict GWAS significance thresholds with knowledge of protein function, 
e.g., protein-protein interactions (for examples see refs (Baranzini et al., 2009; Wang et 
al., 2009; Ruano et al., 2010), and gene-expression changes (Hsu et  al., 2010; Zhong et 
al., 2010a; Zhong et al., 2010b).
This strategy also strengthened previously identified GWAS significant  associations 
with BD. Candidate-Gene-Network analyses of GWAS and it integration with gene-
expression results lent additional support to CACNA1C and ANK3, the most robust 
results from BD GWAS to date, and suggested that their network environment is 
associated with apoptosis signalling pathways and cellular processes regulated by 
calcium, such as vesicle exocytosis (Tables 4.6 and 4.7). 
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Our gene-based meta-analysis highlighted regions previously known to harbour BD 
susceptibility variants and pointed to a possible new locus on chromosome 12q13.12. 
This region has high LD spanning over 200 kb and several plausible BD candidate 
genes. For example, DHH is involved in the WNT signalling pathway  which is a 
candidate pathway for BD and target of BD drug treatments, such as lithium (Gould and 
Manji, 2002). Unfortunately, not much biological characterisation exists for the second 
most associated gene, LMBR1L, except that it has been shown to be a lipocain receptor 
(Wojnar et  al., 2001) and is expressed in many tissues, including the CNS (Wu et al., 
2009).
The best GWAS gene-based association within the PPIN-1576 sub-network was with 
the corticotropin releasing hormone receptor 1 (CRHR1, Bonn GWAS gene p-values = 
1 x10-5), a gene with key  mechanistic roles in the hypothalamic-pituitary-adrenal (HPA) 
axis, which has been associated with stress response and mood disorders (Gillespie et 
al., 2009). Other noteworthy  genetic associations were with MAPT, a gene associated 
with neurodegenerative diseases (MIM +157140), and several membrane transporters 
previously  associated with neuropsychiatric disorders such as KCNQ2 (Hahn and 
Neubauer, 2009), GRM3 (Harrison et al., 2008) and GRM7 (Walsh et al., 2008; Saus et 
al., 2010).
Several of the biological functions over-represented in PPIN-1576 are in line with 
those reported in previous GSA analyses of BD GWAS (Holmans et al., 2009; 
O'Dushlaine et al., 2011). For example, Holmans et al. (2009) found significant 
association with GO0005179 (p-value = <0.0001 in Table 4 of Holmans et al., 2009), 
which is a parent in the Gene Ontology classification of gonadotropin hormone-
releasing activity (GO0005183), where we also found association (Table 4.4). To the 
best of our knowledge, the hemopoiesis and erythropoietin pathway has not been 
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previously  associated with BD. There is evidence that Lithium, the most widely used 
drug for BD, can modulate several aspects of hemopoiesis (Young, 1980; Focosi et al., 
2009) and our findings point to changes in hemopoiesis as part of the genetic aetiology 
of BD. Additional studies will be needed to clarify the relationship between BD and 
hematopoiesis.
In line with previous reports (Baranzini et al., 2009; Wang et al., 2009; O'Dushlaine 
et al., 2011), we found that system-level genetic associations in complex traits are 
heterogeneous (Figure 4.3 and Additional Table 4.1). However, this heterogeneity  is 
approachable and GWAS can be mined for biological processes underlying complex 
traits, as recently  reviewed in Wang et  al. (2010). Although overcoming genetic 
heterogeneity was a major motivation of our study, we do acknowledge the merit of 
increasing the sample size to improve statistical power; unmistakably this has been a 
successful approach for some complex traits, e.g., (Teslovich et al., 2010). However, in 
some situations increasing sample size is not an option, for example in the case of rare 
diseases. Many  non-replicated signals are likely to be false positives or represent true 
disease-susceptibility  alleles whose effect  is not detected in all studies due to low 
statistical power. It is also possible that the effect  of these alleles is not expressed due to 
differences in haplotype background across populations, exposure to environmental 
factors or ascertainment differences across studies, among others possibilities. Despite 
this, by clustering these weak signals with prior knowledge of biological pathways and 
networks, it is possible to identify molecular systems underlying complex traits.
A major limitation of our approach, and those based on predefined gene-sets, e.g., 
those of Wang et al. (2007), Baranzini et al. (2009), Holmans et al. (2009) and 
O'Dushlaine et al. (2011), was the relatively low or biased coverage of the protein 
interactome, which only  included ~8000 genes of the ~21000 genes covered by the 
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GWAS analysed. However, this will improve as more experiments are annotated in the 
public databases. We think the poor replication of the GWAS findings on the OFC gene-
expression compared with DLPFC can be partially explained due to true differences in 
gene-expression between these two brain regions (Pearson’s correlation between gene-
expression fold changes of both regions = 0.35, 95% confidence interval = 0.33 - 0.37, 
N = 7,157) and differing degrees of involvement or sensitivity  to BD pathology. Perhaps 
primarily, the OFC’s lower power was due to the smaller sample size (1/3 of the DLPFC 
study size).
In summary, we found a significant and replicable association with a network 
involved in regulation of gonadotropin hormone-releasing activity, transmission of 
nerve impulse and hemopoiesis. We also found that CGNet analyses can add support to 
genome-wide significant associations. We suggest that these approaches are highly 
complementary  to large meta-analytical studies based on single SNP analyses. Our 
results warrant  replication in additional genetic and gene-expression samples. 
Functional studies will be needed to understand the pathological effects of interactions 






C Sklar Bonn DLPFC Gene Symbol
WTC
CC Sklar Bonn DLPFC
CRHR1 0.819 0.295
1.5E-0
5 0.048 MYH2 0.595 0.333 0.856 0.747
MAPT 0.392 0.259
1.4E-0
4 0.228 GLP2R 0.665 0.378 0.392 0.712
GAD1 0.306 0.439 0.239 0.001 YWHAE 0.594 0.228 0.076 0.154
RGS4 0.329 0.296 0.391 0.001 TP73 0.081 0.807 0.869 0.161
SYNCRIP 0.710 0.030 0.932 0.001 GRK1 0.276 0.082 0.882 0.464
PIK3CB 0.614 0.849 0.276 0.001 MAPK3 0.311 NA 0.501 0.082
NRXN1 0.838 0.510 0.311 0.001 LTF 0.395 0.708 0.574 0.083
MYO7A 0.363 0.038 0.133 0.002 ESRRG 0.684 0.162 0.483 0.083





C Sklar Bonn DLPFC Gene Symbol
WTC
CC Sklar Bonn DLPFC
SCTR 0.502 0.361 0.002 0.260 IQGAP2 0.439 0.541 0.084 0.611
VDAC1 0.146 0.800 0.975 0.002 TRPV4 0.408 0.350 0.086 0.346
SLC25A4 0.202 0.274 0.707 0.002 CCND1 0.214 0.582 0.351 0.086
NR3C1 0.639 0.039 0.455 0.003 CCNE1 0.711 0.537 0.086 0.538
KCNQ2 0.257 0.318 0.003 0.176 PLCD1 0.645 0.120 0.596 0.091
GLP1R 0.567 0.926 0.473 0.003 EDF1 0.540 0.096 0.980 0.523
PDLIM5 0.429 0.486 0.814 0.065 PPEF1 0.420 0.096 NA 0.122
STRN4 0.375 0.386 0.646 0.576 GRM5 0.516 0.490 0.777 0.097
PCP4 0.518 0.287 0.894 0.004 TRPC3 0.665 0.683 0.722 0.120
HSP90AA1 0.635 0.361 0.744 0.004 MYLK 0.724 0.100 0.668 0.610
RALB 0.725 0.940 0.148 0.005 ATP2B1 0.550 0.356 0.102 0.126
SYT1 0.441 0.894 0.123 0.005 KCNQ3 0.235 0.105 0.620 0.157
GAD2 0.646 0.749 0.043 0.005 TIAM1 0.777 0.456 0.863 0.109
KCNN4 0.356 0.143 0.005 0.545 RIPK1 0.536 0.245 0.132 0.110
RAF1 0.632 0.512 0.475 0.888 KCNN2 0.543 0.860 0.601 0.113
GRK4 0.493 0.788 0.689 0.006 RELA 0.554 0.645 0.115 0.305
FAS 0.006 0.159 0.135 0.189 ACTC1 0.666 0.375 0.953 0.618
TCF3 0.139 NA 0.804 0.006 RNF11 0.681 0.494 0.949 0.117
PRKD1 0.509 0.821 0.612 0.007 PPEF2 0.529 0.296 0.761 0.128
DLG3 0.170 0.026 NA 0.008 VIPR1 0.683 0.349 0.125 0.820
SH3GL2 0.316 0.242 0.941 0.008 CALCR 0.154 0.536 0.127 0.367
SNTA1 0.648 0.044 0.978 0.009 OPRD1 0.379 0.135 0.603 0.222
TRPV6 0.673 0.554 0.170 0.009 NRGN 0.270 0.262 0.817 0.415
TRPV1 0.015 0.124 0.051 0.010 IQGAP1 0.833 0.731 0.812 0.139
SNCA 0.902 0.290 0.281 0.011 POLR2A 0.140 0.667 0.854 0.876
RPS6KB2 0.191 0.746 0.498 0.012 NEDD9 0.727 0.788 0.269 0.146
CLTB 0.672 0.372 0.610 0.131 OBSCN 0.253 0.604 0.151 NA
RIT2 0.833 0.176 0.413 0.013 ESR2 0.639 0.219 0.372 0.152
GRM3 0.144 0.013 0.344 0.950 ATN1 0.327 0.907 0.773 0.152
RALA 0.549 0.736 0.014 0.718 MYO9B 0.317 0.185 0.164 0.161
MAPK1 0.702 0.491 0.015 0.037 AKAP5 0.194 0.735 0.547 0.162
EGFR 0.262 0.015 0.378 0.072 FYN 0.199 0.194 0.762 0.169
ASCL2 0.806 0.015 0.058 0.420 ESR1 0.501 0.168 0.568 0.188
AKAP9 0.543 0.132 0.016 0.024 SRC 0.484 0.172 0.337 0.426
CAMKK2 0.775 0.670 0.709 0.018 KCNQ5 0.650 0.175 0.310 NA
CAMK1 0.019 0.250 0.861 0.416 RGS2 0.340 0.554 0.782 0.176
SNAP25 0.555 0.075 0.334 0.020 GNB2L1 0.669 0.182 0.536 0.225
MYOG 0.215 0.158 0.020 0.752 GNA13 0.816 0.378 0.185 0.311
KRAS 0.725 0.551 0.357 0.020 BTK 0.509 0.262 NA 0.188
GRB7 0.421 0.055 0.021 0.723 HTR2C 0.786 0.821 NA 0.190
BRAF 0.586 0.022 0.474 0.892 JUN 0.354 0.249 0.750 0.192
CALD1 0.633 0.525 0.694 0.022 KRT18 0.767 0.543 0.328 0.197
SLC4A3 0.732 0.188 0.131 0.957 NEUROD1 0.483 0.199 0.572 0.962
SGK3 0.621 0.296 0.715 0.590 ADCYAP1R1 0.749 0.200 0.820 0.694
CPSF6 0.557 0.736 0.174 0.026 SYT9 0.200 0.876 0.535 NA
GRM4 0.129 0.226 0.742 0.026 TRPV2 0.413 0.918 0.592 0.207





C Sklar Bonn DLPFC Gene Symbol
WTC
CC Sklar Bonn DLPFC
TRPC4 0.128 0.026 0.975 0.135 DDX5 0.881 0.790 0.522 0.225
ITPKA 0.504 0.026 0.662 0.542 HMMR 0.625 0.216 0.362 0.480
TCF4 0.633 0.675 0.525 0.029 PPP1R14A 0.320 0.216 0.385 NA
CALM1 0.793 0.474 0.581 0.030 ACTA1 0.297 0.364 0.218 0.288
GAP43 0.415 0.610 0.506 0.031 ADCY8 0.219 0.434 0.429 0.357
CNN1 0.032 0.100 0.394 0.038 MYF6 0.224 0.280 0.240 0.361
PHKG1 0.126 0.034 0.444 0.966 AFAP1 0.760 0.700 0.269 0.224
REL 0.775 0.530 0.162 0.407 ITGB1 0.818 0.230 0.401 0.299
MIP 0.229 0.143 0.228 0.036 RAG1AP1 0.879 0.701 0.836 0.239
NUMB 0.709 0.447 0.490 0.068 TTN 0.571 0.239 0.451 0.511
MYO10 0.468 0.183 0.197 0.038 DTX1 0.253 0.328 0.399 NA
COPB1 0.310 0.468 0.041 0.068 PDE1A 0.628 0.257 0.583 0.321
CSNK1A1 0.596 0.849 0.765 0.042 CBLC 0.664 0.323 0.393 0.260
LYST 0.291 0.042 0.736 0.142 RAB3B 0.263 0.922 0.723 0.575
ITPKB 0.056 0.446 0.076 0.042 PTH2R 0.555 0.464 0.897 0.358
NOTCH1 0.137 0.621 0.206 0.042 STRN3 0.523 0.498 0.718 0.267
CFTR 0.112 0.966 0.412 0.043 EWSR1 0.413 0.619 0.626 0.275
CHAT 0.531 0.255 0.641 0.806 GRIN2D 0.607 0.833 0.276 0.363
GRIN1 0.647 NA 0.889 0.046 CAMK2G 0.762 0.434 0.718 0.292
MYF5 0.248 0.280 0.046 0.109 FER 0.308 0.364 0.621 0.483
CABIN1 0.720 0.457 0.427 0.047 PRKCE 0.436 0.723 0.627 0.321
PIK3C3 0.446 0.822 0.364 0.049 GJB1 0.663 0.642 NA 0.326
CSNK2A1 0.667 0.141 0.255 0.050 PDPK1 NA NA NA 0.337
OPRM1 0.539 0.051 0.152 0.249 RYR1 0.372 0.685 0.344 0.829
GJA1 0.069 0.361 0.795 0.052 TUBB NA NA NA 0.354
STRN 0.108 0.885 0.704 0.406 ADD1 0.804 0.827 0.428 0.389
AR 0.058 0.793 NA 0.309 PTPRA 0.402 0.941 0.517 0.436
HK2 0.059 0.584 0.338 0.861 CSNK2A2 0.855 0.744 0.688 0.405
ITCH 0.713 0.109 0.494 0.622 CBL 0.484 0.566 0.760 0.981
INSR 0.237 0.862 0.060 0.473 ADAP1 0.935 0.428 0.671 NA
RRAD 0.905 0.098 0.198 0.060 MYOD1 0.591 0.693 0.450 0.737
ADD2 0.492 0.481 0.903 0.066 TNNI2 0.452 0.637 0.748 0.460
RGS10 0.470 0.764 0.373 0.067 CAMKK1 0.480 0.978 0.642 NA
GRM7 0.482 0.573 0.515 0.068 NDFIP2 0.865 0.519 0.756 NA
KRT1 0.483 0.070 0.291 1.000 CNGA2 0.675 0.528 NA NA
COPB2 0.791 0.071 0.845 0.290 OCLN NA NA NA 0.945
Additional Table 4.1. Gene p-values of the PPIN-1576 sub-network genes. 
For GWAS data sets we transformed the gene z-score into p-values and for the 
DLPFC we report the p-values from the differential expression analysis. 

































52 1.15 2.08 -0.44 2.07 0.58 2.52 3.25 0.026 1.27 2.36 0.337
PPIN-67
01 1.13 1.81 -0.66 1.96 0.68 2.42 3.10 0.042 1.34 2.34 0.354
PPIN-34
68 0.37 0.22 -0.56 1.39 0.98 1.66 2.16 0.506 1.86 2.30 0.384
PPIN-30
67 0.74 0.57 0.79 1.45 0.97 -0.58 0.62 1.000 0.66 1.49 0.957
PPIN-60
58 -0.33 1.07 -1.03 0.69 1.00 1.76 1.73 0.852 1.20 1.33 0.987
PPIN-68
99 1.40 -1.10 0.02 0.61 1.00 -0.87 -0.19 1.000 0.48 0.77 1.000
PPIN-45
42 -0.25 -0.18 -0.28 0.04 1.00 1.50 1.09 0.999 0.57 0.44 1.000
PPIN-45
33 1.18 0.26 -0.18 0.71 1.00 -1.79 -0.76 1.000 -0.10 0.43 1.000
PPIN-31
85 0.45 0.57 -0.10 0.47 1.00 -1.42 -0.68 1.000 0.09 0.40 1.000
PPIN-62
44 0.01 0.79 0.53 0.39 1.00 -0.72 -0.23 1.000 -0.18 0.15 1.000
PPIN-12
75 0.00 0.64 -0.11 0.17 1.00 0.35 0.37 1.000 -0.09 0.05 1.000
PPIN-13
12 -0.12 -1.27 -0.85 -1.43 1.00 -0.08 -1.06 1.000 -0.74 -1.53 1.000
PPIN-28
75 -1.10 -1.62 -1.56 -2.37 1.00 -0.17 -1.79 1.000 -0.70 -2.16 1.000
PPIN-34
99 -1.07 -1.14 -1.07 -1.35 1.00 0.07 -0.90 1.000 0.03 -0.93 1.000
PPIN-38




87 0.30 0.09 -0.18 -0.09 1.00 0.64 0.39 1.000 -0.21 -0.21 1.000
PPIN-29
06 1.43 -1.21 0.18 -0.41 1.00 0.34 -0.05 1.000 -0.78 -0.84 1.000
PPIN-37
4 0.27 -0.59 1.78 0.95 1.00 0.55 1.05 0.999 0.54 1.05 0.999
PPIN-48
00 0.72 0.32 0.37 2.70 0.14 1.53 2.99 0.060 2.92 3.97 0.002
PPIN-48
77 0.83 1.65 -0.59 2.80 0.11 2.78 3.95 0.002 2.59 3.81 0.003
PPIN-52
45 -0.66 0.24 1.13 1.43 0.97 1.14 1.82 0.791 1.82 2.30 0.384
PPIN-56
88 1.32 -0.04 0.39 1.88 0.74 1.32 2.27 0.412 1.52 2.41 0.304
PPIN-57
5 1.15 -1.00 -0.80 -1.03 1.00 2.24 0.85 1.000 -1.34 -1.68 1.000
PPIN-61
52 1.58 0.43 2.35 3.49 0.01 1.17 3.29 0.022 1.98 3.86 0.002
PPIN-63
83 1.64 0.18 -0.04 1.76 0.84 1.24 2.12 0.536 1.09 2.02 0.631
PPIN-83
5 0.18 -0.84 0.44 -0.84 1.00 -0.20 -0.74 1.000 -1.03 -1.33 1.000
DCTN5
PPIN-15
7 0.57 0.77 1.68 2.26 0.41 -0.32 1.37 0.982 1.25 2.48 0.255
PPIN-60
20 0.83 0.75 1.59 1.93 0.70 -0.75 0.83 1.000 0.77 1.91 0.720

































21 -0.31 0.66 1.45 0.80 1.00 1.02 1.28 0.991 2.05 2.01 0.632
PPIN-16
93 -0.61 -0.29 -0.81 -0.94 1.00 0.48 -0.33 1.000 -0.15 -0.77 1.000
PPIN-21
41 -1.30 -0.72 0.11 -1.26 1.00 1.28 0.01 1.000 -0.30 -1.11 1.000
PPIN-23
16 -0.72 0.52 -0.48 -0.41 1.00 0.18 -0.16 1.000 0.35 -0.04 1.000
PPIN-24
87 -0.40 1.03 -0.58 0.06 1.00 1.67 1.23 0.995 2.04 1.49 0.959
PPIN-26
00 1.46 -1.09 0.20 0.46 1.00 0.90 0.96 1.000 1.20 1.17 0.997
PPIN-32
53 -1.83 -0.64 -0.50 -1.85 1.00 1.28 -0.40 1.000 -0.07 -1.35 1.000
PPIN-36
59 -1.68 0.20 0.99 -0.61 1.00 2.05 1.02 0.999 0.64 0.02 1.000
PPIN-40
39 -0.42 -0.07 0.29 -0.20 1.00 1.78 1.12 0.998 0.15 -0.04 1.000
PPIN-71
86 -0.31 0.60 -0.74 -0.19 1.00 1.00 0.57 1.000 2.29 1.48 0.960
PALB2
PPIN-66
58 0.33 0.17 -2.20 -0.29 1.00 -0.82 -0.78 1.000 0.28 -0.00 1.000
PPIN-69
0 -0.27 -0.10 -1.66 -0.47 1.00 -0.74 -0.86 1.000 0.37 -0.07 1.000
PBRM1
PPIN-12 1.24 1.22 -1.90 0.73 1.00 1.96 1.90 0.728 1.84 1.82 0.795
PPIN-30
70 1.30 0.35 -0.76 0.76 1.00 2.16 2.06 0.588 1.80 1.82 0.796
PPIN-33
68 0.87 0.33 -1.62 0.09 1.00 1.84 1.37 0.983 1.65 1.23 0.995
PPIN-37
19 1.39 0.47 2.12 2.16 0.50 -0.39 1.25 0.994 0.35 1.77 0.826
PPIN-97
3 1.88 1.12 -1.61 1.24 0.99 2.04 2.32 0.368 1.00 1.59 0.926
Additional Table 4.2. Candidate-Gene-Networks of Bipolar Disorder. Table reports 
z-scores for GWAS and gene-expression studies and their meta-analysis results. 
Significance p-values of the meta-analysis results were corrected by the 45 networks 
tested using Sidak’s correction. ZGWAS, ZGWAS-DLPFC and ZGWAS-OFC are the meta-analysis 
z-scores by pooling GWAS and GWAS with each brain gene-expression results 
separately, respectively. DLPFC = doroslateral prefrontal cortex and OFC = 
orbitofrontal cortex tissue 
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Chapter V





Bipolar disorder (BD) is a chronic, episodic, and pathological disturbance resulting 
in extreme moods ranging from mania to severe depression and is usually accompanied 
by disturbances in cognition and behaviour. Psychotic features such as delusions and 
hallucinations often occur. There is robust evidence for a genetic contribution in the 
aetiology  of the disorder, with an estimated sibling recurrence risk 7-10 times higher 
than the general population risk and a heritability of 80-90% (McGuffin et al., 2003; 
Craddock et al., 2005). Diagnosis of BD is based solely on clinical features because, as 
yet, there are no validated diagnostic tests such as those available for many physical 
illnesses. There is some evidence suggesting BD is heterogeneous in clinical 
presentations, genetic aetiology and course of pharmacological response (Suppes et al., 
2000; Alda, 2004). A major goal of molecular psychiatric genetics is to improve the 
diagnostic classification of BD. With a better understanding of the biological systems 
underpinning BD, this could be possible and may in turn lead to more efficacious 
treatments.
Several genomic regions have been implicated through linkage (McQueen et al., 
2005), and genome-wide association studies (GWAS) of BD (Ferreira et al., 2008; 
Breen et al., 2011; Cichon et al., 2011). Increasing evidence suggests an overlap in 
genetic susceptibility  with schizophrenia (Purcell et al., 2009), a psychotic disorder with 
many similarities to BD, and often seen in extended families of affected individuals 
with BD (see review by Craddock et al. (2005)). In particular, association findings have 
been reported with both disorders in DAOA (D-amino acid oxidase activator)(Prata et 
al., 2009), DISC1 (Disrupted in schizophrenia 1)(Chubb et  al., 2008), NRG1 
(neuregulin 1)(Goes et al., 2009), DTNBP1 (dystrobrevin binding protein 1)(Breen et 
al., 2006), CACNA1C (calcium channel, voltage-dependent, L type, alpha 1C subunit) 
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(Ferreira et  al., 2008; Green et  al., 2010) and ZNF804A (zinc finger protein 804A) 
(O'Donovan et al., 2008). 
Analysis of disease sub-phenotypes can provide increased statistical power to detect 
disease-susceptibility  associations if the subgroup is genetically  more homogeneous or 
the sub-phenotype has a higher heritability  (Burmeister et al., 2008). Hamshere et al. 
(2009a) performed single marker association on BD sub-phenotypes using the WTCCC 
BD sample and found an association within the gene B3GALT5 on chromosome 
21q22.1 with the subtype schizoaffective bipolar disorder. In addition, they showed the 
schizoaffective bipolar disorder subtype had the strongest genetic signal among the six 
sub-phenotypes analysed. They suggested that individuals with broadly defined bipolar 
schizoaffective features either have a particularly strong genetic contribution or, as a 
group, are genetically more homogeneous than the other sub-phenotypes tested. In 
addition, Craddock et al. (2010) and Breuer et al. (2010) have reported significant 
association between the gamma-aminobutyric acid (GABA)-A receptor genes and the 
schizoaffective bipolar disorder subtype. Overall, current evidence suggests that the use 
of BD subtypes can help to identify additional loci which may be informative in 
understanding the aetiology of BD.
As discussed previously, single marker genetic association tests in moderately 
powered studies are unlikely to distinguish true associations from false, when the odds 
ratios of susceptibility alleles are low, or disease-susceptibility variants are rare (Schaid, 
2004). In the case of BD and its sub-phenotypes, either or both situations are likely  to 
apply. Gene and gene-set association methods can increase power to detect true 
association by clustering susceptibility variants within genes and biological processes 
(Baranzini et al., 2009; Wang et al., 2010; O'Dushlaine et al., 2011). We have shown this 
strategy can reveal additional replicated genes that eluded single marker analyses in the 
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WTCCC samples (see Chapter III) and an integrative biology approach is useful to 
reveal biological processes associated with BD susceptibility  (see Chapter IV). In this 
study, we explored the use of disease sub-phenotypes in combination with gene and 
gene-set association methods to identify  genes and biological processes associated with 
specific patient subgroups and their symptoms.
5.2. Material and Methods
5.2.1. Samples
We used the BD sample investigated in the WTCCC study. A detailed description of 
the sample has been provided elsewhere (WTCCC, 2007). All individuals were from the 
UK and over the age of 16 years. Clinical assessment included a semi-structured 
interview and review of case notes. BD cases (n=1868) had experienced at least  one 
episode of clinically significant elevated mood according to the following Research 
Diagnostic Criteria (RDC) (Spitzer et al., 1978): bipolar I disorder (BPI; n=1316), 
schizoaffective disorder bipolar type (SABP; n=279), bipolar II disorder (BPII; n=171) 
and manic disorder (n=102). Diagnoses following were also ascertained with the DSM-
IV (American Psychiatric Association, 1994) criteria and gave the following sub-
classification of bipolar disorder cases: bipolar I disorder (n=1594), schizoaffective 
disorder bipolar type (n=98), bipolar II disorder (n=134), and bipolar disorder not 
otherwise specified (n=42). Controls came from two sources: (a) the UK 1958 birth 
cohort longitudinal epidemiological sample (n=1458), and (b) the UK Blood Donor 
Service (n=1480). Controls were not screened for absence of psychiatric illness or 
family history. It has previously been shown that  these two control samples can be 
combined for use as controls in genetic association studies using UK disease samples, 
including the current BD sample (WTCCC, 2007).
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5.2.1.1. bipolar disorder sub-phenotypes
We extracted sub-phenotypes from the available clinical data (OPCRIT (Craddock et 
al., 1996)), as described previously by Hamshere et al. (2009a) and WTCCC (2007). 
The sub-phenotypes, analysed here, were defined using the RDC diagnosis as: 
i) Suicidality: the sub-phenotype positive group was suicidal ideation/
behaviour (n=793).
ii) Postnatal episode: postnatal episode of mood disorder (n=378).
iii) Lifetime Psychosis: multiple psychotic features (n=1065).
iv) Rapid Cycling: present during lifetime (n=222).
v) Age of Onset: age of onset for BD was used as quantitative trait.
vi) Schizoaffective bipolar sub-type: positive diagnosis (n=279).
A more detailed breakdown of the sub-phenotypes of this samples has been described 
elsewhere (Hamshere et al., 2009).
5.2.2. Genotypic data and statistical analyses
The WTCCC dataset comprised 469,557 single nucleotide polymorphisms (SNPs) 
distributed across the genome. Individuals were excluded as described in (WTCCC, 
2007). For the current analysis, SNP inclusion criteria were genotype quality over 90%, 
a minor allele frequency of at least 1% in the total sample, call rate >99% in the total 
sample, Hardy-Weinberg equilibrium p-value > 10-5 in cases, and Hardy-Weinberg 
equilibrium p value > 10-3 in controls. 
Single marker associations using a logistic regression for case-control association 
tests using the sub-phenotype positive groups and population controls were undertaken 
in PLINK (Purcell et al., 2007). We set genome-wide significance and suggestive 
thresholds at a p-value = 5 x 10-8 and 7.5 x 10-7 to apply a Bonferroni correction equal to 
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0.05/(number of tests) and 0.5/(number of test), respectively, with the number of test 
genome-wide equal to ~694,000 as per (Dudbridge and Gusnanto, 2008).
5.2.3. Imputation
We performed imputation using the software IMPUTE (Marchini et al., 2007) with 
the 1000 genomes project and HapMap  Phase 3 data combined as reference panels. 
Software and files were downloaded from the IMPUTE website (http://
mathgen.stats.ox.ac.uk/impute/impute.html).
5.2.4. Gene and networks analysis
We calculated gene-based association p-values using the FORGE software on 
approximately 20,000 protein-coding, lincRNA and miRNA genes annotated in 
Ensembl v59. SNPs were mapped to genes if they  were located 20 kb upstream or 
downstream of the annotated coordinates. We utilised the Z FIX gene-association p-
values calculated by the software FORGE and performed gene-set analyses with the 
gene p-values and gene-sets derived from the protein-protein interaction network 
(PPIN), as described in Chapter II. We interpreted the biology of the significant PPIN 
sub-networks using MetaCore (GeneGo, Inc. www.genego.com). Please see Section 
3.2.3 for details on the analyses performed with the tools and data sets provided by 
GeneGO. Throughout the thesis we have used a FDR threshold of 0.1 to select 
interesting sub-networks. However, in order to account for the multiple testing 
performed by analysing six phenotypes we have set our FDR threshold to 0.01 
(approximately 0.1/6 or 0.16) and consider an FDR < 0.1 only as suggestive evidence. 
5.2.4.1. Analysis of GABA(A) receptor genes in SABP
We also applied the gene-set association method implemented in PLINK that was 
used by  two previous studies (Breuer et al., 2010; Craddock et al., 2010) to analyse the 
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GWAS of the SABP sub-phenotype. Details of the method can be found on the PLINK 
website. Briefly, the association analysis was performed using the PLINK SNP-set 
association method, which works with the following procedure (obtained from PLINK’s 
website):
i) For each SNP in the set determine which other SNPs are in LD, above a 
certain threshold of r2;
ii) Perform standard single SNP analysis, in this case a case-control association 
a chi-square test or a logistic regression with covariates;
iii) For each SNP-set, select up  to N "independent" SNPs (as defined in step  1) 
with p-values below a p-value threshold P. The best SNP is selected first; 
subsequent SNPs are selected in order of decreasing statistical significance, 
after removing SNPs in LD with previously selected SNPs;
iv) From these subset of SNPs, the statistic for each SNP-set is calculated as the 
mean chi-square with one degree of freedom statistics of these single SNP;
v) Permute the dataset a large number of times, keeping LD between SNPs 
constant (i.e. permute phenotype labels);
vi) For each permuted dataset, repeat steps 2 to 4 above;
vii) Empirical p-value for the SNP-set is the number of times the permuted set-
statistic exceeds the original one for that SNP-set.
5.3. Results 
5.3.1. Genome-wide association study of BD sub-phenotypes
After quality filtering, 370,322 SNPs were tested for association in the WTCCCC 
BD sample. No SNP reached genome-wide significance at p-values < 5 x 10-8 but six 
reached our suggestive significance level of p-value < 7.5 x 10-7 (Table 5.1). Three 
CHAPTER V GWAS OF BD SUB-PHENOTYPES  
137
SNPs associated with SABP were located at chromosome 21q22.1 (rs734413, P = 2.7 x 
10-7, OR = 1.7 (95% CI= 1.4 - 2.0); rs4818065, P = 2.4 x 10-7, OR = 1.7 (1.4 - 2.0); 
rs4818066, P = 4.0 x 10-7, OR = 1.7 (1.4 - 2.0)) are in a region of strong LD overlapping 
with the genes B3GALT5 and ENSG00000225330 (Figure 5.1). We noted a second 
apparently  independent association signal approximately 100 kb away from the main 
signal and overlapping both a longer isoform of B3GALT5 and the gene C21orf88 
(ENSG00000184809). We re-analysed the region covering both association signals with 
the HyperLasso regression method as it permits the identification of independent 
associations signals in a region (Hoggart et al., 2008) and found supportive evidence for 
the presence of a second signal at rs11088486 (r2 with rs734413 = 0.02), under both a 
dominant (P = 7.1 x 10-4, OR = 0.6 (0.5 - 0.8)) and additive (P = 0.001, OR = 0.7 (0.6 - 
0.9)) genetic model. We found no evidence for interaction between these variants (P = 
0.8). Imputation of typed and untyped markers confirmed these results but did show 
evidence of new associations surpassing them. Although, this may seem a negative 
results it also provides some support for the original results because imputation can 
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Sub-phenotype Chromosome Position SNP p-value Genes within 20 kb
Postnatal 
Episode 5 94263154 rs26998 7 x10
-7 MCTP1
SABP
3 49865617 rs2352974 4 x10-7 TRAIP, CAMKV
15 87413740 rs16942644 7 x10-7 --
21 39954674 rs734413 3 x10-7 B3GALT5
21 39959593 rs4818065 2 x10-7 B3GALT5
21 39959669 rs4818066 4 x10-7 B3GALT5
Table 5.1. GWAS results for Bipolar Disorder sub-phenotypes. Reported SNPs 
reached suggestive evidence at a p-value < 7.5 x 10-7. Gene annotation based on 
Ensembl database.
improve genotype quality  at poorly  genotyped SNPs 9. Imputation showed association 
with an untyped non-synonymous variant  (rs3746887, P = 3.0 x 10-7, OR = 0.60 (0.49 - 
0.74), imputation posterior probability = 0.996) leading to a methionine/threonine 
change within the protein galactosyltransferase (PF01762) domain. This amino-acidic 
change is not predicted to have a large effect in the protein’s function (Ramensky et  al., 
2002).
A fourth SNP associated with SABP was located at chromosome 3p21.31 
(rs2352974, P = 4.0 x 10-7, OR = 1.6 (1.3 - 1.9)) within the first intron of TRAIP gene 
(Figure 5.2). Evidence of association in this region is supported by two additional SNPs 
located approximately 12 kb away and in strong LD (rs2271961, P = 1.5 x 10-6, r2 = 
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9 Genotype imputation makes use of haplotype information. This can improve genotype 
calls at typed SNPs when their genotypes do not agree with those expected based on the 
haplotypic information. This strategy  is implemented in many imputation algorithms 
(see (Marchini and Howie, 2010) for a review) and is also the basis for the 
BEAGLECALL method design to improve genotype calls (Browning and Yu, 2009).
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Figure 5.1. Association at 21q22.1. -log10 of the association p-values under 
an additive model are shown in the y-axis. Blue line represents the 
recombination rate in cM/Mb and the r2 between SNPs and rs4818065 is 
shown as red scale. Genes are depicted as green lines and chromosomal 
position indicated in the x-axis.
0.97; rs2271960, P = 2.9 x 10-6, r2 = 0.96) (Figure 5.2). The fifth association with SABP 
(rs16942644, P = 7.0 x 10-7, OR = 1.8 (1.4 - 2.2)) was at  chromosome 15q26.1 in a 
region with a signature of transcriptional enhancer activity (data from (Ernst et  al., 
2011; Ernst and Kellis, 2010) as displayed at http://genome-preview.ucsc.edu). This 
suggests that rs16942644 may affect transcript levels of one or more genes near by. The 
closest gene is approximately 25 kb away and codes for an alpha/beta hydrolase domain 
containing protein (ABHD2). 
The sixth association reaching suggestive significance was at chromosome 3p21.31 
(rs26998, P = 7.0 x 10-7, OR = 1.5 (1.3 - 1.8)) within a possible transcriptional enhancer 
(data from (Ernst et al., 2011; Ernst and Kellis, 2010) as displayed at http://genome-
preview.ucsc.edu) in an intron of the gene MCTP1 (multiple C2 domains, 
transmembrane 1 isoform S).
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rs2352974 region









































Figure 5.2. Association at 3p21.31. -log10 of the association p-values under 
an additive model are shown in the y-axis. Blue line represents the 
recombination rate in cM/Mb and the r2 between SNPs and rs2352974 is 
shown as red scale. Genes are depicted as green lines and chromosomal 
position indicated in the x-axis.
5.3.2. Gene-based genome-wide association of BD sub-phenotypes
We performed gene-based GWAS analysis for each of the BD sub-phenotypes. 
There were significant association with four genes with SABP and in one gene with 
Suicidal subtypes, respectively (Table 5.2). In line with the single SNP results, SABP 
subtype showed the greater number of significant results. Gene-based associations for 
SABP highlighted the 3p21.31 locus but not the B3GALT5 gene (gene p-value = 
0.0014, FDR = 0.5). 
Figure 5.3 shows details of the association with suicidal behaviour at the CBLN1 
locus. Eight of the nine SNPs mapped to CBLN1 had p-values < 0.05 and these are 
localised at  two association signals separated by  a region of high recombination. 
Inspection of a wider region surrounding the genes showed that more significant 
associations lay beyond our 20 kb mapping limits. Two almost independent associations 
exist at rs12598711 and rs1816581 with p-values of 1x10-4 and 3x10-4, respectively, and 
r2 =0.1.
Figure 5.4 shows a heat-map of gene-based statistics for genes with FDR < 0.2 in the 
analysis of sub-phenotypes and BD diagnosis. Comparison of these gene-statistics 
suggests some gene associations detected in the analysis of the main BD diagnosis are 
strengthened in the analysis of specific sub-phenotypes, e.g., PPIL5 and CBLN1 had p-
values 3 to 4 orders of magnitude smaller in the Suicidality  sub-phenotype analysis, 
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ENSG00000180316 PNPLA1 1.2 x10-6 0.005
ENSG00000164076 CAMKV 1.6 x10-6 0.005
ENSG00000183763 TRAIP 1.6 x10-6 0.005
ENSG00000173699 SPATA3 2.1 x10-5 0.050
SUICIDAL ENSG00000102924 CBLN1 1.8 x10-6 0.029
Table 5.2. Genes with FDR < 0.05 for bipolar sub-phenotype analysis.
whereas others seem to be exclusively detected in sub-phenotypes, e.g., PNPLA1 had a 
p-value = 1 x 10-6 and 0.24 in the SABP sub-phenotype and BD analyses, respectively. 
5.3.3. Network-based genome-wide association analyses
Next, we performed network analysis using the protein-protein interaction network 
(PPIN) aiming to identify groups of interacting gene’s products enriched for association 
signals. We identified significant and suggestive sub-networks only for RDC SABP 
(Table 5.3). The most associated sub-network (PPIN-1156, z-score = 4.17, FDR = 0.04) 
contains genes previously associated with several kidney diseases in both human and 
the mouse (Wolf and Stahl, 2003; Hauser et al., 2009). Inspection of publicly available 
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Figure 5.3. Association at CBLN1 locus. -log10 of the association p-values under an 
additive model are shown in the y-axis. Blue line represents the recombination rate in 
cM/Mb and the r2 between SNPs and the minimum p-values in the region (panel title)is 
shown as red scale (see Figure legend). Genes are depicted as green lines and 
chromosomal position indicated in the x-axis. A) Figure including SNPs used in the 
gene based analysis (20 kb around the gene) and B) SNPs up to 500 kb around the gene.
A
B
data provided evidence for their expression in human and mouse brain (Lein et al., 
2007; Johnson et al., 2009; Uhlen et  al., 2010). Interestingly, mutations in KIRREL3 
have been associated with intellectual disability (Bhalla et al., 2008) and axon migration 
(Serizawa et al., 2006). Two other sub-networks had FDRs approaching our significance 
threshold. These were characterised by  biological processes related to transcriptional 
regulation and cell proliferation, such as chromatin modification (p-value = 2 x 10-15), 
negative regulation of cell proliferation (p-value = 7 x 10-5) and anti-apoptosis mediated 
by external signals (p-value = 1 x 10-4) (Table 5.3). 
5.3.3.1. Analysis of GABA(A) receptor genes in SABP
We explored the association between the 19 GABA(A) receptor genes and SABP 
reported by  Craddock et al. (2010) and Breuer et  al. (2010) with p-values = 7x10-6 and 
0.009, respectively. The authors of these reports did not explore the robustness of their 
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BD PSYCHOSIS SUICIDAL RAPID CYCLING PUERPERAL RDC SABP AGE_ONSET
CMTM8 5.4 2.5 4.1 2.8 1.8 2.2 0.1
DUSP28 5.2 3.8 2.9 1.5 0.3 1.5 0.1
ZNF224 5.1 3.7 3.1 1.7 1.3 2.3 0.1
RNPEPL1 4.9 3.6 3.0 1.2 0.4 1.2 0.1
LAMP3 4.7 3.4 4.4 2.6 1.9 3.0 0.4
MKI67 4.4 1.8 4.9 1.0 3.3 0.2 0.5
ZNF284 4.3 3.2 3.2 1.5 1.3 1.7 0.2
KLHDC1 4.2 3.8 4.4 0.4 2.2 1.7 2.1
ZNF791 4.2 3.5 2.3 1.3 3.2 0.9 0.3
AC007346.2 4.1 3.4 1.8 1.2 0.7 1.7 0.2
KLHDC2 4.1 3.5 4.1 0.4 2.1 1.2 1.8
ANKMY1 4.1 2.5 2.9 2.0 0.3 0.9 0.0
SPEF1 4.0 3.7 2.0 1.4 0.8 0.8 2.0
CENPB 3.9 3.8 2.0 1.3 0.8 0.8 2.1
DBF4 3.9 4.5 2.3 1.1 1.8 1.5 0.2
PPIL5 3.2 3.3 4.8 0.6 1.7 1.5 1.8
AL139099.3 3.1 3.2 4.4 0.4 1.6 1.6 1.5
MGAT2 3.1 3.2 4.4 0.4 1.6 1.6 1.5
RPL36AL 3.1 3.2 4.4 0.4 1.6 1.6 1.5
SNAP47 3.0 3.7 1.9 1.4 0.4 0.5 0.1
ZBED3 2.7 1.5 0.3 0.0 0.6 4.4 2.0
MST1 2.6 2.2 0.3 1.2 0.8 3.8 0.5
DPF3 2.6 3.9 1.4 0.5 1.8 0.5 0.3
RPS29 2.6 2.6 4.3 1.2 1.5 0.8 2.3
AC007064.28 2.5 2.1 1.7 0.4 2.9 3.9 0.3
XKR3 2.5 2.2 1.5 0.4 3.3 4.3 0.2
HDAC11 2.4 4.8 0.6 0.6 0.6 1.4 0.0
ZCCHC2 2.4 2.0 1.1 0.5 0.1 4.6 0.5
CBLN1 2.3 1.5 5.7 1.8 3.7 0.8 0.2
TOMM40 2.2 2.1 0.7 0.0 1.4 4.3 0.6
AC064801.1 2.1 2.1 1.7 0.6 0.1 4.3 0.5
IRGM 2.1 2.8 1.3 0.1 5.1 0.7 0.7
AC006021.1 2.0 2.4 1.3 1.2 0.5 4.0 0.1
UBQLN4 1.8 3.8 1.8 0.1 1.6 2.0 1.8
SERGEF 1.7 4.1 0.5 0.4 1.1 1.4 0.2
GABRB1 1.7 1.8 2.0 0.2 0.3 3.9 0.2
CAMKV 1.2 1.7 0.4 0.6 0.3 5.8 0.8
TRAIP 1.2 1.7 0.4 0.6 0.3 5.8 0.8
SPATA3 1.1 3.2 1.5 0.6 1.8 4.7 0.3
TNNC2 1.1 1.3 0.7 0.7 0.6 4.2 0.4
AL355916.1 1.1 1.4 1.5 1.3 4.9 0.6 1.2
AC009879.1 1.0 1.3 1.0 0.2 5.0 1.6 0.8
PNPLA1 0.6 1.3 0.3 1.4 0.1 5.9 0.1
G0S2 0.3 1.0 0.4 0.1 0.1 4.4 1.3
TRIM9 0.2 0.1 0.2 0.3 1.1 0.1 5.1
HYDIN 0.1 0.1 0.4 0.3 0.0 0.7 4.6
PRUNE 0.0 0.2 0.0 0.1 0.1 0.3 4.9
Figure 5.4. Association of genes with FDR < 0.2 in different BD sub-
phenotypes. Cells are coloured by -log10 of the gene p-value with more 
intense tones representing larger values.
results regarding the choice of r2, p-value and maximum number of SNPs in the PLINK 
SNP-set analysis thresholds. They choose thresholds that are usually regarded as 
standard. However, despite using values widely accepted, it is still necessary  to explore 




score FDR Genes Biological Processes
PPIN-1156 4.17 0.04
CD2AP KIRREL KIRREL3 
NPHS1 NPHS2 no significante results
PPIN-12 4.01 0.06
A C T B A C T L 6 A A H R 
ARID1A ARID1B ARID2 
BRCA1 BRWD1 CBX5 
C C N E 1 C E B P B C H D 4 
CHMP5 CREB1 CTNNB1 
ESR1 ETS2 FANCA H3F3A 
HSF1 IKZF1 MPHOSPH6 
M P P 6 N R 3 C 1 P A X 6 
PBRM1 PHB RAP1A RB1 
RELB RFXAP SMARCA4 
S M A R C B 1 S M A R C C 1 
SMARCE1 SS18 STAT2 
S T K 1 1 T M F 1 T P 5 3 
ZMYND11
Chromatin modification (P 
= 2 x 1 0 - 1 5 ) , R e l a x i n 
signaling (P = 6x10-5), 
Negative regulation of cell 
proliferation (P = 7x10-5), 
Anti-Apoptosis mediated 
by  external signals by 
Estrogen (P = 1x10-4)
PPIN-973 3.96 0.07
A C T B A C T L 6 A A H R 
ARID1A ARID1B ARID2 
BRCA1 BRWD1 CBX5 
C C N E 1 C E B P B C H D 4 
CHMP5 CI ITA CREB1 
C T N N B 1 E S R 1 E T S 2 
FANCA H3F3A HDAC2 
H D A C 4 H D A C 5 H S F 1 
IKZF1 MPHOSPH6 MPP6 
NR3C1 PAX6 PBRM1 PHB 
RAF1 RAP1A RB1 RELB 
RFX5 RFXANK RFXAP 
S M A R C A 4 S M A R C B 1 
SMARCC1 SMARCE1 SS18 
STAT2 STK11 TMF1 TP53 
ZMYND11
Chromatin modification (P 
= 4 x 1 0 - 1 2 ) , R e l a x i n 
signaling (P = 4x10-4), 
Negative regulation of cell 
proliferation (P = 2x10-4)
Table 5.3. PPIN subnetwork with FDR < 0.1 for SABP bipolar subtype. For each 
sub-network we report its z-score from the test of association with the phenotype and 
its FDR. Genes in bold had a p-value < 0.05. Significance for the overlap of each sub-
network and GeneGO’s biological process was calculated assuming a null 
hypergeometric distribution (see Methods for additional details). All categories 
reported reached an FDR < 0.001
the sensitivity of the results and conclusion to these values. We repeated the analysis 
with the same data used by Craddock et al. (2010), with exception of their initial SNP 
pruning step  in Haploview, and utilised different LD r2 (0.1, 0.3, 0.5, 0.7 and 1), p-value 
(1, 0.5, 0.05, 0.01, 1x10-3 and 1x10-5) and a maximum number of SNPs thresholds. In 
practice the maximum number of SNPs was affected by the other thresholds, so the 
maximum number ranged from 5 to 207 out of the 383 SNPs mapped to the 19 genes. 
Figure 5.5 presents the results of these analyses. It seems clear that the choice of 
parameters influences the empirical p-value, which ranged from 5 x 10-5 to 1 x 10-2.  
We found only a marginal association (p-value = 0.065) when analysing the 19 
GABA(A) receptor genes as a gene-set using the gene-set analysis methods 
implemented in FORGE (described in Chapter II).
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Figure 5.5. Effect of analysis parameters on association of GABA(A) genes and 
SABP. -log10 of the association p-value is shown in the y-axis and x-axis shows the 
maximum number of SNPs included in the association SNP-set. Note that along the x-
axis we have plotted only the values used in our analysis and not a continuous range. 
Different combinations of p-value and r2 thresholds were used the figure legend 
indicates their coding.
5.3.4. Further exploration of Schizoaffective bipolar disorder subtype 
associations
Throughout our analysis and as previously highlighted by others (Hamshere et al., 
2009b), we found that  the SABP sub-phenotype provided better genetic mapping 
results. Therefore, we focused our replication efforts on the SABP findings. When 
performing these analyses, we did not have access to a SABP sample for replication and 
decided to follow an alternative strategy to explore this association and provide 
additional supporting evidence. Quantitative genetic evidence has shown that while 
SABP has substantial heritability, genetic risk is completely  shared with schizophrenia 
(SCZ) and bipolar disorder, suggesting that few, if any, SABP specific genes exist 
(Cardno et  al., 2002). Therefore, we explored the association of the two SABP genetic 
associations in SCZ and additional BD samples. However, it is important to note that we 
could not exclude SABP cases from the replication samples’ cases. This affects our 
interpretation of the association with a broader phenotype and suggests that a positive 
association may be explained by a non-ascertained, cryptic, SABP subgroup, whereas 
negative association may suggest a lack of association with a broader diagnosis. We 
selected for replication three SNPs present in either or both the Illumina and Affymetrix 
arrays used in the replication samples available, which had complete or near complete 
tagging (e.g., r2 =1, rs3746887 for rs734413) of the four markers. We found no evidence 
of association for either locus in the remaining BD samples of the WTCCC (2007), 
Sklar et al. (2008) or Cichon et al. (2011) (see Table 5.4 for sample details). We failed to 
replicate the chromosome 3p21.31 locus and the second weaker signal at 21q22.1 in the 
SCZ samples from the SGENE consortium (rs6802890 P = 0.80; rs11700626 as proxy 
for rs11088486 P = 0.68). However, we did find mild evidence for association for 
rs3746887 in a combined analysis of the SGENE and SGENE-plus studies (Table 5.4). 
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We found no evidence of association in two independent samples of BD for the 
SABP genes and networks (Table 5.5). In the future, we will attempt to replicate this 
association in SCZ and SABP samples. 






TRAIP -0.23 -0.07 -0.21 0.58
SPATA3 -0.06 -0.12 -0.12 0.55
PNPLA1 -0.28 -0.61 -0.63 0.74
CAMKV -0.23 0.09 -0.10 0.54
Subnetworks
PPIN-12 1.22 -1.90 -0.48 0.68
PPIN-1156 -0.57 0.43 -0.10 0.54
PPIN-973 1.12 -1.61 -0.35 0.64
Table 5.5. Association of Schizoaffective bipolar type genes and networks in other 
BD samples. Sklar and Bonn refer to the GWAS reported by  Sklar et al. (2008) and 
Cichon et al. (2011).


















WTCCC Bipolar c 0.40
1.04 
(0.94-1.16) 1868 2938
Sklar et al (2008) 0.46
1.05 
(0.93-1.18) 1461 2008















Table 5.4. Replication results of association for rs734413.  a WTCCC BD cases with 
RDC SABP diagnosis. b WTCCC BD cases without RDC SABP diagnosis. c ALL BD 
cases. dReplication p-values are one-tailed.
5.4. Discussion
5.4.1. Genome-wide association of BD sub-phenotypes
Despite its high heritability (approximately  80%) (McGuffin et al., 2003), the genetic 
underpinnings of BD remain largely unknown. Increasing evidence suggests substantial 
phenotypic heterogeneity  for BD and other neuropsychiatric disorders, and analysis of 
sub-phenotypes has been suggested as a strategy to increase genetic homogeneity  (Alda, 
2004; Burmeister et al., 2008). A higher number of genetic associations are found with 
SABP than expected by  chance compared to other BD sub-types (Hamshere et al., 
2009a; Tuller et al., 2009), suggesting a molecular genetic examination of the SABP 
group may be fruitful. 
We identified two regions that reach suggestive significance after Bonferroni 
correction for SABP. Lacking SABP replication samples, it was attempted to explore 
further this associations on other relevant phenotypes. We choose a cross-phenotype 
analysis in multiple BD and SCZ cohorts based on the quantitative genetic evidence 
available for SABP (Cardno et al., 2002). While we failed to show association for one 
region, 3p21.31, our results did suggest that the genetic variants identified in 21q22.2 
confer susceptibility  for SCZ and not BD (rs734413, P = 2.7 x 10-7, OR = 1.7 (95% CI= 
1.4 - 2.0) for SABP, P = 0.02, OR = 1.06 (95% CI= 1.01 - 1.13) for SCZ, P = 0.7 for 
BP). Several genes in the proximity to the 21q22.1 locus are interesting candidates. 
B3GALT5, a member of the beta-1,3-galactosyltransferase gene family, participates in 
the synthesis of glycoproteins, glycolipids and other glycan structures. There has long 
been interest in abnormal levels of glyocolipids in SCZ (Cherayil, 1969; Tkachev et  al., 
2007) and there is evidence for reduced expression of genes involved in N- and O-
linked glycan and glycosphingolipid biosynthesis pathways as well as oligodendrocyte 
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marker genes in SCZ and BD patients compared with controls (Tkachev et al., 2003; 
Narayan et  al., 2009). Glycosphingolipids are crucial for the glycoso-synapse, involved 
in myelin-axon communication, suggesting a possible link with the white matter deficit 
reported in SCZ, including decreased oligodendrocyte number, white matter volume and 
myelin-associated gene expression (Davis et al., 2003; Kubicki et al., 2005). The benign 
nature of the amino-acid change at rs3746887 (Adzhubei et al., 2010) does not directly 
support it as a causal variant but further functional studies would be needed for 
verification. In addition, other genes in the genomic area may be of potential interest. 
For example, two genes, SH3BGR (SH3 domain binding glutamic acid-rich protein) 
and WRB (tryptophan rich basic protein), map to the Down’s Syndrome Congenital 
Heart Disease region at 21q22.2 and are widely expressed in the central nervous system. 
PCP4 (Purkinje cell protein 4) is a calmodulin-binding protein involved in intracellular 
Ca+2 signalling (Erhardt et al., 2000; Slemmon et al., 2000; Kanazawa et al., 2008).
These results extend the findings from previous studies showing genetic variation in 
21q22.2 as risk factor for SABP by  providing mild evidence for its involvement in the 
aetiology of SCZ.
5.4.2. Gene and gene-sets set associations
In addition to genes at the 3p21.31 locus, gene-based analysis provided significant 
result for PNPLA1 (patatin-like phospholipase domain containing 1), a gene with little 
biological characterisation. It is known to code for a papatin-like lipid hydrolase 
(Kienesberger et al., 2009) and is widely expressed in the brain, including in Purkinje 
neurones (Ponten et al., 2009). Our PPIN network results pointed to sub-networks 
involved in cell-to-cell contact as well as regulation of chromatin and cell proliferation. 
Common variants within genes involved in cell-to-cell adhesion have been previously 
associated with SCZ and BD (O'Dushlaine et al., 2011) and copy number variants 
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affecting cell adhesion genes associated with SCZ and autism (Stefansson et al., 2008; 
Betancur et al., 2009; Bucan et  al., 2009; Rujescu et al., 2009). This supports the 
involvement of cell-to-cell adhesion in the aetiology of neuropsychiatric disorders. 
Our gene-based results pointed to CBLN1 (cerebellin 1 precursor) as a susceptibility 
loci for suicidal behaviour (Table 5.2 and Figure 5.3). The association extends over the 
gene with the gene-based association explained by the contribution of two signals in 
low LD (r2 =0.1). CBLN1 has been shown to be important for the integrity of synapses 
and is considered a necessary member of a synaptic organiser complex also involving 
neurexins and the glutamate receptor delta-2 (Matsuda et al., 2010; Uemura et al., 
2010). We did not find evidence of association for CBLN1 in the Sklar (Z FIX p-values 
= 0.1) or Bonn (Z FIX p-values = 0.78) GWAS datasets. Replication in independent 
samples ascertained for suicidal behaviour will be needed.
Despite only reaching a suggestive significance level, the PPIN-12 sub-network 
might be of special interest. Valproate, a widely used antipsychotic drug, has direct 
effects on chromatin remodelling through its action on histone deacetylases (Rosenberg, 
2007). Furthermore, both valproate and lithium have neurogenic or neuroprotective 
effects (Lagace and Eisch, 2005) and valproate has been shown to facilitate cell 
differentiation (Huangfu et al., 2008). Our results suggest valproate may counteract the 
effect of risk alleles influencing cell differentiation, potentially through their effect in 
chromatin remodelling pathways. A potential relevance of this network analysis results 
is to suggests that networks associated in GWAS could be used as signatures to identify 
potential new pharmacological treatments, for example with the methods proposed by 
Lamb et al. (2006).
Detailed inspection of the method used by Craddock et al. (2010) and Breuer et al. 
(2010) showed it to be sensitive to the parameter values chosen (r2, p-value and number 
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of SNPs in the SNP-set). We showed that when the parameter values are varied the 
empirical p-value varies considerably (Figure 5.5), complicating the interpretation of 
the reported association between the GABA(A) receptor genes and SABP. Using our 
GWAS gene-set analysis methods, we found a weak evidence of association between 
the 19 GABA(A) receptor genes and SABP (p-value = 0.065). There are major 
differences between the methods used in the reports of Breuer et al. (2010) and 
Craddock et al. (2010) and those used throughout our studies. For example, we only 
need specify the reference population to calculate SNP-SNP correlations and can make 
use of all SNP association information (details of the method are provided in Chapter 
II). 
Finally, we acknowledge that our gene and network association results must be 
considered as preliminary due to the small sample size and low statistical power of our 
BD sub-phenotype samples. As discussed above, replication of SABP genetic mapping 
results in BD and SCZ studies is encouraged by quantitative genetic research in SABP. 
However, from our results, it seems unlikely that an association with SABP will be 
replicated in BD samples (Figure 5.4) as SABP associations appear to be specific to this 
sub-phenotype (also observed by Hamshere et al. (2009a)). Therefore, replication of our 
findings in SABP samples sets would be desirable. 
5.5. Conclusion
Overall, we demonstrate the merit  of applying GWAS and system biology 
approaches to psychiatric sub-phenotypes. First, sub-phenotypes are often characterised 
by more pronounced homogenous clinical and phenotypic presentations, enabling a 
better interpretation of the genotype phenotype relationship. For example, from Figure 
5.4, it is reasonable to hypothesise the association at CMTM8 with BD diagnosis may 
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be more relevant in understanding the genetic basis of suicidal behaviour than BD age 
of onset or schizoaffective features. In addition, small sample sizes are expected for 
many sub-phenotypes of clinical relevance. Therefore, methods to identify biologically 
relevant themes by clustering mild associations could be of special interest for these 
samples. However, caution is needed when interpreting results from studies with small 
sample sizes because many false positives are expected due to low statistical power. 
Nevertheless, these methodological strategies may be helpful to tip the fine balance 
between the risk of identifying false positives and highlighting interesting biological 
findings that may help to guide the design of follow up studies. 
In summary, our results confirm the utility of SABP for genetic mapping. We did not 
find compelling evidence of replication in our single SNP results in either BD or SCZ 
samples. However, our data suggests the effect of SABP susceptibility  variants may be 
diluted in samples ascertained only for a BD diagnosis. We highlighted associations 
with genes and biological processes for SABP, which warrant further exploration and 
replication efforts. The analysis of BD sub-phenotypes is a useful strategy to improve 
the understanding of the genetic effect of BD risk variants.
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Chapter VI




Genome-wide association studies constitute a valuable tool to study  the genetic basis 
of human diseases. However, they are not without limitations and the design of a study 
will might large dictate them. For example, lack of statistical power, incomplete 
coverage of genetic variants, and phenotypic heterogeneity can burden genetic 
association and their replication success. It is likely  that many of these limitations will 
be overcome with new technologies leading to GWAS primarily  based on whole-
genome sequencing and imputation (Altshuler et al., 2010; Durbin et al., 2010). Disease 
diagnosis will also improve with better understanding of genetic and environmental risk 
factors and development of new diagnostic technologies (Auffray  et  al., 2010). 
However, with these improvements increasing challenges will also arise for the 
interpretation and discovery of genetic association signals, particularly in highly 
complex diseases (Donnelly, 2011).
In the previous chapters evidence is presented to suggest that it is possible to 
augment the amount and interpretability  of the information extracted from GWAS using 
gene and gene-set associations and integrative biology analyses with gene-expression 
and protein-protein interaction data-sets. Several lessons emerged from these results and 
these are discussed below.
6.1.1. Gene-based association is a good complement to single SNP 
analyses
Asymptotic gene p-values were found to agree well with empirical estimates and are 
faster than p-values calculated by phenotype permutations or sampling methods, such as 
VEGAS (Liu et al., 2010). However, sampling-based gene p-values seem to be a good 
compromise between the speed of asymptotic estimates and the accuracy of phenotype 
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permutations (the current gold standard). Gene-based association results using these 
methods were much closer to the expected distribution on the null hypothesis (uniform 
distribution of p-values). Hence, these are considered to represent an improved 
statistical estimate and the method of choice if the computing power is available.
In the future, it  will be interesting to see if gene-based association analysis becomes 
a popular tool to analyse GWAS. If these results prove generalizable, many studies 
without significant SNPs may suggest plausible candidates for follow up studies, which 
in the long run may be useful in improving our biological understanding and devising 
new treatments.
Gene-based association results highlighted most regions found by single marker 
analyses and additional ones that  were replicated in other studies. Even in their simplest 
form, i.e. correcting the minimum p-value, gene-based association complemented single 
SNP analyses. Hence, gene-based analyses should become an integral step of the GWAS 
analysis pipeline, as imputation is increasingly so, for example (Marchini and Howie, 
2010).  
6.1.2. GWAS can be used to reveal biological processes associated with 
disease susceptibility
Gene-based association can be used in conjunction with gene-set analyses to 
highlight biological processes enriched with genetically associated variants. For 
example, in a GWAS of Crohn’s disease (CD) we identified associations with the IL12 
and IL23 signalling pathways; in the case of rheumatoid arthritis (RA), we identified 
enrichment in the biological categories of immune system and extracellular matrix; and 
with hypertension (HT), we identified a PPIN sub-network involved in cortisone, 
androstenedione and testosterone biosynthesis and metabolism. There is evidence for 
the role of immune-system biological processes in the aetiology of CD and RA and for 
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the association between cortisone and testosterone hormone levels in HT and heart 
disease (Stewart et al., 1996; English et al., 1997; Smith et al., 2005; Jones, 2010; 
Perusquia and Stallone, 2010), supporting the validity of our results.  
In bipolar disorder (BD), convergent evidence10  emerged from GWAS for a PPIN 
sub-network enriched among risk alleles in genes that are also differentially  expressed 
in brain in BD cases compared with controls. Interestingly, the genes of this network 
mapped to the human post-synaptic density (hPSD), a large protein complex critical for 
neuronal function which is altered in several behavioural phenotypes (Bayes et al., 
2011). This convergent evidence warrants additional study on independent genetic and 
gene-expression data sets. If this association gains strength, it may support the initiation 
of follow up studies on several fronts. For example, the hPSD is currently estimated to 
comprise about ~1500 proteins organised in a modular architecture with modules 
differentiated by  their biological functions (Armstrong et al., 2006; Pocklington et al., 
2006a; Pocklington et al., 2006b; Bayes et  al., 2011). Because of their relatively small 
number (compared with the ~20,000 annotated protein coding genes), these genes might 
be the target of sequencing efforts in large sample sets. A second possibility  would be to 
use the PPIN sub-network genes as a gene signature in drug repositioning studies. This 
strategy has shown potential for several diseases, see (Lamb et al., 2006), and has not 
been explored as an application of GWAS.
My preliminary attempt to compare seven diseases at the gene-set  level showed that 
nominally  associated gene-sets (uncorrected p-values < 0.05) recovered meaningful 
groups: three immune-system diseases together (RA, type 1 diabetes (T1D) and CD) 
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10  Here by convergent evidence I refer to the fact  of finding supportive association 
results from two different genomic platforms measuring different biological molecules. 
This evidence should not be regarded as replication since the quantities compared are 
not the same but it  is rather convergent because two independent lines of evidence 
coalesced into the same conclusion.   
and a group of two comorbid conditions (coronary artery disease (CAD) and T2D 
(Choy et al., 2008; Huang et  al., 2008; Guh et al., 2009)). Interestingly, by clustering 
diseases using only the most significant PPIN sub-networks, we recovered a group with 
HT, T2D and CAD driven by the PPIN-2605. These sub-networks are involved in 
cortisone, androstenedione and testosterone hormone biosynthesis and metabolism, 
abnormal levels of which have been associated with risk for these three diseases 
(English et  al., 1997). Similar analyses including diseases with poor etiological 
characterisation may provide a new hypothesis for their genetic underpinning based on 
a guilt-by-similarity approach.
6.1.3. Combination of GWAS and gene-expression studies
Gene-expression studies constitute one of the most common genomic data-sets 
available and meta-analysis of multiple studies has shown that biological signatures are 
pervasive, even in the presence of technical confounders (Dudley et al., 2009; Zheng-
Bradley et al., 2010). However, a major limitation of gene-expression studies is that 
mRNA levels are affected by both etiological causes and consequences of disease 
pathology. On the other hand, GWAS studies are not confounded in this manner but  it is 
difficult to differentiate true biological signals because the signal-to-noise ratio is low. 
Therefore, by  bringing together the two approaches in integrative analyses, it may be 
possible to identify, using readily  available datasets, genes and biological processes that 
are more likely  to be drivers of pathology. These are of interest when developing new 
pharmacological interventions and disease diagnostics (Schadt, 2009). Driver genes can 
also be identified with system genetic studies but these need both molecular phenotypes 
and genetic variant measures on the same sample sets (see review by  Schadt (2009)), 
which is feasible but such data sets are not available for many diseases. For example, in 
the case of mental illnesses, it is difficult to access the affected tissues. Even when 
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human brains are available, it is difficult to select  the appropriate brain region for study 
because of the complexity and our still limited understanding of brain function. We 
think this makes genetic studies all the more valuable since gene-expression and 
measurement of other molecules will be affected by the availability of tissue, brain 
region of choice and environmental factors (e.g., drugs) whereas genotypes are not 
affected by these factors. Recently, genotype data has been released for the samples 
used in our gene-expression analyses (Choi et al., 2011). It would be a logical next step 
to perform eQTL analysis on the genes of the significant sub-network to assess if BD 
susceptibility risk alleles also drive gene-expression changes.
6.1.4. Candidate-Gene-Networks
A prediction from network biology was used (Goh et  al., 2007; Park et al., 2009) to 
generate a new test for genes associated via GWAS 11 . This showed that alleles 
conferring risk for BD and other diseases cluster within groups of genes with (often) 
known biological function. Our Candidate-Gene-Networks (CGNets) analysis can be 
seen as a way to strengthen the evidence for genes previously associated with a trait on 
the basis of genetic or other information by showing that their network environment is 
also associated with the phenotype. If an association is found, it  provides internal 
consistency in the sense that  it agrees with what we already  know about genes 
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11  As discussed previously through the thesis, specifically on Chapters I and IV. 
Network analyses of genes associated with human diseases have shown that when a 
gene is associated with a phenotype, its interacting partners or other genes involved in 
the same biological processes are more likely to be associated with the same phenotype 
than expected by  chance (Goh et al., 2007; Ideker and Sharan, 2008; Wu et al., 2008; 
Park et al., 2009). This knowledge has led to bioinformatic methods to prioritise genes 
for diseases (e.g. (Wu et al., 2008; Yang et al., 2009)) and propose functions for 
uncharacterised genes (Jensen et al., 2009; Yang et al., 2009). We make use of the same 
concept and expect that if a gene is associated with a disease, its network partners 
should also be more associated than expected by chance.
associated with human diseases. At the moment the negative predictive value of the 
CGNet results are unknown. 
Using this strategy  it was possible to strengthen the evidence for CACNA1C and 
ANK3, two loci robustly  associated with BD by meta-analysis of GWAS (Ferreira et al., 
2008). This approach can be used with any trait and it is similar in principle to the text 
mining tool GRAIL (Raychaudhuri et  al., 2009). GRAIL identifies links between loci by 
analysing the co-citation pattern in PubMed (www.pubmed.org). These links are used to 
improve evidence supporting a gene. An advantage of the CGNet strategy is that it does 
not require a previous publication record for two genes to be associated, which may be 
beneficial for poorly characterised genes with known interaction information.
6.1.5. Gene and gene-set association are also affected by statistical power
Re-analysis of the WTCCC phase 1 study of seven different GWAS in common 
disorders, showed that in general gene and gene-set analyses had the same pattern of 
results as single SNP analyses. For example, association was found with gene-sets in 
CD, T1D and RA, three autoimmune diseases which have had successful results in 
GWAS, but  no associations with BD were found using a single study. At the moment it 
is not possible to distinguish whether these different results are explained by  differences 
in the distribution of effect sizes (e.g., effect sizes for CD may be larger than for BD), in 
locus heterogeneity  or in frequency spectrum of risk alleles. Large meta-analyses of 
GWAS of BD and other psychiatric diseases are underway (Psychiatric GWAS 
Consortium, 2009). Availability of large and well powered studies for a variety of 
phenotypes will help the comparison of findings at the SNP, gene and gene-set level 12. 
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12 Statistical power is affected by  several factors, e.g. whether the phenotype is discrete 
or quantitative. It is a common mistake to equate power to sample size, see Yang et al 
(2010b), meaning that comparison of findings across phenotypes will need to account 
for differences in power. 
These may reveal differences and commonalities with valuable information in order to 
understand the genetic architecture of different diseases. In turn, this information may 
guide future studies.
6.1.6. The importance of replication
In the BD study, significant association were only found by pooling the results from 
three independent GWAS and a gene-expression study. This suggests that, although risk 
alleles cluster in common biological processes, their total combined effect (at least as 
measured by our methods) is weak and use of several GWAS cohorts is crucial to 
establish compelling evidence of association. This contrasts with the scenario of 
immune-system related diseases (CD, T1D or RA) where with a single GWAS we could 
identify relevant biological process. It  may also be useful to attempt replication in 
different genomic data sets to highlight targets for follow up studies, e.g., signalling 
pathways where both risk alleles and functional changes co-occur.
Gene-set associations of BD found in this study are similar in significance to the 
results presented for GSA of schizophrenia GWAS (O'Dushlaine et al., 2011). Although 
comparison of p-values may not be adequate, the fact that both studies highlight 
association around p-values ~ 10-3 may suggest that replication samples and meta-
analyses will be essential for GSA in psychiatric genetics. A major concern for GWAS 
meta-analysis is the so called winner’s curse effect, also known as decline effect  or 
regression to the mean (Yu et al., 2007; Zollner and Pritchard, 2007; Lehrer, 2010). It 
refers to the fact  that effect size estimates tend to decrease (sometimes to zero!) as more 
studies are analysed. It is usually assumed to arise from biases in experimental design 
but mere chance and publication biases are likely  to play  a role (Lehrer, 2010). It will be 
interesting to evaluate if gene-set analyses are equally sensitive to the winner’s curse 
effect. Gene-set analyses may be more robust to it than single SNP analyses because 
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they  do not rely on a single very significant finding but rather on several weak ones 
clustered using prior information of common biological processes. If so, this facet may 
add to the value of the GSA approach as an information mining tool for GWAS.
To date, the only  replicated gene-set association with BD was the association 
between the GABA(A) receptor genes and the SABP subtype (Breuer et al., 2010; 
Craddock et al., 2010). After detailed inspection of their analyses, the methodology 
employed in these studies, was found to be sensitive to the choice of different 
parameters, the influences of which the authors did not  explore. The association 
between the GABA(A) receptor genes and the SABP subtype may be real but its 
statistical significance is uncertain. Pedroso and Breen (2009) also noted other problems 
with reports of gene-set analyses of GWAS. For example, several authors did not correct 
for the number of variants in the gene or gene-set (Torkamani et al., 2008; Walsh et al., 
2008; Askland et al., 2009) and others did not assess the effect of model parameters 
(Holmans et al., 2009; Breuer et al., 2010; Craddock et al., 2010). GSA of GWAS is 
maturing but it is still an exploratory technique and researchers must be cautious when 
applying and interpreting these reports.
6.1.7. Genetic heterogeneity is a double-edged sword
A major motivation of the studies presented in this thesis was to explore the ability  of 
systems biology analyses to overcome genetic heterogeneity. In the BD associated 
network, we found that different genes drive the association in different studies, 
suggesting that these single SNP associations are relevant and worth of study even 
though we found no replicated evidence of association. A similar pattern of gene (or 
locus) heterogeneity has been reported in GWAS of CD (Wang et al., 2009) and 
multiple sclerosis (Baranzini et al., 2009). 
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What does this heterogeneity mean? Are there two kinds of genetic effects: those that 
consistently replicate in different studies and those that do not? Is the proportion of 
these two effects different between diseases (their genetic architecture)? Or do we see 
this heterogeneity because we failed to account for factors that alter the genetic effects, 
e.g. environmental exposures? Let  us assume we do acknowledge that allelic 
heterogeneity is common (which is widely accepted for genes associated with 
Mendelian inheritance) and even that gene heterogeneity is also present. Will we also 
acknowledge pathway or biological process heterogeneity? How far should we push the 
heterogeneity argument to maximise the information extracted but without breaking a 
basic principle of the scientific practice, i.e. the replication of results?
6.1.8. Smaller sample size to achieve a more tightly defined phenotype 
may also increased power
An important challenge of psychiatric genetics is to help refine clinical diagnosis. 
My exploration of genetic mapping in BD sub-phenotypes suggests that this approach 
may be fruitful. It  is possible that the genetic architecture of some disease subtypes may 
be simpler and lead to faster improvement of diagnostic tools, and possibly allow 
patient stratification by drug response which would be very important, even if only 
applicable to a small patient population.
6.1.9. GWAS as a starting point for system biology analyses of mental 
illness
By identifying biological processes of relevance to understanding disease aetiology, 
GWAS can guide researchers to new experimental models. For example, GWAS pointed 
to autophagy  as an important pathological mechanism to explain CD (Lees et al., 2011). 
This cellular process is now a target  of studies aiming to better understand the 
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mechanism of this association to identify new treatments (Sirota et al., 2009; Behrends 
et al., 2010; Fleming et al., 2011). A recent report provided results from a large scale 
proteomic study of the autophagy pathway (Behrends et al., 2010). This represents a 
unique resource to explore the mechanistic links and biological roles of CD 
susceptibility alleles at the biological systems levels. Psychiatric genetics may benefit in 
the same way from additional studies describing the post-synaptic density (Bayes et  al., 
2011). Studies exploring disease aetiology using functional approaches to describe 
biological networks have revealed great complexity  in the structure and functions of 
signalling cascades and how they are affected by disease associated perturbations 
(Bakal et al., 2008; Chen et al., 2008; Emilsson et al., 2008; Yang et al., 2009; Jorgensen 
and Linding, 2010; Pennell et  al., 2010). Studies aiming to understand the consequences 
of susceptibility alleles or genes on the dynamic behaviour of these functional networks 
will take us away from discussing the small effect size of risk alleles into more complex 
representations and modelling of disease biology (for examples see (Chen et al., 2008; 
Emilsson et al., 2008; Schadt, 2009)). This is in no way an easy task but it is one, 
which, in the long term will allow thoughtful design of new treatments and diagnostic 
systems based on accurate knowledge of disease causation. For example, large scale 
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system genetic analyses13  in both human and mouse were able to identify a causal 
network associated with metabolic traits (Chen et al., 2008; Emilsson et al., 2008). In 
these studies the causal network was a co-expression network highly enriched with 
genes that  have a causal or driver role on metabolic traits. An important lesson from 
these studies is that despite the fact that these metabolic traits are complex and therefore 
underpinned by many alleles it is possible to identify broad underpinning biological 
processes. By revealing a causal network the authors shifted the focus of research and 
discussion from the many alleles of small effect affecting the traits and expression of the 
network’s genes to the biological function of this network, its cell type of action and 
developmental and physiological roles. The authors showed that the network identified 
in human and mouse overlap significantly and both correspond to a signalling pathway 
involved in macrophage biology. Because this network has a causal role it may be 
possible to plan intervention that would lead to a phenotypic change or disease 
prevention. It is important to note that these studies included more than 30,000 human 
subjects and 1000 mice. This represents far more subjects than most individual human 
and mouse studies use, suggesting than not only  a technological revolution is needed to 
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13 System genetics refers to the combination of genetic and functional biology data, e.g., 
gene expression measurements. The task is to identify causal association between the 
biological molecules and a trait  of interest. The basic idea behind the methods used is 
that genotypes are unaffected by the phenotypes therefore is we can identify a 
correlation between a genotype and a biological molecule (i.e., an expression 
quantitative trait  in the case of gene-expression studies) and a correlation between this 
molecule and the trait of interest  there must be a causal pathway between the genotype 
to the phenotype mediated by  the changes in gene-expression. For our discussion it is 
important to note that whereas an allele can have a weak correlation with a trait it can 
have a strong correlation with a molecular phenotype (e.g., gene-expression). Therefore, 
despite that the effect size of the trait correlation is small needing large samples to find 
it, the causal influence on the gene-expression change can be found more easily. We 
refer the interested reader to a selection of references in this wide topic (Schadt et al. 
2005; Friedman, 2004; Chen et al., 2008; Emilsson et al., 2008; Schadt, 2009; Schadt et 
al. 2009; Schadt et al. 2009a; Schadt et al. 2009b; Hsu et al., 2009; Millstein et al., 
2009; Yang et al., 2009; Zhu et al., 2008).
undertake these approaches but also a major change in mind set when designing 
biological experiments. If causality  is to be disentangled, then quantitative studies on 
well powered samples must be used together with a systems biology an experimental 
design that accounts for systems biology.
GWAS are showing good potential to help delineate biological processes of 
relevance in order to understand the mechanisms underpinning psychiatric illness and 
other human diseases. Nevertheless, many limitations still remain but current advances, 
as we have shown in this thesis, are promising.
6.2. Limitations of my study
6.2.1. Assumptions of the asymptotic methods
In my analyses I made several assumptions. I think the most important is that the 
correlation between the SNPs approximates the correlation between the SNPs’ test 
statistics (see Chapter II). This has been shown to be the case for the chi-square 
statistics with one degree of freedom (Han et al., 2009). Although to my knowledge this 
has not been proven for other statistical tests, e.g., logistic regression with covariates, 
several authors have also used it  in their methods (for examples see (Nyholt, 2004; Li 
and Ji, 2005; Galwey, 2009)). This is likely to be an important factor in explaining the 
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non-uniformity of the asymptotic gene-wide p-values 14. Gene p-values were calculated 
by phenotype permutations (i.e. statistics for the SNPs in the gene were calculated and 
the null distribution was derived by randomising the phenotype and calculating the 
statistics again) for over 900 genes and showed asymptotic estimates which 
approximate the empirical p-values well (Pearson correlation r > 0.98). Simulation-
based p-values were also implemented, which we found produce gene p-values with a 
more uniform distribution than those produced by asymptotic methods. Possibilities to 
overcome the limitations introduced by using this assumption were evaluated and there 
may be some alternatives. For example, given the correlation matrix between the SNPs, 
it is possible to obtain a correlation matrix that explains the observed similarity  between 
the test statistics. This would allow a better variance-covariance matrix to be obtained 
for the test statistics and would allow fast asymptotic methods to be used.
6.2.2. Statistical power of gene and gene-set association methods
Simulated data could be used to quantify  statistical power differences between gene-
based association methods. However, this approach was not employed mainly due to 
time constraints. Instead, different methods were compared in several different real 
GWAS, a strategy also followed by others, e.g., (Donnelly  and Marchini, 2009). Other 
authors have also evaluated the improvement in replication provided by gene-wide 
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14As discussed in Chapter II, gene-wide p-values should agree with the uniform 
distribution only when the genetic associations are representative of the null hypothesis. 
Some of the data sets analysed in this thesis, e.g., GWAS of Crohn’s disease, have 
substantial genetic signals and therefore their quantile-quantile plots deviate form the 
null distribution, particularly  at the tail of low p-values. Nonetheless, uniformity  of p-
values is usually  considered a criteria for a valid study, for an example see review by 
McCarthy  et  al. (2008). Some criteria like these were described in the earlier GWAS 
when many studies had small samples sizes and results which did not deviate from the 
null hypothesis. On the other hand, more recent large meta-analyses with tens of 
thousands of samples have quantile-quantile plots that deviate significantly from the 
null distribution. Criteria like uniformity of p-values are evolving but are still valuable 
in cases where a significant excess of signals is not expected.
association and found results in line with the results I presented in Chapter III (Peng et 
al., 2010). An important difference of their study was that they compared the replication 
success analysing independent GWAS, a strategy free of the possible biases we may 
have introduced by using the GWAS Catalogue. These independent results support the 
conclusions of this study.
6.2.3. SNP versus gene and gene-set meta-analyses
Meta-analyses of GWAS of BD have provided evidence of association for the 
CACNA1C, ANK3, NCAN and PBRM1 loci (Ferreira et al., 2008; Breen et al., 2011; 
Cichon et al., 2011). None of these genes reached significance in the gene-based meta-
analysis but several of the regions highlighted by the gene-based meta-analysis had high 
but sub-threshold significance in these studies. Results obtained by  SNP and gene-based 
meta-analyses were not compared because access to genotype data from all BD studies 
was lacking.
As part of an ongoing parallel project (with unpublished results) I have analysed 
three GWAS that had the same set of SNPs and performed gene-based analysis on the 
SNP meta-analysis results and on the three individual GWAS separately. The top 20 
genes from the SNP and gene-based meta-analysis overlapped significantly, suggesting 
that if the GWAS overlap  completely in their SNP set using the SNP meta-analysis 
results or meta-analysing gene-based results is largely equivalent.
It is likely that SNP based meta-analysis will be a more powerful strategy, 
particularly when the causal variant  is common and well tagged. This is likely to be the 
case with the increasing accuracy  of imputation methods and increasingly  deep 
coverage of reference sample sets (Altshuler et al., 2010; Durbin et al., 2010). However, 
in the presence of allelic heterogeneity  and low frequency variants, gene-based 
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association will also be a useful complement. In the future, simulation studies may help 
clarify the merit of each approach.
6.2.4. The choice of gene-sets 
There are numerous sources from which to construct gene-sets and interaction 
networks. These will introduce different biological information and biases into the 
analyses (Lehner and Lee, 2008; Fernandes et al., 2010). In our studies, we used data 
from the Human Protein Reference Database (Keshava Prasad et al., 2009), a highly 
curated set of interactions which had been previously applied to analyses of GWAS 
(Baranzini et al., 2009) and the data presented here suggests that it provides better 
results than other gene-sets, e.g., Gene Ontology (Ashburner et al., 2000). Different 
interaction information is informative on different biological aspects but our analyses 
have been relatively basic in terms of exploiting the interactions beyond simply 
knowing that two proteins can interact with each other. For example, we do not exploit 
the direction of the interaction or its nature, i.e. phosphorylation, degradation, etc. It has 
been shown that combining different  information sources can lead to an improved 
representation of cell and organism level behaviour (Lage et al., 2007; Lee et  al., 2008; 
Zhu et al., 2008; Lee et al., 2010). By combining different interaction sets, it  is possible 
to construct probabilistic networks, in which interactions seen multiple times (and with 
higher confidence) are assigned a higher probability  of being true. An additional 
advantage of these integrated networks is the increased coverage across the interactome 
(Lehner and Lee, 2008). In the future, it  would be appropriate to develop networks of 
specific relevance for psychiatric diseases, as has been done for Alzheimer’s disease 
(Soler-Lopez et al., 2011) and cardiac pathologies (Lage et al., 2010). A starting point 
may be to build a good representation of the interaction between genes in the human 
post-synaptic density, as this is becoming increasingly important to study behaviour in 
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both humans and mice. However, it  should be noted that there is not a clear benchmark 
to compare the results obtained with different interaction networks, making the choice 
of the network and the information used to build it sensitive to biases.
6.3. Future development of gene and GSA of 
GWAS
6.3.1. Simultaneous analysis of multiple data-sets
At the moment, all methods consider different studies independently  but it may prove 
advantageous to combine the evidence at the gene-set level but using information from 
the different studies simultaneously. This may be achieved by using Bayesian 
hierarchical models (Gelman et al., 2004; Ji and Liu, 2010). This strategy  would allow 
the inclusion of prior distributions for the SNP, gene and gene-set effects. Addition of 
priors may also enable a better integration with different non-genetic data-sets, e.g., 
gene-expression or proteomics, because the difference in effect size distribution will be 
learnt from the data. For example, one of the issues encountered during our integrative 
analyses of BD GWAS (Chapter V) was that the gene-expression data found numerous 
significant gene-sets on its own, probably because gene-set analyses were designed for 
gene-expression data and that gene-expression changes are much larger than changes in 
allele frequencies. In practical terms, it suggests that there is a different expectation 
regarding the changes in magnitude found in GWAS and gene-expression studies, i.e., 
an odds-ratio of 2 is very interesting in a GWAS but not in a gene-expression study. 
Development of models considering multiple data sets and data types and allowing for 
different distribution of effect sizes may be very relevant as biomedical research in 
mental health moves into systems biology studies integrating genetic, neuroimaging, 
DISCUSSION AND FUTURE DIRECTIONS
169
gene-expression and proteomics (for example see (Furney et al., 2010; Thambisetty et 
al., 2010; Simmons et al., 2011)).
6.3.2. Construction of interaction network for mental disorders
Publicly available protein interaction networks only contain information for a 
fraction of annotated human genes, e.g., HPRD used here has ~ 8000. This certainly  had 
an impact on our analyses since GWAS will cover most of the annotated genes. For 
example, the gene HAPLN4 (best SNP p-values = 4 x 10-6, gene p-value = 7 x 10-6, 
FDR = 0.13) is in the region reported genome-wide significant  for BD by Cichon et al. 
(2011). HAPLN4 is a structural protein involved in the brain extracellular matrix and 
has been associated with brain remodelling (Spicer et al., 2003). There was no 
interaction for HAPLN4 in our datasets, so it was left out of our network analyses. 
Furthermore, most interaction networks have major biases towards protein-coding genes 
and are depleted of interaction involving non-coding RNA, lipids, and polysaccharides. 
Non-coding RNA are becoming a centre of attention for biomedical research and 
psychiatry is not an exception. Therefore, construction of an interaction network 
including many more molecule types and data sets would be beneficial to our systems 
biology  analyses. There is an increasing quantity  of functional genomics datasets, which 
include gene-expression, epigenomics and transcription factor binding, which could be 
mined to construct probabilistic networks with better coverage of the interactome. 
Unbiased experiments, like those based on high throughput sequencing, will allow for 
more non-coding RNA to be included. System genetic analyses on datasets containing 
functional data and genetic variation may  allow us to go beyond gathering correlation 
information and enable us to establish causal relationships. Extensive data from model 
organisms, like the mouse or fly, will provide across species comparisons to borrow 
information from other organisms. Interaction networks derived from a holistic strategy 
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will undoubtedly  lead to better systems biology analyses and in turn better interpretation 
of GWAS. 
The methods we used are all frequentist in statistical nature. A natural extension of 
our analyses would be to apply Bayesian statistics. Several Bayesian methods to analyse 
all SNPs within a gene or genome simultaneously have been proposed and 
implemented, e.g., see (Hoggart  et al., 2008; Omont et al., 2008), but have not yet  been 
widely  applied to GWAS. An additional attractive possibility of Bayesian statistics is to 
perform model comparisons between different gene association methods. For instance, 
one could use three models: a) the best  SNP within the gene, b) combined information 
and c) combined information but including the interaction effects between SNPs in the 
same gene. Model selection would allow selection of the model that best  explains the 
association within the gene while accounting for the complexity of each model, e.g., 
tests of interaction effects increase the multiple testing so that a model should be 
selected only if it  improves the association considerably. A similar approach has been 
proposed to determine whether associations in a region are better explained by  a single 
causal variant or by multiple causal variants (Donnelly and Marchini, 2009). 
6.3.3. Analysis of large-scale sequencing projects and rare variants
During the coming years there will be an avalanche of data from sequencing projects, 
e.g., 1000 genomes (www.1000genomes.org) or UK10K (www.uk10k.org). These data 
pose new challenges for statistical genetic and bioinformatics analyses. Post-hoc 
analyses (i.e. after quality control), will need to cope with large amounts of data and 
probably  with noise different from the error present in the current genotypes generated 
by microarray genotyping. There is increasing interest in development of new analytical 
methods for association of low frequency variants. Risk for several mental illnesses has 
been associated with rare variants identified by exome sequencing (Vissers et  al., 2010). 
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It is hypothesised that rare variants may play a prominent role in the aetiology of 
psychiatric diseases (Uher, 2009), some of the most recent exome sequencing studies in 
schizophrenia support this hypothesis (Girard et al., 2011). 
Due to the low statistical power to detect  association with rare variants gene, region-
based analyses constitute the main analysis strategy (Asimit and Zeggini, 2010; Bansal 
et al., 2010; Morris and Zeggini, 2010). There have not been reports on gene-set 
analyses using rare variants, but the current strategies could be extended to gene-sets. 
However, we may find that power to detect rare variant associations at the gene-set 
level will be reduced due to multiple testing. Reduction of multiple testing by focusing 
on variants having evident functional effects on protein coding genes may be a 
possibility, but will undoubtedly miss interesting risk variants associated with DNA or 
RNA regulation. In principle, the methods presented in this thesis could be used for a 
combined analysis of genetic variants through the frequency spectrum. Weighting the 
variants by the predicted functional relevance or frequency may help  the analysis of rare 
variants (Li et al., 2010). 
Simultaneous analysis of all individual genetic variants by incorporating information 
on genes and gene networks may  prove useful in recovering biological processes 
associated with diseases. This may be achieved using hierarchical regression models as 
it was demonstrated by  Heron et al. (2011) to include SNPs functional annotation (e.g., 
if the SNP is conserved or if it is a known disease quantitative trait loci). This strategy 
may also incorporate additional information like parent of origin effects, which can be 
detected in studies using a family  design (Kong et al., 2009). Furthermore, it might be 
possible to incorporate information emerging from the increasing amount of functional 
genomics data available to develop  increasingly complex but also more biologically rich 
analyses. For example, the known tissue expression level or epigenetic state of a gene 
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could be used to dismiss or down-weight contribution of its risk variants and help detect 
genes and variants of relevance for different tissues.
By far the greatest  of all challenges will be to deliver personalised medicine (or to 
convince biomedical researchers that such a thing is not possible). Personalised 
medicine has been the great promise of the human genome project and, without 
disregarding important achievements, it has not been delivered to date. Whole genome 
sequencing studies may  bring us closer to this promise. As noted in the introduction, a 
key problem with this challenge is our poor understanding of causality in complex 
biological systems. If we do not grasp  what causal relationship  risk alleles (of small or 
large effects) have with molecular phenotypes and physiological syndromes (diseases), 
it will be increasingly daunting to transform linear strings of information (millions of 
DNA sequence positions) and a plethora of 3D data points (gene and protein expression, 
brain and whole body imaging over time and space) into an accurate prediction of 
disease risk.
6.3.4. Additional integration with other omics datasets
Gene-based analyses may have an important role for bioinformaticians seeking to 
integrate disease signatures from different genomics platforms. Several repositories, 
such as dbGAP (www.ncbi.nlm.nih.gov/gap) or EGA (www.ebi.ac.uk/ega), provide 
summary  statistics from published GWAS. These could be use to derive gene-based 
statistics without the need to access raw genotype data and perform cumbersome quality 
control procedures. Provision of gene based association statistics may also go some way 
towards allaying concerns about data protection, when individual SNP association data 
is released (Homer et al. 2008). If methods, like the ones used here, become popular, 
data repositories may also opt to provide gene-wide association results. This may 
improve the role of GWAS in data integration efforts, particularly  those looking across 
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numerous disease types. For example, availability  of pre-computed post-quality control 
data for gene-expression microarray experiments has had a positive impact on data 
availability for the wider scientific community, who are not experts in data-analysis. We 
have taken some preliminary  steps to establish such bioinformatic resources. Our first 
step has been to provide a web server implementing our FORGE analyses (https://
compbio.brc.iop.kcl.ac.uk:8443/forgeweb). The web server was developed in 
collaboration with David To and Richard Dobson at the NIHR Biomedical Research 
Centre at IoP and SLAM (KCL, UK).
I and Dr. Gerome Breen (IoP, KCL) are currently  developing approaches to mine the 
Connectivity Map (CMAP) (Lamb et al., 2006) database for drug-disease interactions. 
The CMAP project provides gene-expression values for drug treatments of cell lines. 
We have an initial set up to identify drugs that induce gene-expression changes in genes 
identified from GWAS (Inti Pedroso and Gerome Breen, unpublished). Preliminary 
results are promising and we have been able to recover true drug-disease pairs. Current 
efforts are focused on improving the bioinformatic pipeline and quantifying the false 
positive/false negative rate of this approach. We plan on providing this pipeline as a 
drug repositioning tool as part of the FORGE web server for the wider scientific 
community. 
6.4. Final remarks
I started this thesis with a brief outline of GWAS and the state-of-the-art gene-set 
analyses of GWAS. Several major challenges facing large scale genetic studies were 
immediately apparent. Using these challenges as a starting point, this thesis aimed to 
provide a strategy that would help  psychiatric genetics to use GWAS as starting point to 
define biological systems for detailed mechanistic studies. Hopefully this will lead to a 
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new generation of diagnostic tools and treatments.  This thesis aims and main 
achievements were:
i) To develop, implement and provide the wider scientific community  with 
software tools to perform gene-set and network analyses of GWAS. In Chapter 
II I described the development of the FORGE software suite to perform these 
analyses. Availability  of the software has generated collaborations with 
researchers working on amyotrophic lateral sclerosis ( Prof Ammar Al-
Chalabi), anorexia nervosa (Prof David Collier), autism (Dr Sarah Curran) and 
unipolar depression (IoP Depression Consortium, led by Prof Peter McGuffin). 
In collaboration with David To and Dr Richard Dobson, I have developed a 
web server to fac i l i ta te the use of these methods (h t tps : / /
compbio.brc.iop.kcl.ac.uk:8443/forgeweb).
ii) Assess the ability  of these methods to find replicated genetic associations. 
Additionally  in Chapter III I presented evidence showing that gene-set analyses 
find true disease loci which eluded single marker association. Applied to BD in 
Chapter IV, a combination of gene and gene-set analyses allowed the discovery 
of convergent evidence of association of a protein interaction network. From 
the evidence presented in Chapter IV I was able to describe locus heterogeneity 
in BD and show how systems biology analyses help overcome its challenges.
iii) Evaluate the feasibility of GWAS for data integration with other genomic 
datasets in a system biology  framework. Through Chapters II to V I 
successfully  integrated BD GWAS results with the protein interaction network 
and gene-expression studies.
iv) Provide association evidence for genes and biological processes to help the 
wider scientific community  to define biological systems for the detailed study 
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of risk variants. In Chapter III, I showed that systems biology analyses (i.e. 
network analyses) of GWAS can point  to biological processes of etiological 
relevance for Crohn’s disease, rheumatoid arthritis and type 1 diabetes. In 
Chapter IV, I provided convergent genomic evidence of association with BD 
for a group of interacting gene products. These genes were characterised by 
biological functions of relevance, such as transmission of nerve impulse, and a 
significant fraction of them were mapped to the human post-synaptic density. 
In Chapter V, I showed that these methods may also be useful to study BD sub-
phenotypes and identify  biological processes that can be related to more 
discrete symptoms.
Genome wide association studies in one shape or form are likely  to continue to play 
a significant  role in biomedical research for the foreseeable future. The technologies 
used to execute these studies have evolved tremendously  during the course of this PhD, 
which started in the era of the SNP chip and ends in the era of next generation 
sequencing (NGS). Both technologies are likely to continue in parallel for the next few 
years, as microarray genotyping continues to be the most cost effective method for large 
cohorts, complemented with NGS exon sequencing. As NGS technologies become more 
affordable, whole-genome re-sequencing is likely to become the method of choice for 
GWAS, ultimately  ushering in the era of the personal genome. When this era arrives, the 
tools described here may go some way to help uncover the genetic basis of human 
diseases at the level of individual genes and biological processes. It is the hope of the 
author that the software, methods and experience presented in this thesis will help 
others to mine GWAS to improve translational research and subsequently  the quality of 
life of patients.
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This Appendix present the Perl code of the FORGE software suite. We have only 
included the main pieces of code and not example files and utility scripts. If you wish to 
check the code of the software not included here please visit the FORGE code website 
https://github.com/inti/FORGE.
8.2. Appendix Table of contents
 8.3 FILES IN THE DISTRIBUTION  212
 8.4 FORGE.PL  215
 8.5 GSA.PL   251
 8.6 META_ANALYSIS.PL  282
 8.7 COVMATRIX.PM   291
 8.8 GWAS_IO.PM  298
 8.9 GWAS_STATS.PM   307
 8.6 PARETO_DISTR_FIT.PM  319
BIBLIOGRAPHY
211
8.3. Files in the distribution
A copy of the FORGE software suite programs is available in this Appendix A. The 
files distributed with FORGE are:
• forge.pl: script to perform gene-based association and gene-set  association with a 
SNP-to-gene-set mapping strategy.
• gsa.pl: script to perform gene-set analyses based on gene p-values.
• meta_analysis.pl: script to perform meta-analyses. Its output included fixed and 
random-effects statistics, and statistical heterogeneity estimates. All statistical 
methods used in this script are described in section 2.1 under the fixed and random-
effects models.
• CovMatrix.pm: perl module with routines to calculate correlation matrixes using a 
shrinkage approach. Original methods are described in (Schafer and Strimmer, 
2005) and implemented in the R library ‘corpcor’. Our Perl routines are 
implementations of these R methods and we performed tests on synthetic data to 
ensure no coding errors were introduced and results were identical within double 
precision when possible.
• GWAS_IO.pm: perl routines to deal with input and output of commonly use 
format in GWAS.
• GWAS_STATS.pm: perl routines to calculate some statistics, e.g. meta-analysis 
statistics.
• Pareto_Distr_Fit.pm: perl routines to estimate p-values using extreme value 
distribution theory as described in (Knijnenburg et al., 2009) but estimating the 
parameters of the generalised Pareto distribution by the method of Zhang (2010) 
instead of maximum likelihood. 
• affy_to_rsID.tab: files with mapping between Affymetrix and rs-ids.
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• Utilities: folder with utility scripts
- Calculate_add_LFDR_values.R: R script to calculate False Discovery Rate 
values and add as columns to the input files.
- mapped_assoc_to_genes.pl: using a file with SNP association and SNP-to-
gene mappings it outputs a new file with both informations, i.e., SNP 
associations with chromosomal positions and genes it is mapped to.
- row_merge.pl: script to merge files based on one of more columns with ids.
- snp_2_geneAnnot.pl: script to generate SNP-to-gene mapping files using the 
Ensembl database human gene annotation.
• example: folder with example files
- example.assoc: SNP association file as produced by PLINK.
- whole_genome_example.tab: SNP association file with SNPs representing a 
whole-genome analysis.
- example.bed, example.bim and example.fam: genotype files in pedigree 
binary format for gene ILR23 and a random dichotomous phenotype.
- example.prob: same as above but is IMPUTE genotype probability format.
- example.map, example.ped: same as above but in pedigree format.
- example.gene_pvals: file with gene p-values.
- example.gmt: an example gene-set definition file.
- example.snp_weight, example.snp_weight2: example files with SNP weights 
to use in gene-based analyses.
- example.snpmap: example SNP-to-gene mapping file.
- gene_sets: folder with gene-set definition files.
- biocarta.gmt: 301 gene-sets from BioCarta (www.biocarta.com).
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- human.gol4.gmt: 2058 gene-sets from Gene Ontology database (Ashburner et 
al., 2000).
- kegg.gmt: 212 gene-sets from KEGG data base (Kanehisa et al., 2008).
- ppin_hprd_13April2010_min2_max500.gmt: 7391 gene-sets derived from 
the Human Protein Reference Database (Keshava Prasad et al., 2009) protein-
protein interaction network (PPIN). 
- ppin_hprd_22March2009_min10_max500.gmt: 6888 gene-sets from the 
PPIN. Same as above but a different data base release.

















use Carp qw( confess );
$SIG{__DIE__} =  \&confess;
$SIG{__WARN__} = \&confess;




our ( $help, $man, $out, $snpmap, $bfile, $assoc, $gene_list,
    @genes, $all_genes, $analysis_chr, $report, $spearman,
    $affy_to_rsid, @weights_file, $w_header, $v, $lambda,
    $print_cor, $pearson_genotypes,$distance, $sample_score,
    $ped, $map, $ox_gprobs,$sample_score_self, $w_maf,
    $ss_mean, $gc_correction,$g_prob_threshold,
! $bgl_gprobs, $flush, $include_gene_type, $exclude_gene_type, 
$gmt,
! $gmt_min_size,$gmt_max_size, $use_ld_as_corr,$mnd_sim_target, 
! $mnd_sim_max, $mnd_sim_wise_correction_methods, $mnd
);
GetOptions(
! 'help|h' => \$help,
! 'man' => \$man,
! 'ped=s' => \$ped,
! 'map=s' => \$map,
! 'bfile=s'    => \$bfile, 
! 'out|o=s'   => \$out, #name of the output file
! 'assoc|a=s' => \$assoc,
! 'gene_list|g=s'   => \$gene_list,
! 'genes=s' => \@genes,
! 'all_genes'       => \$all_genes,
! 'chr=s'!=> \$analysis_chr,  
! 'snpmap|m=s@'      => \$snpmap,
! 'report=i'  => \$report,
! 'correlation|cor=s' => \$spearman,
! 'affy_to_rsid=s' => \$affy_to_rsid,
! 'verbose|v' => \$v,
! 'lambda=f' => \$lambda,
! 'gc_correction' => \$gc_correction,
! 'print_cor' => \$print_cor,
! 'pearson_genotypes' => \$pearson_genotypes,
! 'use_ld' => \$use_ld_as_corr,
! 'distance|d=i' => \$distance, 
! 'sample_score' => \$sample_score,
! 'weights|w=s' => \@weights_file,
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! 'w_header' => \$w_header,
! 'ox_gprobs=s' => \$ox_gprobs,
! 'bgl_gprobs=s' => \$bgl_gprobs,
! 'g_prob_threshold=f' => \$g_prob_threshold,
! 'weight_by_maf|w_maf' => \$w_maf,
! 'ss_mean' => \$ss_mean,
! 'flush=i' => \$flush,
! 'gmt=s@' =>! \$gmt,
! 'gmt_min_size=i' =>!\$gmt_min_size,
! 'gmt_max_size=i' =>!\$gmt_max_size,
! 'gene_type|type=s@' => \$include_gene_type,
! 'exclude_gene_type|exclude_type=s@' => \$exclude_gene_type, 
! 'mnd' => \$mnd,
! 'mnd_target=i' => \$mnd_sim_target,
! 'mnd_max=i' => \$mnd_sim_max,
! 'mnd_methods=s' => \$mnd_sim_wise_correction_methods,
) or pod2usage(0);
pod2usage(0) if (defined $help);
pod2usage(-exitstatus => 2, -verbose => 1) if (defined $man);
pod2usage(0) if (not defined $assoc);
my $LOG = new IO::File; 
$LOG->open(">$out.log") or print_OUT("I can not open [ $out.log ] to 
write to",$LOG) and exit(1);
print_OUT("Check http://github.com/inti/FORGE/wiki for updates",$LOG);
print_OUT("LOG file will be written to [ $out.log ]",$LOG);
# define parameters for mnd simulation
defined $mnd_sim_target or $mnd_sim_target = 10;
defined $mnd_sim_max or $mnd_sim_max = 100_000;
if (defined $mnd_sim_wise_correction_methods){
! $mnd_sim_wise_correction_methods = [ split(/\,/,
$mnd_sim_wise_correction_methods) ];
} else { $mnd_sim_wise_correction_methods = [0,1,2,3]; }
if (defined $mnd){
! use PDL::LinearAlgebra qw (mchol);
! use Pareto_Distr_Fit qw (Pgpd);
! print_OUT("Will run multivariate normal distribution simulations 
to estimate significance",$LOG);
! print_OUT("   '-> max number [ $mnd_sim_max ] or until statistic 
is seen [ $mnd_sim_target ] times",$LOG);
! my @m = ('sidak','fisher','z_fix','z_random');
! @m = @m[@$mnd_sim_wise_correction_methods];
! print_OUT("   '-> for each gene best p-value will be selected 
among the methods [ @m ] ",$LOG);
}
# defines min and max size for gene-set analyses
defined $gmt_min_size or $gmt_min_size = 2;
defined $gmt_max_size or $gmt_max_size = 999_999_999;
# flush output every $flush number of genes are ready 
defined $flush or $flush = 1000;
# define distance threshold,
defined $distance or $distance = 20;
print_OUT("Max SNP-to-gene distance allowed [ $distance ] kb",$LOG);
# $report is use to specify how often report the advance when reading 
input files
defined $report or $report = 50_000;
# tell if analysis is restricted to a specific chromosome
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defined $analysis_chr and print_OUT("Restricting analysis to 
chromosome [ $analysis_chr ]",$LOG);
#  defined lambda value for Genomic Control correction
defined $lambda or $lambda = 1;
# defined threshold value for genotype probabilities
defined $g_prob_threshold or $g_prob_threshold = 1.0;
# tell if user wants to print the *.correlation file 
defined $print_cor and print_OUT("Defined -print_cor: I will print the 
*.correlation file (it is bulky)",$LOG);
#set output file if not set already.
defined $out or $out = "gene_based_fisher_v041.OUT";
# tell if user wants to correct p-values by genomic control 
if ($lambda != 1){ print_OUT("SNP p-value will be corrected with 
lambda = [ $lambda ]",$LOG);}
# define option to read genotype probability files
my $geno_probs = undef;
my $geno_probs_format = undef;
# find out which format the file is with the command line options
if (defined $ox_gprobs) {
    $geno_probs = $ox_gprobs ;
! $geno_probs_format = 'OXFORD';
    print_OUT("Genotype probabilities in OXFORD format will be read 
from [ $geno_probs ]",$LOG);
} elsif (defined $bgl_gprobs) {
    $geno_probs = $bgl_gprobs ;
! $geno_probs_format = 'BEAGLE';
    print_OUT("Genotype probabilities in BEAGLE format will be read 
from [ $geno_probs ]",$LOG);
}
# generate an index of the genotype probability files
# this speads up the IO
my ($gprobs, $gprobs_index);
if (defined $geno_probs){
    $gprobs = IO::File->new();
    $gprobs_index = IO::File->new();
    my $index_name = "$geno_probs.idx";
     $gprobs->open("<$geno_probs") or print_OUT("I can not open 
genotype probability file [ $geno_probs ]",$LOG) and exit(1);
    if (not -e "$geno_probs.idx") {
    !print_OUT("   '-> Making index for genotype probabilities in 
[ $index_name ] file",$LOG);
    !$gprobs_index->open("+>$index_name") or print_OUT("Can't open 
$index_name for read/write: $!\n",$LOG);
    !build_index(*$gprobs, *$gprobs_index);
    } else {
        print_OUT("   '-> Found [ $geno_probs.idx ] file for genotype 
probabilities",$LOG);
        $gprobs_index->open("<$geno_probs.idx") or print_OUT("Can't 
open $index_name for read/write: $!\n",$LOG) and exit(1);
! binmode($gprobs_index);
    }
} 
# print header for output file
my $OUT = new IO::File; 
$OUT->open(">$out") or print_OUT("I can not open [ $out ] to write 
to",$LOG) and exit(1);
# header for MND sampling analysis
if (not defined $mnd){
! print $OUT "Ensembl_ID\tHugo_id\tgene_type\tchromosome\tstart
\tend";




! print $OUT "\tB_fix\tVar_fix\tB_P_fix\tB_random\tVar_random
\tB_P_random";
! print $OUT "\tI-squared\tQ\tQ_p-value\ttau_squared";
! print $OUT "\tn_effect_Galwey\tn_effect_Gao\tn_snps\n";
} else { # header for asymptotic analysis
! print $OUT "Ensembl_ID\tHugo_id\tgene_type\tchromosome\tstart
\tend";
! print $OUT "\tmin_p\tVEGAS\tSIM_SIDAK\tSIM_FISHER\tSIM_Z_FIX
\tSIM_Z_RANDOM";
! print $OUT "\tI-squared\tQ\tQ_p-value\ttau_squared";
! print $OUT "\tSIM_BEST_P\tSIM_BEST_method\tN_SIM";
! print $OUT "\tSEEN_VEGAS\tSEEN_SIDAK\tSEEN_FISHER\tSEEN_Z_FIX
\tSEEN_RANDOM";
! print $OUT "\tGPD_VEGAS\tGPD_VEGAS_LOW\tGPD_VEGAS_UP";
! print $OUT "\tGPD_SIDAK\tGPD_SIDAK_LOW\tGPD_SIDAK_UP";
! print $OUT "\tGPD_FISHER\tGPD_FISHER_LOW\tGPD_FISHER_UP";
! print $OUT "\tGPD_Z_FIX\tGPD_Z_FIX_LOW\tGPD_Z_FIX_UP";
! print $OUT "\tGPD_Z_RANDOM\tGPD_Z_RANDOM_LOW\tGPD_Z_RANDOM_UP";
! print $OUT "\tn_effect_Galwey\tn_effect_Gao\tn_snps\n";
}
# i will read the gene_list and i will load data for just this genes 
to speed up.
if ( not defined $all_genes and not defined @genes and not defined 
$gene_list){
  $all_genes = 1;
  print_OUT("Note: You did not provide an option for the set of genes 
to be analyzed. I will analyze all genes covered by the SNP 
association file. Check documentation for options -genes and -
gene_list otherwise",$LOG);
}
if ( not defined $all_genes ) { # in case user want to analyze all 
genes
  if ( not defined @genes ) { # in case user gave a list of genes in 
the command line
    print_OUT("Reading Gene List from [ $gene_list ]",$LOG);
    # read file with gene list and store gene names.
    open( GL, $gene_list ) or print_OUT("I can not open 
[ $gene_list ]",$LOG) and exit(1);
    @genes = <GL>;
    chomp(@genes);
    close(GL);
  } else { 
! print_OUT("Read Gene List command line [ @genes  ]",$LOG); 
  }
} else {
! print_OUT("Going to analyze all genes on [ @$snpmap ] file.",
$LOG); 
}
# Now lets going to read the affy id to rsid mapping. This is used to 
keep all ids in the
# same nomenclature
my %affy_id = ();
if ( defined $affy_to_rsid ) { # if conversion file is defined
   print_OUT("Reading AFFY to rsID mapping from [ $affy_to_rsid ]");
   open( AFFY, $affy_to_rsid ) or print_OUT("I can not open 
[ $affy_to_rsid ]",$LOG) and exit(1);
   while (my $affy = <AFFY>){
      chomp($affy);
      my @b = split(/\t+/,$affy);
      $affy_id{$b[0]} = $b[1];
   }




# Read file with genetic association results.
print_OUT("Reading association file: [ $assoc ]",$LOG);
# create hash to store SNP information
my $assoc_chis = [] if (defined $gc_correction);
my %assoc_data = ();
open( ASSOC, $assoc ) or print_OUT("I can not open [ $assoc ]",$LOG) 
and exit(1);
my $line = 0;
my %header = ();
while (  my $a = <ASSOC> ) {
  $a =~ s/^\s+//;
  $a =~ s/^\t+//;
  $a =~ s/\s+/\t/g;
  # here I get the header line of the file. With the name of the 
columns I can use the cols
  # SNP and P to extract the information.
  my @data = split( /[\s+\t+]/, $a );
   if ( $line == 0 ){
      %header = %{get_header(\@data)};
      $line++;
      next;
   }
   # In case there is not cols with SNP and P names.
   exists $header{"SNP"} or print_OUT("Not p-value columns available, 
these are the headers i found [ " . (keys %header) . " ]",$LOG) and 
exit(1);
   exists $header{"P"} or print_OUT("Not p-value columns available, 
these are the headers i found [ " . (keys %header) . " ]",$LOG) and 
exit(1);
   # if there is a cols specifying the association test done. Only use 
result from ADD tests, this is only for compatibility with PLINK 
  if ( exists $header{"TEST"}){
      next if ( $data[$header{"TEST"}] ne "ADD");
   }
  #if (defined $v ) { print $data[$header{"SNP"}]," ", $data[$header
{"P"}],"\n"; }
!   # if there is an affy id convert it to rsid.
   if ( defined $affy_to_rsid ) {
      if ($data[$header{"SNP"}] !~ m/^rs/){
         if (exists $affy_id{$data[$header{"SNP"}]}){ $data[$header
{"SNP"}] = $affy_id{$data[$header{"SNP"}]};}
      }
   }
   # skip if no P-value or p-value equal NA
   next if ( $data[$header{"P"}] eq "NA");
   next if ( $data[$header{"P"}] eq "");
   
   #generate a pseudo-hash for each snp with the association info
  my $A2 = "NA";
  my $A1 = "NA";
  my $OR = 1;
! my $SE = undef;
  my $BETA = undef;
  my $R2 = undef;
  my $STAT = undef;
  if (exists $header{"A2"}){ $A2 = $data[$header{"A2"}];}
  if (exists $header{"A1"}){ $A1 = $data[$header{"A1"}];}
  if (exists $header{"OR"}){ 
!   $OR = $data[$header{"OR"}];
!   if ((exists $header{"L95"}) and (exists $header{"U95"})){ 
! !   $SE = $header{"U95"} - $header{"L95"};
!   }
  }
  if (exists $header{"BETA"}){ $BETA = $data[$header{"BETA"}]; }
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  if (exists $header{"R2"}){ $R2 = $data[$header{"R2"}]; }
  if (exists $header{"STAT"}){ $STAT = $data[$header{"STAT"}]; }
  if ((not defined $SE) and (exists $header{"SE"})){ $SE = $data
[$header{"SE"}]; }
  my $effect = undef;
  if (exists $header{"OR"}){
    $effect = "or";
  } elsif (exists $header{"BETA"}){
        $effect = "beta";
  } elsif (exists $header{"STAT"}){
        $effect = "stat";
  }
  # do some checking
  if (defined $sample_score){
    # if there are not direction of effect defined quite analysis and 
spit and error.
    if (not defined $effect){
        print_OUT("ERROR: No effect size measure or direction of 
effect provided. I can not perform Sample Score analysis",$LOG);
        print_OUT("ERROR: Please provide an odd-ratio, beta or 
regression coefficient value under the header OR, BETA or STAT, 
respectively",$LOG);
        exit(1);
    } 
  }
  $assoc_data{ $data[$header{"SNP"}] } = {
                                        'pvalue' => 1 ,
                                        'id' => $data[$header{"SNP"}],
                                        'a1' => $A1,
                                        'a2' => $A2,
                                        'or' => $OR,
! ! ! ! ! ! ! ! ! ! 'se' => 
$SE,
                                        'beta' => $BETA,
                                        'stat' => $STAT,
                                        'r2' => $R2,
                                        'effect_size_measure' => 
$effect,
        ! ! ! ! };
   # correct for genomic control if a lambda > 1 was specified.   
   if ($lambda == 1) {
   ! push @{ $assoc_chis }, $data[$header{"P"}];
! $assoc_data{ $data[$header{"SNP"}] }->{'pvalue'} = $data[$header
{"P"}];
   } elsif ($lambda > 1) {# transform the p-value on a chi-square, 
correct it by the inflation factor and transform it again on a p-value 
   ! $assoc_data{ $data[$header{"SNP"}] }->{ 'pvalue' }= 1 - 
gsl_cdf_chisq_P( gsl_cdf_chisq_Pinv( $data[$header{"P"}], 1 )/$lambda, 
1 );
   } else { 
! print_OUT("\nPlease check the lambda value is correct\n",$LOG);
! exit(1);
   }  
}
close(ASSOC);
if (scalar keys %assoc_data == 0){ 




print_OUT("[ " . scalar (keys %assoc_data) . " ] SNPs with association 
data",$LOG);




! print_OUT("Calculating lambda for genomic control correction",
$LOG);
! my $gc_lambda = get_lambda_genomic_control($assoc_chis);
! print_OUT("   '-> lambda (median) of [ $gc_lambda ]",$LOG);
! if ($gc_lambda > 1){
! ! print_OUT("   '-> Applying GC correction",$LOG);
! ! my $assoc_chis = [];
! ! foreach my $snp (keys %assoc_data) {
! ! ! if ( $assoc_data{ $snp }->{ 'pvalue' } == 1){
! ! ! ! push @{ $assoc_chis }, $assoc_data{ $snp }->
{ 'pvalue' };
! ! ! ! next;
! ! ! }
! ! ! my $snp_chi = gsl_cdf_chisq_Pinv ( 1 - $assoc_data
{ $snp }->{ 'pvalue' }, 1 );
! ! ! $snp_chi /=  $gc_lambda;
! ! ! $assoc_data{ $snp }->{ 'pvalue' }= 1 - 
gsl_cdf_chisq_P( $snp_chi, 1 );
! ! ! push @{ $assoc_chis }, $assoc_data{ $snp }->
{ 'pvalue' };
! ! }
! ! $gc_lambda = get_lambda_genomic_control($assoc_chis);
! ! print_OUT("   '-> After correction the lambda is 
[ $gc_lambda ]",$LOG);
! } else {
! ! print_OUT("   '-> GC correction not applied because lambda 
is less than 1",$LOG);
! }
}
#read snp-to-gene mapping and store in a hash with key equal gene name 
and value
# an array with the snps in the gene.
my @bim = ();
my @fam = ();
my $ped_map_genotypes;
if (defined $bfile) {
! # read the bim file with snp information and fam file with sample 
information
! @bim = @{ read_bim("$bfile.bim",$affy_to_rsid,\%affy_id) };
! @fam = @{ read_fam("$bfile.fam") };
! print_OUT("[ " . scalar @bim .  " ] SNPs and [ " . scalar @fam .  
" ] samples in genotype file",$LOG);
} elsif (defined $ped and defined $map){
! my ($fam_ref,$bim_ref);
! ($fam_ref,$ped_map_genotypes,$bim_ref) = read_map_and_ped($ped,
$map,$affy_to_rsid,\%affy_id);
! @fam = @$fam_ref;
! @bim = @$bim_ref;
print_OUT("[ " . scalar @bim .  " ] SNPs and [ " . scalar @fam .  " ] 
samples in genotype file",$LOG);
} elsif (defined $geno_probs){
! print_OUT("Getting list of genotyped SNPs from [ $geno_probs ]",
$LOG);
! @bim = @{ get_snp_list_from_ox_format($gprobs, $gprobs_index) } 
if ($geno_probs_format eq 'OXFORD');
! @bim = @{ get_snp_list_from_bgl_format($gprobs, $gprobs_index) } 
if ($geno_probs_format eq 'BEAGLE');
! print_OUT("[ " . scalar @bim .  " ] SNPs in genotype file",$LOG);
}
my %bim_ids = ();
my $index = 0;
map {






for (my $i = 0; $i < scalar @$snpmap; $i++){
! if ($snpmap->[$i] =~ m/\#\d+\-\d+\#/) {
! ! print_OUT("   '-> Found [ # ] key on [ $snpmap->[$i] ]. I 
will generate file names for chromosome interval.");
! ! my ($s,$e) = ($snpmap->[$i] =~ m/\#(\d+)\-(\d+)\#/);
! ! push @{$snpmap}, @{ make_file_name_array_interval($snpmap-
>[$i],$s,$e) };
! ! splice(@$snpmap,$i,1);! ! !
! }
! if ($snpmap->[$i] =~ m/\#/) {
! ! print_OUT("   '-> Found [ # ] key on [ $snpmap->[$i] ]. I 
will generate file names for 26 chromosomes.");




my %gene = ();
my %snp_to_gene = ();
my %ids_map = ();
foreach my $snp_gene_mapping_file (@$snpmap){
! if (not -e $snp_gene_mapping_file){
! ! print_OUT("   '-> File [ $snp_gene_mapping_file ] does not 
exist, moving on to next file",$LOG);
! ! next;
! }
! open( MAP, $snp_gene_mapping_file ) or print_OUT("Can not open 
[ $snp_gene_mapping_file ] file",$LOG) and exit(1);
! print_OUT("   '-> Reading [ $snp_gene_mapping_file ]",$LOG);
! while ( my $read = <MAP> ) {
!   chomp($read);
!   # the line is separate in gene info and snps. the section are 
separated by a tab.
!   my ($chr,$start,$end,$ensembl,$hugo,$gene_status,$gene_type,
$description,@m) = split(/\t+/,$read);
! ! #check if gene was in the list of genes i want to analyze
! ! unless ( defined $all_genes ) {
! ! ! next unless ( ( grep $_ eq $hugo, @genes ) or ( grep 
$_ eq $ensembl, @genes ) );
! ! }
! ! if (defined $analysis_chr){
! ! ! next if ($analysis_chr ne $chr);
! ! }
! ! my @first_snp_n_fields =  split(/\:/,$m[0]);
!   if (4 !=  scalar @first_snp_n_fields){ $description .= splice
(@m,0,1); }
!   # get all mapped snps within the distance threshold,
!   my @mapped_snps = ();
!   foreach my $s (@m) {
! ! my ($id,$pos,$allele,$strand) = split(/\:/,$s);
! ! next if (not defined $id);
! ! if (( $pos >= $start) and ($pos <= $end)){ push 
@mapped_snps, $id; }
! ! elsif ( ( abs ($pos - $start) <= $distance*1_000 ) or 
( abs ($pos - $end) <= $distance*1_000 )) { push @mapped_snps, $id; }
!   }
!    
!    next if (scalar @mapped_snps == 0);
!    # create a pseudo-hash with the gene info
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!    $gene{$ensembl} = {
! ! ! 'hugo'      => $hugo,
! ! ! 'ensembl'   => $ensembl,!
! ! ! 'chr'       => $chr,
! ! ! 'start'     => $start,
! ! ! 'end'       => $end,
! ! ! 'gene_type' => $gene_type,
! ! ! 'snps'      => [],
! ! ! 'minp'      => -9,
! ! ! 'genotypes' => null,
! ! ! 'geno_mat_rows' => [],
! ! ! 'cor' => null,
! ! ! 'weights' => null,
! ! ! 'pvalues' => [],
! ! ! 'effect_size' => undef,
! ! ! 'effect_size_se' => undef,
! ! ! 'gene_status' => $gene_status,
! ! ! 'desc' => $description,
!    };
!    # go over mapped snps and change convert affy ids to rsid.
!    # and make a non-redundant set.
!    my %nr_snps = ();
!    foreach my $s (@mapped_snps) {
! !   if ( defined $affy_to_rsid ) {
! ! !  if ($s !~ m/^rs/){
! ! ! ! if (exists $affy_id{$s}){ $s = $affy_id{$s};}
! ! !  }
! !   }
! !   # exclude snps not in the association file nor in the 
bim file
! !   next unless ( exists $assoc_data{$s} );
! !   next unless ( exists $bim_ids{$s});
! !   $nr_snps{$s} = "";
!    }
!    @mapped_snps = keys %nr_snps;
!    
!    # go over the snps mapped to the gene and check if they are in 
the map
!    # and association files. If so, store the min p-value for the 
gene.
!    # if any of the snps is in the files the remove the gene from 
the analysis.
!    foreach my $s (@mapped_snps) {
! !   if (defined $v ){ print_OUT("Mapping [ $s ] to 
[ $ensembl ]",$LOG);}
! !   next if ( grep $_ eq $s, @{ $gene{$ensembl}->{snps} } );
! !   push @{ $snp_to_gene{$s} }, $ensembl;
! !   push @{ $gene{$ensembl}->{snps} }, $s;!
! !   if ( $gene{$ensembl}->{minp} == -9) {
! ! !  $gene{$ensembl}->{minp} = $assoc_data{$s}->
{pvalue};
! !   } elsif ( $assoc_data{$s}->{pvalue} < $gene{$ensembl}->
{minp} ) {
! ! !  $gene{$ensembl}->{minp} = $assoc_data{$s}->
{pvalue};
! !   }
!    }
!    # remove gene if none of its snps is in the analysis.
!    if ( scalar @{ $gene{$ensembl}->{snps} } == 0 ) { 
! !    delete( $gene{$ensembl} ); 
!    } else { 
! !    if (defined $v ){ print_OUT("Gene $ensembl $hugo 
included in the analysis with [ ", scalar @{ $gene{$ensembl}->
{snps} }, " ] mapped SNPs",$LOG); }
! !    $ids_map{$hugo} = $ensembl;!    
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!    }




print_OUT("  '->[ " . scalar (keys %gene) . " ] Genes read from SNP-2-
Gene Mapping files",$LOG);
print_OUT("  '->[ " . scalar (keys %snp_to_gene) . " ] SNPs mapped to 
Genes and with association results will be analyzed",$LOG);
# complain if there is genes ledt for analysis
if (scalar keys %gene == 0){
        print_OUT("No genes mapped",$LOG);
        exit(1);
}
# read gene-set definition file
if (defined $gmt){
! my $total_gene_sets=0;
! print_OUT("Reading gene-set definitions",$LOG);
! foreach my $gene_set_file (@$gmt){
! ! print_OUT("  '-> Reading [ $gene_set_file ]",$LOG);
! ! open (GMT,$gene_set_file) or print_OUT("I can not open 
[ $gene_set_file ] to read from.",$LOG) and die $!;
! ! while (my $line = <GMT>){
! ! ! chomp($line);
! ! ! my ( $p_name, $p_desc, @p_genes ) = split( /\t+/, 
$line );
! ! ! my @gene_with_snp = ();
! ! ! # loop over the genes and check if the ids match 
with any with SNPs
! ! ! foreach my $gn (@p_genes) {
! ! ! ! if ( $gn =~ m/\// ) {
! ! ! ! ! $gn =~ s/\s+//g;
! ! ! ! ! my @genes = split( /\/{1,}/, $gn );
! ! ! ! ! map {
! ! ! ! ! ! if ( exists $ids_map{$_} ){
! ! ! ! ! ! ! push @gene_with_snp, 
$ids_map{$_};
! ! ! ! ! ! } elsif ( exists $gene{$_} ){
! ! ! ! ! ! ! push @gene_with_snp, $_;
! ! ! ! ! ! } else {
! ! ! ! ! ! ! next;
! ! ! ! ! ! }
! ! ! ! ! } @genes;
! ! ! ! } else {
! ! ! ! ! if ( exists $ids_map{$gn} ){
! ! ! ! ! ! push @gene_with_snp, $ids_map
{$gn};
! ! ! ! ! } elsif ( exists $gene{$gn} ){
! ! ! ! ! ! push @gene_with_snp, $gn;
! ! ! ! ! } else {
! ! ! ! ! ! next;
! ! ! ! ! }
! ! ! ! }
! ! ! }
! ! ! my %tmp = ();
! ! ! map { $tmp{$_} = ""; } @gene_with_snp;
! ! ! @gene_with_snp = keys %tmp; 
! ! ! # skip gene-set if does not complain with size 
constrains! ! !
! ! ! next if (scalar @gene_with_snp < $gmt_min_size);
! ! ! next if (scalar @gene_with_snp > $gmt_max_size);
! ! !
! ! ! %tmp = ();
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! ! ! my ($chrs,$starts,$ends) = "";
! ! !
! ! ! foreach my $g (@gene_with_snp) { 
! ! ! ! $chrs .= "$gene{$g}->{chr},";
! ! ! ! $starts .= "$gene{$g}->{start},";
! ! ! ! $ends .= "$gene{$g}->{end},";
! ! ! ! foreach my $s (@{ $gene{$g}->{snps} }){
! ! ! ! ! $tmp{$s} = "";! ! ! !
! ! ! ! }
! ! ! }
! ! ! my @p_snps = keys %tmp;
! ! ! next if (scalar @p_snps < 2);
! ! !
! ! ! map { push  @{ $snp_to_gene{ $_ } }, $p_name; } 
@p_snps;
! ! !
! ! ! $gene{$p_name} = {
! ! ! ! 'chr'       => $chrs,
! ! ! ! 'start'     => $starts,
! ! ! ! 'end'       => $ends,
! ! ! ! 'gene_type' => 'gene_set',
! ! ! ! 'snps'      => [@p_snps],
! ! ! ! 'minp'      => -9,
! ! ! ! 'genotypes' => null,
! ! ! ! 'geno_mat_rows' => [],
! ! ! ! 'cor' => null,
! ! ! ! 'weights' => null,
! ! ! ! 'pvalues' => [],
! ! ! ! 'effect_size' => undef,
! ! ! ! 'effect_size_se' => undef,
! ! ! ! 'gene_status' => 'KNOWN',
! ! ! ! 'ensembl' => $p_name,
! ! ! ! 'hugo' => $p_desc,
! ! ! ! 'desc' => $p_desc,
! ! ! ! 'name' => $p_name,
! ! ! ! 'genes' => [@gene_with_snp],
! ! ! };
! ! ! $total_gene_sets++;
! ! }
! }
! print_OUT("  '-> Just read [ $total_gene_sets ] gene-sets with 
mapped genes with size [ $gmt_min_size ] and [ $gmt_max_size ]",$LOG);
}
# exclude genes if gene type were specified
if (defined $exclude_gene_type or defined $include_gene_type){
! print_OUT("Going to filter genes based on user defined options",
$LOG);
! if (defined $exclude_gene_type){
! ! print_OUT("   '-> Will exclude gene-types [ @
$exclude_gene_type ]",$LOG);
! }
! if (defined $include_gene_type){
! ! print_OUT("   '-> Will include gene-types [ @
$include_gene_type ]",$LOG);
! }
! foreach my $gn (keys %gene){
! ! # apply filter by gene type
! ! if (defined $exclude_gene_type){
! ! ! delete ($gene{$gn}) if ( grep $_ eq $gene{$gn}->
{gene_type} , @$exclude_gene_type );
! ! }
! ! if (defined $include_gene_type){
! ! ! if (exists $gene{$gn}) {
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! ! ! ! delete ($gene{$gn}) if (not grep $_ eq $gene
{$gn}->{gene_type}, @$include_gene_type );




print_OUT("Will analyse [ " . scalar (keys %gene) . " ] genes",$LOG);
# start a hash to store the SNP-to-SNP correlation values
my %correlation = ();
# if provided get the SNP-to-SNP correlation values from a tab 
separated file with 3 cols:snp1 snp2 correlatio_value
if (defined $spearman){
   print_OUT("Reading SNP correlation from [ $spearman ]",$LOG);
   open( SPRMN, $spearman ) or print_OUT("I cannot open 
[ $spearman ]",$LOG) and exit(1);
   while (my $ln = <SPRMN>){
      chomp($ln);
      my @a = split(/\s+/,$ln);
!   # take the square of the correlation if they are r2 and user 
wants to use r values
      $correlation{$a[0]}{$a[1]} = $a[2];
      $correlation{$a[1]}{$a[0]} = $a[2];
!   # set self correlation to 1
      $correlation{$a[0]}{$a[0]} = 1;
      $correlation{$a[1]}{$a[1]} = 1;
   }
}
# start output file and print its header
print_OUT("Output file will be written to [ $out ]",$LOG);
# create a variable that will store a ref to a hash with the weights
my $weights = {};
if (defined @weights_file){
    print_OUT("Starting to read SNP weigths",$LOG);
    # create hash refs to store the name of the weight categories
    my $w_classes = {};
    my $w_counter = 0; # category counter, in case the file has not a 
header.
    # loop over the files and read the weights
    foreach my $w_f (@weights_file){
        ($weights,$w_counter,$w_classes) = read_weight_file($w_f,
$w_counter,$w_classes,$weights, $w_header,\%snp_to_gene);
    }
    print_OUT("  '-> [ " . scalar (keys %{$weights}) . " ] weights 
read",$LOG);
    # make a single weight vector for each snp
    foreach my $snp (keys %{$weights}){
        # get the snp weights sorted by category name
        my @tmp_all_w = map { $weights->{$snp}{$_}; } sort {$a cmp $b} 
keys %{ $w_classes };
        # make piddle
        $weights->{$snp} = [@tmp_all_w];
    }
}
#start count to report advance 
my $count = 0;
print_OUT("Starting to Calculate gene p-values",$LOG);
# if there are more than 100 genes change the $report variable in 
order to report every ~ 10 % of genes.
unless (scalar keys %gene < 100){
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  $report = int((scalar keys %gene)/100 + 0.5)*10;
}
# the genotype stack will store SNP genotypes if the SNP was mapped to 
more than 1 gene.
# the SNP genotype will be deleted after is no longer needed.
# this reduces the IO and speeds up
my %snp_genotype_stack = ();
# if user defined a genotypes file. read genotypes and store a 
genotype matrix (rows: samples, cols: genotypes)for each gene 
if (defined $geno_probs) { # in case not plink binary files provided 
and only a genotype prob file is given
! print_OUT("Reading genotype probabilities from [ $geno_probs ]",
$LOG);
! foreach my $gn (keys %gene){
! ! my $snp_list = [];
! ! my $lines = [];
! ! foreach my $mapped_snp (@{$gene{$gn}->{snps}}){
! ! ! next if (not exists $assoc_data{ $bim[$bim_ids
{$mapped_snp}]->{snp_id} } );
! ! ! if (defined $v){ print_OUT("Adding SNP [  $bim
[ $bim_ids{$mapped_snp} ]->{snp_id}  ] to genotypes of $gn",$LOG); }
! ! ! push @{$snp_list}, $mapped_snp;
! ! ! push @{$gene{$gn}->{geno_mat_rows}}, $mapped_snp;
! ! ! push @{$gene{$gn}->{pvalues}}, $assoc_data
{ $mapped_snp }->{pvalue};
! ! ! push @{$lines}, $bim_ids{$mapped_snp} + 1;
! ! }
! ! my ($p_mat,$d_mat) = extract_genotypes_for_snp_list
($snp_list,$lines,$g_prob_threshold,$geno_probs_format,$gprobs,
$gprobs_index);
! ! $gene{$gn}->{genotypes} = $d_mat;
! ! # check the range of the values. if the range is 0 then 
the SNP is monomorphic and shoudl be dropped
! ! my ($min,$max,$min_d,$max_d)= $gene{$gn}->{genotypes}-
>minmaximum;
! ! my $non_zero_variance_index = which(($max - $min) != 0);
! ! # check if any SNPs needs to be dropped
! ! if ($non_zero_variance_index->isempty()){
! ! ! print_OUT(" [ $gn ] All SNPs are monomorphic, going 
to next gene",$LOG) if (defined $v);
! ! ! next;
! ! }
! ! my $old_size = scalar @{ $gene{$gn}->{geno_mat_rows} };
! ! my $new_size = scalar list $non_zero_variance_index;
! ! if ( $old_size != $new_size){
! ! ! $gene{$gn}->{genotypes} = $gene{$gn}->{genotypes}->
(,$non_zero_variance_index);
! ! ! $gene{$gn}->{geno_mat_rows} = [@{$gene{$gn}->
{geno_mat_rows}}[$non_zero_variance_index->flat->list] ];
! ! ! $gene{$gn}->{pvalues} = [@{$gene{$gn}->{pvalues}}
[$non_zero_variance_index->flat->list] ];
! ! ! if (defined $v){
! ! ! ! my $diff = $old_size - $new_size;
! ! ! ! print_OUT("Dropping [ $diff ] monomorphic 
SNPs",$LOG);
! ! ! }
! ! }
! !
! ! # Calculate the genotypes correlation matrix
! ! my $more_corrs = "";
! ! ($gene{$gn}->{cor},$gene{$gn}->{cor_ld_r},$more_corrs)  = 
deal_with_correlations($gene{$gn},\%correlation,$use_ld_as_corr);




! ! # Calculate the weights for the gene
! ! $gene{$gn}->{weights} = deal_with_weights(\@weights_file,
$gene{$gn},$w_maf,$weights);
! !
! ! # Calculate average max genotype prob and use it as 
weitghs
! ! $gene{$gn}->{weights} *= daverage $gene{$gn}->{genotypes};
! ! $gene{$gn}->{weights} /= $gene{$gn}->{weights}->sumover;
! !
! ! # calculate gene p-values
! ! my $z_based_p = z_based_gene_pvalues($gene{$gn},$mnd);
! ! if (ref($z_based_p) ne 'HASH' and $z_based_p == -9){
! ! ! $z_based_p = {
! ! ! ! 'B_stouffer_fix' => "NA",
! ! ! ! 'B_stouffer_random' => "NA",
! ! ! ! 'B_fix' => "NA",
! ! ! ! 'B_random' => "NA",
! ! ! ! 'V_fix' => "NA",
! ! ! ! 'V_random' => "NA",
! ! ! ! 'Chi_fix' => "NA",
! ! ! ! 'Chi_random' => "NA",
! ! ! ! 'Z_P_fix' => "NA",
! ! ! ! 'Z_P_random' => "NA",
! ! ! ! 'Q' => "NA",
! ! ! ! 'Q_P' => "NA",
! ! ! ! 'I2' => "NA",
! ! ! ! 'tau_squared' => "NA",
! ! ! ! 'N' => scalar @{ $gene{$gn}->
{geno_mat_rows} },
! ! ! };
! ! } 
! ! my $pvalue_based_p = gene_pvalue($gn);
! !
! ! # check which analysis strategy to follow 
! ! if (not defined $mnd){ # asymptotic 
! ! ! print $OUT join "\t",($gene{$gn}->{ensembl},$gene
{$gn}->{hugo},$gene{$gn}->{gene_type},$gene{$gn}->{chr},$gene{$gn}->
{start},$gene{$gn}->{end},
! ! ! $gene{$gn}->{pvalues}->min,
! ! ! $pvalue_based_p->{sidak_min_p},
! ! ! $pvalue_based_p->{fisher},
! ! ! $pvalue_based_p->{fisher_chi},
! ! ! $pvalue_based_p->{fisher_df},
! ! ! $z_based_p->{'B_fix'},
! ! ! $z_based_p->{'V_fix'},
! ! ! $z_based_p->{'Z_P_fix'},
! ! ! $z_based_p->{'B_random'},
! ! ! $z_based_p->{'V_random'},
! ! ! $z_based_p->{'Z_P_random'},
! ! ! $z_based_p->{'I2'},
! ! ! $z_based_p->{'Q'},
! ! ! $z_based_p->{'Q_P'},
! ! ! $z_based_p->{'tau_squared'},
! ! ! $pvalue_based_p->{Meff_Galwey},
! ! ! $pvalue_based_p->{Meff_gao},
! ! ! scalar @{ $gene{$gn}->{geno_mat_rows} });
! ! ! print $OUT "\n";
! ! } else { # MND Sampling
! ! ! my $simulated_p = {
! ! ! ! 'sidak' => 'NA',
! ! ! ! 'fisher' => 'NA',
! ! ! ! 'z_fix' => 'NA',
! ! ! ! 'z_random' => 'NA',
! ! ! ! 'vegas' => 'NA',
! ! ! ! 'wise_p' => 'NA',
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! ! ! ! 'wise_method' => 'NA',
! ! ! ! 'N' => 0,
! ! ! ! 'seen_vegas'! => 'NA',
! ! ! ! 'seen_sidak'! => 'NA',
! ! ! ! 'seen_fisher' => 'NA',
! ! ! ! 'seen_fix' => 'NA',
! ! ! ! 'seen_random' => 'NA',
! ! ! ! 'pareto_sidak_Phat' => 'NA',
! ! ! ! 'pareto_sidak_Phatci_low'  => 'NA',
! ! ! ! 'pareto_sidak_Phatci_up'! =>  'NA',
! ! ! ! 'pareto_fisher_Phat' => 'NA',
! ! ! ! 'pareto_fisher_Phatci_low' => 'NA',
! ! ! ! 'pareto_fisher_Phatci_up' =>  'NA',
! ! ! ! 'pareto_fix_Phat'!=> 'NA',
! ! ! ! 'pareto_fix_Phatci_low' => 'NA',
! ! ! ! 'pareto_fix_Phatci_up' => 'NA',
! ! ! ! 'pareto_random_Phat' ! => 'NA',
! ! ! ! 'pareto_random_Phatci_low' =>  'NA',
! ! ! ! 'pareto_random_Phatci_up' =>  'NA',
! ! ! ! 'pareto_vegas_Phat'! ! => 'NA',
! ! ! ! 'pareto_vegas_Phatci_low' =>  'NA',
! ! ! ! 'pareto_vegas_Phatci_up'! => 'NA',
! ! ! };
! ! !
! ! ! if ($z_based_p->{'Z_P_fix'} =~ m/[\d+]/){





! ! ! }
! ! !
! ! ! print $OUT join "\t",($gene{$gn}->{ensembl},$gene
{$gn}->{hugo},$gene{$gn}->{gene_type},$gene{$gn}->{chr},$gene{$gn}->
{start},$gene{$gn}->{end},
! ! ! $gene{$gn}->{pvalues}->min,
! ! ! $simulated_p->{vegas},
! ! ! $simulated_p->{sidak},
! ! ! $simulated_p->{fisher},
! ! ! $simulated_p->{z_fix},
! ! ! $simulated_p->{z_random},
! ! ! $z_based_p->{'I2'},
! ! ! $z_based_p->{'Q'},
! ! ! $z_based_p->{'Q_P'},
! ! ! $z_based_p->{'tau_squared'},
! ! ! $simulated_p->{wise_p},
! ! ! $simulated_p->{wise_method},
! ! ! $simulated_p->{N},
! ! !
! ! ! $simulated_p->{'seen_vegas'}, # number of times 
stats was seen
! ! ! $simulated_p->{'seen_sidak'},
! ! ! $simulated_p->{'seen_fisher'},
! ! ! $simulated_p->{'seen_fix'},
! ! ! $simulated_p->{'seen_random'},
! ! !
! ! ! $simulated_p->{'pareto_vegas_Phat'}, # VEGAS
! ! ! $simulated_p->{'pareto_vegas_Phatci_low'},
! ! ! $simulated_p->{'pareto_vegas_Phatci_up'},
! ! !
! ! ! $simulated_p->{'pareto_sidak_Phat'},
! ! ! $simulated_p->{'pareto_sidak_Phatci_low'},
! ! ! $simulated_p->{'pareto_sidak_Phatci_up'},
! ! !
! ! ! $simulated_p->{'pareto_fisher_Phat'}, # fisher
! ! ! $simulated_p->{'pareto_fisher_Phatci_low'},
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! ! ! $simulated_p->{'pareto_fisher_Phatci_up'},
! ! !
! ! ! $simulated_p->{'pareto_fix_Phat'},# z fix
! ! ! $simulated_p->{'pareto_fix_Phatci_low'},
! ! ! $simulated_p->{'pareto_fix_Phatci_up'},
! ! !
! ! ! $simulated_p->{'pareto_random_Phat'}, # z random
! ! ! $simulated_p->{'pareto_random_Phatci_low'},
! ! ! $simulated_p->{'pareto_random_Phatci_up'},
! ! !
! ! ! $pvalue_based_p->{Meff_Galwey},
! ! ! $pvalue_based_p->{Meff_gao},
! ! ! scalar @{ $gene{$gn}->{geno_mat_rows} });
! ! ! print $OUT "\n";
! ! }
! !
! ! # remove LD measures and genotypes from the stack that 
will not use again to free memory
! ! foreach my $snp (  @{ $gene{$gn}->{geno_mat_rows} } ){
! ! ! if (scalar @{ $snp_to_gene{ $snp } } == 1){
! ! ! ! foreach my $pair ( keys %{$correlation{$snp}})
{
! ! ! ! ! delete($correlation{$snp}{$pair});
! ! ! ! ! delete($correlation{$pair}{$snp});
! ! ! ! }
! ! ! ! delete($snp_genotype_stack{ $snp });
! ! ! ! delete($snp_to_gene{ $snp });
! ! ! } else {
! ! ! ! splice(@{ $snp_to_gene{ $snp } },0,1);
! ! ! }
! ! }






} elsif (defined $bfile) {
  print_OUT("Reading genotypes from [ $bfile.bed ]",$LOG);
  # open genotype file
  my $bed = new IO::File;
  $bed->open("<$bfile.bed") or print_OUT("I can not open binary PLINK 
file [ $bfile ]",$LOG) and exit(1);
  binmode($bed); # set file type to binary
  # check if the file is a PLINK file in the proper format by checking 
the first 3 bytes
  my ($buffer,$n_bytes); 
  my $plink_bfile_signature = "";
  read $bed, $plink_bfile_signature, 3;
  if (unpack("B24",$plink_bfile_signature) ne 
'011011000001101100000001'){
    print_OUT("Binary file is not in SNP-major format, please check 
you files\n",$LOG);
    exit(1);
  } else { print_OUT("Binary file is on SNP-major format",$LOG); }
  # calculate how many bytes are needed  to encode a SNP
  # each byte has 8 bits with information for 4 genotypes
  my $N_bytes_to_encode_snp = (scalar @fam)/4; # four genotypes per 
byte
  # if not exact round it up
  if (($N_bytes_to_encode_snp - int($N_bytes_to_encode_snp)) != 0  )
{ $N_bytes_to_encode_snp = int($N_bytes_to_encode_snp) + 1;}
  # loop over all genes and extract the genotypes of the SNPs
  foreach my $gn (keys %gene){
!   
    # this will store the genotypes
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    my $matrix;
    # loop over the snps mapped to the gene
    foreach my $mapped_snp (@{$gene{$gn}->{snps}}){
! ! # skip if it does not have association information
! ! next if (not exists $assoc_data{ $bim[$bim_ids
{$mapped_snp}]->{snp_id} } );
      
! ! if (defined $v){ print_OUT("Adding SNP [  $bim[ $bim_ids
{$mapped_snp} ]->{snp_id}  ] to genotypes of $gn",$LOG); }
! ! if (exists $snp_genotype_stack{$mapped_snp}) {
! ! if (defined $v){
! ! ! ! print_OUT("   '-> SNP [ $mapped_snp] already 
read",$LOG);
! ! ! }
! ! ! push @{ $matrix }, $snp_genotype_stack{$mapped_snp};
! ! } else { 
! ! ! # because we know the index of the SNP in the 
genotype file we know on which byte its information starts
! ! ! my $snp_byte_start = $N_bytes_to_encode_snp*$bim_ids
{$mapped_snp};
! ! ! # here i extract the actual genotypes
! ! ! my @snp_genotypes = @{ extract_binary_genotypes
(scalar @fam,$N_bytes_to_encode_snp,$snp_byte_start,$bed) };
! ! ! # store the genotypes.
! ! ! # if a snp does not use the 8 bits of a byte the 
rest of the bits are fill with missing values
! ! ! # here i extract the number of genotypes 
corresponding to the number of samples
! ! !
! ! ! my $maf = get_maf([@snp_genotypes[0..scalar @fam - 
1]] ); # check the maf of the SNP
! ! ! next if ($maf == 0 or $maf ==1);  # go to next if it 
is monomorphic
! ! ! push @{ $matrix }, [@snp_genotypes[0..scalar @fam - 
1]];
! ! ! $snp_genotype_stack{$mapped_snp} = [@snp_genotypes
[0..scalar @fam - 1]];! ! !
! ! }
! !
! ! # add snp id to matrix row names
! ! push @{ $gene{$gn}->{geno_mat_rows} }, $mapped_snp;
! ! # store the p-value of the snp
! ! push @{ $gene{$gn}->{pvalues} }, $assoc_data
{ $mapped_snp }->{pvalue}; 
! ! my $effect_measure = $assoc_data{ $mapped_snp }->
{effect_size_measure};
! ! if (defined $effect_measure){
! ! ! if ($effect_measure eq 'or'){
! ! ! ! push @{ $gene{$gn}->{effect_size} }, log 
$assoc_data{ $mapped_snp }->{$effect_measure};
! ! ! } else {
! ! ! ! push @{ $gene{$gn}->{effect_size} }, 
$assoc_data{ $mapped_snp }->{$effect_measure};
! ! ! }
! ! ! if (defined $assoc_data{ $mapped_snp }->{se}){
! ! ! ! if ($effect_measure eq 'or'){
! ! ! ! ! #push @{ $gene{$gn}->{effect_size_se} }, 
abs log $assoc_data{ $bim[ $bim_ids{$mapped_snp} ]->{snp_id} }->{se};
! ! ! ! ! push @{ $gene{$gn}->{effect_size_se} }, 
$assoc_data{ $mapped_snp }->{se};
! ! ! ! } else {
! ! ! ! ! push @{ $gene{$gn}->{effect_size_se} }, 
$assoc_data{ $mapped_snp }->{se};
! ! ! ! }




    }
    # generate the genotype matrix as a PDL piddle
    $gene{$gn}->{genotypes} = pdl $matrix;
!   
! # Calculate the genotypes correlation matrix
! my $more_corrs = "";
! ($gene{$gn}->{cor},$gene{$gn}->{cor_ld_r},$more_corrs)  = 
deal_with_correlations($gene{$gn},\%correlation,$use_ld_as_corr);
! %correlation = (%correlation,%{$more_corrs});
!   
! # Calculate the weights for the gene
! $gene{$gn}->{weights} = deal_with_weights(\@weights_file,$gene
{$gn},$w_maf,$weights);
! # calculate gene p-values
! my $z_based_p = z_based_gene_pvalues($gene{$gn},$mnd);
! if (ref($z_based_p) ne 'HASH' and $z_based_p == -9){
! ! $z_based_p = {
! ! ! 'B_stouffer_fix' => "NA",
! ! ! 'B_stouffer_random' => "NA",
! ! ! 'B_fix' => "NA",
! ! ! 'B_random' => "NA",
! ! ! 'V_fix' => "NA",
! ! ! 'V_random' => "NA",
! ! ! 'Chi_fix' => "NA",
! ! ! 'Chi_random' => "NA",
! ! ! 'Z_P_fix' => "NA",
! ! ! 'Z_P_random' => "NA",
! ! ! 'Q' => "NA",
! ! ! 'Q_P' => "NA",
! ! ! 'I2' => "NA",
! ! ! 'tau_squared' => "NA",
! ! ! 'N' => scalar @{ $gene{$gn}->{geno_mat_rows} },
! ! };
! } 
! my $pvalue_based_p = gene_pvalue($gn);
!
! # check which analysis strategy to follow 
! if (not defined $mnd){ # asymptotic 
! ! print $OUT join "\t",($gene{$gn}->{ensembl},$gene{$gn}->
{hugo},$gene{$gn}->{gene_type},$gene{$gn}->{chr},$gene{$gn}->{start},
$gene{$gn}->{end},
! ! ! $gene{$gn}->{pvalues}->min,
! ! ! $pvalue_based_p->{sidak_min_p},
! ! ! $pvalue_based_p->{fisher},
! ! ! $pvalue_based_p->{fisher_chi},
! ! ! $pvalue_based_p->{fisher_df},
! ! ! $z_based_p->{'B_fix'},
! ! ! $z_based_p->{'V_fix'},
! ! ! $z_based_p->{'Z_P_fix'},
! ! ! $z_based_p->{'B_random'},
! ! ! $z_based_p->{'V_random'},
! ! ! $z_based_p->{'Z_P_random'},
! ! ! $z_based_p->{'I2'},
! ! ! $z_based_p->{'Q'},
! ! ! $z_based_p->{'Q_P'},
! ! ! $z_based_p->{'tau_squared'},
! ! ! $pvalue_based_p->{Meff_Galwey},
! ! ! $pvalue_based_p->{Meff_gao},
! ! ! scalar @{ $gene{$gn}->{geno_mat_rows} });
! ! ! print $OUT "\n";
! } else { # MND Sampling
! ! my $simulated_p = {
! !   'sidak' => 'NA',
! !   'fisher' => 'NA',
! !   'z_fix' => 'NA',
! !   'z_random' => 'NA',
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! !   'vegas' => 'NA',
! !   'wise_p' => 'NA',
! !   'wise_method' => 'NA',
! !   'N' => 0,
! !   'seen_vegas'! => 'NA',
! !   'seen_sidak'! => 'NA',
! !   'seen_fisher' => 'NA',
! !   'seen_fix' => 'NA',
! !   'seen_random' => 'NA',
! !   'pareto_sidak_Phat' => 'NA',
! !   'pareto_sidak_Phatci_low'  => 'NA',
! !   'pareto_sidak_Phatci_up'! =>  'NA',
! !   'pareto_fisher_Phat' => 'NA',
! !   'pareto_fisher_Phatci_low' => 'NA',
! !   'pareto_fisher_Phatci_up' =>  'NA',
! !   'pareto_fix_Phat'! => 'NA',
! !   'pareto_fix_Phatci_low' => 'NA',
! !   'pareto_fix_Phatci_up' => 'NA',
! !   'pareto_random_Phat' !=> 'NA',
! !   'pareto_random_Phatci_low' =>  'NA',
! !   'pareto_random_Phatci_up' =>  'NA',
! !   'pareto_vegas_Phat'! ! => 'NA',
! !   'pareto_vegas_Phatci_low' =>  'NA',
! !   'pareto_vegas_Phatci_up'! => 'NA',
!   };
! !
!   if ($z_based_p->{'Z_P_fix'} =~ m/[\d+]/){





!   }
! !
!   print $OUT join "\t",($gene{$gn}->{ensembl},$gene{$gn}->{hugo},
$gene{$gn}->{gene_type},$gene{$gn}->{chr},$gene{$gn}->{start},$gene
{$gn}->{end},
! !   $gene{$gn}->{pvalues}->min,
! !   $simulated_p->{vegas},
! !   $simulated_p->{sidak},
! !   $simulated_p->{fisher},
! !   $simulated_p->{z_fix},
! !   $simulated_p->{z_random},
! !   $z_based_p->{'I2'},
! !   $z_based_p->{'Q'},
! !   $z_based_p->{'Q_P'},
! !   $z_based_p->{'tau_squared'},
! !   $simulated_p->{wise_p},
! !   $simulated_p->{wise_method},
! !   $simulated_p->{N},
!   
! !   $simulated_p->{'seen_vegas'}, # number of times stats 
was seen
! !   $simulated_p->{'seen_sidak'},
! !   $simulated_p->{'seen_fisher'},
! !   $simulated_p->{'seen_fix'},
! !   $simulated_p->{'seen_random'},
!   
! !   $simulated_p->{'pareto_vegas_Phat'}, # VEGAS
! !   $simulated_p->{'pareto_vegas_Phatci_low'},
! !   $simulated_p->{'pareto_vegas_Phatci_up'},
!   
! !   $simulated_p->{'pareto_sidak_Phat'},
! !   $simulated_p->{'pareto_sidak_Phatci_low'},
! !   $simulated_p->{'pareto_sidak_Phatci_up'},
! !   
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! !   $simulated_p->{'pareto_fisher_Phat'}, # fisher
! !   $simulated_p->{'pareto_fisher_Phatci_low'},
! !   $simulated_p->{'pareto_fisher_Phatci_up'},
! !   
! !   $simulated_p->{'pareto_fix_Phat'},# z fix
! !   $simulated_p->{'pareto_fix_Phatci_low'},
! !   $simulated_p->{'pareto_fix_Phatci_up'},
! !   
! !   $simulated_p->{'pareto_random_Phat'}, # z random
! !   $simulated_p->{'pareto_random_Phatci_low'},
! !   $simulated_p->{'pareto_random_Phatci_up'},
! ! !   
! !   $pvalue_based_p->{Meff_Galwey},
! !   $pvalue_based_p->{Meff_gao},
! !   scalar @{ $gene{$gn}->{geno_mat_rows} });
! !   print $OUT "\n";
    }
  
! # remove LD measures and genotypes from the stack that will not 
use again to free memory
! foreach my $snp (  @{ $gene{$gn}->{geno_mat_rows} } ){
!   if (scalar @{ $snp_to_gene{ $snp } } == 1){
! !   foreach my $pair ( keys %{$correlation{$snp}}){
! ! !   delete($correlation{$snp}{$pair});
! ! !   delete($correlation{$pair}{$snp});
! !   }
! !   delete($snp_genotype_stack{ $snp });
! !   delete($snp_to_gene{ $snp });
!   } else {
! !   splice(@{ $snp_to_gene{ $snp } },0,1);
!   }
! }
    # delete the gene's data to keep memory usage low
    delete($gene{$gn});
    $count++;
    &report_advance($count,$report,"Genes");!
  }
} elsif (defined $ped and defined $map){
! my $genotypes = pdl @{ $ped_map_genotypes };
! foreach (my $index_snp = 0; $index_snp <  scalar @bim; $index_snp
++){
! # store SNP genotypes only if it has association data
! ! if (exists $assoc_data{ ${ $bim[$index_snp] }{snp_id} } ){
! !   # for every gene mapped to this SNP, push inside the 
genotype matrix this SNP genotypes.
! ! ! foreach my $gn (@{ $snp_to_gene{${ $bim
[$index_snp] }{snp_id} } }){
! ! ! ! if (defined $v){ print_OUT("Adding SNP [  $
{ $bim[$index_snp] }{snp_id}  ] to genotypes of $gn",$LOG); }
! ! ! ! next if ( grep $_ eq ${ $bim[$index_snp] }
{snp_id} , @{ $gene{$gn}->{geno_mat_rows} } );
! ! ! !
! ! ! ! my $maf = get_maf([ $genotypes(,$index_snp)-
>list ] ); # check the maf of the SNP
! ! ! ! next if ($maf == 0 or $maf ==1);  # go to next 
if it is monomorphic
! ! ! !
! ! ! !
! ! ! ! # add the genotypes to the genotype matrix
! ! ! ! $gene{$gn}->{genotypes} = $gene{$gn}->
{genotypes}->glue(1,$genotypes(,$index_snp));
! ! ! ! push @{ $gene{$gn}->{geno_mat_rows} }, ${ $bim
[$index_snp] }{snp_id};
! ! ! ! push @{ $gene{$gn}->{pvalues} }, $assoc_data
{ ${ $bim[$index_snp] }{snp_id} }->{pvalue};
! ! ! !
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! ! ! ! my $effect_measure = $assoc_data{ ${ $bim
[$index_snp] }{snp_id}  }->{effect_size_measure};
! ! ! ! if (defined $effect_measure){
! ! ! ! ! if ($effect_measure eq 'or'){
! ! ! ! ! ! push @{ $gene{$gn}->
{effect_size} }, log $assoc_data{ ${ $bim[$index_snp] }{snp_id} }->
{$effect_measure};
! ! ! ! ! } else {
! ! ! ! ! ! push @{ $gene{$gn}->
{effect_size} }, $assoc_data{ ${ $bim[$index_snp] }{snp_id} }->
{$effect_measure};
! ! ! ! ! }
! ! ! ! ! if (defined $assoc_data{ ${ $bim
[$index_snp] }{snp_id} }->{se}){
! ! ! ! ! ! if ($effect_measure eq 'or'){
! ! ! ! ! ! ! #push @{ $gene{$gn}->
{effect_size_se} }, abs log $assoc_data{ $bim[ $bim_ids
{$mapped_snp} ]->{snp_id} }->{se};
! ! ! ! ! ! ! push @{ $gene{$gn}->
{effect_size_se} }, $assoc_data{ ${ $bim[$index_snp] }{snp_id} }->
{se};
! ! ! ! ! ! } else {
! ! ! ! ! ! ! push @{ $gene{$gn}->
{effect_size_se} }, $assoc_data{ ${ $bim[$index_snp] }{snp_id} }->
{se};
! ! ! ! ! ! }
! ! ! ! ! }
! ! ! ! }
! ! ! ! if (scalar @{ $gene{$gn}->{snps} } == scalar @
{ $gene{$gn}->{geno_mat_rows} }){
! ! ! ! ! # Calculate the genotypes correlation 
matrix
! ! ! ! ! my $more_corrs = "";
! ! ! ! ! ($gene{$gn}->{cor},$gene{$gn}->
{cor_ld_r},$more_corrs)  = deal_with_correlations($gene{$gn},\
%correlation,$use_ld_as_corr);
! ! ! ! ! %correlation = (%correlation,%
{$more_corrs});
! ! ! ! !
! ! ! ! ! # Calculate the weights for the gene
! ! ! ! ! $gene{$gn}->{weights} = 
deal_with_weights(\@weights_file,$gene{$gn},$w_maf,$weights);
! ! ! ! !
! ! ! ! ! # calculate gene p-values
! ! ! ! ! my $z_based_p = z_based_gene_pvalues
($gene{$gn},$mnd);
! ! ! ! ! if (ref($z_based_p) ne 'HASH' and 
$z_based_p == -9){
! ! ! ! ! ! $z_based_p = {
! ! ! ! ! ! ! 'B_stouffer_fix' => "NA",
! ! ! ! ! ! ! 'B_stouffer_random' => "NA",
! ! ! ! ! ! ! 'B_fix' => "NA",
! ! ! ! ! ! ! 'B_random' => "NA",
! ! ! ! ! ! ! 'V_fix' => "NA",
! ! ! ! ! ! ! 'V_random' => "NA",
! ! ! ! ! ! ! 'Chi_fix' => "NA",
! ! ! ! ! ! ! 'Chi_random' => "NA",
! ! ! ! ! ! ! 'Z_P_fix' => "NA",
! ! ! ! ! ! ! 'Z_P_random' => "NA",
! ! ! ! ! ! ! 'Q' => "NA",
! ! ! ! ! ! ! 'Q_P' => "NA",
! ! ! ! ! ! ! 'I2' => "NA",
! ! ! ! ! ! ! 'tau_squared' => "NA",
! ! ! ! ! ! ! 'N' => scalar @{ $gene{$gn}-
>{geno_mat_rows} },
! ! ! ! ! ! };
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! ! ! ! ! }
! ! ! ! !
! ! ! ! ! my $pvalue_based_p = gene_pvalue($gn);
! ! ! ! !
! ! ! ! ! print $OUT join "\t",($gene{$gn}->
{ensembl},$gene{$gn}->{hugo},$gene{$gn}->{gene_type},$gene{$gn}->
{chr},$gene{$gn}->{start},$gene{$gn}->{end},
! ! ! ! ! $gene{$gn}->{pvalues}->min,
! ! ! ! ! $pvalue_based_p->{sidak_min_p},
! ! ! ! ! $pvalue_based_p->{fisher},
! ! ! ! ! $pvalue_based_p->{fisher_chi},
! ! ! ! ! $pvalue_based_p->{fisher_df},
! ! ! ! ! $z_based_p->{'B_fix'},
! ! ! ! ! $z_based_p->{'V_fix'},
! ! ! ! ! $z_based_p->{'Z_P_fix'},
! ! ! ! ! $z_based_p->{'B_random'},
! ! ! ! ! $z_based_p->{'V_random'},
! ! ! ! ! $z_based_p->{'Z_P_random'},
! ! ! ! ! $z_based_p->{'I2'},
! ! ! ! ! $z_based_p->{'Q'},
! ! ! ! ! $z_based_p->{'Q_P'},
! ! ! ! ! $z_based_p->{'tau_squared'},
! ! ! ! ! $pvalue_based_p->{Meff_Galwey},
! ! ! ! ! $pvalue_based_p->{Meff_gao},
! ! ! ! ! scalar @{ $gene{$gn}->
{geno_mat_rows} });
! ! ! ! ! print $OUT "\n";
! ! ! ! ! # remove LD measures and genotypes from 
the stack that will not use again to free memory
! ! ! ! ! foreach my $snp (  @{ $gene{$gn}->
{geno_mat_rows} } ){
! ! ! ! ! ! if (scalar @{ $snp_to_gene
{ $snp } } == 1){
! ! ! ! ! ! ! foreach my $pair ( keys %
{$correlation{$snp}}){
! ! ! ! ! ! ! ! delete($correlation
{$snp}{$pair});
! ! ! ! ! ! ! ! delete($correlation
{$pair}{$snp});
! ! ! ! ! ! ! }
! ! ! ! ! ! ! delete($snp_genotype_stack
{ $snp });
! ! ! ! ! ! ! delete($snp_to_gene
{ $snp });
! ! ! ! ! ! } else {
! ! ! ! ! ! ! splice(@{ $snp_to_gene
{ $snp } },0,1);
! ! ! ! ! ! }
! ! ! ! ! }
! ! ! ! ! # delete the gene's data to keep memory 
usage low
! ! ! ! ! delete($gene{$gn});
! ! ! ! ! $count++;
! ! ! ! ! &report_advance($count,$report,"Genes");
! ! ! ! } # close if 
! ! ! } # close foreach my $gn 
! ! } # close if exists
! } # close foreach loop over snps
} else {
  print_OUT("WARNING: Gene p-values will be calculated with the 
precomputed correlation only. If correlation for some SNPs pairs are 





# if the user want to get the correlation values print the 
*.correlation file
if (defined $print_cor){
  open (COR,">$out.correlation") or print_OUT("Cannot open 
[ $out.correlation ] to write to",$LOG) and exit(1);
  foreach my $snp1 (keys %correlation) {
    foreach my $snp2 (keys %{$correlation{$snp1}}  ) {
      next if ($snp1 eq $snp2);
      printf COR ("$snp1 $snp2 %.3f\n",abs($correlation{ $snp1 }
{ $snp2 }));
      delete($correlation{ $snp1 }{ $snp2 });









! my $w_files = shift;
! my $gn = shift;
! my $w_by_maf =shift;
! my $weights = shift;
! my $back = null;
! my $N = scalar @{ $gn->{geno_mat_rows} };
! if (defined @$w_files){
        ! $back = generate_weights_for_a_gene($gn->{geno_mat_rows},
$weights);
    !} else {
        ! $back = ones $N;
        ! $back *= 1/$N;
        ! $back /= $back->dsum;
    !}
! # if desired weigth by the 1/MAF
! if (defined $w_by_maf){
! ! my $MAF_w = get_maf_weights($gn->{genotypes});
! ! $back *= $MAF_w->transpose;
! }
!
! # Correct the weights by the LD in the gene.
! # the new weight will be the weigthed mean of the gene.
! # the new weight will be the weigthed mean of the gene weights.
! # the weights for the mean are the correlation between the SNP, 
In that way the
! # weights reflect the correlation pattern of the SNPs 
! # weights reflect the correlation pattern of the SNPs
! my $C;
! if (defined $gn->{cor_ld_r}){
! ! $C = $gn->{cor_ld_r};
! } else {
! ! $C = $gn->{cor};
! } 
! my $w_matrix = $back * abs($C); # multiply the weights by the 
correaltions
! my @dims = $w_matrix->dims();
! $w_matrix = pdl map { $w_matrix->(,$_)->flat->sum/$back->dsum; } 
0 .. $dims[1] - 1; # sum the rows divided by sum of the weights used
! if ($w_matrix->min == 0){ $w_matrix += $w_matrix->(which




! $w_matrix /= $w_matrix->sum; # make sure weights sum 1
!





! my $target = shift; # min times stat must be seen to finish 
simulations
! my $MAX = shift; # max number of simulations
! my $sidak = shift;
! my $k = shift;
! my $fisher = shift;
! my $z_fix = shift;
! my $z_random = shift;
! my $gene_data = shift; # hash ref with gene informatio
! my $compare_wise_p = shift; # ARRAY ref
! !
! my $max_step_size = 100_000;
! my $total = 0;
! my $step= 1000;
! my ($cov,$status) = check_positive_definite($gene_data->{cor},
1e-8);
! if ($status == 1){





! my $cholesky = mchol($cov);
! my $SEEN = zeroes 4;
! my $stats_bag = [];
! my $fake_gene = {
! ! 'pvalues' => "",
! ! 'effect_size' => $gene_data->{'effect_size'},
! ! 'effect_size_se' => $gene_data->{'effect_size_se'},
! ! 'cor' => $gene_data->{'cor'},
! ! 'weights' => $gene_data->{'weights'},
! ! 'geno_mat_rows' => $gene_data->{'geno_mat_rows'},
! };
!
! my $vegas_stat = dsum gsl_cdf_chisq_Pinv(1-$gene_data->{pvalues},
1);
! my $vegas_count = 0;
! my $fix_null_stats = [];
! my $random_null_stats = [];
! my $sidak_null_stats = [];
! my $fisher_null_stats = [];
! my $vegas_null_stats = [];
!
! while ($SEEN->min < $target){
! ! my ($sim,$c) = rmnorm($step,0,$cov,$cholesky);
! ! my $sim_chi_df1 = $sim**2;
! ! $vegas_count += dsum( $sim_chi_df1->xchg(0,1)->dsumover >= 
$vegas_stat);
! ! push @{ $vegas_null_stats }, $sim_chi_df1->xchg(0,1)-
>dsumover->list;
! ! my $sim_p =  1 - gsl_cdf_chisq_P($sim_chi_df1,1);
! ! $sim_chi_df1 = '';
! ! $sim = '';
! ! for (my $sim_n = 0; $sim_n < $sim_p->getdim(0); $sim_n++){
! ! ! $fake_gene->{'pvalues'} = $sim_p->($sim_n,)->flat;
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! ! ! my $sim_n_gene_p = z_based_gene_pvalues($fake_gene,
$mnd);
! ! !
! ! ! my ($sim_fisher_chi_stat,$sim_fisher_df) = 
get_makambi_chi_square_and_df($gene_data->{cor},$gene_data->{weights},
$fake_gene->{'pvalues'} );
! ! ! my $sim_fisher_p_value = sclr double  1 - 
gsl_cdf_chisq_P($sim_fisher_chi_stat, $sim_fisher_df );
! ! ! my $sim_sidak = 1 - (1 - $fake_gene->{'pvalues'}-
>min)**$k;
! ! !
! ! ! $SEEN->(0)++ if ( $sidak >= $sim_sidak );
! ! ! $SEEN->(1)++ if ( $fisher >= $sim_fisher_p_value );
! ! ! $SEEN->(2)++ if ( $z_fix >= $sim_n_gene_p->
{'Z_P_fix'} );
! ! ! $SEEN->(3)++ if ( $z_random >= $sim_n_gene_p->
{'Z_P_random'} );
! ! ! push @{ $fix_null_stats    }, -1 * 
gsl_cdf_ugaussian_Pinv( $sim_n_gene_p->{'Z_P_fix'} );
! ! ! push @{ $random_null_stats }, -1 * 
gsl_cdf_ugaussian_Pinv( $sim_n_gene_p->{'Z_P_random'} );
! ! ! push @{ $sidak_null_stats  }, -1 * 
gsl_cdf_ugaussian_Pinv( $sim_sidak );
! ! ! push @{ $fisher_null_stats }, -1 * 
gsl_cdf_ugaussian_Pinv( $sim_fisher_p_value );
! ! !
! ! ! my @sim_gene_ps = ( $sim_sidak,$sim_fisher_p_value,
$sim_n_gene_p->{'Z_P_fix'},$sim_n_gene_p->{'Z_P_random'} );
! ! ! push @{$stats_bag}, [ @sim_gene_ps[ @
$compare_wise_p ] ];
! ! }
! ! $total += $step;
! ! if ($SEEN->min != 0){
! ! ! $step = 1.1*(10*($total)/$SEEN->min);
! ! } elsif ($step < $max_step_size){ 
! ! ! $step *=10; 
! ! }
! ! if ($step > $MAX){ $step = $MAX; }
! ! last if ($total > $MAX);
! }
! my $back = {
! ! 'sidak' => sclr ($SEEN->(0)+1)/($total +1),
! ! 'fisher' => sclr ($SEEN->(1)+1)/($total +1),
! ! 'z_fix' => sclr ($SEEN->(2)+1)/($total +1),
! ! 'z_random' => sclr ($SEEN->(3)+1)/($total +1),
! ! 'vegas' => ($vegas_count +1)/($total +1),
! ! 'N' => $total,
! };
!
! $fix_null_stats! ! = pdl $fix_null_stats;
! $random_null_stats! = pdl $random_null_stats;
! $sidak_null_stats! = pdl $sidak_null_stats;
! $fisher_null_stats! = pdl $fisher_null_stats;
! $vegas_null_stats! = pdl $vegas_null_stats;
!
! my $fix_observed! = -1 * gsl_cdf_ugaussian_Pinv( $z_fix );
! my $random_observed = -1 * gsl_cdf_ugaussian_Pinv( $z_random );
! my $sidak_observed! = -1 * gsl_cdf_ugaussian_Pinv( $sidak );
! my $fisher_observed = -1 * gsl_cdf_ugaussian_Pinv( $fisher );
! my ($pareto_fix_Phat,! $pareto_fix_Phatci_low,!
! $pareto_fix_Phatci_up)! ! = Pareto_Distr_Fit::Pgpd





( $random_observed,! $random_null_stats,! 250,0.05);
! my ($pareto_sidak_Phat,! $pareto_sidak_Phatci_low,
! $pareto_sidak_Phatci_up)! = Pareto_Distr_Fit::Pgpd
( $sidak_observed,! $sidak_null_stats,! 250,0.05);
! my ($pareto_fisher_Phat,$pareto_fisher_Phatci_low,
! $pareto_fisher_Phatci_up)!= Pareto_Distr_Fit::Pgpd
( $fisher_observed,! $fisher_null_stats,! 250,0.05);
! my ($pareto_vegas_Phat,! $pareto_vegas_Phatci_low,
! $pareto_vegas_Phatci_up)! = Pareto_Distr_Fit::Pgpd
( $vegas_stat,! ! $vegas_null_stats,! 250,0.05);
!
! $back->{'seen_vegas'}! = $vegas_count;
! $back->{'seen_sidak'}! = sclr $SEEN->(0);
! $back->{'seen_fisher'}! = sclr $SEEN->(1);
! $back->{'seen_fix'}! = sclr $SEEN->(2);
! $back->{'seen_random'}! = sclr $SEEN->(3);
! # pareto p-values
! # sidak
! $back->{'pareto_sidak_Phat'}! ! = sclr $pareto_sidak_Phat;
! $back->{'pareto_sidak_Phatci_low'}! = $pareto_sidak_Phatci_low;
! $back->{'pareto_sidak_Phatci_up'}! =  $pareto_sidak_Phatci_up;
!
! # fisher
! $back->{'pareto_fisher_Phat'}! ! = sclr $pareto_fisher_Phat;
! $back->{'pareto_fisher_Phatci_low'}! = $pareto_fisher_Phatci_low;
! $back->{'pareto_fisher_Phatci_up'}! =  $pareto_fisher_Phatci_up;
! !
! # fix
! $back->{'pareto_fix_Phat'}! ! ! = sclr 
$pareto_fix_Phat;
! $back->{'pareto_fix_Phatci_low'}! = $pareto_fix_Phatci_low;
! $back->{'pareto_fix_Phatci_up'}! =  $pareto_fix_Phatci_up;
!
! # random
! $back->{'pareto_random_Phat'}! ! = sclr $pareto_random_Phat;
! $back->{'pareto_random_Phatci_low'} =  $pareto_random_Phatci_low;
! $back->{'pareto_random_Phatci_up'}! =  $pareto_random_Phatci_up;
!
! # vegas
! $back->{'pareto_vegas_Phat'}! ! = sclr $pareto_vegas_Phat;
! $back->{'pareto_vegas_Phatci_low'} =  $pareto_vegas_Phatci_low;
! $back->{'pareto_vegas_Phatci_up'}! =  $pareto_vegas_Phatci_up;
!
! my @methods = ('sidak','fisher','z_fix','z_random');
! @methods = @methods[@$compare_wise_p];
! my $methods_p = pdl ($back->{sidak},$back->{fisher},$back->
{z_fix},$back->{z_random});
! $stats_bag = pdl $stats_bag;
! $stats_bag = gsl_cdf_ugaussian_Pinv($stats_bag);
! my $stat_cor = cov_shrink($stats_bag);
! my ($stats_Meff_gao,$stats_Meff_galwey) = number_effective_tests
(\$stat_cor->{cor});
! my $min = $methods_p->minimum_ind();
! $back->{'wise_p'} = sclr 1 - ( 1 - $methods_p->( $min ) )**
$stats_Meff_gao;
! $back->{'wise_method'} = $methods[$min];
! $back->{'stats_gao'} = $stats_Meff_gao;






! my $gn = shift;
! my $correlation = shift;
! my $use_ld = shift;
! my %new_corrs = ();
! my $shrunken_matrix = cov_shrink($gn->{genotypes}->transpose);
! my $pearson_cor = $shrunken_matrix->{cor};
! my $n = scalar @{ $gn->{'geno_mat_rows'} };
! my $cor_ld_r = undef; #zeroes $n,$n; 
! if (defined $use_ld){
! ! $cor_ld_r = stretcher(ones $n); 
! ! for (my $i = 0; $i < $n; $i++){
! ! ! for (my $j = $i; $j < $n; $j++){
! ! ! ! next if ($j == $i);
! ! ! ! if (exists $correlation->{$gn->
{'geno_mat_rows'}->[$i]}{$gn->{'geno_mat_rows'}->[$j]}){
! ! ! ! ! set $cor_ld_r, $i, $j, $correlation->
{$gn->{'geno_mat_rows'}->[$i]}{$gn->{'geno_mat_rows'}->[$j]};
! ! ! ! ! set $cor_ld_r, $j, $i, $correlation->
{$gn->{'geno_mat_rows'}->[$i]}{$gn->{'geno_mat_rows'}->[$j]};
! ! ! ! } else {
! ! ! ! ! my $ld = calculate_LD_stats([ $gn->
{'genotypes'}->(,$i)->list ],[ $gn->{'genotypes'}->(,$j)-
>list ]);!
! ! ! ! ! set $cor_ld_r, $i, $j, $ld->{r};
! ! ! ! ! set $cor_ld_r, $j, $i, $ld->{r};
! ! ! ! !
! ! ! ! ! $new_corrs{ $gn->{'geno_mat_rows'}->
[$i] }{ $gn->{'geno_mat_rows'}->[$j] } = $ld->{r};
! ! ! ! ! $new_corrs{ $gn->{'geno_mat_rows'}->
[$j] }{ $gn->{'geno_mat_rows'}->[$i] } = $ld->{r};
! ! ! ! }
! ! ! }
! ! }
! } else {





! my $genotypes = shift;
! my $MAF_w = $genotypes->sumover/(2*$genotypes->getdim(0));
! my $maf_to_flip = which($MAF_w >0.5);
! $MAF_w->index($maf_to_flip) .= 1 - $MAF_w->index($maf_to_flip);
! $MAF_w /= $MAF_w->sum;




    my $snps = shift;
    my $weights = shift;
    # get the weights for each snp in the gene
    # if there are no weights for an SNP all will be set to 0. Meaning
    # This SNP will get the min weight in all categories present.
    my @w_mat_rows = ();
    foreach my $s (@{$snps}) {
        if (not exists $weights->{$s}) { $weights->{$s} = []; }
        push @w_mat_rows, $weights->{$s};
    }
    # make a matrix with the weigths and get its dimensions
    my $W = pdl @w_mat_rows;
    if (scalar @w_mat_rows == 1){
        $W = ones 1;
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    } else {
        $W = abs($W);
        @w_mat_rows = ();
        my @dims = $W->dims();
        # re-scale the weights to be between 0 and 1 (columns)
        for (my $i = 0; $i < $dims[0]; $i++) {
            next if ($W->($i,)->flat->sumover == 0);
            $W->($i,) = ($W->($i,) - $W->($i,)->min) / $W->($i,)->max;
        }
        # sum the weight for each snp
        $W = pdl map { $W->(,$_)->flat->sum; } 0 .. $dims[1] - 1;
        # make the weight for the gene sum 1.
        if ($W->min == 0){
            $W += $W->(which($W > 0))->min/$dims[0];
        }
        $W /= $W->sum;
    }
    return($W);
}
sub make_file_name_array {
! my $file = shift;
! my @back = ();
! my @body = split(/\#/,$file);
! for my $chr (1..26){





! my $file = shift;
! my $s = shift;
! my $e = shift;
! my @back = ();
! my @body = split(/\#.*\#/,$file);
! for my $chr ($s..$e){





    my $gn = shift;
    if (defined $v){ print_OUT("____ $gn ____",$LOG); }
    my $n_snps = scalar @{ $gene{$gn}->{geno_mat_rows}};
    # if the gene has just 1 SNP we make that SNP's p value the gene 
p-value under all methods
! if ($n_snps < 2){





! ! ! 'fisher' => -1,
! ! ! 'fisher_df' => -1,
! ! ! 'fisher_chi' => -1,
! ! ! 'sidak_min_p' => -1,
! ! ! 'Meff_gao' => -1,
! ! ! 'Meff_Galwey' => -1,
! ! });
! }




   # calculate number of effective tests by the Gao ($k) and Galwey 
($Meff_galwey) method.!   
   my ($k,$Meff_galwey) = number_effective_tests(\$gene{$gn}->{cor});
   # get the log of the SNP p-value
! if (ref($gene{$gn}->{pvalues}) eq "ARRAY"){
! ! $gene{$gn}->{pvalues} = pdl @{ $gene{$gn}->{pvalues} };
! }
   # calculate the chi-square statistics for the Makambi method and 
its p-value
    #
    #### WORK ON THE GENE WEIGHTS ####
    #
    if (defined $v){ print_OUT("Weigth = [ $gene{$gn}->{weights} ]",
$LOG); }
   my ($forge_chi_stat,$forge_df) = get_makambi_chi_square_and_df
($gene{$gn}->{cor},$gene{$gn}->{weights},$gene{$gn}->{pvalues});
   my $fisher_p_value = sclr double  1 - gsl_cdf_chisq_P
($forge_chi_stat, $forge_df );
   
!
! my $sidak = sclr double 1-(1- $gene{$gn}->{pvalues}->min)**$k;
! $forge_df = sclr $forge_df;
! $forge_chi_stat = sclr $forge_chi_stat;
! my $back = {
! ! 'fisher' => $fisher_p_value,
! ! 'fisher_df' => $forge_df,
! ! 'fisher_chi' => $forge_chi_stat,
! ! 'sidak_min_p' => $sidak,
! ! 'Meff_gao' => $k,
! ! 'Meff_Galwey' => $Meff_galwey,
! };
   # print out the results
  









# this subroutine take an array and return a hash were every element 
of the line is
# a key and the value is the index in the array
sub get_header {
   my $in = shift;
   my %back = ();
   for (my $i = 0;$i< scalar @$in; $i++){
      $back{$$in[$i]} = $i;
   }
   return(\%back);
}
# this subroutine print the advance of of something
BIBLIOGRAPHY
243
# it receives 3 parameter: index, rep and tag. index is the advance so 
far, report how often to report and tag is name for the printing
# it will print a report when index if divisible by rep
sub report_advance {
!   my ($index,$rep,$tag) = @_;
   if (( $index/$rep - int($index/$rep)) == 0) {print_OUT(" '->Done 
with [ $index ] $tag",$LOG); }
}
sub print_OUT {
! my $string = shift;
! my @file_handles = @_; !
! print scalar localtime(), "\t$string\n";
! unless (scalar @file_handles == 0){
! ! foreach my $fh (@file_handles){





    my $file = shift; # file name
    my $w_counter = shift; # weigth counter, to be use if the file has 
not header
    my $class_names =shift; # header of weights 
    my $weights = shift; # weight for each snp
    my $header_present = shift;
    my $snp_2_gene = shift;
    print_OUT("  '-> Reading weigths from [ $file ]",$LOG);
    open (WEIGHTS,$file) or print_OUT("I cannot open [ $file ]",$LOG) 
and exit(1);
    my $count = 0;
    my $w_header = ();
    while(my $line = <WEIGHTS>){
        chomp($line);
        my ($snp_id,@w) = split(/[\s\t\,]/,$line);
        if ( defined $affy_to_rsid ) {
            if ($snp_id !~ m/^rs/){
                if (exists $affy_id{$snp_id}){ $snp_id = $affy_id
{$snp_id};}
            }
        }
        # if it is the first line check if the user declared header in 
the file
        if ($count == 0){
            if (defined $header_present){
                $w_header = get_header([@w]);
                $count++;
                next;
            } else {
                map {   $w_header->{$w_counter} = $w_counter;
                        $w_counter++;
                    } @w;
            }
            $count++;
        }
        next if (not exists $snp_2_gene->{$snp_id});
        foreach my $category (sort { $w_header->{$a} <=> $w_header->
{$b} } keys %{$w_header}){
            my $val = $w[$w_header->{$category}];
            $val = 0 if ($val eq "NA");
            $val = 0 if ($val eq "");
            $weights->{$snp_id}{$category} = $val;
            $class_names->{$category} = "";
        }
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    close(WEIGHTS);





! -h, --help! ! print help message
! -m, --man! ! print complete documentation
! -report! ! how often to report advance
! -verbose, -v! ! useful for debugging
! Input Files:
! -ped! ! ! Genotype file in PLINK PED format
! -map! ! ! SNP info file in PLINK MAP format
! -bfile! ! ! Files in PLINK binary format, corresping file 
with extension *.bed, *.bim and *.fam.
! -ox_gprobs      Genotype probabilities in OXFORD format.
! -bgl_gprobs! ! Genotype probabilities in BEAGLE format.
! -assoc, -a! ! SNP association file, columns header is 
necessary and at leat columns with SNP and P names must be present
! -snpmap, -m! ! Snp-to-gene mapping file
! -affy_to_rsid! Affy id to rs id mapping file
! -gmt! ! ! Gene-set definition file
! Output Files:
! -out, -o! ! Name of the output file
! -print_cor! ! print out SNP-SNP correlations
! Analsis modifiers:
! -gene_list, -g! ! Only analyse genes on the file provided
! -genes! ! ! Provide some gene name in command line, only 
these genes will be analyzed
! -all_genes! ! Analyze all genes in the snp-to-gene mapping 
file
! -chr! ! ! Anlyze a specific chromosome
! -gene_type, -type! Only analyses genes of this type, e.g. 
protein_coding
! -exclude_gene_type, -exclude_type! Exclude genes of this type 
from the analysis, e.g. pseudogenes
! -distance, -d! Max SNP-to-gene distance allowed (in kb)
! -correlation, -cor! SNP-SNP correlation file
! -pearson_genotypes! Calculate SNP-SNP correlation with a pearson 
correlation for categorical variables
! -use_ld! ! ! Use Linkage Disequilibrium as measure of 
SNP-SNP correlation
! -lambda! ! lambda value to correct SNP statistics, if 
genomic control is used
! -gc_correction! ! Determine the lamda for the genomic 
control correction from the input p-values
! -gmt_min_size! Min number of genes in gene-sets to be 
analysed. default = 2
! -gmt_max_size! Max number of genes in gene-sets to be 
analysed. default = 999999999
! -g_prob_threshold! Floating number. Genotype probabilites below 
this threshold will be set to missing
 
! Multivariate Normal Distribution sampling




! -mnd_target! ! minimum number of times the statistics must be 
seen to calculate the empirical p-value (default=10)
! -mnd_max! ! maximim number of simulation (default = 
1000000)
! -mnd_methods! choose best method and correct using simulation 
backgroud. must specify integers: 0=sidak,1=fisher,2=z-fix,3=z-random,
4=VEGAS
! ! ! ! ! for example to choose between the sidak 
and z-random method use -mnd_methods 0,3
! Weigthing
! -weights, -w            File with SNP weights
! -w_header               Indicate if the SNP weight file has a 
header.
! -weight_by_maf, -w_maf  Weight each SNP its the minor allele 
frequency (MAF). The actual weight is 1/MAF.
!









How often to report advance. Provide an integer X and the program will 




Genotype file in PLINK PED format. See http://pngu.mgh.harvard.edu/
~purcell/plink/data.shtml for details on data format
=item B<-map>
SNP info file in PLINK MAP format
=item B<-bfile>
Files in PLINK binary format, with extension *.bed, *.bim and *.fam.
=item B<-ox_gprobs>
File with genotype probabilities in OXFORD format. See http://
www.stats.ox.ac.uk/%7Emarchini/software/gwas/file_format_new.html for 
details in the file format. An example is
1! rs10489629! 67400370 2 4 1 0 0 0 1 0 1 0 0
Columns are chromosome, SNP id, SNP position, minor alelle (A), major 
alelle (B), prob for AA at sample1,  prob for AB at sample1,  prob for 




Genotype probabilities in BEAGLE format. Please see http://





SNP association file, columns header is necessary and at leat columns 
with SNP and P names must be present. 
 
=item B<-snpmap, -m>
SNP-to-gene mapping file. Format is tab separated with 
fields:chromosome,start,end,Ensembl id, hugo id, description, SNP1, 
SNP2, ..., SNPN. 
Each SNP has 4 fields separated by colons: id,position,alleles and 
strand. This may look overcomplicated but allows to map any kind of 
variation and store its information without having to use additional 
files. An example look like:
1       67632083        67725662        ENSG00000162594 IL23R   KNOWN   
protein_coding  Interleukin-23 receptor Precursor (IL-23R) 
[Source:UniProtKB/Swiss-Prot;Acc:Q5VWK5]             
rs7538938:67132262:T/C:1        rs72669476:67132582:C/T:1       
rs72019237:67132863:C/-:1       rs61197134:67132871:C/-:1       
rs11208941:67133111:T/C:1 
=item B<-affy_to_rsid>








Name of the output file. Output file will be tab separated with the 
following columns: Ensembl_ID,Hugo 
id,gene_type,chromosome,start,end,min p-value in the gene, Sidak 
corrected minimum p-value, FORGE p-value, FORGE chi-square, FORGE 
degrees of freedom, Eigen value ratio method gene p-value, EVR chi-
square, EVR degrees freedom, number of snps in gene, number effective 
tests(Gao et al;PDMID:19434714)
An example would look like:ENSG00000162594! IL23R
! protein_coding! 1! 67632083! 67725662! 3.491e-02
! 4.132e-01! 2.128e-01! 8.42305! 6.04941! 1.119e-01
! 28.17326! 10.116917!  15
=item B<-print_cor>
 
print out SNP-SNP correlations
 
=item B<-gene_list, -g>
Only analyse genes on the file provided. Ids must match either Ensembl 
Ids or Hugo ids present in the SNP-to-gene mapping file
=item B<-genes>
Provide some gene name in command line, only these genes will be 




Analyze all genes in the snp-to-gene mapping file
=item B<-chr>
Anlyze a specific chromosome, Chromosome code must match that of the 
SNP-to-gene mapping file
=item B<-gene_type, -type>
Only analyses genes of this type, e.g. protein_coding
=item B<-exclude_gene_type, -exclude_type>
 
Exclude genes of this type from the analysis, e.g. pseudogenes
=item B<-distance, -d>
 
Max SNP-to-gene distance allowed (in kb) 
 
=item B<-correlation, -cor>
SNP-SNP correlation file. Space separated file with 3 columns, first 2 




Calculate SNP-SNP correlation with a pearson correlation for 




Use Linkage Disequilibrium as measure of SNP-SNP correlation. Default 
is Pearson's correlation.
=item B<-lambda>
lambda value to correct SNP statistics, if genomic control is used
=item B<-gc_correction>
Correct the SNP pvalues by the genomic control method. It will 
calculate the lambda from the data itself. PLEASE MAKE SURE YOU DO NOT 




Min number of genes in gene-sets to be analysed. default = 2
=item B<-gmt_max_size>
 
Max number of genes in gene-sets to be analysed. default = 999999999
=item B<-g_prob_threshold>










minimum number of times the statistics must be seen to calculate the 
empirical p-value (default=10)
=item B<-mnd_max>!
maximim number of simulation (default = 1000000)
=item B<-mnd_methods>
choose best method and correct using simulation backgroud. must 
specify integers: 0=sidak,1=fisher,2=z-fix,3=z-random,4=VEGAS
for example to choose between the sidak and z-random method use -
mnd_methods 0,3
Is you used results of the method VEGAS please cite as ... "gene p-
values calculated with the method VEGAS (Liu, 2010) as implemented in 
FORGE (Pedroso, submitted)" ...
Liu JZ, McRae AF, Nyholt DR, Medland SE, Wray NR, Brown KM, Hayward 
NK, Montgomery GW, Visscher PM, Martin NG, Macgregor S: A versatile 
gene-based test for genome-wide association studies. Am J Hum Genet 
2010;87:139–145
=item B<-weights, -w>
File with SNP weights. Multiple files with weights can be used by 
providing the -weights for each file. the file with weigths can be 
tab, space or comma separated.
the first columns must be the snp id and the rest the weights. It is 
possible to have a header in the file, in which case you must use the 
option -w_header as well. SNP weights are use in the gene analysis and
to calculate the sample scores. How to use different sources of 
information to make a simple weight for the SNP is a not trivial 
issue. To simplify things I: a) for each gene's SNPs I make the weight 
of each category sum 1,
b) then I sum these re-sacel weights for each SNP and c) finally make 
sure the weight within the gene sum 1.
Please note that SNPs without weights will internally get the weights 
set to zero. 
=item B<-w_header>
Indicate if the SNP weight file has a header.
=item B<-weight_by_maf, -w_maf>








=item B<1. Basic Analysis>
 
To perform a basic gene-based testing with the example files run:
 
>perl forge.pl -bfile example/example -assoc example/example.assoc -
snpmap example/example.snpmap -out test




To perform a basic gene-based and gene-set testing with the example 
files run:
>perl forge.pl -bfile example/example -assoc example/example.assoc -
snpmap example/example.snpmap -out test -gmt example/example.gmt
You will need to run a whole-genome analysis when using gene-sets. 
Check option below.
=item B<3. Using simulations to estimate significance>
 
To perform a basic gene-based analysis and estimate significance by 
simulation
 
>perl forge.pl -bfile example/example -assoc example/example.assoc -
snpmap example/example.snpmap -out test -mnd
=item B<4. Running a whole-genome analysis>
To perform a whole-genome analysis using our SNP-to-gene annotation 
files. Please note we do not provide example files for this.
The # symbol in the SNP-to-gene annotation file name means "analyse 
from chromosome 1 to 26".
>perl forge.pl -bfile whole_genome_genotypes -assoc 
whole_genome_genotypes.assoc -snpmap Ensemble_gene_SNP_v59/
ensemblv59_SNP_2_GENE.chr#.txt -out whole_genome.txt -mnd
This syntax can be modified a bit to analysis sub-sets of chromosomes 
by chaging ensemblv59_SNP_2_GENE.chr#.txt with 
ensemblv59_SNP_2_GENE.chr#20-22#.txt, in this case to analyse 
























our (! $help, $man, $gmt, $pval,
! $perm, $out, $max_size, 
! $min_size, $recomb_intervals,
! $report,$gene_sets,$ref_list,
! $set_stat, $input_z, $verbose_output,
! $append, $add_file_name,$all_are_background,
! $cgnets,$complete_interval_sampling,
! $best_x_interval, $gs_coverage, $interval_merge,
! $interval_merge_by_chr, $node_similarity, $cgnets_all,
! $Neff_gene_sets, $max_processes, $snp_assoc, $bfile,





! 'help' => \$help,
! 'man' => \$man,
! 'gmt=s@' => \$gmt,
! 'file=s' => \$pval,
! 'perm=i' => \$perm,
! 'out|o=s' => \$out,
! 'max_size=i' => \$max_size,
! 'min_size=i' => \$min_size,
! 'recomb_intervals=s' => \$recomb_intervals,
! 'report=i' => \$report,
! 'gene_sets=s@' => \$gene_sets,
! 'gene_set_list=s'   => \$gene_set_list,
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! 'ref_list=s' => \$ref_list,
! 'set_stat=s' => \$set_stat, # stat to calculate over the 
sub-networks
! 'z_score' => \$input_z,
! 'verbose_output|v' => \$verbose_output,
! 'append' => \$append,
! 'add_file_name' => \$add_file_name,
! 'backgroung_all_genes' => \$all_are_background,
! 'cgnets=s' => \$cgnets,
! 'best_per_interval' => \$best_x_interval,
! 'complete_interval_sampling' => \
$complete_interval_sampling,
! 'gs_coverage=f' => \$gs_coverage,
! 'interval_merge=i' => \$interval_merge,
! 'interval_merge_by_chr' => \$interval_merge_by_chr,
! 'node_similarity=s'=> \$node_similarity, # NOT documented
! 'cgnets_all' => \$cgnets_all,
! 'Neff_gene_sets' => \$Neff_gene_sets,
! 'n_runs=i' => \$max_processes,
! 'snp_assoc=s@' => \$snp_assoc,
! 'bfile=s'! => \$bfile,
! 'snpmap|m=s@' => \$snpmap,
! 'distance|d=i' => \$distance,
! 'affy_to_rsid=s' => \$affy_to_rsid,
! 'quick_gene_cor' => \$quick_gene_cor,
! 'gene_cor_max_dist=i' => \$gene_cor_max_dist,
! 'print_ref_list' => \$print_ref_list,
! 'mnd' => \$mnd,
! 'mnd_n=i' => \$mnd_N,
! 'gene_p_type' => \$gene_p_type,
) or pod2usage(0);
pod2usage(0) if (defined $help);
pod2usage(-exitstatus => 2, -verbose => 2) if (defined $man);
pod2usage(0) if (not defined $pval);
pod2usage(0) if (not defined $out);
pod2usage(0) if (not defined $gmt);
my $LOG = new IO::File; 
$LOG->open(">$out.log") or print_OUT("I can not open 
[ $out.log ] to write to",$LOG) and exit(1);
print_OUT("Check http://github.com/inti/FORGE/wiki for updates",
$LOG);
print_OUT("LOG file will be written to [ $out.log ]",$LOG);
if (defined $gs_coverage){
! print_OUT("Removing pathway with less than [ " . 
$gs_coverage*100 . " % ] coverage",$LOG);
}
defined $gs_coverage or $gs_coverage = 0;
defined $interval_merge_by_chr and $interval_merge = "inf";
if (defined $interval_merge and defined $best_x_interval){
! print_OUT("Using segment distance of [ $interval_merge ] to 





! print_OUT("Will run [ $perm ] permutations to estimate the 
mean and std deviation of the statistics undel the null",$LOG);
! if (defined $best_x_interval){
! ! print_OUT("Permutations with bext-per-interval option 




if (defined $input_z and not defined $perm){ $perm = 10_000; }
defined $interval_merge or $interval_merge = 0;
defined $distance or $distance = 20;
defined $report or $report = 250;
defined $max_size or $max_size = 99_999_999; 
defined $min_size or $min_size = 10;
if (defined $mnd){
! defined $mnd_N or $mnd_N = 1_000_000;
! use Pareto_Distr_Fit qw( Pgpd );
! if (defined $gene_p_type) {
! ! unless (grep $_ eq $gene_p_type, 
('sidak','fisher','z_fix','z_random')){
! ! ! print_OUT("I do not recognise the gene p-valyes 
type entered [ $gene_p_type ]\n");
! ! ! print_OUT("Option are sidak, fisher, z_fix and 
z_random");
! ! ! print_OUT("bye!");
! ! ! exit(1);
! ! }
! } else { $gene_p_type = 'z_fix'; }
! print_OUT("Will use multivariate normal distribution 
sampling to estimate gene-gene correlations. Using [ $mnd_N ] 
simulations with the [ $gene_p_type] gene p-value");
}!
print_OUT("Will analyses Gene-set between [ $min_size ] and 
[ $max_size ] in size",$LOG);
if (defined $recomb_intervals) {
! if ((defined $best_x_interval) and (defined 
$complete_interval_sampling)){
! ! print_OUT("Please choose one of the two sampling 
scheems -best_per_interval or -complete_interval_samplig\nFor 
more information type gsa.pl -man",$LOG);
! ! exit(1);
! }
! if (not defined $complete_interval_sampling){
! ! $best_x_interval = 1;
! ! print_OUT("Using best gene per recombination interval 
for permutation sampling",$LOG);
! } elsif (defined $complete_interval_sampling) {






defined $set_stat or $set_stat = 'mean';
my $network_stat = defined_set_stat($set_stat);
print_OUT("Gene-set statistics set to [ $set_stat ]",$LOG);
my %ref_genes = ();
if (defined $ref_list){
! open (REF,$ref_list) or die $!; 
! my @tmp = <REF>;
! chomp(@tmp);
! map {$ref_genes{lc($_)} = ""; } @tmp;
! print_OUT("[ " . scalar (keys %ref_genes) . " ] read from 
[ $ref_list ]",$LOG);
}
my %gene_data = ();
print_OUT("Reading gene stats [ $pval ]",$LOG);
open( PVAL, $pval ) or die $!;
while (my $line = <PVAL>) {
! chomp($line);
! my ( $gn, $p ) = split( /\t/, $line );
! $gn = lc($gn);
! if (defined $ref_list){
! ! next if (not exists $ref_genes{$gn});
! }
! next if ( $p eq "NA" );
! unless (defined  $input_z){
! ! next if ( $p !~ m/\d/);
! ! if ( $p == 0 ) {
! ! ! print_OUT("WARNING: This gene [ " . uc($gn) . 
" ] has p-value equal [ $p ], I do not know how to transformit 
to Z score",$LOG);
! ! ! next;
! ! }
! }
! my $z = 0;
! if (defined $input_z){
! ! $z = abs($p);
! } else {
! ! if ($p == 1){ $p = 0.99999999; }
! ! $z = -1 * gsl_cdf_ugaussian_Pinv($p);
! }
! $z = eval($z);
! if ( exists $gene_data{$gn} ) {
! ! if ( $gene_data{$gn}->{stat} > $z ) { 
! ! ! $gene_data{$gn}->{stat} = $z; 
! ! ! $gene_data{$gn}->{pvalue} = $p;
! ! }
! !
! } else { 
! ! $gene_data{$gn} = {
! ! ! ! ! 'stat' => $z,
! ! ! ! ! 'pvalue'=> $p,
! ! ! ! ! 'recomb_int' => [],
! ! ! ! ! 'node_similarity'=> null,
! ! ! ! ! 'genotypes' => null,
! ! ! ! ! 'snps' => undef,
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! ! ! ! ! 'chr' => undef,
! ! ! ! ! 'start' => undef,





print_OUT("   '-> [ " . scalar (keys %gene_data) . " ] genes 
will be analysed",$LOG);
# if a CGNets analysis is performed.
# read the list of genes for which gene-sets are to be analysed
# discard the ones without gene-statistic and report how many 
are left
my @candidate_genes = ();
if (defined $cgnets){
! open (LIST, $cgnets) or die $!;
! print_OUT("Reading CGNets seed genes from [ $cgnets ]",
$LOG);
! @candidate_genes = <LIST>;
! close(LIST);
! chomp(@candidate_genes);
! my %tmp = ();
! map { $tmp{lc($_)} = ""; } @candidate_genes;
! @candidate_genes = keys %tmp;
! print_OUT("  '-> [ " . scalar @candidate_genes . " ] unique 
CGNets seeds read",$LOG);
! for (my $i = 0; $i < scalar @candidate_genes; $i++){
! ! $candidate_genes[$i] = lc($candidate_genes[$i]);
! ! if (not exists $gene_data{$candidate_genes[$i]})
{ splice(@candidate_genes,$i,1); }
! }
! if (scalar @candidate_genes == 0){
! ! print_OUT("None of the CGNets seed genes has 
statistics",$LOG);
! ! print_OUT("Bye for now",$LOG);
! ! exit(1);
! }
! print_OUT("  '-> of them [ " . scalar @candidate_genes . 
" ] have statistics",$LOG);
}
my %recomb_int = ();
if ( defined $recomb_intervals) {




! print_OUT("Reading Gene-sets from command line [ " . @




if ( defined $gene_set_list ) { # in case user gave a list of 
genes in the command line
! print_OUT("Reading Gene-set List from [ $gene_set_list ]",
$LOG);
! # read file with gene list and store gene names.
! open( GL, $gene_set_list ) or print_OUT("I can not open 
[ $gene_set_list ]",$LOG) and exit(1);
! my @gs = <GL>;
! chomp(@gs);
! push  @{$gene_sets},@gs; 
! close(GL);
} 
# stats for all genes in pathways
my %genes_in_paths = ();
my %gene_2_paths_map = ();
# store all pathways and it information 
my @pathways        = ();
foreach my $gene_set_file (@$gmt){
! print_OUT("Reading gene-set definitions from 
[ $gene_set_file ]",$LOG);
! open( GMT, $gene_set_file ) or print_OUT("Cannot open 
[ $gene_set_file ]") and die $!;
! while ( my $path = <GMT> ) {
! ! my ( $p_name, $p_desc, @p_genes ) = split( /\t/, 
$path );
! ! if (defined $gene_sets){
! ! ! next unless (grep $_ eq $p_name,@$gene_sets); 
! ! }
! ! my @p_stats = ();
! ! my @gene_with_p = ();
! ! my $total = 0;
! ! foreach my $gn (@p_genes) {
! ! ! $gn = lc($gn);
! ! ! if ( $gn =~ m/\// ) {
! ! ! ! $gn =~ s/\s+//g;
! ! ! ! my @genes = split( /\/{1,}/, $gn );
! ! ! ! map {
! ! ! ! ! $total++;
! ! ! ! ! next if ( not exists $gene_data
{$_} );
! ! ! ! ! push @p_stats, $gene_data{$_}->
{stat};
! ! ! ! ! push @gene_with_p, $_;
! ! ! ! } @genes;
! ! ! } else {
! ! ! ! $total++;
! ! ! ! next if ( not exists $gene_data{$gn} );
! ! ! ! push @p_stats, $gene_data{$gn}->{stat};
! ! ! ! push @gene_with_p, $gn;
! ! ! }
! ! }
! ! next if ( scalar @p_stats < $min_size );
! ! next if ( scalar @p_stats > $max_size );
! ! next if ( $gs_coverage > (scalar @p_stats)/$total);
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! ! my $p = { 'name' => $p_name,
! ! ! ! 'desc' => $p_desc ,
! ! ! ! 'stats' => [],
! ! ! ! 'N_all' => $total,
! ! ! ! 'N_in' => undef,
! ! ! ! 'genes' => \@gene_with_p,
! ! ! ! 'gene_recomb_inter_redundant' => [],
! ! ! ! 'intervals' => undef,
! ! ! ! 'node_weigths' => null,
! ! ! ! 'z_stat_raw' => undef,
! ! ! ! 'z_stat_empi' => undef,
! ! ! ! 'snps' => undef,
! ! ! ! };
! !
! ! # this section reduces the gene sets to sets of genes 
of non-overlapping recombination intervals
! ! # it first check in which recombination intervals the 
genes are
! ! # then it will keep those that do not share recomb 
inter with other genes.
! ! # the cases where more than one gene belong to the 
same recombination interval
! ! # are solve by choosing the best p-value per 
recombination interval.
! ! $p->{N_in} = scalar @{$p->{'genes'}} if (not defined 
$p->{N_in});
! ! if (scalar @{ $p->{'stats'} } == 0){  
! ! ! @{ $p->{'stats'} } = map { $gene_data{$_}->
{stat} } @{$p->{'genes'}};  
! ! }
! ! map { 
! ! ! $genes_in_paths{$_} = $gene_data{$_}->{stat}; 
! ! ! push @{ $gene_2_paths_map{$_} }, $p->{name};
! ! } @{ $p->{genes} };
! ! map { $genes_in_paths{$_} = $gene_data{$_}->{stat}; } 
@{ $p->{"gene_recomb_inter_redundant"} };





! foreach my $gn (keys %ref_genes){
! ! if (exists $gene_data{lc($gn)}->{stat}){





# if analysing only 1 pathway then reference list are all genes 
in pathways
if (scalar @pathways == 1){
! foreach my $gn (keys %gene_data){
! ! if (exists $gene_data{lc($gn)}->{stat}){







print_OUT("   '-> [ " . scalar @pathways . " ] gene-sets will be 
analysed",$LOG);
# Now lets going to read the affy id to rsid mapping. This is 
used to keep all ids in the
# same nomenclature
my %affy_id = ();
if ( defined $affy_to_rsid ) { # if conversion file is defined
! print_OUT("Reading AFFY to rsID mapping from 
[ $affy_to_rsid ]",$LOG);
! open( AFFY, $affy_to_rsid ) or print_OUT("I can not open 
[ $affy_to_rsid ]") and exit(1);
! while (my $affy = <AFFY>){
! ! chomp($affy);
! ! my @b = split(/\t+/,$affy);




my %snps_covered = ();
if (defined $snp_assoc){
! print_OUT("Reading SNPs included in analysis",$LOG);
! foreach my $file (@$snp_assoc){
! ! open (ASSOC,$file) or print_OUT("Cannot open 
[ $file ]") and die $!;
! ! while(my $line = <ASSOC>){
! ! ! my @d = split(/[\t+\s+]/,$line);








my %bim_ids = ();
my @bim = ();
my @fam = ();
my $bed = new IO::File;
if (defined $bfile){
! print_OUT("Checking genotypes on [ $bfile.bed ]",$LOG);
! # open genotype file
! $bed->open("<$bfile.bed") or print_OUT("I can not open 
binary PLINK file [ $bfile ]") and exit(1);
! binmode($bed); # set file type to binary
! my $plink_bfile_signature = "";
! read $bed, $plink_bfile_signature, 3;
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! if (unpack("B24",$plink_bfile_signature) ne 
'011011000001101100000001'){
! ! print_OUT("Binary file is not in SNP-major format, 
please check you files",$LOG);
! ! exit(1);
! } else { 
! ! print_OUT("Binary file is on SNP-major format",$LOG); 
! }
! # read the bim file with snp information and fam file with 
sample information
! @bim = @{ read_bim("$bfile.bim",$affy_to_rsid,\%affy_id) };
! @fam = @{ read_fam("$bfile.fam") };
! print_OUT("[ " . scalar @bim .  " ] SNPs and [ " . scalar 
@fam .  " ] samples in genotype file",$LOG);
! my $index = 0;
! map {
! ! $bim_ids{$_->{snp_id}} = $index;
! ! $index++;
! } @bim;
! # calculate how many bytes are needed  to encode a SNP
! # each byte has 8 bits with information for 4 genotypes
! $N_bytes_to_encode_snp = (scalar @fam)/4; # four genotypes 
per byte
! # if not exact round it up
! if (($N_bytes_to_encode_snp - int




! print_OUT("Loading SNP-2-Gene mapping",$LOG);
! for (my $i = 0; $i < scalar @$snpmap; $i++){
! ! if ($snpmap->[$i] =~ m/\#/){
! ! ! print_OUT("   '-> Found [ # ] key on [ $snpmap-
>[$i] ]. I will generate file names for 26 chromosomes",$LOG);
! ! ! push @{$snpmap}, @{ make_file_name_array
($snpmap->[$i]) };
! ! ! splice(@$snpmap,$i,1);
! ! }
! }
! foreach my $snp_gene_mapping_file (@$snpmap){
! ! if (not -e $snp_gene_mapping_file){
! ! ! print_OUT("   '-> File 
[ $snp_gene_mapping_file ] does not exist, moving on to next 
file",$LOG);
! ! ! next;
! ! }
! ! my $MAP = '';
! ! if ( $snp_gene_mapping_file =~ m/.gz$/) {
! ! ! print_OUT ("   '-> Reading 
[ $snp_gene_mapping_file ]",$LOG);
! ! ! $MAP = new IO::Uncompress::Gunzip 
$snp_gene_mapping_file;
! ! } else {
! ! ! $MAP = new IO::Handle;
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! ! ! my $fh = new IO::File;
! ! ! print_OUT ("   '-> Reading 
[ $snp_gene_mapping_file ]",$LOG);
! ! ! $fh->open("$snp_gene_mapping_file");
! ! ! $MAP->fdopen(fileno($fh),"r");
! ! }
! !
! ! while (my $read = $MAP->getline()) {
! ! ! chomp($read);
! ! ! # the line is separate in gene info and snps. 
the section are separated by a tab.
! ! ! my ($chr,$start,$end,$ensembl,$hugo,
$gene_status,$gene_type,$description,@m) = split(/\t+/,$read);
! ! ! #check if gene was in the list of genes i want 
to analyze
! ! ! my $gene_id = undef;
! ! ! if ( exists $gene_data{lc($hugo)}){
! ! ! ! $gene_id= lc($hugo);
! ! ! } elsif (exists $gene_data{lc($ensembl)}){
! ! ! ! $gene_id= lc($ensembl);
! ! ! } else {
! ! ! ! next;
! ! ! }! !
! ! ! # exlude genes that are not in gene-sets
! ! ! next unless (exists $genes_in_paths{lc($hugo)} 
or exists $genes_in_paths{lc($ensembl)});
! ! ! my @first_snp_n_fields =  split(/\:/,$m[0]);
! ! ! if (4 !=  scalar @first_snp_n_fields)
{ $description .= splice(@m,0,1); }
! ! !
! ! ! # get all mapped snps within the distance 
threshold,
! ! ! my @mapped_snps = ();
! ! ! foreach my $s (@m) {
! ! ! ! my ($id,$pos,$allele,$strand) = split(/
\:/,$s);
! ! ! ! next if (not defined $id);
! ! ! ! if (( $pos >= $start) and ($pos <= $end))
{ push @mapped_snps, $id; }
! ! ! ! elsif ( ( abs ($pos - $start) <= 
$distance*1_000 ) or ( abs ($pos - $end) <= $distance*1_000 )) 
{ push @mapped_snps, $id; }
! ! ! }
! ! !
! ! ! next if (scalar @mapped_snps == 0);
! ! !
! ! ! # go over mapped snps and change convert affy 
ids to rsid.
! ! ! # and make a non-redundant set.
! ! ! my %nr_snps = ();
! ! ! foreach my $s (@mapped_snps) {
! ! ! ! if ( defined $affy_to_rsid ) {
! ! ! ! ! if ($s !~ m/^rs/){




! ! ! ! ! }
! ! ! ! }
! ! ! ! # exclude snps not in the association file 
nor in the bim file
! ! ! ! next unless ( exists $snps_covered{$s} );
! ! ! ! next unless ( exists $bim_ids{$s} );
! ! ! ! $nr_snps{$s} = "";
! ! ! }
! ! ! @mapped_snps = keys %nr_snps;
! ! ! if ( scalar @mapped_snps == 0 ){
! ! ! ! delete( $genes_in_paths{ $gene_id } );
! ! ! ! next;
! ! ! }
! ! ! $gene_data{$gene_id}->{snps} = [@mapped_snps];
! ! ! $gene_data{$gene_id}->{chr} = $chr;
! ! ! $gene_data{$gene_id}->{start} = $start;





! print_OUT("Reading genotypes for genes",$LOG);
}
# mean of all stats across the genome
my $background_values;
if (defined $all_are_background) {
! my @values = ();
! foreach my $gn (keys %gene_data){
! ! push @values, $gene_data{$gn}->{stat};
! }
! $background_values = pdl @values;
} else {
! $background_values = pdl values %genes_in_paths;
}
print_OUT("  '-> [ " . scalar $background_values->list() . " ] 
genes will be used to calculate the patameters of null",$LOG);
$background_values->inplace->setvaltobad( "inf" );
$background_values->inplace->setvaltobad( "-inf" );
my $mu = $background_values->davg;
# sd of all stats across the genome
my $sd = $background_values->stdv;
print_OUT("  '-> Background mean = [ $mu ] and stdv [ $sd ]",
$LOG);
if (defined $print_ref_list){
! print_OUT("Printing reference list to [ $out.refList ]",
$LOG);
! my @ids= ();
! if (defined $all_are_background) {
! ! @ids = keys %gene_data;
! } else {




! open (REFLIST,">$out.refList") or print_OUT("I cannot write 
to [ $out.refList ]") and exit(1);
! print REFLIST join "\n", @ids;
! close(REFLIST);
}
my %snp_genotype_stack = ();
my %correlation_stack  = ();
my %gene_genotype_var  = ();
my $i = 0;
if (defined $bfile){
! my @new_pathways = ();
! foreach my $p (@pathways) {
! ! report_advance($i++,$report,"Gene-Sets Genotypes",
$LOG);
! ! next if ( scalar @{ $p->{genes} } < $min_size );
! !
! ! my @new_genes = ();
! ! foreach my $gn ( @{$p->{ genes } } ){
! ! ! next if ( not exists $genes_in_paths{$gn} );
! ! ! next if ( not exists $gene_data{$gn} );
! ! ! next if ( not defined $gene_data{$gn}->
{snps} );
! ! ! next if ( $gene_data{$gn}->{genotypes}->isempty 
== 0 );
! ! ! # this will store the genotypes
! ! ! my $matrix = [];
! ! ! my @gn_snps_with_genotypes = ();
! ! ! foreach my $snp ( @{ $gene_data{$gn}->
{snps} } ){
! ! ! ! if (exists $snp_genotype_stack{$snp}) {
! ! ! ! ! push @{ $matrix }, 
$snp_genotype_stack{$snp};
! ! ! ! ! push @gn_snps_with_genotypes, $snp;
! ! ! ! } else { 
! ! ! ! ! # because we know the index of the 
SNP in the genotype file we know on which byte its information 
starts
! ! ! ! ! my $snp_byte_start = 
$N_bytes_to_encode_snp*$bim_ids{$snp};
! ! ! ! ! # here i extract the actual 
genotypes
! ! ! ! ! my @snp_genotypes = @
{ extract_binary_genotypes(scalar @fam,$N_bytes_to_encode_snp,
$snp_byte_start,$bed) };
! ! ! ! ! # store the genotypes.
! ! ! ! ! # if a snp does not use the 8 bits 
of a byte the rest of the bits are fill with missing values
! ! ! ! ! # here i extract the number of 
genotypes corresponding to the number of samples
! ! ! ! !
! ! ! ! ! my $maf = get_maf([@snp_genotypes
[0..scalar @fam - 1]] ); # check the maf of the SNP
! ! ! ! ! next if ($maf == 0 or $maf ==1);  # 
go to next if it is monomorphic
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! ! ! ! ! push @{ $matrix }, [@snp_genotypes
[0..scalar @fam - 1]];
! ! ! ! ! push @gn_snps_with_genotypes, $snp;
! ! ! ! ! $snp_genotype_stack{$snp} = 
[@snp_genotypes[0..scalar @fam - 1]];!! !
! ! ! ! }
! ! ! }
! ! ! next if (scalar @gn_snps_with_genotypes == 0);
! ! ! $gene_data{$gn}->{snps} = 
[@gn_snps_with_genotypes];
! ! ! $gene_data{$gn}->{genotypes} = pdl $matrix;
! ! ! push @new_genes, $gn;
! ! }
! !
! ! next if (scalar @new_genes < $min_size);
! !
! ! $p->{genes} = [ @new_genes ];
! ! my @stats = map { $gene_data{$_}->{stat} } @{ $p->
{genes} }; 
! ! $p->{stats} = [ @stats ];
! ! $p->{N_in} = scalar @{ $p->{genes} };
! ! my ($more_corr,$more_var,$G_cor) = "";




! ! $p->{ genotypes_corr } = ${ $G_cor };
! ! %correlation_stack = ( %correlation_stack, %
{$more_corr} );
! ! %gene_genotype_var = ( %gene_genotype_var, %
{$more_var} );
! !
! ! # store the pathway information
! ! push @new_pathways, $p;
! !
! ! foreach my $gn (  @{ $p->{genes} } ){
! ! ! if (scalar @{ $gene_2_paths_map{$gn} } == 1){
! ! ! ! delete($gene_data{$gn}->{genotypes});
! ! ! } else {
! ! ! ! splice( @{ $gene_2_paths_map{$gn} },0,1);
! ! ! }
! ! }
! }
! @pathways = @new_pathways;
!
! %snp_genotype_stack = ();
! %correlation_stack = ();
! %gene_genotype_var  = ();
}
print_OUT("  '->[ " . scalar (keys %gene_data) . " ] Genes read 
from SNP-2-Gene Mapping files with genotpe data",$LOG);
if (scalar (keys %gene_data) == 0){





# if permutation are performed store null distribution in here
my %null_size_dist = ();
print_OUT("Writing output to [ $out ]",$LOG);
if (defined $append){
! open (OUT,">>$out") or die $!;
} else {
! open (OUT,">$out") or die $!;
! print OUT "name\traw_p\traw_z";
!
! if (defined $bfile and defined $snpmap and defined 
$snp_assoc){
! ! print OUT "\tZ_fix\tV_fix\tZ_P_fix\tZ_random
\tV_random\tZ_P_random\tI2\tQ\tQ_P\ttau_squared";
! ! if (defined $mnd){







! if (defined $perm){
! ! print OUT ("\tempi_p:$set_stat\tempi_z:$set_stat
\tmean_set\tmean_null\tsd_null");
! } 
! print OUT ("\tN_in\tN_all\tdesc");
! if (defined $add_file_name){
! ! print OUT "\tdataset";
! }
! print OUT "\n";
}
print_OUT("Starting to Analyse the [ " . scalar @pathways . " ] 
gene-sets",$LOG);
my $c = 0;
while (my $p = shift @pathways) {
! report_advance($c,$report,"Gene-Sets");
! $c++;
! next if ( $p->{N_in} < $min_size);
! my $m = $p->{N_in};
! my $Sm = mean( $p->{stats} );
! my $z_score = ( ( $Sm - $mu ) * (sqrt($m) ) ) / $sd;
! $p->{z_stat_raw} = $z_score;
!
! if ( $z_score == -0 ) {
! ! print OUT "$p->{name}\tNA\t$z_score";
! } else {
! ! printf OUT ("$p->{name}\t%.3e\t%.3f", 1 - 
gsl_cdf_ugaussian_P($z_score),$z_score);
! }




! ! my $z = pdl $p->{stats};
! ! my $var = dsum($p->{gene_cor_mat});
! ! my $se = $z->nelem * ones $z->nelem;
! ! my $Z_STATS = get_fix_and_radom_meta_analysis($z,
$se,undef,$p->{gene_cor_mat});
! ! my $num = 100;
! ! my $simulated_set_stats = simulate_mnd_gene_set($p,
$Z_STATS,10,$mnd_N);
! ! printf OUT ("\t%.3e\t%.3e\t%.3e\t%.3e\t%.3e\t%.3e\t%.
3e\t%.2f\t%.3e\t%.3e\t%.3e\t%.3e\t%.3e\t%.3e\t%.3e\t%.3e\t%.3e\t
%.3e\t%.3e\t%.3e\t%.3e", 
! ! ! $Z_STATS->{'B_fix'},
! ! ! $Z_STATS->{'V_fix'},
! ! ! $Z_STATS->{'Z_P_fix'},
! ! ! $Z_STATS->{'B_random'},
! ! ! $Z_STATS->{'V_random'},
! ! ! $Z_STATS->{'Z_P_random'},
! ! ! $Z_STATS->{'I2'},
! ! ! $Z_STATS->{'Q'},
! ! ! $Z_STATS->{'Q_P'},
! ! ! $Z_STATS->{'tau_squared'},
! ! ! $simulated_set_stats->{'z_fix'},
! ! ! $simulated_set_stats->{'z_random'},
! ! ! $simulated_set_stats->{'seen_fix'},
! ! ! $simulated_set_stats->{'seen_random'},
! ! ! $simulated_set_stats->{'N'},
! ! ! $simulated_set_stats->{'pareto_fix_Phat'},
! ! ! $simulated_set_stats->
{'pareto_fix_Phatci_low'},
! ! ! $simulated_set_stats->{'pareto_fix_Phatci_up'},
! ! ! $simulated_set_stats->{'pareto_random_Phat'},
! ! ! $simulated_set_stats->
{'pareto_random_Phatci_low'},






! if (defined $perm){
! ! $Sm = &$network_stat( $p->{stats} );
! ! if (defined $recomb_intervals){
! ! ! my $rand_stats = pdl @{ get_null_distribution
($perm,[keys %genes_in_paths],$p,\%recomb_int, \%gene_data) };
! ! ! $null_size_dist{$m} = { 'mean' => $rand_stats-
>average, 'sd' => $rand_stats->stdv };
! ! } else {
! ! ! if (not defined $null_size_dist{$m}){
! ! ! ! my $rand_stats = pdl @
{ get_null_distribution($perm,[keys %genes_in_paths],$p,\
%recomb_int, \%gene_data)};
! ! ! ! $null_size_dist{$m} = { 'mean' => 
$rand_stats->average, 'sd' => $rand_stats->stdv };




! ! my $z_score_empirical = ( ( $Sm - $null_size_dist
{$m}->{mean}) )/$null_size_dist{$m}->{sd};
! !
! ! $p->{z_stat_empi} = $z_score_empirical;
! !
! ! if ( $z_score == -0 ) {
! ! ! print OUT "\tNA\tNA\t";
! ! } else {




! ! print OUT "\t$m\t$p->{N_all}\t$p->{desc}";
! ! if (defined $add_file_name){
! ! ! print OUT "\t$pval";
! ! }
! ! if (defined  $verbose_output){
! ! ! map { print OUT "\t$_:",$gene_data{$_}->
{stat}; } sort { $gene_data{$b}->{stat} <=> $gene_data{$a}->
{stat} } @{$p->{genes}};
! ! }
! ! print OUT "\n";
! } else {
! ! print OUT "\t$m\t$p->{N_all}\t$p->{desc}";
! ! if (defined $add_file_name){
! ! ! print OUT "\t$pval";
! ! }
! ! if (defined  $verbose_output){
! ! ! map { print OUT "\t$_:",$gene_data{$_}->
{stat}; } sort { $gene_data{$b}->{stat} <=> $gene_data{$a}->
{stat} } @{$p->{genes}};
! ! }
! ! print OUT "\n";





! my $gene_set_data = shift; # HASH ref
! my $set_stats = shift; # HASH ref
! my $target = shift;
! my $MAX = shift;
!
! my $max_step_size = 10_000;
! my $total = 0;
! my $step=100;
!
! my $se = $gene_set_data->{gene_cor_mat}->getdim(0) * ones 
$gene_set_data->{gene_cor_mat}->getdim(0);
! my $SEEN = zeroes 2;
!
! my $cholesky = mchol($gene_set_data->{gene_cor_mat});
! my $fix_stat = [];
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! my $random_stat = [];
! while ($SEEN->min < $target){
! !
! ! my ($sim,$c) = rmnorm($step,0,$gene_set_data->
{gene_cor_mat},$cholesky);
! ! my $sim_chi_df1 = $sim**2;
! ! my $sim_p =  1 - gsl_cdf_chisq_P($sim_chi_df1,1);
! ! for (my $sim_n = 0; $sim_n < $sim_p->getdim(0); 
$sim_n++){
! ! ! my $sim_z = flat -1*gsl_cdf_ugaussian_P($sim_p-
>($sim_n,));




! ! ! #print $set_stats->{'Z_P_fix'}," >= ", 
$sim_set_stats->{'Z_P_fix'}," || ", $set_stats->
{'Z_P_random'} ," >= ", $sim_set_stats->{'Z_P_random'},"\n";
! ! ! $SEEN->(0)++ if ( $set_stats->{'Z_P_fix'} >= 
$sim_set_stats->{'Z_P_fix'} );
! ! ! $SEEN->(1)++ if ( $set_stats->{'Z_P_random'} >= 
$sim_set_stats->{'Z_P_random'} );
! ! ! push @{$fix_stat}, -1*gsl_cdf_ugaussian_Pinv
($sim_set_stats->{'Z_P_fix'});
! ! ! push @{$random_stat}, -1*gsl_cdf_ugaussian_Pinv
($sim_set_stats->{'Z_P_random'});
! ! }
! ! $total += $step;
! !
! ! if ($SEEN->min != 0){
! ! ! $step = 1.1*(10*($total)/$SEEN->min);
! ! } elsif ($step < $max_step_size){ 
! ! ! $step *=10; 
! ! }
! ! if ($step > $MAX){ $step = $MAX; }
! ! last if ($total > $MAX);
! }
!
! my $fix_null_stats = pdl $fix_stat;
! my $random_null_stats = pdl $random_stat;
! my $fix_observed = -1*gsl_cdf_ugaussian_Pinv($set_stats->
{'Z_P_fix'});










! my $back = {
! ! 'z_fix' => sclr ($SEEN->(0)+1)/($total +1),
! ! 'z_random' => sclr ($SEEN->(1)+1)/($total +1),





! $back->{'seen_fix'} = sclr $SEEN->(0);
! $back->{'seen_random'} = sclr $SEEN->(1);
! $back->{'pareto_fix_Phat'} = sclr $pareto_fix_Phat;
! $back->{'pareto_fix_Phatci_low'} = $pareto_fix_Phatci_low;
! $back->{'pareto_fix_Phatci_up'} =  $pareto_fix_Phatci_up;
! $back->{'pareto_random_Phat'} = sclr $pareto_random_Phat;
! $back->{'pareto_random_Phatci_low'} =  
$pareto_random_Phatci_low;






! my $string = shift;
! my @file_handles = @_; !
! print scalar localtime(), "\t$string\n";
! unless (scalar @file_handles == 0){
! ! foreach my $fh (@file_handles){





! my $G = shift;
! my $C = cov_shrink($G->transpose);!




! my $start_uno = shift;
! my $end_uno = shift;   
! my $start_dos = shift;   
! my $end_dos = shift;
! my $back = 0;
=h
!               start_1 .......................... end_1
!  start_2 .......................... end_2
!  
=cut
! if (($start_uno > $start_dos) and ($start_uno < $end_dos) )
{$back = 1; }
!
=h
!  start_1 .......................... end_1
!                   start_2 .......................... 
end_2!  
=cut
! if (($start_dos > $start_uno) and ($start_dos < $end_uno) )





! start_1 .......................... end_1
! start_2 .......................... end_2
=cut
! if (($start_uno == $start_dos) or ($end_uno == $end_dos) )
{$back = 1; }
!




! my $genes = shift; # ARRAY ref
! my $gene_data = shift; # HASH ref
! my $gene_gene_corr = shift; # HASH reaf
! my $var = shift; # HASH ref
! my $quick_cor = shift; # 0,1
! my $max_gene_dist = shift; # integer!
! my $mnd= shift; # 0,1
! my $mnd_N = shift; # integer
! my $gene_p_type = shift; # 0,1
!
! my %new_corrs = ();
! my %new_vars = ();
! my $G_cov = ""; # will store the correlation between 
genotypes.
!
! # define correlation matrix
! my $corr = stretcher(ones scalar @$genes); 
! if (defined $mnd){
! ! my $G = null;
! ! my $genotypes_stack = [];
! ! my @mat_gene_idx = ();
! ! my $old_end = -1;
! ! for (my $i = 0; $i < scalar @$genes; $i++){
! ! ! push @{$genotypes_stack}, $gene_data->{ $genes-
>[$i] }->{genotypes};!!
! ! ! $mat_gene_idx[ $i ]= { 
! ! ! ! 'id' => $genes->[$i], 
! ! ! ! 'start' => $old_end + 1, 
! ! ! ! 'end' =>  $old_end + 1 - 1 + $gene_data->
{ $genes->[$i] }->{genotypes}->getdim(1),
! ! ! };
! ! ! $old_end = $mat_gene_idx[ $i ]->{end};
! ! }
! ! $G = $G->glue(1,@$genotypes_stack);
! ! my $G_corr = cov_shrink($G->transpose);
! ! my $status = undef;
! ! ($G_cov,$status) = check_positive_definite($G_corr->
{cor},1e-8);
! ! if ($status == 1){
! ! ! print "Matrix never positive definite";
! ! ! exit(1);
! ! }
! ! my $cholesky = mchol($G_cov);
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! ! my ($sim,$c) = rmnorm($mnd_N,0,$G_cov,$cholesky);
! !
! ! my $sim_chi_df1 = $sim**2;
! ! my $sim_p =  1 - gsl_cdf_chisq_P($sim_chi_df1,1);
! ! my @null_stats = (); 
! ! my %effective_tests = ();
! ! my $stats_bag = [];
! ! for (my $stat_sim = 0; $stat_sim < $sim_p->getdim(0); 
$stat_sim++){
! ! ! my $r_p = $sim_p->($stat_sim,)->flat;
! ! ! my  @null_stats = ();
! ! ! foreach my $g (@mat_gene_idx){
! ! ! ! my $fake_gene = {
! ! ! ! ! 'pvalues' => $r_p->($g->{start}:$g->
{end}),
! ! ! ! ! 'effect_size' => undef,
! ! ! ! ! 'effect_size_se' => undef,
! ! ! ! ! 'cor' => $G_cov->($g->{start}:$g->
{end},$g->{start}:$g->{end}),
! ! ! ! ! 'weights' => ((ones $r_p->($g->
{start}:$g->{end})->nelem)/$r_p->($g->{start}:$g->{end})-
>nelem),
! ! ! ! ! 'geno_mat_rows' => [ $r_p->($g->
{start}:$g->{end})->list ],
! ! ! ! };
! ! ! ! my $n_stat = undef;
! ! ! ! if ($gene_p_type eq 'sidak' or $r_p->($g->
{start}:$g->{end})->nelem == 1){
! ! ! ! !
! ! ! ! ! if (not defined $effective_tests
{ $g->{id} }){
! ! ! ! ! ! $effective_tests{ $g->{id} } = 
number_effective_tests(\$G_cov->($g->{start}:$g->{end},$g->
{start}:$g->{end}));
! ! ! ! ! }
! ! ! ! ! $n_stat = 1 - (1 - $fake_gene->
{'pvalues'}->min)**$effective_tests{ $g->{id} };
! ! ! ! ! $n_stat = gsl_cdf_ugaussian_Pinv
($n_stat );
! ! ! ! !
! ! ! ! } elsif ($gene_p_type eq 'fisher'){
! ! ! ! ! my ($sim_fisher_chi_stat,
$sim_fisher_df) = get_makambi_chi_square_and_df($fake_gene->
{cor},$fake_gene->{weights},$fake_gene->{'pvalues'} );
! ! ! ! ! my $sim_fisher_p_value = sclr double  
1 - gsl_cdf_chisq_P($sim_fisher_chi_stat, $sim_fisher_df );
! ! ! ! ! $n_stat = gsl_cdf_ugaussian_Pinv
($sim_fisher_p_value);
! ! ! ! } elsif (($gene_p_type eq 'z_fix') or 
($gene_p_type eq 'z_random')){
! ! ! ! ! my $sim_z_gene = 
z_based_gene_pvalues($fake_gene,$mnd);
! ! ! ! ! $n_stat = gsl_cdf_ugaussian_Pinv
($sim_z_gene->{'Z_P_fix'}) if ($gene_p_type eq 'z_fix');
! ! ! ! ! $n_stat = gsl_cdf_ugaussian_Pinv
($sim_z_gene->{'Z_P_random'}) if ($gene_p_type eq 'z_random');
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! ! ! ! }
! ! ! ! push @null_stats, $n_stat;
! ! ! }
! ! ! push @{$stats_bag}, [@null_stats];
! ! }
! ! $stats_bag = pdl $stats_bag;
! ! my $gene_stats_cor = cov_shrink($stats_bag);
! ! $corr = $gene_stats_cor->{cor};
! } else {
! ! for (my $i = 0; $i < scalar @$genes; $i++){
! ! ! # get name of gene i
! ! ! my $gn_i = $genes->[$i];
! ! !
! ! ! # get indexes for its SNPs in the snp 
correlation matrix
! ! ! my $idx_i = sequence $gene_data->{ $gn_i }->
{genotypes}->getdim(1);
! ! ! # get its variance if it has not been 
calculated already
! ! ! if (not exists $var->{ $gn_i }){
! ! ! ! $var->{ $gn_i } =  get_genotype_matrix_var
($gene_data->{ $gn_i }->{genotypes});
! ! ! ! $new_vars{ $gn_i } = $var->{ $gn_i };
! ! ! }
! ! ! for (my $j = $i; $j < scalar @$genes; $j++){
! ! ! ! next if ($j == $i); 
! ! ! ! # get name of gene j
! ! ! ! my $gn_j = $genes->[$j];
! ! ! !
! ! ! ! # if defined a quick gene-gene correlation 
the correlation will only be calculate between genes in 
! ! ! ! # the same chromosome
! ! ! ! if (not exists $gene_gene_corr->{ $gn_i }
{ $gn_j } and defined $quick_cor){
! ! ! ! ! # if chromosomes are different set 
the correlation to 0
! ! ! ! ! if ($gene_data->{ $gn_i }->{chr} ne 
$gene_data->{ $gn_j }->{chr} ) {
! ! ! ! ! ! $gene_gene_corr->{ $gn_i }
{ $gn_j } = 0;
! ! ! ! ! ! $new_corrs{$gn_j}{$gn_i} = 0;
! ! ! ! ! } else { # if are in the same 
chromosome
! ! ! ! ! ! # if user provided a maximum 
distance to evaluate correlations!
! ! ! ! ! ! if (defined $max_gene_dist){
! ! ! ! ! ! ! # if they overlap we will 
need to calculate the correlation
! ! ! ! ! ! ! # return 0 from 
check_overlap mean there is no overlap
! ! ! ! ! ! ! if (check_overlap
($gene_data->{ $gn_i }->{start},$gene_data->{ $gn_i }->
{end},check_overlap($gene_data->{ $gn_j }->{start},$gene_data->
{ $gn_j }->{end}) == 0 )){
! ! ! ! ! ! ! !
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! ! ! ! ! ! ! ! # check the distance 
between the gene coordinates
! ! ! ! ! ! ! ! if ( $gene_data->
{ $gn_i }->{start} > $gene_data->{ $gn_j }->{end}   ){
! ! ! ! ! ! ! ! ! #! !                     
start_i.....end_i
! ! ! ! ! ! ! ! ! #!
! start_j.....end_j
! ! ! ! ! ! ! ! ! if 
( ($gene_data->{ $gn_i }->{start} - $gene_data->{ $gn_j }->
{end}) > $max_gene_dist * 1000 ){
! ! ! ! ! ! ! ! !
! $gene_gene_corr->{ $gn_i }{ $gn_j } = 0;
! ! ! ! ! ! ! ! !
! $new_corrs{$gn_j}{$gn_i} = 0;
! ! ! ! ! ! ! ! ! }
! ! ! ! ! ! ! ! } elsif 
( $gene_data->{ $gn_j }->{start} > $gene_data->{ $gn_i }->
{end}  ){
! ! ! ! ! ! ! ! ! #!
! start_i.....end_i
! ! ! ! ! ! ! !
! #! ! ! ! ! ! ! start_j.....end_j
! ! ! ! ! ! ! ! ! if 
( ($gene_data->{ $gn_j }->{start} - $gene_data->{ $gn_i }->
{end}) > $max_gene_dist * 1000 ){
! ! ! ! ! ! ! ! !
! $gene_gene_corr->{ $gn_i }{ $gn_j } = 0;
! ! ! ! ! ! ! ! !
! $new_corrs{$gn_j}{$gn_i} = 0;
! ! ! ! ! ! ! ! ! }
! ! ! ! ! ! ! ! }
! ! ! ! ! ! ! !
! ! ! ! ! ! ! }
! ! ! ! ! ! !
! ! ! ! ! ! } 
! ! ! ! ! }
! ! ! ! }
! ! ! !
! ! ! ! # next if this correlation was already 
calculated
! ! ! ! if (exists $gene_gene_corr->{ $gn_i }
{ $gn_j }){
! ! ! ! ! set $corr, $i ,$j, $gene_gene_corr->
{ $gn_i }{ $gn_j };
! ! ! ! ! set $corr, $j ,$i, $gene_gene_corr->
{ $gn_i }{ $gn_j };
! ! ! ! ! next;
! ! ! ! }
! ! ! ! # get indexes for its SNPs in the snp 
correlation matrix
! ! ! ! my $idx_j = $gene_data->{ $gn_i }->
{genotypes}->getdim(1) + sequence $gene_data->{ $gn_j }->
{genotypes}->getdim(1);




! ! ! ! if (not exists $var->{ $gn_j }){
! ! ! ! ! $var->{ $gn_j } =  
get_genotype_matrix_var($gene_data->{ $gn_j }->{genotypes});
! ! ! ! ! $new_vars{ $gn_j } = $var->
{ $gn_j };
! ! ! ! }
! ! ! !
! ! ! ! # combine the genotype data information
! ! ! ! my $r_i_j = zeroes $gene_data->{ $gn_i }->
{genotypes}->getdim(1), $gene_data->{ $gn_j }->{genotypes}-
>getdim(1);
! ! ! ! for ( my $i_snp = 0; $i_snp < $gene_data->
{ $gn_i }->{genotypes}->getdim(1); $i_snp++ ){
! ! ! ! ! my $genotype_i = $gene_data->
{ $gn_i }->{genotypes}->(,$i_snp);
! ! ! ! !
! ! ! ! ! for ( my $j_snp = 0; $j_snp < 
$gene_data->{ $gn_j }->{genotypes}->getdim(1); $j_snp++ ){
! ! ! ! ! !
! ! ! ! ! ! my $genotype_j = $gene_data->
{ $gn_j }->{genotypes}->(,$j_snp);
! ! ! ! ! ! my $c = corr( $genotype_j, 
$genotype_i );
! ! ! ! ! ! set $r_i_j, $i_snp, $j_snp, $c-
>sclr;
! ! ! ! ! !
! ! ! ! ! }
! ! ! ! }
! ! ! ! my $c_i_j = double $r_i_j->dsum()/sqrt
( $var->{ $gn_i } * $var->{ $gn_j }  );
! ! ! ! set $corr, $i ,$j, $c_i_j;
! ! ! ! set $corr, $j ,$i, $c_i_j;
! ! ! !
! ! ! ! $new_corrs{$gn_j}{$gn_i} = $new_corrs
{$gn_i}{$gn_j} = $c_i_j;






  my $cor = shift; # a pdl matrix with the varoable correlations
  my $w = shift; # a pdl vector with the weights;
  # make sure weiths sum one
  $w = $w*abs($cor); # multiply the weights by the correaltions
  my @dims = $w->dims();
  $w = pdl map { $w->(,$_)->flat->sum/$w->sum; } 0 .. $dims[1] - 
1; # sum the rows divided by sum of the weights used
  if ($w->min == 0){ $w += $w->(which($w == 0))->min/$w-
>length; } # make sure NO weights equal 0




  # calculate the correlation matrix before the applying the 
weights
  # I have change this calculation following the results of the 
paper of Kost et al. this should improve the approximation of 
the test statistics
  # Kost, J. T. & McDermott, M. P. Combining dependent p-values. 
Statistics & Probability Letters 2002; 60: 183-190.
  # my $COR_MAT = (3.25*abs($cor) + 0.75*(abs($cor)**2));
  my $COR_MAT = (3.263*abs($cor) + 0.710*(abs($cor)**2) + 0.027*
(abs($cor)**3)); 
  my $second = $COR_MAT*$w*($w->transpose); # apply the weights 
  ($second->diagonal(0,1)) .= 0; # set the diagonal to 0
  my $varMf_m = 4*sumover($w**2) + $second->flat->sumover; # 
calculate the variance of the test statistics
  my $df = 8/$varMf_m; # the degrees of freedom of the test 
statistic
  return ($df);
}
sub check_if_exist {
! my $bait = shift;
! my $array = shift;
! return( grep $_ eq $bait, @$array);
}
sub check_if_overlap {
! my $array1 = shift;
! my $array2 = shift;
! my $match = 0;
! if (scalar @$array1 < scalar @$array2){
! ! foreach my $g (@$array1){ $match += check_if_exist
($g, $array2); }
! } else {






! my $ar       = shift;
! my $elements = scalar @$ar;
! my $sum      = 0;
! my $sumsq    = 0;
! foreach (@$ar) {
! ! $sum   += $_;
! ! $sumsq += ( $_**2 );
! }




! my $ar = pdl @_;
APPENDIX A GSA.PL
274
! $ar->inplace->setvaltobad( "inf" );




        my $N = shift; # number of statisitics to be generated
! my $genes = shift;
! my $path_info = shift;
        my $sub_net_genes = $path_info->{genes}; # genes in the 
subnetwork
        my $size = scalar @$sub_net_genes; # size of the 
subnetwork
        my $comb_int = shift; # recombination interval 
information
! my $gene_stats = shift;
        my @rand_stat = (); # array to store the statistics from 
each permutation
        for (my $i = 0; $i < $N; $i++){
! ! if (defined $verbose_output){
! ! ! &report_advance($i,100,"Permutations");
! ! }
! ! # if sampling conditional to recombination intervals, 
first check is any group of genes  
! ! # from the subnetwotk are in the same recombination 
interval. If not then sample normally.
! ! my %intervals = ();
! !
! ! my @normal_sampling = ();
! ! my @interval_sampling = ();
! ! if (defined $recomb_intervals){
! ! ! if ( defined $path_info->{intervals}){
! ! ! ! %intervals = %{$path_info->{intervals}};
! ! ! } else {
! ! ! ! foreach my $g (@$sub_net_genes){
! ! ! ! ! foreach my $int (@{$gene_stats->
{$g}->{recomb_int}}){
! ! ! ! ! ! push @{ $intervals{$int} }, $g;
! ! ! ! ! }
! ! ! ! }
! ! ! }
! ! ! while (my ($int,$int_genes) = each %intervals){
! ! ! ! if (scalar @$int_genes > 1){ push 
@interval_sampling,$int_genes; } # genes that are in the same 
recombination interval
! ! ! ! else { push @normal_sampling, @
$int_genes;} # all other genes
! ! ! }
! ! } else {
! ! ! @normal_sampling = @$sub_net_genes; # if not 
recombination interval information has been provided sampling is 
normal
! ! }




! ! my @sampled_genes_interval = (); # to store genes 
from the sampling with recomb intervals
! ! # get genes from separated recombination intervals by 
sampling unconditional to the recombination intervals
! ! if (scalar @normal_sampling > 0){
! ! ! # if sampling is not conditional on the node 
degree
! ! ! my @index = @{ get_rand_index(scalar @$genes, 
scalar @normal_sampling)};
! ! ! @sampled_genes_normal = @$genes
[@index];! ! !
! ! }
! ! # if some genes need to be sampled conditional on 
recombination intervals
! !
! ! if (scalar @interval_sampling > 0){
! ! ! # loop over all group of genes
! ! ! for (my $interval = 0; $interval < scalar 
@interval_sampling; $interval++){
! ! ! ! # get the genes ids
! ! ! ! my @interval_genes = @{ $interval_sampling
[$interval] };
! ! ! ! my @seed_intervals = map { @{ $gene_stats-
>{ $_ }->{recomb_int} } } @interval_genes;
! ! ! ! my %tmp = ();
! ! ! ! foreach my $int (@seed_intervals) {
! ! ! ! ! map { $tmp{$_} = "" }  @{ $comb_int-
>{$int}->{genes} };
! ! ! ! }
! ! ! ! my @interval_seed = keys %tmp;
! ! ! ! my @all_intervals = keys %{ $comb_int };
! ! ! ! # sample one gene and then sample the rest 
from its interval
! ! ! ! my $idx = int(rand(scalar 
@all_intervals));
! ! ! ! my @interval_sampling_universe = @
{ $comb_int->{$all_intervals[$idx]}->{genes} };
! ! ! ! # skip the interval if has less genes than 
need to be sampled
! ! ! ! if (scalar @interval_genes > 
@interval_sampling_universe){
! ! ! ! ! $interval--;
! ! ! ! ! next;
! ! ! ! }
! ! ! ! my $ratio = scalar @interval_seed/scalar 
@interval_sampling_universe;
! ! ! ! $ratio = 1/$ratio if ($ratio >1);
! ! ! ! my $rand = rand();
! ! ! ! if ($ratio < $rand){
! ! ! ! ! $interval--;
! ! ! ! ! next;
! ! ! ! }




! ! ! ! my @selected_genes = sort { $gene_stats->
{ $b }->{stat} <=> $gene_stats->{ $a }->{stat}} 
@interval_sampling_universe[@index];
! ! ! ! if (defined $best_x_interval){
! ! ! ! ! my $top_per_rand_invertal = shift 
@selected_genes;
! ! ! ! ! push @sampled_genes_interval , 
{ 'id'=>$top_per_rand_invertal, 'n' => scalar 
@interval_sampling_universe };
! ! ! ! } else {
! ! ! ! ! foreach my $s (@selected_genes){
! ! ! ! ! ! push @sampled_genes_interval, 
{ 'id'=>$s, 'n' => scalar @interval_sampling_universe };
! ! ! ! ! }
! ! ! ! }
! ! ! }
! ! }
! ! my @sampled_gene_stats = map { $gene_stats->{$_}->
{stat}; } @sampled_genes_normal;
! ! foreach my $sampled_gene ( @sampled_genes_interval ){
! ! ! if (defined $best_x_interval){
! ! ! ! my $sidak_p = 1 - ( 1 - $gene_data
{ $sampled_gene->{id} }->{pvalue} )**$sampled_gene->{n};
! ! ! ! $sidak_p -= 1e-15 if ($sidak_p ==1);
! ! ! ! $sidak_p =  $gene_data{$sampled_gene->
{id}}->{pvalue} * $sampled_gene->{n} if ($sidak_p ==0);
! ! ! ! push @sampled_gene_stats, -1 * 
gsl_cdf_ugaussian_Pinv($sidak_p);
! ! ! } else {
! ! ! ! push @sampled_gene_stats, $gene_stats->
{ $sampled_gene->{id} }->{stat};
! ! ! }
! ! }
! ! my $s = &$network_stat(\@sampled_gene_stats);
! ! push @rand_stat, $s;
        }
        return(\@rand_stat);
}
sub defined_set_stat {
        my $stat = shift;
        if ($stat eq 'stouffer_z_score') {  
! ! return(\&stat_set_stouffer_z_score);
! } elsif ($stat eq 'mean'){ 
! ! return(\&stat_set_mean_z_score);
! } else { die("The statistics [ $stat ] you want to apply to 
the sub-networks is not recognized\n\n"); }
}
sub stat_set_mean_z_score {
! my $stat = shift;
! my $back = 0;
! map { $back += $_ } @$stat;






! my $stat = shift;
! $stat = pdl @$stat;




! my $max = shift;
! my $N = shift;
        my @universe = (0..$max-1);
        my @index = ();
! for (1 .. $N){
                my $i = int(rand(scalar @universe));





! my ($index,$rep,$tag) = @_;
! if (( $index/$rep - int($index/$rep)) == 0) {




! my $file = shift;
! my @back = ();
! my @body = split(/\#/,$file);
! for my $chr (1..26){






 Perl implementation of PAGE: parametric analysis of gene set 
enrichment. As bonus includes strategies to correct for gene 
clusters.
=head1 DESCRIPTION
B<This program> will read a file with gene symbols and 
statistics and performed the PAGE gene-set analysis. It reads a 
at least two files: a file with gene id's and p-values and a 
second file with the gene-set definitions. Please check the 
original paper Kim SY, Volsky DJ: PAGE: parametric analysis of 
gene set enrichment. BMC Bioinformatics 2005, 6:144. for details 
of the method. In addition it implements correction for Linkage 
Disequilibrium which is useful when analysing results from 
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genome-wide association studies. Please check http://github.com/




 ! -h, --help! ! print help message
 ! -m, --man! ! print complete documentation
 ! -report! ! ! how often to report advance
 ! -gmt! ! ! gene-set definitions on GMT format
 ! -file! ! ! gene p-value file
 ! -out, -o! ! output file
 ! -max_size! ! max gene-set size
 ! -min_size! ! min gene-set size
! -ref_list! ! set reference list for the analysis
!
! Analysis modifiers
 ! -set_stat! ! statistics to calculate over the sub-
networks
! -z_score! ! input values are z_scores (the absolute 
values will be used)
! -cgnets! ! ! File with gene ids. Only gene-sets 
that contain them will be analyzed.
! -cgnets_all!! Set all genes in gene-sets as CGNets seed. 
it basically runs the CGNets analysis for all genes.
! -Neff_gene_sets! ! Calculate the number effective gene-
sets being analysed.
! -gs_coverage! number [0,1]. Fraction of the gene-set 
that must be covered by the
! ! ! ! experiment for the gene set to be 
considered in the analysis
! -recomb_intervals!correct for genes that are in the same 
recombination interval
! -interval_merge! ! Integer. Recombination intervals 
closer than this number will be merge. It is helpfull to
! ! ! ! assess the effect of residual long range 
LD. It can be very strict if you use a large number.
! -interval_merge_by_chr!Same as before but will define a 
whole chromosome as the interval. It is the extreme of the
! ! ! ! previous option and overrides it.
! -best_per_interval! Used by default if recomb_intervals 
is used. If two or more genes are in the
! ! ! ! same recombination interval, the one with 
the best statistic will be selected. This behavior
! ! ! ! will be mantained on the permutation 
sampling to calculate the null. No permutation will be run




 ! -append! ! ! Append results to output file rather 
than overwrite it





! -perm! ! ! number of permutations
! -complete_interval_sampling! Implements a method to correct 
for recombination intervals but using all










how often to report advance. Provide an integer X and the 
program will report adnvance after X networks are analyzed.
=item B<-gmt>
ggene-set definitions on GMT format
=item B<-file>
gene p-value file. Tab separated file with at least two columns: 
gene_id and p-value. please make sure that not p-values equal to 




output file: ithe output file looks like 
GO0007156! 9.032e-06! 4.288!4.474e-06! 4.441
GO0016339! 1.656e-04! 3.590!2.306e-04! 3.502
columns are: 
1) gene-set id
2) PAGE asymtotic p-value, z_score, 
3) p-value calculated with the null distribution calculated via 
sampling
4) z score calculated with a null distribution calculated via 
sampling.








correct for genes that are in the same recombination interval. 
On GWAS analysis one would often derive one p-value per genes 
and these will be correlated if the genetic variants on 
different genes are in Linkage Desequilibrium, as for example 
when genes lay on the same recombination interval (pice of 
genome between two recombination hot-spots). The proble is that 
the statistics calculated across the sub-network asssume that 
the gene p-values are independent. With this option is possible 
to provide a set of genomic interval that group genes, e.g. 
recombination interval. This information will be use during the 
MC sampling. For example, if we have a network with 10 genes, 5 
of which lay on the same recombination interval. With the -
recomb_intervals option set on the montecarlo sampling 5 of the 
genes will be obtain from a single recombination interval 
(elsewhere in the genome), thus assuring the genetic structure 
in the subnetwotk is somehow preserved. 
=item B<-interval_merge>
Integer. Recombination intervals closer than this number will be 
merge. It is helpfull to assess the effect of residual long 
range LD. It can be very strict if you use a large number.
=item B<-interval_merge_by_chr>
Same as before but will define a whole chromosome as the 
interval. It is the extreme of the previous option and overrides 
it.
=item B<-z_score>
Input values are z_score intead of p-values, for calculations 
the absolute value of the z-score will be taken. Permutations 
must be performed together with this option.
=item B<-append>
Append results to output file rather than overwrite it
=item B<-add_file_name>
Add the input file name to the result. Usefull is analysing 
different data sets that wil be concatenated in on single file
=item B<-ref_list>




statistics to calculate over the sub-networks. options are 
stouffer_z_score and mean. mean if the default
=item B<-best_per_interval>
Used by default if recomb_intervals is used. If two or more 
genes are in the same recombination interval, the one with the 
best statistic will be selected. This behavior will be 
mantainedon the permutation sampling to calculate the null.
=item B<-complete_interval_sampling>
Implements a method to correct for recombination intervals but 
using all statistics in the recombination interval.
=item B<-cgnets>
Implements the CGNet analysis. It receives a list of genes and 
will restric the analysis to gene-sets that contain them.
=item B<-cgnets_all>
Set all genes in gene-sets as CGNets seed. it basically runs the 
CGNets analysis for all genes.
=item B<-Neff_gene_sets>
Calculate the number effective gene-sets being analysed. It can 
be quite slow is many pathways are under analysis but it will 







Script to perform meta-analysis using fix and random-effects statistics. It also 








use GWAS_STATS qw( get_lambda_genomic_control );
our (! $help,$man, $out, $w, $in_files,
! ! $stouffer,$w_col,$random,$stat_or,
! ! $stat_col,$id_col, $stat_pvalue,$header, 




! 'help|h'! ! ! => \$help,
! 'man'! ! ! ! => \$man,
! 'out|o=s'! ! ! => \$out, #name of the output file
! 'file|f=s@'!! ! => \$in_files,
! 'weights|w=f@'! ! => \$w,
! 'w_col=i@'! ! ! => \$w_col,
! 'id_col=i@'!! ! => \$id_col,
! 'stat_col=i@'! ! => \$stat_col,
! 'stat_pvalue'! ! => \$stat_pvalue,
! 'stat_or'! ! ! => \$stat_or,
! 'header'! ! ! => \$header,
! 'min_studies|min_st=i' => \$min_studies,
! 'gc_correction=i@'! ! => \$gc_correction,
! 'gc_correction_all'! ! => \$gc_correction_all,
! 'lambda=i@'!! ! => \$lambda,
! 'sdtze=i@'! ! ! => \$sdtze,
) or pod2usage(0);
pod2usage(0) if (defined $help);
pod2usage(-exitstatus => 2, -verbose => 1) if (defined $man);
pod2usage(0) if (not defined $in_files);
defined $min_studies or $min_studies = -1;
if (not defined $stat_pvalue and not defined $stat_or){
! print_OUT("Please state wheter is a p-value [ -





if (scalar @$in_files < 2){
! print_OUT("Please provide at least two input files");
! exit(1);
}
my %data     = ();
my @studies  = ();
my %total_seen = (); # records how many times and ids has been 
seen
# Defined weights
# weights can be either variable specific is provided with the 
option -w_col 
# or study specific if provided with the option -w
# if the option -w_col is defined then for each file the 
variable weight will be extracted
my @study_weights = list ones scalar @$in_files;
if (defined $w){
! @study_weights = @$w;
}
# defined gc_correction for all studies
if (defined $gc_correction_all){
! $gc_correction = [ list ones scalar @$in_files ];
}
open(OUT,">$out") or die $!;
print_OUT("Writting output to [ $out ]");
foreach my $file (@$in_files) {
! # get name of input file 
! my $st = $file;
! ($st) = ( $file =~ m/[\/\w+]{1,}\/(.*)/ ) if ($file =~ m/
\//);
! # get the study weights. if not provided will be 1
! my $st_w = shift @study_weights;
! # get the column number of variable specific weight 
! my $st_w_col = shift @$w_col if (defined $w_col);
!
! # get the stat_col
! my $st_stat_col = 2;
! $st_stat_col = shift @$stat_col if (defined $stat_col);
!
! # get the stat_col
! my $st_id_col = 1;
! $st_id_col = shift @$id_col if (defined $id_col);
!
!
! push @studies, $st; # store the name of this study for the 
print out.
! # print out some infor about the information read in the 
file
! print_OUT("Reading [ $file ]");
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! print_OUT("   '-> Variables in col [ $st_w_col ]") if 
(defined $w_col);
! print_OUT("   '-> Study weight [ $st_w ]") if (defined $w);
! print_OUT("   '-> Study stat in col [ $st_stat_col ]") if 
(defined $stat_col);
! open( IN, $file ) or print_OUT("I cannot open file 
[ $file ]\n") and die $!;
! my $counter = 0;
! while ( my $line = <IN> ) {
! ! if (defined $header and $counter == 0){
! ! ! $counter++;
! ! ! next;
! ! }
! ! chomp($line);
! ! # split line
! ! my @d = split( /[\s+\t+]/, $line );
! ! # set the variable weight to the var of the study
! ! my $var_w = double $st_w;
! ! # modify the vartiable weight if a columns with its 
variance is given
! ! $var_w /= $d[ $st_w_col -1 ] if ( defined $w_col );
! ! $var_w = sclr $var_w; # make a perl scalar to simply 
calculations later
! ! # get the variable stat
! ! my $var_stat = $d[ $st_stat_col - 1 ]; 
! ! if (defined $stat_pvalue){ 
! ! ! if ( $var_stat == 1 ){
! ! ! ! $var_stat = double 1-2.2e-16;
! ! ! }
! ! ! $var_stat = -1 * gsl_cdf_ugaussian_Pinv
( $var_stat );
! ! } elsif (defined $stat_or){
! ! ! $var_stat = log $var_stat;
! ! }
! ! # store the data as a pseudohash
! ! $data{ $d[ $st_id_col -1 ] }{$st} = { 'w' => $var_w, 
'stat' => $var_stat };





! print_OUT("Calculating lambda for genomic control 
correction");
!
! my %studies_p = ();
! foreach my $var (keys %data){
! ! my $f_counter = 0;
! ! foreach my $file ( @$in_files ){
! ! ! my $st = $file;
! ! ! ($st) = ( $file =~ m/[\/\w+]{1,}\/(.*)/ ) if 
($file =~ m/\//);
! ! ! if (not exists $data{$var}{$st}){
! ! ! ! $f_counter++; 
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! ! ! ! next;
! ! ! }
! ! ! next unless ($gc_correction->[$f_counter++] == 
1);
! ! ! push @{ $studies_p{$st} }, 1 - 
gsl_cdf_ugaussian_P($data{$var}{$st}->{stat});
! ! } 
! }
! foreach my $st ( keys %studies_p ){
! ! print_OUT(" '-> [ $st ]");
! ! my $gc_lambda = get_lambda_genomic_control($studies_p
{$st});
! ! print_OUT("   '-> lambda (median) of 
[ $gc_lambda ]");
! ! if ($gc_lambda > 1){
! ! ! print_OUT("   '-> Applying GC correction in 
[ $st ]");
! ! ! my $assoc_p = [];
! ! ! foreach my $var (keys %data) {
! ! ! ! next unless (exists $data{$var}{$st});
! ! ! ! my $p = 1 - gsl_cdf_ugaussian_P($data
{$var}{$st}->{stat});
! ! ! ! if ( $p == 1){
! ! ! ! ! push @{ $assoc_p }, $p;
! ! ! ! ! next;
! ! ! ! }
! ! ! ! my $var_chi = gsl_cdf_chisq_Pinv ( 1 - 
$p , 1 );
! ! ! ! $var_chi /=  $gc_lambda;
! ! ! ! $p = gsl_cdf_chisq_P( $var_chi, 1 );
! ! ! ! $data{$var}{$st}->{stat} = 
gsl_cdf_ugaussian_Pinv( $p );
! ! ! ! push @{ $assoc_p }, 1 - $p;
! ! ! }
! ! ! $gc_lambda = get_lambda_genomic_control
($assoc_p);
! ! ! print_OUT("   '-> After correction the lambda 
is [ $gc_lambda ]");
! ! } else {
! ! ! print_OUT("   '-> GC correction not applied 












foreach my $gn ( keys %data ) {
! my $count = scalar keys %{$data{ $gn } };
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! next if ($count < 2); # next if only one study looked at 
this gene
! next if ($count < $min_studies);
! next if ($total_seen{ $gn } > scalar @studies);
! my $all_w = [];
! my $all_b = [];
! # collect stat and weights for each study
! foreach my $st ( keys %{ $data{ $gn } } ) {
! ! push @{$all_w}, $data{ $gn }{$st}->{'w'};
! ! push @{$all_b}, $data{ $gn }{$st}->{'stat'};
! }
! $all_w = pdl $all_w;
! if ($all_w->minimum() == 1 and $all_w->maximum() ==1){
! ! $all_w *= $all_w->nelem;
! } else {
! ! $all_w = 1/$all_w;
! }
! my $metaResults = get_fix_and_radom_meta_analysis($all_b,
$all_w);
!
! my $max_b = maximum pdl $all_b;
! my $min_p = gsl_cdf_ugaussian_P( -1 * $max_b );
! my $binomial_rank_p = 1 - gsl_cdf_binomial_P(1,$min_p,
$metaResults->{'N'});
! printf OUT ("$gn\t%.6f\t%.6f\t%.6f\t%.6f\t%.6e\t%.6f\t%.6f
\t%.6f\t%.6f\t%.6e\t%.6f\t%.6e\t%.6f\t%.6f\t$metaResults->{'N'}
\t%.6e", 
! ! ! ! $metaResults->{'B_stouffer_fix'},
! ! ! ! $metaResults->{'B_fix'},
! ! ! ! $metaResults->{'V_fix'}, 
! ! ! ! $metaResults->{'Chi_fix'},
! ! ! ! $metaResults->{'Z_P_fix'},
! ! ! ! $metaResults->{'B_stouffer_random'},
! ! ! ! $metaResults->{'B_random'},
! ! ! ! $metaResults->{'V_random'}, 
! ! ! ! $metaResults->{'Chi_random'},
! ! ! ! $metaResults->{'Z_P_random'},
! ! ! ! $metaResults->{'Q'},
! ! ! ! $metaResults->{'Q_P'},
! ! ! ! $metaResults->{'tau_squared'},
! ! ! ! $metaResults->{'I2'},
! ! ! ! $binomial_rank_p,
! ! ! ! );
! map {
! ! if (defined $w_col){
! ! ! if   ( exists $data{ $gn }{$_} ) { printf OUT 
("\t%.6f(%.3f)",$data{ $gn }{$_}->{'stat'},1/$data{ $gn }{$_}->
{'w'}); }
! ! ! else { print OUT "\tNA"; }!! !
! ! } else {
! ! ! if   ( exists $data{ $gn }{$_} ) { printf OUT 
("\t%.6f",$data{ $gn }{$_}->{'stat'}); 
! ! ! ! #print Dumper($data{ $gn }),"\n";
! ! ! }
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! ! ! else { print OUT "\tNA"; }
! ! }
! } @studies;
! print OUT "\n";





! my $B = shift;
! my $SE = shift;
! my $external_w = shift;
! my $VarCov = shift;
! if (ref($B) eq 'ARRAY') { $B = pdl $B; }
! if (ref($SE) eq 'ARRAY') { $SE = pdl $SE; }
! if (ref($external_w) eq 'ARRAY') { $external_w = pdl 
$external_w; }
! my $N = $B->nelem;
! if (not defined $VarCov) {
! ! $VarCov = stretcher(ones $N);
! }
! my $W = null;
! if ( (ref($external_w) eq 'PDL') and (nelem($external_w > 
0) > 0) and (dsum( ($external_w - $external_w->davg)**2 ) > 0 ))
{
! ! $W = 1/($SE + 1/$external_w); 
! } else {
! ! $W = 1/$SE; 
! }
! # calculate fix effect estimate
! my $norm_w_fix = $W/$W->dsum;
! #my $B_fix = dsum($B*$W)/$W->dsum;
! #my $V_fix = dsum($W*$W->transpose*$VarCov);
! my $B_fix = dsum($B*$norm_w_fix)/$norm_w_fix->dsum;
! my $V_fix = dsum($norm_w_fix*$norm_w_fix->transpose*
$VarCov);
! my $fix_chi_square_df1 = ($B_fix**2)/$V_fix;
!
! my $stouffer_w_fix = $W/dsum($W**2);
! my $B_stouffer_fix = dsum($B*$stouffer_w_fix)/sqrt(dsum
($stouffer_w_fix*$stouffer_w_fix->transpose*$VarCov));
!
! # calculate heteroogeneity parameter Q
! my $Q = 0.0;
! {
! ! my $cor = $VarCov->copy();
! ! $cor->diagonal(0,1) .=0;
! ! $cor = (3.263*abs($cor) + 0.710*(abs($cor)**2) + 
0.027*(abs($cor)**3));
! ! my $df = 8/(dsum($cor*$W*$W->transpose) + 4*dsum
($W**2));
! ! my $Q_naive = dsum ($W * (($B_fix - $B)**2));
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! ! $Q = sclr gsl_cdf_chisq_Pinv( gsl_cdf_chisq_P
(  $df*0.5*$Q_naive, $df), $N - 1);
! }!
! # calculate heteroogeneity parameter I-squared
! my $I_squared = 0.0;
! if ($Q > ($N - 1)){
! ! eval { $I_squared = 100*($Q - ($N - 1))/$Q; };
! ! if ($@){
! ! ! $I_squared = 0.0;
! ! }
! }
! # calculate tau-squared
! my $tau_squared = 0.0;
! if ($Q > ($N - 1)){
! ! eval { $tau_squared = ($Q - ($N - 1))/(dsum($W) - 
dsum($W**2)/$W->dsum); };
! ! if ($@){
! ! ! # tau-squared equal 0 if was < 0
! ! ! $tau_squared = 0.0;
! ! }
! }
! # calculate the random effect estimate
! my $w_star = null;
! if ( (ref($external_w) eq 'PDL') and (nelem($external_w > 
0) > 0) and (dsum( ($external_w - $external_w->davg)**2 ) > 0 ))
{
! ! $w_star = 1/( $tau_squared + $SE + 1/$external_w);
! } else {
! ! $w_star = 1/( $tau_squared + $SE);
! }
! my $norm_w_random = $w_star/$w_star->dsum;
! my $B_random = dsum( $B*$norm_w_random)/$norm_w_random-
>dsum;
! #my $B_random = dsum( $B*$w_star)/$w_star->dsum;
! my $V_random = dsum($norm_w_random*$norm_w_random-
>transpose*$VarCov);
! #! my $V_random = dsum($w_star*$w_star->transpose*
$VarCov);
! my $random_chi_square_df1 = ($B_random**2)/$V_random;
!
! my $stouffer_w_random = $w_star/dsum($w_star**2);




! my $back =  {
! ! 'B_stouffer_fix' => $B_stouffer_fix,
! ! 'B_stouffer_random' => $B_stouffer_random,
! ! 'B_fix' => $B_fix,
! ! 'B_random' => $B_random,
! ! 'V_fix' => $V_fix,
! ! 'V_random' => $V_random,
! ! 'Chi_fix' => $fix_chi_square_df1,
! ! 'Chi_random' => $random_chi_square_df1,
! ! 'Q' => $Q,
! ! 'I2' => $I_squared,
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! ! 'tau_squared' => $tau_squared,
! ! 'N' => $N,
! ! 'Z_P_fix' => gsl_cdf_gaussian_P( -1 * $B_fix ,sqrt
($V_fix )),
! ! 'Z_P_random' => gsl_cdf_gaussian_P( -1 * 
$B_random,sqrt($V_random) ),





! my $string = shift;
! print scalar localtime(), "\t$string\n";











 -h, --help! ! print help message
 -m, --man!! print complete documentation
 -report! ! ! how often to report advance





























Perl module with routines to calculate correlation matrixes using a shrinkage 





use Exporter qw (import);
# define verbose = undef;
my $v = undef;









if ($@) { 




our (@EXPORT, @EXPORT_OK, %EXPORT_TAGS);
@EXPORT = qw( check_positive_definite cov_shrink 
make_positive_definite is_positive_definite);! # symbols to 
export by default
@EXPORT_OK = qw( check_positive_definite cov_shrink 
make_positive_definite is_positive_definite); # symbols to 
export on request
sub wt_moments{
! my ($x, $w) = @_; 
! $w = pvt_check_w($w, $x->getdim(1));
! my $h1 = 1/(1 - dsum($w * $w));
! my $m = dsumover($w * $x->transpose);
! my $v = $h1 * (dsumover($w * transpose($x**2)) - dsumover
($w * $x->transpose)**2);
! return({ 'mean' => $m, 'var' => $v});
}
sub wt_scale{
! my $x = shift;
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! my $w = shift;
! my $center = shift;
! my $scale = shift;
! $w = pvt_check_w($w,$x->getdim(1));
    my $wm = { 'mean' => $x->xchg(0,1)->daverage, 'var' => $x-
>xchg(0,1)->stdv**2 }; 
    if ($center eq 'TRUE'){
        $x = $x - $wm->{'mean'};
    }
    if ($scale eq 'TRUE') {
        my $sc = sqrt($wm->{'var'});
        $x = $x/$sc;
    }
    return($x);
}
sub pvt_check_w {
! my ($w, $n) = @_; 
    if (not defined $w) {
        $w = ones $n;
! ! $w /= $n;
! ! $w /= $w->dsum;
    } else {
        if ($w->getdim(0) != $n) {
            warn("Weight vector has incompatible length. Is 
[ " . $w->getdim(0) . " ] should be [ $n ]\n");
        }
        $w = ones $n;
! ! $w /= $n;
! ! $w /= $w->dsum;
        my $sw = sum($w);
        if ($sw != 1){ $w = $w/$sw; }
! }




! my ($m, $tol) = @_; 
! my $d = $m->getdim(1);
! if ($m->getdim(1) != $m->getdim(0)) { die("Input matrix is 
not square!"); }
! my ($es,$esv) = eigens $m;
! if (not defined $tol){ $tol = $d * max(abs($esv)) * 
2e-16; }
! my $delta = 2 * $tol;
! my $tau = $delta - $esv;
! $tau->( which($tau < 0) ) .= 0;
! my $dm = $es x stretcher($tau) x transpose($es);
! return($m + $dm)
}
sub is_positive_definite {
! my $m = shift;
! my $tol = shift;
! my ($es,$esv) = eigens $m;
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! if (not defined $tol){ $tol = $m->getdim(0) * max(abs
($esv)) * 2e-8; }
! if ( sum($esv > $tol) == scalar( $esv->list) ) {
! ! return(0);






 function (m, tol, method = c("Eigen", "chol")) 
 {
 method = match.arg(method)
 if (!is.matrix(m)) 
 m = as.matrix(m)
 if (method == "Eigen") {
 eval = Eigen(m, only.values = TRUE)$values
 if (is.complex(eval)) {
 warning("Input matrix has complex eigenvalues!")
 return(FALSE)
 }
 if (missing(tol)) 
 tol = max(dim(m)) * max(abs(eval)) * .Machine$double.eps




 if (method == "chol") {
 val = try(chol(m), silent = TRUE)







! my ($x, $lambda, $lambda_var, $w, $collapse, $verbose) = 
@_;
    my $n = $x->getdim(1);
! if (not defined $lambda) { $lambda = -1; }
! if (not defined $lambda_var) { $lambda_var = -1; } 
! if (not defined $w) { 
! ! $w = ones $n;
! ! $w /= $n;
! ! $w /= $w->sum;
! }
! my $sc_data = pvt_svar($x, $lambda_var, $w, $verbose);
! my $sc = $sc_data->{'vs'}->sqrt;
! my $c = pvt_powscor($x, 1, $lambda, $w, $collapse, 
$verbose);
! my $cor = $c->{powr};
! # I have commented this if because I do not know when is 
useful. 




! #if ( $c->isempty){ 
! #! $c->{powr} = $c->{powr} * $sc * $sc;
! #} else{
! $c->{powr} = transpose($c->{powr}*$sc)* $sc;
! #}
! my $back = { 
! ! 'lambda_var' => $sc_data->{"lambda_var"},
! ! 'lambda_var_estimated' => $sc_data->
{"lambda_var_estimated"},
! ! 'lambda_cor' => $c->{"lambda"},
! ! 'lambda_cor_estimated' => $c->{"lambda_estimated"},
! ! 'cov' => $c->{powr},





! my ($x, $lambda, $w, $verbose, $type,$target) = @_;
    my ($kind,$func) = undef;
! my $lambda_estimated = undef;
    
    if ($lambda < 0) {
! ! if ($type eq "correlation") {
! ! ! $kind = "lambda (correlation matrix):";
! ! ! $lambda = pvt_corlambda($x, $w, $target);
! ! }
! ! if ($type eq "variance") {
! ! ! $kind = "lambda.var (variance vector):";
! ! ! $lambda = pvt_varlambda($x, $w, $target);
! ! }
        if ($verbose) {
            print  ("Estimating optimal shrinkage intensity 
[ $kind ]");
        }
! ! $lambda_estimated = "TRUE";
        if ($verbose) {
            print  ("lambda [ $lambda ]");
        }
    } elsif ($lambda > 1){  
! ! $lambda = 1;
! ! $lambda_estimated = "FALSE";
! ! if ($verbose) {
! ! ! print  ("Specified shrinkage intensity $kind 
[ $lambda ]");
! ! }
    }
    if ($type eq "correlation") {
        return( { 'lambda' => $lambda, 'lambda_estimated' => 
$lambda_estimated } );
    }
    if ($type eq "variance") {
        return( { 'lambda_var' => $lambda, 
'lambda_var_estimated' => $lambda_estimated } );
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    }
}
sub pvt_powscor {
! my ($x, $alpha, $lambda, $w, $collapse, $verbose) = @_;
    my $xs = wt_scale($x, $w, 'TRUE', 'TRUE');
! my $h1 = 1/(1 - dsum($w * $w));
    my $z = pvt_get_lambda($xs, $lambda, $w, $verbose, 
"correlation", 0);
    my $p = $xs->getdim(0);
! my $powr = null;
! # for debug
! #! $alpha = 0.5;
    if ($z->{'lambda'} == 1 or $alpha == 0) {
        if ($collapse) {
            $powr = ones $p;
        } else {
            $powr = zeroes $p,$p;
! ! ! $powr->diagonal(0,1) .= ones $p;
        }
    } elsif ($alpha == 1) {
! ! my $cross = $xs*$w->transpose->sqrt;
        my $r0 = $h1 * mcrossprod( $xs*$w->transpose->sqrt);
        $powr = (1 - $z->{'lambda'}) * $r0;
        $powr->diagonal(0,1) .= ones $powr->getdim(0);
    } else {
! ! # These methods have not been implemented
! ! # program will throw an error.
        my $zeros = $xs;
        my $svdxs = fast_svd($xs);
        my $m = length($svdxs->{'d'});
        my $UTWU = transpose($svdxs->{'u'}) x ( $svdxs->{'u'}*
$w);
        my $C = $UTWU*$svdxs->{'d'}*$svdxs->{'u'}->transpose;
        $C = (1 - $z->{'lambda'}) * $h1 * $C;
        $C = ($C + transpose($C))/2;
        if ($lambda == 0) {
            if ($m < $p - dsum($zeros)){ 
                warning("Estimated correlation matrix doesn't 
have full rank - pseudoinverse used for inversion.\n");
! ! ! ! $powr = $svdxs->{'v'} x ((mpower($C, 
$alpha) x transpose($svdxs->{'v'})) );
! ! ! }
! ! } else {
            my $F = $m->diagonal(0,1) - mpower($C/$z->{'lambda'} 
+ $m->diagonal(0,1), $alpha);
            $powr = ( $p->diagonal(0,1) - $svdxs->{'v'} x ($F x 
transpose($svdxs->{'v'}) )) * ($z->{'lambda'})**$alpha;
        }
        $powr->diagonal(0,1) = 1;
        #rownames(powr) = colnames(xs)
        #colnames(powr) = colnames(xs)
    }
! $powr = {
! ! 'powr' => $powr,
! ! 'lambda' => $z->{lambda},
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! ! 'lambda_estimated' => $z->{lambda_estimated},
! ! 'class' => "shrinkage",
! };
    return($powr);
}
sub fast_svd {
! my ($m, $tol) = @_; 
    my $n = $m->getdim(1);
    my $p = $m->getdim(0);
    my $EDGE_RATIO = 2;
    if ($n > $EDGE_RATIO * $p) {
        return(psmall_svd($m, $tol));
    } elsif ($EDGE_RATIO * $n < $p) {
        return(nsmall_svd($m, $tol));
    } else {
        return(positive_svd($m, $tol));
    }
}
=head
 sub psmall.svd {
 my ($m, $tol) = @_; 
 my $B = mcrossprod($m);
 my $s = svd($B, 0);
 if (not defined ($tol)) { 
 my $tol = $B->getdim(1) * maximum($s->{'d'}) * 2.220446e-16;
 my $Positive = which($s->{'d'} > $tol);
 my $d = sqrt($s->{'d'}->($Positive));
 my $v = $s->{'v'}->(, $Positive);
 my $u = m %*% v %*% diag(1/d, nrow = length(d))




! my ($x, $lambda_var, $w, $verbose) = @_;
! $w = pvt_check_w($w,$x->getdim(1));
    my $xs = wt_scale( $x,$w,'TRUE', 'FALSE');
! my $wt_mom = wt_moments($xs,$w);
! my $v = $wt_mom->{var};
! my $tgt = median($v);
    my $z = pvt_get_lambda($xs, $lambda_var, $w, 0, "variance", 
$tgt);
    my $vs = $z->{'lambda_var'} * $tgt + (1 - $z->
{'lambda_var'}) * $v;
! my $back = {
! ! 'vs' => $vs,
! ! "lambda_var" => $z->{'lambda_var'},
! ! "lambda_var_estimated" => $z->
{'lambda_var_estimated'},
! ! "class" => "shrinkage",
! };
    return($back);
}
sub pvt_varlambda {
! my ($xc,$w, $target) = @_;
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    my $w2 = dsum($w * $w);
    my $h1 = 1/(1 - $w2);
    my $h1w2 = $w2/(1 - $w2);
    my $zz = $xc**2;
    my $q1 = dsumover(  $zz->transpose*$w  );
    my $q2 = dsumover( ($zz->transpose**2)*$w ) - $q1**2;
    my $numerator = dsum($q2);
! my $lambda = undef;
    my $denominator = dsum(($q1 - $target/$h1)**2);
    if ($denominator == 0) {
! ! $lambda = 1;
! } else {
! ! $lambda = ($numerator/$denominator) * $h1w2; 





! my ($xs, $w, $target) = @_;
    my $w2 = dsum($w * $w);
    my $h1w2 = $w2/(1 - $w2);
    my $sw = sqrt($w);
! my $Q1_squared = (mcrossprod($xs*$sw->transpose))**2;
    my $Q2 = mcrossprod(($xs**2)*$sw->transpose)  - $Q1_squared;
    my $denominator = dsum($Q1_squared) - dsum( $Q1_squared-
>diagonal(0,1));
    my $numerator = dsum($Q2) - dsum( $Q2->diagonal(0,1));
! my $lambda = undef;
! if ($denominator == 0) {
        $lambda = 1;
! } else { 
! ! $lambda = ($numerator/$denominator) * $h1w2;





! my $cov_in = shift;
! my $tol = shift;
!
! defined $tol or $tol = 1e-8;
! my $status = 0;
! my $cov = $cov_in;
! eval { mchol ($cov) };
! my $i = 0;
! while($@ ne ""){
! ! $@ = "";
! ! $i++;
! ! if ($i > 25){
! ! ! last;
! ! }
! ! my ($es,$esv) = eigens $cov;
! ! $cov = make_positive_definite($cov,$tol);
! ! ($es,$esv) = eigens $cov;
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! ! eval { mchol ($cov) };
! }
!
! if (is_positive_definite($cov,$tol) == 1){
! ! $cov = make_positive_definite($cov,$tol);
! }
!
! if(is_positive_definite($cov,$tol) == 1){
! ! $cov = $cov_in;
! ! $cov->diagonal(0,1) .= 1.0001; 
! }
! if(is_positive_definite($cov,$tol) == 1){
! ! $cov->diagonal(0,1) .= 1.001; 
! }
! if(is_positive_definite($cov,$tol) == 1){




! if (is_positive_definite($cov,$tol) == 1){
! ! print "Matrix never positive definite\n";













use Exporter qw (import);
# define verbose = undef;
my $v = undef;





! #use PDL::LinearAlgebra; # commented until re-implement the 





if ($@) { 




our (@EXPORT, @EXPORT_OK, %EXPORT_TAGS);
@EXPORT = qw( build_index line_with_index 
extract_binary_genotypes extract_genotypes_for_snp_list 
get_snp_list_from_bgl_format get_snp_list_from_ox_format 
read_bim read_fam read_map_and_ped );!! ! ! # symbols 
to export by default
@EXPORT_OK = qw( build_index line_with_index 
extract_binary_genotypes extract_genotypes_for_snp_list 
get_snp_list_from_bgl_format get_snp_list_from_ox_format 
read_bim read_fam read_map_and_ped);! ! ! # symbols to 
export on request
# usage: build_index(*DATA_HANDLE, *INDEX_HANDLE)
sub build_index {
    my $data_file  = shift;
    my $index_file = shift;




    while (<$data_file>) {
        print $index_file pack("N", $offset);
        $offset = tell($data_file);
    }
}
# usage: line_with_index(*DATA_HANDLE, *INDEX_HANDLE, 
$LINE_NUMBER)
# returns line or undef if LINE_NUMBER was out of range
sub line_with_index {
    my $data_file   = shift;
    my $index_file  = shift;
    my $line_number = shift;
    
    my $size;               # size of an index entry
    my $i_offset;           # offset into the index of the entry
    my $entry;              # index entry
    my $d_offset;           # offset into the data file
!
    $size = length(pack("N", 0));
    $i_offset = $size * ($line_number - 1);
    
    seek($index_file, $i_offset, 0) or return;
    read($index_file, $entry, $size);
    $d_offset = unpack("N", $entry);
! if (not defined $d_offset){
! ! return('1');
! } else {
! ! seek($data_file, $d_offset, 0);
! ! return scalar(<$data_file>);
! }
}
# this subroutine read the fam file and stores the information 
in an array
# the elements of the array are pseudo hashes with all the 
sample's information
sub read_fam {
! my $fam = shift;
! print "Reading samples info from [ $fam ]\n";
! open( FAM, $fam ) or print "Cannot open [ $fam ] file\n" 
and exit(1);
! my @back = ();
! while ( my $s = <FAM> ) {
! ! my @data = split( /\s+/, $s );
! ! push @back,
        {
! ! ! 'iid'   => $data[0],
! ! ! 'fid'   => $data[1],
! ! ! 'mid'   => $data[2],
! ! ! 'pid'   => $data[3],
! ! ! 'sex'   => $data[4],
! ! ! 'pheno' => $data[5],
        };
! }
! #print_OUT("[ " . scalar @back . " ] samples read");
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! return ( \@back );
}
# this subroutine read the bim file and store information about 
the SNPs
# each element of the array returned is a pseudo hash with the 
SNP information
sub read_bim {
! my $bim = shift;
! my $affy_to_rsid = shift;
! my $affy_id = shift;
! print "Reading SNPs info from [ $bim ]\n";
! open( BIM, $bim ) or print "Cannot open [ $bim ] file\n" 
and exit(1);
! my @back = ();
! while ( my $snp = <BIM> ) {
! ! chomp($snp);
! ! my @data = split( /\t+/, $snp );
! ! # if an affy to rsid mapping was provided change the 
ids
! ! if ( defined $affy_to_rsid ) {
! ! ! if ($data[1] !~ m/^rs/){
! ! ! ! if (exists $affy_id->{$data[1]}){ $data[1] 
= $affy_id->{$data[1]};}
! ! ! }
! ! }
! ! push @back,
        {
! ! ! 'snp_id' => $data[1],
! ! ! 'chr'    => $data[0],
! ! ! 'cm'     => $data[2],
! ! ! 'pos'    => $data[3],
! ! ! 'a2'     => $data[4],
! ! ! 'a1'     => $data[5],
        };
! }
! #print_OUT("[ " .  scalar @back . " ] SNPs on BED file");
! return ( \@back );
}
sub read_map {
! my $map = shift;
! my $affy_to_rsid = shift;
! my $affy_id = shift;
! #print_OUT("Reading SNPs info from [ $map ]");
! open( MAP, $map ) or #print_OUT("Cannot open [ $map ] 
file") and exit(1);
! my @back = ();
! while ( my $snp = <MAP> ) {
! ! chomp($snp);
! ! my @data = split( /\t+/, $snp );
! ! # if an affy to rsid mapping was provided change the 
ids
! ! if ( defined $affy_to_rsid ) {
! ! ! if ($data[1] !~ m/^rs/){
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! ! ! ! if (exists $affy_id->{$data[1]}){ $data[1] 
= $affy_id->{$data[1]};}
! ! ! }
! ! }
! !
! ! push @back, {
! ! ! 'snp_id' => $data[1],
! ! ! 'chr'    => $data[0],
! ! ! 'cm'     => $data[2],
! ! ! 'pos'    => $data[3],
! ! ! 'a2'     => 0,
! ! ! 'a1'     => 0,
        };
! }
! #print_OUT("  '->[ " . scalar @back . " ] SNPs on PED 
file");
! return ( \@back );
}
sub read_map_and_ped {
! my $file = shift;
! my $map = shift;
! my $affy_to_rsid = shift;
! my $affy_id = shift;
!
! my @bim = @{ read_map($map,$affy_to_rsid,$affy_id) };
! #print_OUT("Reading Genotypes from [ $file ]");
! open(PED,$file) or #print_OUT("Cannot open [ $file ] file") 
or exit(1);
! my @back_fam = ();
! my @geno_matrix= ();
! while (my $sample = <PED>){
! ! chomp($sample);
! ! my ($iid,$fid,$mid,$pid,$sex,$pheno,@genotypes) = 
split(/\s+/,$sample);
! ! my $snp_counter = 0;
! ! for (my $g = 0; $g < scalar @genotypes; $g+=2){
! ! ! $geno_matrix[$snp_counter]->{alleles}->
{$genotypes[$g]}++;
! ! ! $geno_matrix[$snp_counter]->{alleles}->
{$genotypes[$g+1]}++;
! ! ! push @{ $geno_matrix[$snp_counter]->
{genotypes} }, "$genotypes[$g]$genotypes[$g+1]";
! ! ! $snp_counter++; 
! ! }
! ! push @back_fam,{
! ! ! 'iid'   => $iid,
! ! ! 'fid'   => $fid,
! ! ! 'mid'   => $mid,
! ! ! 'pid'   => $pid,
! ! ! 'sex'   => $sex,
! ! ! 'pheno' => $pheno,
! ! };
! }
! my @back_genotypes = ();
! my $snp_counter = 0;
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! foreach my $snp (@geno_matrix){
! ! my @alleles = sort { $snp->{alleles}->{$b} <=> $snp->
{alleles}->{$a} } keys %{ $snp->{alleles} };
! ! ($snp->{alleles}->{major},$snp->{alleles}->{minor},
$snp->{alleles}->{missing}) = 0;
! ! for (my $i = 0; $i < scalar @alleles; $i++) {
! ! ! if ($alleles[$i] == 0) { 
! ! ! ! $snp->{alleles}->{missing} =$alleles[$i]; 
! ! ! } else {
! ! ! ! if ( $snp->{alleles}->{major} == 0){
! ! ! ! ! $snp->{alleles}->{major}= $alleles
[$i];
! ! ! ! } else {
! ! ! ! ! $snp->{alleles}->{minor}= $alleles
[$i];
! ! ! ! }




! ! $bim[$snp_counter]->{a1} = $snp->{alleles}->{minor};
! ! $bim[$snp_counter]->{a2} = $snp->{alleles}->{major};
! ! foreach my $g (@{ $snp->{genotypes} }){
! ! ! my $major_homo = "$snp->{alleles}->{major}$snp-
>{alleles}->{major}";
! ! ! my $minor_homo = "$snp->{alleles}->{minor}$snp-
>{alleles}->{minor}";
! ! ! my $hetero1 = "$snp->{alleles}->{major}$snp->
{alleles}->{minor}";
! ! ! my $hetero2 = "$snp->{alleles}->{minor}$snp->
{alleles}->{major}";
! ! ! my $missing = "$snp->{alleles}->{missing}$snp->
{alleles}->{missing}";
! ! ! my $recoded = 0;
! ! ! # homozygous major allele
! ! ! if ($g == $major_homo) {
! ! ! ! $recoded = 3;
! ! ! } elsif ($g == $minor_homo){ # homozygous minor 
allele
! ! ! ! $recoded = 1;
! ! ! } elsif (($g == $hetero1) or ($g == $hetero2))
{ # heterozygous
! ! ! ! $recoded = 2
! ! ! } elsif ($g == $missing) { # missing
! ! ! ! $recoded = 0;
! ! ! } else { #print_OUT(" COULD NOT RECOGNIZE THIS 
GENOTYPE >$g<\n" . Dumper($snp->{alleles}) . "");
! ! ! ! exit(1);
! ! ! }





! #print_OUT("  '-> [ " . scalar @back_fam . " ] samples");
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! my $snp_list = shift;
! my $line_index = shift;
! my $g_prob_threshold = shift;
! my $geno_probs_format = shift; 
! my $gprobs = shift;
! my $gprobs_index = shift;
! my @geno_probs = ();
! my @geno_hard_coded = ();
! # loop over the snps mapped to the gene
! for (my $i = 0; $i < scalar @$snp_list; $i++){
! ! my $line = line_with_index($gprobs, $gprobs_index, 
$line_index->[$i]);! !
! ! my @genos = split(/[\t+\s+]/,$line);
! ! # now loop over all samples for this snps
! ! my $sample_counter = 0;
! ! # counter start from 5 because the first columns are 
chromosome, SNP id, position, minor allele and major allele
! ! # counter increases by three because each sample has 
3 genotype probabilities for the AA, AB and BB, with A the minor 
allele
! ! my $start_index = 0;
! ! $start_index = 5 if ($geno_probs_format eq 'OXFORD');
! ! $start_index = 3 if ($geno_probs_format eq 'BEAGLE');
! ! for (my $g = $start_index; $g < scalar @genos; $g 
+=3){
! ! ! my $snp_prob = pdl @genos[$g..$g+2];
! ! ! my $max_index = maximum_ind($snp_prob);
! ! ! my $value = undef;
! ! !
! ! ! if ($snp_prob->dsum == 0){ 
! ! ! ! $value = 0;
! ! ! } else {
! ! ! ! $value = $snp_prob->($max_index);
! ! ! }
! ! ! if ($value < $g_prob_threshold) {$value = 0;}
! ! ! push @{ $geno_probs[$sample_counter] } , sclr 
$value;
! ! !
! ! ! my $dossage = 0*$snp_prob->(0) + 1*$snp_prob->
(1) + 2*$snp_prob->(2);
! ! ! push @{ $geno_hard_coded[$sample_counter] }, 
sclr $dossage;
! ! ! $sample_counter++;
! ! }
! }
! my $coded_mat = transpose double pdl @geno_hard_coded;






! my $geno_probs = shift;
! my $geno_probs_index = shift;
! my $affy_to_rsid = shift;
! my $affy_id = shift;
!
! my $index = 0;
! my @back = ();
! my $desired_line = 1;
! my $eof = 0;
! while () {
! ! my $line = line_with_index(*$geno_probs, *
$geno_probs_index, $desired_line);
! ! last if ($line eq '1');
! ! my ($snp,$a1,$a2) = split(/\s+/,$line);
! ! if ( defined $affy_to_rsid ) {
! ! ! if ($snp !~ m/^rs/){
! ! ! ! if (exists $affy_id->{$snp}){ $snp = 
$affy_id->{$snp};}
! ! ! }
! ! }! !
! ! push @back,{
! ! ! 'snp_id' => $snp,
! ! ! 'chr'    => 0,
! ! ! 'cm'     => 0,
! ! ! 'pos'    => 0,
! ! ! 'a2'     => $a1,
! ! ! 'a1'     => $a2,
        };
! ! $desired_line++;
! }
! #print_OUT("[ " .  scalar @back . " ] SNPs on BEAGLE format 
genotype probability file");
! return ( \@back );
}
sub get_snp_list_from_ox_format {
! my $geno_probs = shift;
! my $geno_probs_index = shift;
! my $affy_to_rsid = shift;
! my $affy_id = shift;
!
! my $index = 0;
! my @back = ();
! my $desired_line = 1;
! my $eof = 0;
! while () {
! ! my $line = line_with_index(*$geno_probs, *
$geno_probs_index, $desired_line);
! ! last if ($line eq '1');
! ! my ($chr,$snp,$pos,$a1,$a2) = split(/\s+/,$line);
! ! if ( defined $affy_to_rsid ) {
! ! ! if ($snp !~ m/^rs/){
! ! ! ! if (exists $affy_id->{$snp}){ $snp = 
$affy_id->{$snp};}




! ! push @back,{
! ! ! 'snp_id' => $snp,
! ! ! 'chr'    => $chr,
! ! ! 'cm'     => 0,
! ! ! 'pos'    => $pos,
! ! ! 'a2'     => $a1,
! ! ! 'a1'     => $a2,
        };
! ! $desired_line++;
! }
! #print_OUT("[ " .  scalar @back . " ] SNPs on OXFORD format 
genotype probability file");
! return ( \@back );
}
sub extract_binary_genotypes {
! my $n_genotypes = shift; # number of genotypes per SNP
! my $bytes_per_snp = shift; # number of bytes needed to code 
the SNP
! my $byte_position = shift; # starting byte position for 
this SNP
! my $FH = shift; # file handle for the genotype file
! $FH->seek(3 + $byte_position,SEEK_SET); # re-set the file-
handle to position start position of the SNP of interest
! my $buffer = ""; # this will store the information read
! my $n_bytes = read $FH, $buffer, $bytes_per_snp; # read the 
genotypes
! my $data_size = $bytes_per_snp*8; # the amount of data to 
extract is 8 bits per byte
! my $bin_data = unpack("B$data_size",$buffer); 
! my @bits = ( $bin_data =~ m/\d{8}/g );
! my @genotypes = ();
! foreach my $b (@bits){
! ! $b = reverse($b); # for some odd reason PLINK stores 
the genotypes in reverse order
! ! push @genotypes, @{ get_genotypes($b)};# transform 





! my $b = shift; # a byte
! my @back = ();
! my @genotypes = ( $b =~ m/\d{2}/g ); # extract a pair of 
number = a genotype
! foreach my $geno (@genotypes){
! ! # 10 indicates missing genotype, otherwise 0 and 1 
point to allele 1 (minor) or allele 2 (mayor) in the BIM file, 
respectively
! ! if    ( $geno eq '00' ) {  # homozygous 1/1
! ! ! push @back, '1';
! ! } elsif ( $geno eq '11' ) { # -- other homozygous 2/2
! ! ! push @back, '3';
! ! } elsif ( $geno eq '01' ) { # -- heterozygous 1/2
! ! ! push @back, '2';
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! ! } elsif ( $geno eq '10' ) { # -- missing genotype 0/0
! ! ! push @back, '0';
! ! } else { 
! ! ! #print_OUT("This genotype is not recognize 
[ $geno ]"); 













use Exporter qw (import);
# define verbose = undef;
my $v = undef;








! #use PDL::LinearAlgebra; # commented until re-implement the 
use of simulation to calculate p-values
! use PDL::Bad;
};
if ($@) { 




our (@EXPORT, @EXPORT_OK, %EXPORT_TAGS);
@EXPORT = qw(  rmnorm get_maf get_fix_and_radom_meta_analysis 
get_makambi_chi_square_and_df calculate_LD_stats 
get_lambda_genomic_control number_effective_tests 
z_based_gene_pvalues);! # symbols to export by default
@EXPORT_OK = qw(  rmnorm get_maf get_fix_and_radom_meta_analysis 
get_makambi_chi_square_and_df calculate_LD_stats 
get_lambda_genomic_control number_effective_tests 
z_based_gene_pvalues); # symbols to export on request
sub rmnorm {
! my $n = shift;
! my $mean = shift;
! my $c = shift;
! my $chol = shift;
! my @back = ();
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! my $d = $c->getdim(0);
! my $vector = mpdl grandom $d,$n;
! if (not defined $chol) { $chol = mchol($c); }
! my $z = $vector x $chol->transpose;
! my $y = transpose( $mean + transpose($z));
! return($y,$chol);
}
# this subroutine applies the makambi method to combine p-values 
from correlated test
# the method receives a correlation matrix, a set of weights for 
each statistic and a set of probabilies to combine.
# it returns the chi-square and the degrees of freedom of the 
test
sub get_makambi_chi_square_and_df {
! my $cor = shift; # a pdl matrix with the varoable 
correlations
! my $w = shift; # a pdl vector with the weights;
! # make sure weiths sum one
! $w /= $w->sumover;
! my $pvalues = shift; # a pdl vector with the p-values to be 
combined
! # calculate the correlation matrix before the applying the 
weights
! # I have change this calculation following the results of 
the paper of Kost et al. this should improve the approximation 
of the test statistics
! # Kost, J. T. & McDermott, M. P. Combining dependent p-
values. Statistics & Probability Letters 2002; 60: 183-190.
! # my $COR_MAT = (3.25*abs($cor) + 0.75*(abs($cor)**2)); # 
OLD
! my $COR_MAT = (3.263*abs($cor) + 0.710*(abs($cor)**2) + 
0.027*(abs($cor)**3)); # NEW 
! my $second = $COR_MAT*$w*($w->transpose); # apply the 
weights 
! ($second->diagonal(0,1)) .= 0; # set the diagonal to 0
! my $varMf_m = 4*sumover($w**2) + $second->flat->sumover; # 
calculate the variance of the test statistics
! my $df = 8/$varMf_m; # the degrees of freedom of the test 
statistic
! my $chi_stat = dsum(-2 * $pvalues->log * $w); # and the 
chi-square for the combine probability
! $chi_stat = ( $chi_stat/2 ) * $df;
! my $sum = dsum(-2 * $pvalues->log * $w);
! if (defined $v){
! ! print_OUT("df: $df; var: $varMf_m; w: $w; chi-stat:
$chi_stat; SUM: $sum");
! ! print_OUT("P-values: " . $pvalues . "");






! my $gene = shift;
! my $mnd = shift;
! if ( ref($gene->{'pvalues'}) eq 'ARRAY'){ $gene->
{'pvalues'} = pdl @{ $gene->{'pvalues'} }; }
! if ( ref($gene->{'effect_size'}) eq 'ARRAY'){ $gene->
{'effect_size'} = pdl @{ $gene->{'effect_size'} }; }
! if ( ref($gene->{'effect_size_se'}) eq 'ARRAY'){ $gene->
{'effect_size_se'} = pdl @{ $gene->{'effect_size_se'} }; }
!




! if (defined $gene->{cor_ld_r}){
! ! $cov = $gene->{cor_ld_r};
! } else {
! ! $cov = $gene->{cor};
! }
!
! my $pvals = $gene->{'pvalues'};
! $pvals->index( which($pvals == 1) ) .= double 1-2.2e-16;
! $pvals->index( which($pvals == 0) ) .= double 2.2e-16;
! my $B = -1*gsl_cdf_ugaussian_Pinv($pvals);
! my $observed_stat = undef;
! if (defined $gene->{'effect_size_se'}){
! ! $observed_stat = get_fix_and_radom_meta_analysis($B,
$gene->{'effect_size_se'},undef,$cov);
! } else {
! ! my $se = 1/$gene->{'weights'};






! my $p = shift;
! $p = double 1 - pdl $p;




! my $B = shift;
! my $SE = shift;
! my $external_w = shift;
! my $VarCov = shift;
! if (ref($B) eq 'ARRAY') { $B = pdl $B; }
! if (ref($SE) eq 'ARRAY') { $SE = pdl $SE; }
! if (ref($external_w) eq 'ARRAY') { $external_w = pdl 
$external_w; }
! my $N = $B->nelem;
! if (not defined $VarCov) {
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! ! $VarCov = stretcher(ones $N);
! }
! my $W = null;
! if ( (ref($external_w) eq 'PDL') and (nelem($external_w > 
0) > 0) and (dsum( ($external_w - $external_w->davg)**2 ) > 0 ))
{
! ! $W = 1/($SE + 1/$external_w); 
! } else {
! ! $W = 1/$SE; 
! }
! # calculate fix effect estimate
! my $norm_w_fix = $W/$W->dsum;
! #my $B_fix = dsum($B*$W)/$W->dsum;
! #my $V_fix = dsum($W*$W->transpose*$VarCov);
! my $B_fix = dsum($B*$norm_w_fix)/$norm_w_fix->dsum;
! my $V_fix = dsum($norm_w_fix*$norm_w_fix->transpose*
$VarCov);
! my $fix_chi_square_df1 = ($B_fix**2)/$V_fix;
!
! my $stouffer_w_fix = $W/dsum($W**2);
! my $B_stouffer_fix = dsum($B*$norm_w_fix)/sqrt(dsum
($stouffer_w_fix*$stouffer_w_fix->transpose*$VarCov));
!
! # calculate heteroogeneity parameter Q
! my $Q = 0.0;
! {
! ! my $cor = $VarCov->copy();
! ! $cor->diagonal(0,1) .=0;
! ! $cor = (3.263*abs($cor) + 0.710*(abs($cor)**2) + 
0.027*(abs($cor)**3));
! ! my $df = 8/(dsum($cor*$W*$W->transpose) + 4*dsum
($W**2));
! ! my $Q_naive = dsum ($W * (($B_fix - $B)**2));
! ! $Q = sclr gsl_cdf_chisq_Pinv( gsl_cdf_chisq_P
(  $df*0.5*$Q_naive, $df), $N - 1);
! }!
! # calculate heteroogeneity parameter I-squared
! my $I_squared = 0.0;
! if ($Q > ($N - 1)){
! ! eval { $I_squared = 100*($Q - ($N - 1))/$Q; };
! ! if ($@){
! ! ! $I_squared = 0.0;
! ! }
! }
! # calculate tau-squared
! my $tau_squared = 0.0;
! if ($Q > ($N - 1)){
! ! eval { $tau_squared = ($Q - ($N - 1))/(dsum($W) - 
dsum($W**2)/$W->dsum); };
! ! if ($@){
! ! ! # tau-squared equal 0 if was < 0
! ! ! $tau_squared = 0.0;
! ! }
! }
! # calculate the random effect estimate
! my $w_star = null;
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! if ( (ref($external_w) eq 'PDL') and (nelem($external_w > 
0) > 0) and (dsum( ($external_w - $external_w->davg)**2 ) > 0 ))
{
! ! $w_star = 1/( $tau_squared + $SE + 1/$external_w);
! } else {
! ! $w_star = 1/( $tau_squared + $SE);
! }
! my $norm_w_random = $w_star/$w_star->dsum;
! my $B_random = dsum( $B*$norm_w_random)/$norm_w_random-
>dsum;
! #my $B_random = dsum( $B*$w_star)/$w_star->dsum;
! my $V_random = dsum($norm_w_random*$norm_w_random-
>transpose*$VarCov);
! #! my $V_random = dsum($w_star*$w_star->transpose*
$VarCov);
! my $random_chi_square_df1 = ($B_random**2)/$V_random;
! my $stouffer_w_random = $w_star/dsum($w_star**2);
! my $B_stouffer_random = dsum($B*$norm_w_random)/sqrt(dsum
($stouffer_w_random*$stouffer_w_random->transpose*$VarCov));
! my $back =  {
! ! 'B_stouffer_fix' => $B_stouffer_fix,
! ! 'B_stouffer_random' => $B_stouffer_random,
! ! 'B_fix' => $B_fix,
! ! 'B_random' => $B_random,
! ! 'V_fix' => $V_fix,
! ! 'V_random' => $V_random,
! ! 'Chi_fix' => $fix_chi_square_df1,
! ! 'Chi_random' => $random_chi_square_df1,
! ! 'Q' => $Q,
! ! 'I2' => $I_squared,
! ! 'tau_squared' => $tau_squared,
! ! 'N' => $N,
! ! 'Z_P_fix' => gsl_cdf_gaussian_P( -1 * $B_fix ,sqrt
($V_fix )),
! ! 'Z_P_random' => gsl_cdf_gaussian_P( -1 * 
$B_random,sqrt($V_random) ),







!  From Lon Cardon
!  
!  The EM algorithm is used to estimate the recombination 
fraction (parameter theta)
!  between two genetic markers under the assumption of Hardy-
Weinberg equilibrium.
!  
!  For SNPs, consider the 3 x 3 table of marker 1 with 
alleles 'A' and 'a' 
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!  and marker 2 with alleles 'B' and 'b'.  Number the cells 
as follows:
!  
!  AA  |  Aa  |  aa
!  -------------------
!  BB |  0  |   1  |  2
!  Bb |  3  |   4  |  5
!  bb |  6  |   7  |  8
!  
!  Note that all cells arise from unique haplotypes (e.g., 
cell 0 can only comprise
!  two 'AB' haplotypes; cell 1 has one 'AB' and one 'aB', 
etc), _except_ the double
!  heterozygote cell 4, which can have either AB/ab or Ab/aB.  
We need to estimate the
!  probability of these two events.  We assume that pair AB/
ab arises when no
!  recombination occurs (1 - theta) whereas pair Ab/aB arises 
in the presence of recombination
!  (probability theta).  Thus, for the four haplotype 
possibilities at two markers 
!  (AB,ab,Ab,aB), we have:
!  
!  prAB=prAb=praB=prab=.25;  
!  





!  N = nAB + nab + nAb + naB + 2*cell4;
!  
!  while(theta-thetaprev > CONVERGENCE_CRITERIA) 
!  {
!  thetaprev=theta;
!  prAB=(nAB + (1-theta)*cells[4])/N;
!  prab=(nab + (1-theta)*cells[4])/N;
!  prAb=(nAb + theta*cells[4])/N;
!  praB=(naB + theta*cells[4])/N;




!  i.e., D = prAB - frq(A)*frq(B), r^2 = D^2/(frq(A)*frq(B)
*frq(a)*frq(b)),
!  Dprime = D/Dmax, etc.
!  
=cut
    my $first  = shift;
    my $second = shift;
!
    my %genotypes = (!'AABB' => 0, # cell 0
! 'AaBB' => 0, # cell 1
! 'aaBB' => 0, # cell 2
!
! 'AABb' => 0, # cell 3
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! 'AaBb' => 0, # cell 4
! 'aaBb' => 0, # cell 5
!
! 'AAbb' => 0, # cell 6
! 'Aabb' => 0, # cell 7
! 'aabb' => 0  # cell 8
! );
!
! for (my $i = 0; $i < scalar @$first; $i++){
! ! $genotypes{'AABB'}++ if (( $first->[$i] == 1) and 
($second->[$i] == 1));!
! ! $genotypes{'AaBB'}++ if (( $first->[$i] == 2) and 
($second->[$i] == 1));!
! ! $genotypes{'aaBB'}++ if (( $first->[$i] == 3) and 
($second->[$i] == 1));!
! !
! ! $genotypes{'AABb'}++ if (( $first->[$i] == 1) and 
($second->[$i] == 2));!
! ! $genotypes{'AaBb'}++ if (( $first->[$i] == 2) and 
($second->[$i] == 2));!
! ! $genotypes{'aaBb'}++ if (( $first->[$i] == 3) and 
($second->[$i] == 2));!
! !
! ! $genotypes{'AAbb'}++ if (( $first->[$i] == 1) and 
($second->[$i] == 3));!
! ! $genotypes{'Aabb'}++ if (( $first->[$i] == 2) and 
($second->[$i] == 3));!




! my ($nAB,$nAb,$naB,$nab) = double 0.0;
    $nAB = 2*$genotypes{'AABB'} + $genotypes{'AaBB'} + 
$genotypes{'AABb'};
    $nab = 2*$genotypes{'aabb'} + $genotypes{'Aabb'} + 
$genotypes{'aaBb'};
    $nAb = 2*$genotypes{'AAbb'} + $genotypes{'Aabb'} + 
$genotypes{'AABb'};
    $naB = 2*$genotypes{'aaBB'} + $genotypes{'AaBB'} + 
$genotypes{'aaBb'};
    my $AaBb = double $genotypes{'AaBb'};
!
 !
! if (defined $v){
! ! print "Haplotype freqs\n";
! ! print  "Table: $genotypes{'AABB'}  $genotypes{'AaBB'} 
$genotypes{'aaBB'}\n";
!     print  "Table: $genotypes{'AABb'}  $genotypes{'AaBb'} 
$genotypes{'aaBb'}\n";
!     print  "Table: $genotypes{'AAbb'}  $genotypes{'Aabb'} 
$genotypes{'aabb'}\n";
! ! print  "nAB [ $nAB ] nab [ $nab ] nAb [ $nAb ] naB 
[ $naB ] nAaBb [ $AaBb ]\n";
! }
!
    my $N = double $nAB + $nab + $nAb + $naB + 2*$AaBb;
APPENDIX A GWAS_STATS.PM
314
    my $theta = double 0.5;
    my $thetaprev = 2;
   !my $iterations = 0;
    while( abs($theta-$thetaprev) > 0.0001 ) {!
! ! $thetaprev = $theta;
! ! eval {
! ! ! $theta = (($nAb + $theta*$AaBb)*($naB + $theta*
$AaBb))/
! !     (($nAB + (1-$theta)*$AaBb)*($nab + (1-$theta)*
$AaBb) + ($nAb + $theta*$AaBb)*($naB + $theta*$AaBb));
! ! };
! ! if (defined $v){
! ! ! print "iter: $iterations; theta [ $theta ]\n";
! ! }
! ! if ($@){ $theta = 0.5; } #included to avoid division 
by 0
! ! if (isbad(setnantobad($theta))) { $theta = 0.5; }
! ! $iterations++;
    }
!
! my ( $f_A ) = get_maf($first);
! my ( $f_B ) = get_maf($second);
!
! if ($f_B == 0 or $f_A == 0 or $f_B == 1 or $f_A == 1){
! ! return({ 'D'=> 0,
! ! ! 'r2' => 0,
! ! ! 'r' => 0,
! ! ! 'theta' => -1,
! ! ! 'N' =>  0,




    my $D;
    my $r2;
! my $r;
    eval{
! ! $D  = ($nAB+(1-$theta)*$AaBb)/$N - ($f_A*$f_B);
! ! $r2 = $D*$D/($f_A*$f_B*(1-$f_A)*(1-$f_B)); 
! ! $r = $D/sqrt($f_A*$f_B*(1-$f_A)*(1-$f_B));
    };
!
    if ($@){
! ! $D = 0;
! ! $r2 = 0; #for some cases is not possible to calculate 
the r2 due to a 0 in the divisor
! ! $r = 0;
    }
    
    my $Dmax = 0;
    my $d_prime;
    
    if ($D < 0){




! ! $Dmax = (1-$f_A)*(1-$f_B) if ($f_A*$f_B >= ((1-$f_A)*
(1-$f_B)));!
    }
    if ($D > 0){
! ! $Dmax = $f_A*(1-$f_B) if ($f_A*(1-$f_B) < (1-$f_A)*
$f_B);
! ! $Dmax = (1-$f_A)*$f_B if ($f_A*(1-$f_B) >= (1-$f_A)*
$f_B);
    }
    eval{
! ! $d_prime = $D/$Dmax;
    };
    if ($@){
! ! $d_prime = 0;
    }
!
! $D = sclr $D;
! $r2 = sclr $r2;
! if (abs($r2) > 1){ $r2 = $r2/abs($r2); }
! $r = sclr $r;
! if (abs($r) > 1){ $r = $r/abs($r); }
! $N = sclr $N;
! $d_prime = sclr $d_prime;
! $theta = sclr $theta;
!
    my $o = { 'D'=> $D,
! ! 'r2' => $r2,
! ! 'r' => $r,
! ! 'theta' => $theta,
! ! 'N' =>  $N,
! ! 'd_prime' =>  $d_prime,
! };




! my $a = shift;
! if (ref($a) eq 'ARRAY'){
! ! $a = pdl $a;
! }
! my $maf = (2*dsum( $a ==1 ) + 1*dsum( $a ==2 ) )/(2*dsum
($a != 0));




! # implemented as in S. Wellek, A. Ziegler, Hum Hered 67, 
128 (2009).
! # genotypes must be coded as 1,2 and 3,any other coding 
will be use. missing genotypes can be set to anything different 
of 1, 2 or 3.
! # this method will fail is more than 2 out of the four 
homozygoues haplotypes have counts 0. In such case i recommend 
to use the default option of the spearman correlation. 
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! my $snp1 = shift;
! my $snp2 = shift;
! # initialize to 0 all values for the haplotype cells
! my @cells = (0,0,0,0,0,0,0,0,0);
! # count how many observation of every haplotype are
! for (my $i = 0; $i < scalar @$snp1; $i++){
! ! $cells[8]++ if ((${$snp1}[$i] == 1) and (${$snp2}[$i] 
== 1));!
! ! $cells[7]++ if ((${$snp1}[$i] == 2) and (${$snp2}[$i] 
== 1));!
! ! $cells[6]++ if ((${$snp1}[$i] == 3) and (${$snp2}[$i] 
== 1));!
! ! $cells[5]++ if ((${$snp1}[$i] == 1) and (${$snp2}[$i] 
== 2));!
! ! $cells[4]++ if ((${$snp1}[$i] == 2) and (${$snp2}[$i] 
== 2));!
! ! $cells[3]++ if ((${$snp1}[$i] == 3) and (${$snp2}[$i] 
== 2));!
! ! $cells[2]++ if ((${$snp1}[$i] == 1) and (${$snp2}[$i] 
== 3));!
! ! $cells[1]++ if ((${$snp1}[$i] == 2) and (${$snp2}[$i] 
== 3));!
! ! $cells[0]++ if ((${$snp1}[$i] == 3) and (${$snp2}[$i] 
== 3));!
! }
! if (defined $v) {
! ! #print_OUT("  AA Aa aa");
! ! #print_OUT("BB $cells[0]  $cells[1]  $cells[2]");
! ! #print_OUT("Bb $cells[3]  $cells[4]  $cells[5]");
! ! #print_OUT("bb $cells[6]  $cells[7]  $cells[8]");
! }
! my $h1 = sqrt($cells[0]);
! my $h2 = sqrt($cells[2]);
! my $h3 = sqrt($cells[6]);
! my $h4 = sqrt($cells[8]);
! my $corr = 2*($h1 * $h4 - $h2 * $h3)/sqrt(4*($h1 + $h2)*




# this subroutine calculate the number of effective test by the 
Galwey and Gao method.
sub number_effective_tests {
! my $mat = shift;
! # calculate the Eigen value of the correlation matrix
! my $eigens = eigens ${$mat};
! # normalize the values
! my $eigens_norm =  pdl sort { $b <=> $a } list ($eigens/
(dsum $eigens) );
! # calculate number of effective test per Gao et al Gao, X., 
Becker, L. C., Becker, D. M., Starmer, J. D. & Province, M. A. 
Avoiding the high Bonferroni penalty in genome-wide association 
studies. Genet. Epidemiol. (2009).
! # the methos simply count how many Eigen values are needed 
to explain 99.5 % of the variance
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! my $simpleM = 0;
! for( $simpleM = 0; $simpleM < scalar list $eigens_norm; 
$simpleM++){
! ! my $sum = sumover $eigens_norm->slice("0:$simpleM");
! ! if ($sum >= 0.995){
! ! ! $simpleM++;
! ! ! last;
! ! }
! }
! # calculate number of effective test by Galwey, N. W. A new 
measure of the effective number of tests, a practical tool for 
comparing families of non-independent significance tests. Genet. 
Epidemiol. (2009).
! # this method calculate the square of sum of the square-
root of the Eigen values divided by the sum.
! my $numerator = 0;
! my $denominator = 0;
! foreach my $e (list $eigens) {
! ! if ($e > 0){
! ! ! $numerator += sqrt($e);
! ! ! $denominator += $e;
! ! }
! }
! my $Meff_galwey = ($numerator**2)/$denominator;
! if (defined $v){ 
! ! #print_OUT(" simpleM_Gao = $simpleM; Meff_galwey=








Perl routines to estimate p-values using extreme value distribution theory as 
described on (Knijnenburg et  al., 2009) but estimating the parameters of the generalised 












our (@EXPORT, @EXPORT_OK, %EXPORT_TAGS);
@EXPORT = qw( Pgpd );!! ! ! # symbols to export by 
default




!  Computing permutation test P-value of the GPD 
approximation
! !
! !  Input:    x0         original statistic
! ! ! !    y          permutation values
! ! ! !    N          number of permutation values
! ! ! !    Nexc       number of permutations used 
to approximate the tail
! ! ! !    alpha      confidence level
! !  Output:   Phat       estimated P-value
! ! ! !    Phatci     confidence intervals of the 
estimated P-value
!  Original code in Matlab by Theo Knijnenburg, Institute for 
Systems Biology (Dec 11 2008)
=cut
! my $x0 = shift;
! my $y =  shift;
! my $Nexc = shift;
! my $alpha = shift;
! my $N = $y->nelem;
! my $Padth = 0.05;
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! if ($Nexc >= $N-1) {
! ! $Nexc = int(0.1*$N);
! }
!




! my $fitted = 0;
! do {
! ! $y = pdl reverse list qsort $y;
! ! # Defining the tail!
! ! my $z = $y->(1:$Nexc);
! ! $t = davg($y($Nexc:$Nexc+1));
! ! $z = $z-$t;
! !
! ! $frac = $Nexc/$N;
! ! # Fitting the tail and computing the Pvalue
! ! ($a,$k,$cov) = Jin_ZHANG_pareto_fit($z);
! ! #print "$Nexc $a $k $cov\n";
! ! my $p = 1- gsl_cdf_pareto_P($z,$a,$k);
! ! ($PW2_less_005,$PA2_less_005,$W2,$A2) = gpdgoft( $p ,
$k); # goodness-of-fit test
! ! #print "$PW2_less_005,$PA2_less_005,$W2,$A2\n";
! !
! ! if ( $A2 eq 'nan'){
! ! ! $fitted = $PA2_less_005;
! ! } else {
! ! ! $fitted = $PW2_less_005;
! ! }
! ! $Nexc -= 10;
! } until ( ( $fitted == 1 ) or ($Nexc < 11) );!
! if ($fitted == 1){
! ! my ($Phat,$Phatci_low,$Phatci_up) = gpdPval($x0-$t,
$a,$k,$cov,$alpha);
! ! $Phat = $frac*$Phat;
! ! $Phatci_up = $frac*$Phatci_up;
! ! $Phatci_low =$frac*$Phatci_low; 
! ! return($Phat,$Phatci_low,$Phatci_up);





! my $x0 = shift;
! my $a = shift;
! my $k = shift;
! my $cov = shift;
! my $alpha = shift;
! my $Phat = 1 - gsl_cdf_pareto_P($x0,$a,$k);
!
! my $gaussian_random_mat = grandom 2, 10000; 
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! my $reapmat= ones 2, 10000;
! my $par = pdl $a,$k;
! $reapmat = $reapmat * $par; 
! my $chol = mchol($cov);
! my $Q = ($gaussian_random_mat  x $chol->transpose ) + 
$reapmat;
! my $sample =  1 - gsl_cdf_pareto_P($x0,$Q->(0,),$Q->(1,));
! $sample->inplace->setnantobad;
! $sample =  $sample->where(  $sample->isgood() );
!
! my $Phatci_low = pct($sample,$alpha/2);





! my $x = shift; # x is the sample data from the GPD
! my $n = $x->nelem;
! $x = qsort $x;
! my $p = pdl (3 .. 9);
! $p /= 10;
! my $xp = $x->(rint($n*(1-$p)-0.5));
! my $m = 20 + rint( sqrt($n) );
! my $xq = $x->(rint($n*(1-$p*$p)+0.5));
! my $k = log($xq/$xp-1)/log($p);
! $k->inplace->setnantobad;
! $k->inplace->setbadtoval(0);
! my $a = $k*$xp/(1-$p**$k);
! $a->inplace->setnantobad;
! $a->inplace->setbadtoval(0);!
! $a->where( $k == 0 ) .= (-$xp->where( $k == 0 )/log($p-
>where( $k == 0 )) ) ;
! $k = -1;
! my $tmp1 = pdl 1 .. $m;
! my $j_minus05_overm = ($tmp1 -0.5)/$m;
! my $leading = (($n-1)/($n+1))*(1/$x->($n-1));
! my $b =  $leading - ((1- $j_minus05_overm**$k)/$k) * (1/ 
median($a))/2;
! my @tmp = ();
! for (my $i = 0; $i < $m; $i++) { 
! ! push @tmp, $n * lx($b->($i),$x);
! }
! my $L = flat pdl @tmp;
! @tmp = ();
! for (my $i = 0; $i < $m; $i++) {
! ! push @tmp, 1/dsum( exp( $L - $L->( $i) ) );
! }
! my $w = flat pdl @tmp;
! $b = dsum($b*$w);
! $k = -davg(log(1-$b*$x));




! my $cov = mones 2,2;
! $cov(0,0) .= 2*($sigma**2)*(1-$k);
! $cov(1,0) .= $sigma*(1 - $k);
! $cov(0,1) .= $sigma*(1 - $k);




! my $b= shift;
! my $x = shift;
!
! my $k = - davg( log( 1-$b*$x ) );
! if ($b == 0) {
! ! return( $k-1-log(davg($x)) );
! } else {




! my $p = shift;
! my $k = shift;
!
! $p = qsort $p;
! $p->where( (1 - $p) < 2.2e-16 ) .= 2.2e-16;
! my ($W2,$A2) =  fit_stats($p);
! !
! my $W2_less_005 = 0; # 0 no and 1 yes
! my $A2_less_005 = 0; # 0 no and 1 yes
!
! $k = 0.5 if ($k > 0.5);
!
! my $k_vals = pdl 
(-0.9,-0.5,-0.2,-0.1,0,0.1,0.2,0.3,0.4,0.5);
! my $W2_vals  = pdl 
(0.115,0.124,0.137,0.114,0.153,0.16,0.171,0.184,0.201,0.222);
! my $A2_vals = pdl 
(0.771,0.83,0.903,0.935,0.974,1.02,1.074,1.14,1.221,1.321);
!
! my $trend_A2 =  PDL::GSL::INTERP->init('linear',$k_vals,
$A2_vals);




! my $critic_w2 = undef;
! my $critic_a2 = undef;
!
! if ($k < -0.9 or $k > 0.5) {




! ! $critic_a2 = $trend_A2->eval($k,{ Extrapolate => 
1 } );
! } else {
! ! $critic_w2 = $trend_W2->eval($k,{ Extrapolate => 
0 } );
! ! $critic_a2 = $trend_A2->eval($k,{ Extrapolate => 
0 } );
! }
! $A2_less_005 = 1 if ( $A2 >= $critic_a2 );




sub fit_stats { 
! my $p = shift;
! my $n = $p->nelem;
! my $i = 1 + sequence $n;
!
! # Cramer-von Mises statistic
! my $W2 = dsum( ($p - ( (2*$i-1)/(2*$n) ))^2 ) + 1/(12*$n);
! # Anderson Darling statistic
! my $A2 = -$n -  (1/$n) * dsum( ((2*$i-1) * (log($p)) + log
(double 1 - double $p->($n+1-$i - 1)) ));
! return($W2,$A2);
}
1;
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